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ABSTRACT 
The overall aim of this project was to investigate HIV-1 genetic diversity in South Africa 
and to characterise the immune response in mice to a South African subtype C gp120. 
To investigate the relationship between subtype and mode of transmission , samples were 
collected from individuals infected by heterosexual and male homosexual transmission from 
patients attending local HIV/AIDS clinics in Cape Town (n=49) and Bloemfontein (n=4). Isolates 
were subtyped using heteroduplex mobility assay (HMA) based on the V3-V5 region of the env 
geneusing reference plasmids (2 B, 2 C and 1 D) representative of local subtypes. HMA 
identified four env subtypes: A, B, C and D. Subtype B viruses were found in 92.9% (26/28) of 
the male homosexual/bisexual group and subtype C viruses in 77 .2% (17 /22) of the heterosexual 
group. Subtype B viruses were also identified in two heterosexual patients, one patient infected 
by blood transfusion and in two patients with . unknown mode of transmission. Subtype D viruses 
were found in one male homosexual patient and one heterosexual patient and a husband and 
wife couple were infected with subtype A viruses. A significant association between subtype and 
mode of transmission (p=<0.0001) was identified, confirming two independent epidemics. 
To determine the subtype distribution of HIV within urban heterosexual populations 
throughout South Africa , samples were collected from women attending antenatal clinics in 
Johannesburg (n=34) , Pretoria (n=S) and Durban (n=20) . Samples from Bloemfontein (n=24) 
were taken from individuals attending an HIV/AIDS clinic. All eighty-three samples were 
subtyped by HMA in the env region as before. The predominant subtype circulating within the 
urban heterosexual population throughout South Africa was identified as subtype C (92.8%) 
although subtype B was also detected (7.2%) . It may thus be beneficial if a HIV vaccine for 
South Africa is based on a subtype C model. 
In addition, a rapid method for identification of HIV-1 gag subtypes was developed based 
on restriction fragment length polymorphism (RFLP) analysis of 400bp (p17) or 650bp (p17 and 5' 
p24) long PCR fragments. This strategy was applied to eighty-six samples (Cape Town n=47, 
Johannesburg n=20, Bloemfontein n=17 and Durban n=2) previously subtyped by either 
sequence analysis of the gag p17 region (n=31) , heteroduplex mobility assay (HMA) based on 
the env gene (n=76), or both (n=21) . RFLP analysis identified two subtype A, twenty-five subtype 
B, fifty-eight subtype C and one subtype D isolates. There were no discrepancies between RFLP 
and sequence gag subtypes, demonstrating the reliability of this method and no discordance 
between gag RFLP subtypes and env HMA subtypes, indicating no recombinant viruses in the 
genomic regions analysed. 
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The first phylogenetic analysis of a gp120 from a macrophage tropic, non-syncitium 
inducing (NSI) subtype C isolate from South Africa (97ZA347TS) was performed in this study and 
the isolate was found to cluster within the subtype C lineage with a bootstrap value of 100%. The 
gp120 protein of the 97ZA347TS contained twenty-two N-linked glycosylation sites, including an 
additional site within the CD4 binding site, characteristic of subtype C isolates. The phylogenetic 
relationship between 117 published subtype C V3 loop sequences, including three isolates 
sequenced in this study, was also investigated . No sub-clustering was identified within South 
African isolates, or with any country of origin . The isolates were found to be 14% divergent from 
each other. The majority of isolates retained the characteristic GPGQ tetrapeptide crown and the 
loss of a N-linked glycosylation site 5' to the V3 loop at position 265-267. Argenine substitutions 
indicative of a syncitia inducing phenotype, were present in only two of the southern African 
subtype C isolates, NOF and 89ZA067, at position , 276. 
The gp120 from 97ZA34 7TS was cloned into the pcDNA3.1 /Zeo DNA to determine the 
immunogenicity of the gp120 in comparison with the gp120 from a NSI subtype B isolate (SF162). 
The DNA vaccines were immunised intramuscularly into female BALB/c mice and boosted at 
weeks 2, 4 and 6. The antibody response to both DNA vaccines peaked at five to seven-fold 
higher levels than the negative control mice, immunised with the DNA vaccine vector alone. 
To determine the potential cross-reactive response between subtype B and C isolates, 
DNA vaccines expressing 97ZA347TS and SF162 were used to immunise female SALB /c mice 
once intramuscularly, followed by an intraperitoneal challenge with recombinant vaccinia virus 
(VV) expressing the gp120 from subtype C, 97ZA347TS, after nine days. The VV titres in the 
mouse ovaries is an indirect measurement of the CD8+ CTL (cytotoxic T lymphocyte) response in 
the mouse. The CD8+ CTL response was determined, by clearance of the recombinant W from 
the mouse ovaries in comparison to unimmunised mice. The subtype C immunised mice had a 
recombinant W ovarian titre over 500-fold lower than the negative control mice and the subtype 
B immunised mice had an ovarian titre of recombinant W 100 fold lower than the negative 
control mice. A greater control of replication by homologous subtype C recombinant W was 
obtained and a cross-reactive CTL response was demonstrated . Comparison of the amino acids 
in the two isolates indicated 24% difference, which would have an effect on the CTL epitopes in 
common between the isolates. A region with less variability than the gp120 would possibly be 
better in eliciting a cross-reactive CTL response . It is thus possible that with an optimised South 
African macrophage tropic subtype C vaccine , CTL cross-reactivity between subtypes may be 
achieved. This was the first study utilising a murine in vivo challenge method of determining the 
cross-reactive CTL response between different HIV-1 subtypes. 
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1.1) Historical perspective 
Acquired immunodeficiency syndrome (AIDS), as a clin ical entity, was first recognised in 
1981 . In 1983, the causative agent of AIDS was identified by a number of scientific groups: 
lymphadenopathy-associated virus (LAV) was first isolated in 1983 by Montagnier and Barre-
Sinoussi (Barre-Sinoussi et al., 1983) and a human T-cell lymphotropic retrovirus (HTLV-111) was 
isolated by Gallo et al (Popovic et al., 1984) in 1984. In addition, an AIDS-associated retrovirus 
(ARV) was isolated in the same year by Levy from an AIDS patient (Levy et al., 1984). LAV and 
HTLV-111 were subsequently sequenced and found to be only 1-2% divergent (Wong-Staal et al., 
1985) leading to the renaming of the virus as human immunodeficiency virus (HIV) in 1986 (Coffin et 
al., 1986). 
1.2) Origin of HIV 
Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) are retroviruses belonging to 
the lentivirus family. There are five recognised or known groups of primate lentiviruses (Barre-
Sinoussi, 1996): 
I) HIV-1 and simian immunodeficiency virus, or SIVcpz, from a wild-caught 
chimpanzee 
II) HIV-2 (from humans), SIVsm and SIVmac (from captive macaques and feral 
sooty mangabeys) 
Ill) SIVagm (from african green monkeys) 
IV) SIVmnd (from wild-caught mandrills) 
V) SIVsyk (from sykes ·monkeys) 
HIV-1 and HIV-2 are presumed to have entered the human population by cross-species 
(zoonotic) infections (Gao et al., 1999). The sooty mangabey (Cercocebus atys) has been identified 
as the primate reservoir of HIV-2 (Hirsch et al., 1989; Gao et al., 1992 and Chen et al., 1996). Until 
recently, the origin of HIV-1 was not known. However, by sequence analysis of the mitochondrial 
DNA of all chimpanzees known to be infected with SIVcpz, two chimpanzee subspecies were 
identified in Africa and the SIVcpz virus infecting them was phylogenetically characterised (Gao et 
al., 1999). Pan troglodytes troglodytes (central Africa) and P. t. schweinfurthii (eastern Africa) were 
found to harbour SIVcpz viruses which form two highly divergent and subspecies-specific 
phylogenetic lineages. 
The HIV-1 strains that infect man (including Groups M; subtypes A to J, and 0) are closely 
related to the SIVcpz lineage found in P. t. troglodytes (see figure 1.1 ). In addition, a new lentivirus 
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isolate was recently identified from a Cameroonian woman and subsequently found in a further two 
individuals. The highly divergent isolates (as divergent from HIV-1 Group M as SIVcpz-gab) have 
been subsequently been named Group N (Simon et al. , 1998). HIV-1 Group N was found to be a 
mosaic of SIVcpzUS (a new SIVcpz identified) and HIV-1-related sequences, which indicates an 
ancestral recombination event in the chimpanzee host (Gao et al., 1999). The lentivirus, SIVcpz is 
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Figure 1.1 : A phylogenetic tree taken from Gao et al. (1999) showing the relationship between the HIV-1 
group M (U455, LAI , ELI) , group O (ANT70, MVP5180) and group N (YBF30) isolates in comparison to HIV-
2 and SIV lentiviruses , including a recently identified SIV, SIVcpzUS. Branch lengths are indicated by the 
bar (0.1 amino acid replacements per site) . 
The origin of HIV-1 subtypes has been analysed by sequencing strains of HIV-1 from the 
start of the epidemic. Phylogenetic analysis from an isolate obtained from Gabon in 1959 showed 
that the origin of the isolate was near the ancestral node of subtypes B, D and F. These subtypes are 
thus thought to have diverged from a common ancestor shortly before 1959 (Leitner et al., 1997 and 
Zhu et al., 1998). 
1.3) Virus structure and organisation 
Lentiviruses are enveloped viruses, 80-100nm in diameter with conical cores and Mg
2
+ -
dependent reverse transcriptase enzymes. All Retroviridae have two copies of single-stranded (ss) 
RNA, approximately 9.2Kb in length , encoding the gag, pol and env genes, which are converted into 
double-stranded (ds) DNA early in infection by the reverse transcriptase enzyme. In addition , the 
complex lentivirus genome incorporates accessory and regulatory genes (see figure 1.2) (Fields, 
1996). The DNA provirus is integrated into the host chromosome and is then transcribed into new 
viral RNA genomes and shorter sub-genomic RNAs by the cellular DNA-dependent RNA 
4 
polymerases. Viral structural proteins are translated from unspliced or single spliced viral RNAs, 
whereas regulatory and accessory proteins are translated from multiply spliced viral RNAs (Barre-
Sinoussi, 1996). 
LTR vpr 
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Figure 1.2: Figure illustrating the structure of the HIV virion, including the structural proteins making up the outer 
coat (gp120 and gp41) and inner capsid (p17 and p24) as well as the two ssRNA's and the reverse transcriptase 
enzymes. The genome of the virus is also shown, with the different open reading frames of structural, regulatory 
and accessory genes indicated in different colours (Gelderblom , 1997 and UNAIDS, 1998). 
1. 3. 1) Gag proteins 
The Gag proteins form the major structural proteins of the virus. They are initially produced 
as Pr559a9 which is targeted to the cell membrane for budding, where a viral protease cleaves it into 
smaller Gag proteins. The matrix protein (MA), p17 is situated at the N-terminal of Pr55
9a9 and 
undergoes co-translational myristoylation, allowing membrane targeting of the Pr55
9a9 protein (Mervis 
et al. , 1988 and Fields, 1996). 
The MA protein is a trimer, with each monomer consisting of five a-helices and a ~-sheet 
(Cannon et al. , 1997). Lysine residues along the hydrophobic face of the protein stabilise the MA 
trimer during viral assembly at the plasma membrane (Spearman et al. , 1997). The MA protein is 
involved in the early replication cycle and, independently to Vpr, facilitates transport of the pre-
integration complex (PIC) into the host cell nucleus. In this way, HIV, and other lentiviruses, are able 
to infect both dividing and non-dividing cells (Cannon et al. , 1997). The MA protein surrounds the 
viral capsid, CA (p24), and is internal to the envelope. It is also involved in binding to gp41 , 
incorporating the envelope into the virus (Zhou and Resh, 1996). In addition, it was recently 
suggested that the MA protein binds to human cellular factors found on CD4+ and CD8+ cells, 
resulting in increased proliferation of peripheral blood mononuclear cells (PBMC's), thereby 
enhancing HIV replication (De Francesco et al. , 1998). 
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The other Pr559a9 cleavage products, p7/p9 (nucleocapsid proteins, NC) and the proline-rich 
p6 are all localised in the CA protein core of the virus. CA surrounds the viral genome and enzymes, 
NC binds to the RNA genome by two zinc fingers (Gelderblom, 1997) and p6 is needed for complete 
ribonucleoprotein formation and virus budding (Mervis et al., 1988 and Fields, 1996). 
1.3.2) The pol gene 
The pol gene encodes the protease, reverse transcriptase, integrase and RNAse H enzyme 
precursor. The reverse transcriptase consists of p51/p66 subunits and incorporates RNAse H which 
is an RNA specific ribonuclease for RNA/DNA hybrids. The protease is released from the Gag-Pol 
polyprotein by autocatalytic cleavage, after which it targets other sites in the polyprotein . lntegrase, 
which forms part of the pre-integration complex (PIC), mediates the covalent linkage of viral dsDNA 
into the host genome (Fields, 1996). 
1.3.3) Regulatory and accessory genes 
Primate lentiviruses also have regulatory and accessory proteins (see figure 1.2), encoded 
by tat, rev, vit, and net genes. HIV-1 and SIVcpz have vpu, whereas HIV-2, SIVsm, SIVmac and 
SIVagm contain vpx and all primate lentiviruses but SIVagm contain vpr. Vpr, vpx and vit gene 
products are packaged into the virions, but tat, rev, vpu and net are not (Fields, 1996). 
The Tat protein regulates viral gene expression by binding to the trans-activating response 
(TAR) sequence in nascent RNA (Fields, 1996 and Majello et al., 1998). Tat is released by infected 
cells in large amounts and high levels of Tat have been detected in HIV infected patients. This Tat 
protein is taken up by both infected and non-infected cells and is translocated to the cell nucleus 
where transcription of virus in infected cells is enhanced. In both infected and non-infected cells 
factors such as TNF (tumour necrosis factor) , IL6 (interleukin 6) and IL 10 (interleukin l O) are 
activated. Prevention of Tat uptake by antibodies to Tat, leads to an attenuation of HIV infection in 
vitro (Goldstein, 1996). 
The Rev protein facilitates the export of unspliced or single spliced viral RNA from the 
nucleus to the cytoplasm by binding to a rev responsive element (RRE) in viral transcripts. In HIV-1 , 
the RRE is a RNA sequence in the env gene 3' to sequences encoding the gp120/gp41 junction. 
These RNA's are then translated into the Gag-Pol and Env proteins. Without Rev, no structural 
proteins are made (Fields, 1996). 
Production of the Vif protein is dependent on Rev function and although the role of the Vif 
(viral infectivity) protein is not known for certain , two functions have been proposed. During early 
infection , it may transport virions to the nucleus by interaction with the intermediate filaments in the 
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cell cytoskeleton . It may also stabilise the newly synthesised DNA intermediates and function in 
provirus formation (Miller and Sarver, 1997). 
Vpr (viral protein R) is translated late in infection from a single-spliced RNA and is 
dependent on Rev. It is associated with the nucleocapsid in mature virions, mediated by NC p7 and 
p6 in a protein-protein interaction, or with the nucleus or cytoplasmic membranes in infected cells {de 
Rocquigny et al., 1997). The 96 amino acid protein regulates cellular processors in the HIV life cycle 
by interruption of the host cell division in the G2 phase. It is also involved in the targeting of the PIC 
to the nucleus of non-dividing cells {the first cells to be infected) {de Rocquigny et al., 1997). 
Vpu (viral protein U) is a single-spliced Rev dependent viral mRNA, which is translated into 
an amphipathic, 9.2 kDa membrane protein associated with the endoplasmic reticulum or Golgi 
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system. It enhances virus release by formation of ion-conductive channels in its oligomerised form, 
degrades the CD4 receptor and down-regulates MHC class I molecules on the infected cell surface 
{de Rocquigny et al., 1997 and Kerkau et al., 1997). 
Nef (negative factor) is translated from two multiply-spliced mRNA's, independant of Rev 
and is a 27kDa protein, produced in high amounts during early replication . It is important for 
replication and pathogenicity of the virus and may enhance viral infectivity, activate T-cells (Miller 
and Sarver, 1997), down-regulate CD4 and MHC class I molecules on the cell surface (Xu et al., 
1997) and be associated with cellular serine kinase (Fields, 1996). The functions of Nef are 
discussed in more detail in section 1.7.2.6. 
1.3.4) The HIV env glycoprotein 
The env gene encodes the gp 160 precursor protein that is processed by cellular proteases 
into the gp41 and gp120 glycoproteins. All synthesis and processing of the gp160 occurs in the 
secretory pathway at the endoplasmic reticulum (ER). Glycosylation influences both immunological 
and functional properties of the highly variable gp160 and occurs in the Golgi body of the cell (Fields, 
1996). The viral spikes, or knobs occur in low numbers on the surface of mature virions {Layne et 
al., 1992) and are made up of three heterodimers of the gp120 (surface subunit) and gp41 
(transmembrane subunit). The gp120 and gp41 are non-covalently linked, and the gp120 is weakly 
anchored to the surface of the virus or to the plasma membrane of infected cells by the gp41. The 
spikes are arranged in a T=7 levo-rotational symmetry and are shed spontaneously {half-life of about 
30 hours) from the virus. Macrophages infected with HIV have been found to produce virion_s that 
are depleted of spikes, whereas T-cells make abundant amounts of gp120 (Gelderblom et al., 1987; 
Meltzer et al., 1990 and Layne et al., 1992). The gp120 contains the CD4 receptor binding domain 
as well as the co-receptor binding domains (Fields, 1996) (see section 1.4.2 for a more detailed 
description). 
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The gp41 is less glycosylated and more conserved than the gp 120 and is glycine-rich and 
hydrophobic at the N-terminal (20 amino acids) which is the region fusing the virion membrane to the 
plasma membrane during virus entry. A second hydrophobic region spans the virion and cell 
membranes, anchoring the glycoprotein heterodimer. It is postulated that CD4 binding of the gp120 
leads to a conformational change in the gp41, making it more accessible for fusion (Tan et al., 1997). 
A triple coil-coil a-helix structure in the gp41 N-terminal ectodomain (external domain) is the fusion 
active region that penetrates the target cell membrane (Chan et al., 1997; Tan et al., 1997 and 
Weissenhorn et al., 1997). 
1.3.4.1) Gp120 V3 domain 
The gp120 contains conserved (C1-C5) and variable regions (V1-V5) interspersed. Much 
attention has been focused on the third variable domain (V3 domain), a loop of 35 amino acids (aa). 
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It governs cell tropism, cytopathicity and co-receptor usage of the virus . B and T-cell responses are 
aimed at the V3 loop and it is known as the principle neutralising determinant. The tetrapeptide 
crown of the loop is fairly conserved amongst subtypes, as are the cysteine residues at the base of 
the loop that form a disulphide bond . Sequence changes within the loop are conservative, 
substituting with amino acids that have similar chemical properties (Fields, 1996). Amino acid 
changes in the V3 loop from acid to basic, influence viral tropism from macrophage and primary T-
cell tropic towards the ability to replicate in continuous T-cell lines. Specifically, the region between 
the V3 and C2 is important for syncitia formation, tropism and infectivity, C4 is part of the CD4 
binding site and interacts with the V3 loop, affecting the gp120 conformation (Fields, 1996). 
1.4) HIV infection and disease progression 
1.4. 1) Routes of transmission 
HIV is transmitted by various routes, including sexual, parenteral (including blood transfusion 
and intravenous drug use), perinatal transmission and via the breastmilk (WHO Report, 1998). HIV 
is transmitted cell-associated in the semen and in vaginal secretions. Perinatal transmission can 
occur at a number of different stages during pregnancy, delivery and during breast-feeding (Dunn et 
al., 1992; Newell et al., 1996; Newell et al., 1997 and Newell et al., 1998). The highest risk of 
transmission is during delivery (Newell et al., 1996). Approximately 25% of babies born to HIV 
positive mothers in the developing world are infected with a further 14 % of infections occurring 
during breast-feeding (Gray et al., 1996 and Leroy et al., 1998). 
1.4.2) Co-receptor Usage 
Although the main receptor for HIV is CD4, it has long been known that HIV requires more 
than CD4 for entry into the host cells. However, only in 1996 were other co-receptors identified (see 
figure 1.3). 
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Fusin, or LESTR, now known as CXCR4 was first identified as being needed for fusion of the 
virus to the host cell (Feng et al., 1996). The receptor is found in many human cells and is a 
member of the 7-transmembrane G-protein coupled receptor family which activate calcium ion fluxes 
or cyclic AMP in response to certain extracellular ligands (Alkhatib et al., 1996 and Paxton et al., 
1996). CXCR4 is an a-chemokine receptor and is specific, binding only one ligand (Premack and 
Schall, 1996 and de Roda Husman and Schuitemaker, 1998). CXCR4 is the receptor used by T-cell 
adapted syncitia inducing (SI) virus variants which form syncitia when grown in cell culture. 
CCR5 was identified later and is also a member of the G-protein coupled receptor family 
(see figure 1.3). CCR5 is a p-chemokine receptor and belongs to the C-C group that binds more 
than one ligand (Premack and Schall, 1996 and de Roda Husman and Schuitemaker, 1998). It was1 
determined that the CCR5 receptor was the binding site for primary, non-syncitium inducing (NSI) 
HIV isolates that are macrophage or monocyte tropic (Alkhatib et al., 1996). These primary isolates 
and their associated co-receptor CCR5 have been associated with sexually transmitted HIV variants 
(Zaitseva et al., 1997; Paxton et al., 1998a and Paxton et al., 1998b). HIV binds to CD4 first, after 
which there is a conformational change in the gp120 protein allowing co-receptor binding and then 
fusion of the viral envelope and the host cell membrane. The CCR5-binding region is conserved in a 
number of primate lentiviruses, including HIV-1 subtype A, B, C and E, as well as SIV (Nyambi et al., 





































Figure 1.3: The chemokine receptors and ligands to which they bind are illustrated as well as 
the four major chemokine classes. HIV can utilise CCR5, CCR3, CCR2 and CXCR4 co-
receptors, amongst others (Premack and Schall , 1996). 
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A new classification system for SIV/HIV strains based on co-receptor usage has been 
proposed (Berger et al., 1998). Viruses using the CCR5 co-receptor are designated RS, viruses 
using the CXCR4 co-receptor are designated X4 and dual tropic viruses using both receptors are 
classified X4R5. In addition, other co-receptors which may be utilised can also be incorporated into 
the classification system, such as CCR3, which would be designated R3. This classification system 
is more flexible and accurate than the current SI (rapid/high) and NSI (slow/low) classification 
system, especially as more co-receptors are identified (Doms and Moore, 1996 and Fenyo et al., 
1996). 
Natural ligands to these co-receptors inhibit HIV replication by blocking virus attachment to 
the host cells. Macrophage inflammatory protein's (MIP)1 a and MIP1 ~. and regulated-on-activation, 
normal T cell-expressed and secreted (RANTES) are ligands produced by CD8+ T-cells which block 
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the attachment of HIV isolates utilising the CCR5 co-receptor (Trkola et al., 1996 and Wu et al., 
1996). It has been found that people who have increased levels of MIP1a, MIP1~. and RANTES are 
more resistant to HIV infection by primary, macrophage-tropic isolates (Paxton et al., 1996). Stromal 
cell-derived factor 1 (SDF-1 ), on the other hand, is the only ligand identified which can inhibit the 
replication of CXCR4-binding isolates. 
Other co-receptors, or orphan receptors such as CCR2b, CCR3, CCR8, V28, STRL33 
(Bonzo), GPR1, GPR15 (BOB), Chem23 (which is expressed by dendritic cells) and virally encoded 
chemokine receptor analogue, US28, have also been identified (Choe et al., 1996; Doranz et al., 
1996; Deng et al., 1997; Farzan et al., 1997; Liao et al., 1997; Pleskoff et al., 1997; Reeves et al., 
1997; Rucker et al., 1997; Pleskoff et al., 1998 and Samson et al., 1998). The significance of the 
alternative co-receptors in vivo has not yet been determined, although they may be involved in viral 
pathogenesis. CCR3, for example is expressed in microglia along with CCR5 and usage of this 
receptor may result in viral neurotropism (He et al., 1997). 
It has recently been shown that in certain cases there is a switch from the exclusive use of 
CCR5 during early infection, to the use of a broader range of co-receptors such as CCR1, CCR2b, 
CCR4 and BOB in rapid and late progressors. This increase in co-receptor utilisation by the virus 
usually coincides with a decrease in CD4 levels in the host and subsequent progression to AIDS. 
Long term non-progressors (L TNP's), on the other hand, tend to maintain CCR5 as the major co-
receptor and produce higher levels of ~-chemokines than rapid or late progressors (Xiao et al., 
1998). 
People who remain HIV-negative, despite repeated exposure to the virus have been 
identified. Sequence analysis of the CCR5 gene has shown that there is a 32 base pair deletion 
(Ll32) leading to a truncated protein in certain individuals. If the individual is homozygous for the 32 
base pair deletion, it leads to a non-functional CCR5 receptor and in most cases, partial resistance to 
macrophage tropic primary isolates (Liu et al., 1996 and Samson et al., 1996). Individuals 
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heterozygous for the l'l32 deletion are not protected from infection, but have slower disease 
progression (Dean et al., 1996 and Huang et al., 1996). It has been established that the frequency 
of the homozygous l'l32 deletion is higher in populations of European descent and the further North, 
the higher the frequency. For example, in Fin land 2.6% out of 194 HIV-negative people are 
homozygous for the !l32 mutation (Pastinen et al., 1998), whereas in Cypress only 0.1 % of 1002 
HIV-negative people are homozygous for the l'l32 deletion (Christodoulou et al., 1997). No 
homozygous l'l32 deletions have been identified in non-Caucasians in Venezuela (Dean et al., 1996), 
Japan, or Central Africa (Samson et al., 1996). 
A second mutation has been detected in the CCRS gene that results in a non-functional 
protein. It is a T ~ A point mutation, causing an early stop codon, designated m303. The m303 
mutation, together with a l'l32 deletion on the other allele may render PBMC's resistant to primary 
isolates. In a study of 209 blood donors in France, under 1 % had the mutation, making it 1 O to 20 
times less frequent than the l'l32 deletion (Quillent et al., 1998). In addition , an A/G polymorphism in 
the CCRS promoter has been identified which may affect the rate of disease progression after 
infection. The polymorphism, termed 59029-G (glycine instead of alanine at base pair 59029), when 
homozygous, appears to lead to decreased CCRS mRNA production, thereby facilitating a decrease 
in the amount of CCRS receptor which is expressed. Individuals homozygous for 59029-G/G 
progress to AIDS 3.8 years slower on average than those homozygous for 59029-A/A (McDermott et 
al., 1998). 
In 1997 the CCR2b-641 mutation (caused by valine to isoleucine substitution) in the 
transmembrane domain of CCR2b was identified. The CCR2b-641 mutation was associated with a 
delay in disease progression by two to four years in the first study performed (Smith et al., 1997). It 
was subsequently shown that delay in disease progression associated with the CCR2b-641 mutation 
may be linked to CCRS-restricted NSI HIV-1 viruses, as the delay was less in individuals 
homozygous for the mutation who were infected with SI valiants. In addition, no delay in disease 
progression was observed in individuals heterozygous for the CCR2b-641 mutation, who were 
infected with SI HIV-1 valiants (van Jij et al., 1998). However, in a later study, no delay in disease 
progression in intravenous drug users (IVDUs) heterozygous for the CCR2b-641 mutation infected 
with CCRS-restricted NSI viruses was shown either. It was postulated that immunologic differences 
may exist between the IVDUs from the later study and the homosexual men in the prior study, where 
a delay in disease progression was shown . There may also be differences in the HIV variants that 
infect IVDUs as compared with homosexual men, or possibly the different routes of transmission 
account for the lack of a delay in disease progression (Schinkel et al., 1999). Clearly more work 
needs to be done in order to investigate the effect of the CCR2b-641 mutation. 
Mutations associated with a change 'in disease progression may also be in the natural ligand 
that binds the receptor. Stromal cell-derived factor 1 (SDF-1) , the major ligand for CXCR4 may have 
a polymorphism in the 3' untranslated region- of the gene. Individuals homozygous for the SDF-1-3'A 
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mutation were found to have delayed disease progression , possibly by up-regulation of the 
production of the protein. The protective effect is more pronounced in late stage AIDS, possibly due 
to most of the viruses being SI/X4 viruses (Balter et al., 1998 and Winkler et al., 1998). High 
frequency of the 3'A mutation of the SDF-1 gene was detected in Cambodia (Rousset et al., 1999). 
1.4.3) Mechanisms of infection and spread of the virus 
It is thought that the first cells to be infected are cells of the dendritic macrophage lineage, 
such as Langerhans' cells and lymphocytes. Immature dendritic cells (DCs) have been shown to 
allow only RS HIV to replicate, although mature DCs can support both M or T tropic HIV replication 
when co-cultured with CD4+ T cells (Zaitseva et al., 1997 and Granelli-Piperno et al., 1998). It has 
been determined by the use of CCRS!i32 engineered DCs that although no viral replication occurs in 
these DCs, they are able to pass the virus on to CCRS wild-type CD4+ T-cells. The resistance of 
people with homozygous CCRS!i32 mutations is thus not DC-mediated. HIV in infected DCs can 
survive without proliferating for the time it tak~s for the DCs to migrate from the mucosa to the 
draining lymph nodes, allowing infection of CD4+ T-cells in the lymph node (Dybul, et al., 1998). 
Latently infected folicular dendritic cells in the germinal centres of the lymph organs 
(Panteleo and Fauci, 1996) are long term reservoirs for the virus, allowing viral replication when the 
cell is activated by infection. These latent reservoirs have been shown to be small, 10
4 to 106 
infected cells per host although there is a low turnover of 60 to 6000 cells per day, allowing low 
levels of HIV replication in the reservoirs (Ho, 1998). 
1.4.4) HIV-1 disease progression 
From the lymphoid cells the virus disseminates in the blood, or lymph as free virus, or in cell-
associated form (Miller et al., 1989; Spira et al., 1996; Dittmar et al., 1997 and Pope et al., 1997). 
During primary infection, there is a high level of viraemia (±10
7 copies of RNNml) and the cell-
associated virus allows spread of the infection and the initiation of the immune response (Panteleo 
and Fauci, 1996). Both bone derived, and lymphoid dendritic cells can carry virus, thereby infecting 
the CD4 lymphocytes. 
HIV initiates a humoral and cellular immune response to the virus, which leads to the initial 
decrease in the levels of viral load. The clinical course of infection can be divided into three phases; 
primary infection, clinical latency and AIDS (see figure 1.4). The majority of HIV-infected people are 
typical progressors, that is, they progress to AIDS within eight to ten years without therapy. Three 
other types of progression have also been identified: 
i)rapid progressors, who progress to AIDS within two to three years 
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ii)long term nonprogressors (L TNPs), who may not reach progression to AIDS even after ten 
years 
iii)long term survivors, who progress to disease in a similar time frame to typical progressors, 
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Figure 1.4: An illustration of the four types of disease progression in individuals infected with HIV, illustrated by the levels of 
CD4+ T-cells (lines with symbols) and viraemia (straight lines). In all cases there is a rise in viraemia at six to nine weeks, 
with a concomitant drop CD4+ T-cells. The CD4+ T-cell count then rises and the level of HIV viraemia decreases up until 
approximately twelve weeks for all groups, except the L TNPs who maintain CD4+ levels at approximately 900-1000 cells/mm
3 
and low viraemia . The level of viraemia in rapid progressors steadily increa~es and CD4+ T-cells decrease until death after 
approximately five years, whereas in typical progressors the level of viraemia only increases after seven to eight years. Long 
term survivors have a similar increase in viraemia after seven to eight years, but their CD4+ T-cell count does not decease. 
Although the level of viraemia increases after seven to eight years in long term survivors, their CD4+ T-cell count does not 
drop below approximately 300 ceils/mm
3 for an extended period of time (Pantaleo and Fauci, 1996). 
1.4.5) The replication cycle, virion assembly and budding 
The gp120 envelope protein of HIV initially binds to the CD4+ receptor on the host cell, 
which induces a conformational change in the gp120 protein, allowing it to bind the relevant co-
receptor molecule. There is a further conformational change in the gp120, exposing the three coiled 
coil N-terminal fusion peptides (ectodomain) of the gp41 transmembrane protein (see section 1.3.4). 
The actual mechanism whereby the gp41 fusion peptides insert themselves into the host cell 
membrane, initiating fusion is not known. After the HIV virion and host cell membranes fuse, 
however, the viral core enters the host cell (see figure 1.5) (Chan et al., 1997; Tan et al., 1997; 
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Figure 1.5: The replication cycle, assembly and budding of the HIV virion is illustrated (Barre-Sinoussi, 
1996). After entry viral particles uncoat, releasing the nucleoprotein complex. Reverse transcriptase 
initiates DNA synthesis from the tRNA'Y• primer, bound to the viral RNA. Proviral DNA is integrated into 
the host genome near the LI and Alu retroposon elements. Viral RNA is synthesised in the nucleus with 
viral cis-acting elements, transactivators and several host cellular proteins. Full length HIV transcripts 
produce progeny viral RNA, mRNA for Gag and Gag-Pol polyproteins in the cytoplasm and precursors 
for more than 30 spliced mRNA's producing the Env proteins and accessory proteins. Multiply spl iced 
mRNA's are produced early, encoding Tat, Rev and Nef (non-viral proteins) and later the unspliced and 
single spliced mRNA's encoding virion structural proteins are produced (Fields, 1996). 
The Gag polyprotein (Pr559a9) and Gag-Pol polyproteins (Pr1609ag-pol) interact with the cell 
plasma membrane via the C-terminal of the MA protein where self-assembly of the spherical 
ribonucleoprotein (RNP) core occurs (Yu et al., 1992 and Dorfman et al., 1994). Once the RNP is 
completely sealed, incorporating the diploid RNA genome bound to the NC protein, the immature 
virion buds out of the cell, tightly surrounded by a lipid bilayer. The Vpu and p6 (C-terminal region of 
the Pr559a9) facilitate budding of the immature virion (Gottlinger et al., 1989) which is densely 
studded with gp120 oligomers that are spontaneously shed as the virion matures (Gelderblom, 
1997). Host cell proteins are also present in the virion ; p-microglobulin, HLA-a., HLA-P (which 
exceeds the numbers of gp120 and gp41, thereby masking the virus from the immune system), 
CD55 (decay-accelerating factor) and cyclophilin-A (which may play a role in virion uncoating). The 
cyclophilin A has been found to be necessary for in vitro growth of the Group M HIV-1 and SIVcpz, 
but not Group O HIV-1 viruses (Braaten et al., 1996). 
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1.5) Epidemiology 
1.5.1) The Global HIV Epidemic 
The HIV epidemic is persistently spreading, with 33.4 million people estimated to be living with 
HIV/AIDS as of the end of 1998 (see figure 1.6) and more than 16 000 new infections per day. In 
1997 alone, 5.8 million new infections occurred, of which 4 million were in sub-Saharan Africa. More 
than 95% of infections occur in developing countries and sub-Saharan Africa has the highest 
prevalence of infected people (7.4%) with 22.5 million individuals infected, of which approximately 
50% are women. This reflects the main mode of transmission, which is by heterosexual contact, and 
in turn leads to the staggering numbers of new infections by vertical transmission. In 1997, out of 
590 000 new infections in children under the age of fifteen, 530 000 occurred in sub-Saharan Africa 
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Figure 1.6: The total number of adults and children living with HIV as of December 1998. Sub-Saharan Africa has the 
greatest number of infections with 22.5 million people living with HIV (UNAIDS, 1998). 
1.5.2) Sub-Saharan Africa 
The African HIV epidemic started in the early 1980's as a broad belt stretching across the 
equatorial regions of the continent. By 1987, however, the epidemic in Africa had spread 
southwards. At present, the highest HIV prevalence on the continent occurs in southern Africa. 
Rates of HIV infection in West African countries have plateaued at levels lower than in East and 
southern Africa, except in certain countries, such as Cote d'Ivoire and Nigeria. Unfortunately, these 
countries have some of the highest populations in Africa, and even with only 4.1 % prevalence in 
Nigeria, it amounts to 2.2 million people infected (MAP, 1997 and UNAIDS and WHO, 1998). 
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The most devastating epidemics to date occur in southern Africa , however. In South Africa, 
out of a total of 3.6 million infected people, 900 000 were infected in 1998 alone. Indeed, over 50% 
of the new infections occurring in southern Africa are in South Africa (UNAIDS, 1998). The epidemic 
in South Africa has increased logarithmically' from a prevalence of just under 1 % of women attending 
antenatal clinics infected in 1990, to 22.8% a·t the end of 1998, a 33.8% national increase since 1997 
(Department of Health, 1999). The South African epidemic will be discussed in more detail in 
Chapter 2.1 and Chapter 3.1. There are other countries in southern Africa which have even higher 
seroprevalence in women attending antenatal clinics. !n Francistown, in Botswana, 45% of women 
were HIV-positive at the end of 1997 and i'n Beit ·Bridge, a large agricultural centre in Zimbabwe, HIV 
prevalence rose in pregnant women from 32% in 1995 to 59% in 1996 (MAP, 1997). 
Urban areas tend to have higher HIV infection rates than rural areas, although this is not true 
in all cases. For example, in Uganda, one of the first countries to be affected by the epidemic, HIV 
seroprevalence has decreased in both rural and urban areas due to an intensive prevention and 
education programme. It is important that the education and prevention programmes continue once 
the levels of infection have declined, however. In neighbouring Tanzania, which also had declining 
HIV infection rates in 1996, there is now ~n explosive epidemic (Renjifo et al,. 1998). Most east 
African countries are not showing decreases in rates of infection. This is, at least in part, due to the 
trans-African highway that runs up the east coast of the continent which fuels the epidemic. In 
I 
countries such as Kenya, seroprevalence in pregnant women is up to 25% in urban regions such as 
the capital , Nairobi (MAP, 1997 and UNAIDS and WHO, 1998). 
1.5.2.1) Determinants of the spread of HIV in Africa 
There are a number of possible explanations why sub-Saharan Africa has over 60% of the 
worlds HIV/AIDS cases and why certain reg ions in Africa have more explosive epidemics than other 
regions. In Africa , over 95% of HIV infections are due to heterosexual or vertical transmission. 
Blood transfusion , however, is also a concern . It was determined that in sub-Saharan Africa in 1995 
nearly a quarter of the 2.5 million blood transfusions had not been screened for HIV antibodies 
(MAP, 1997). Cultural, behavioural, biological, socio-economical and political factors also play a role 
in the spread of HIV. In addition , the stigma of being infected with HIV and the resulting shame and 
denial of the infected person has also contributed to the continued spread of the disease (UNAIDS, 
1998). 
Cultural aspects include religion , the use of contraception and condoms, male circumcision 
as well as certain sexual practices. Sexual behaviour plays a major role in the spread of HIV and the 
use of condoms or a decrease in the number of sexual partners in certain countries, such as 
Senegal , has lead to a lower rate of infection . Certain vaginal products or the use of drying agents 
as well as anal intercourse or intercourse during menses may lead to a higher risk of infection from 
an infected partner. In addition , biological factors including the disease stage of the partner, which 
impacts on the viral load, the type of HIV (HIV-1 or HIV-2) and the presence of other sexually 
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transmitted diseases (STDs) all influence the chance of HIV infection during intercourse (MAP, 
1998). Genital ulceration has been shown to lead to an increased risk of transmission and therefore 
treatment of STDs could to some extent prevent the transmission of HIV by the sexual route 
(Grosskurth et al., 1995; Laga et al., 1995 and Wawer et al., 1998). 
Socio-economic factors also contribute to the spread of HIV and in West Africa, for example 
in the Great Lakes region and especially southern Africa where there are mass population 
movements, mostely due to migrant male workers. These men move away from their homes in 
search of work and may spend weeks or even months living and working away from home. Many of 
these dislocated men turn to commercial sex workers (CSWs) while away from home and upon their 
return spread HIV to their wives and partners (Quinn, 1996). In Abidjan, the capital of Cote d' lvoire, 
about 80% of the CSWs were HIV-positive in 1995 (Decasas, 1995 and Quinn, 1996). It has been 
shown that populations, where sex with CSWs is common, have rapid spread of HIV. In addition, it 
has been found that many concurrent partnerships leads to the more efficient spread of HIV than 
serial monogamy (MAP, 1997). Movement of people by urbanisation is also increasing significantly 
and by the year 2000 it is expected that as much as a third of the population may be residing in 
urban centres for many African countries (Quinn, 1996). Migration to and from South Africa will be 
discussed in more detail in Chapter 3.1 . 
Political upheaval and war are other reasons for mass movement of people allowing the 
spread of HIV (Quinn, 1996 and UNAIDS and WHO, 1998). In Rwanda, for example, the HIV 
prevalence in people who had lived in refugee camps during the conflict was 8.5%, in comparison to 
1.3% in the same population when they were living in their rural settlements (UNAIDS, 1998). 
1.5.2.2) Prevention of infection in Africa 
Education programs have played a role in the decline of HIV in certain countries in Africa 
such as Uganda and Senegal. These include: the encouragement of condom use and a decrease 
the number of sexual partners, as well as education about risky sexual behaviour and educ~tion of 
pregnant women about the risks of breast-feeding (Robinson et al., 1995; Ngugi et al., 1996 and 
Jackson et al., 1997). It has been determined that the treatment of sexually transmitted diseases (for 
example in Mwanza, Tanzania) also has a positive impact limiting the spread of HIV (Laga et al., 
1995 and Wawer et al., 1998). In addition, a short-term zidovudine, reverse transcriptase inhibitor, 
(ZDV) regimen was shown to decrease perinatal transmission by 51 % in a Thailand study (Marseille 
et al., 1998). This is more applicable for developing countries than the expensive long term regimen 




The Asian epidemic only started in the early 1990s in Thailand 's intravenous drug using 
(IVDU) and CSW populations, but by 1997 had expanded throughout south-east Asia . South-east 
Asia and India, which has its own predominantly heterosexual epidemic, are the worst affected 
regions in Asia. China , which is at the start of its epidemic, has over 400 000 HIV/AIDS cases and 
two separate epidemics; one infecting IVDUs in the south-west China and the other heterosexuals 
along the eastern coast-line, where prostitution is common. India, with four million infected people, 
has the highest number of HIV infections in any country in the world. Infections are mostly spread 
through heterosexual transmission and IVDU. In 1996, in IVDUs in Manupur, HIV rates reached 
73% in some drug clinics (UNAIDS and WHO, 1998). 
Thailand has embarked on a campaign of awareness in IVDUs and heterosexual 
populations to decrease the number of HIV infections, although levels are increasing in other 
countries. Cambodia, despite an increase in condom use, Viet Nam and Myanmar all show rapid 
increases in infection rate , especially in CSW and IVDU's. Just over one-fifth of the worlds 
population infected with HIV live in Asia and the pacific and this is expected to reach one quarter by 
the year 2000 (UNAIDS and WHO, 1998). 
1.5.4) South America and the Caribbean 
Men who have sex with men (MSM) and IVDUs are the major populations infected with HIV 
in South America , but increasing rates of transmission in women show an increase in the number of 
heterosexual infections. In Brazil one quarter of AIDS cases are female. Heterosexual transmission, 
reflected by the prevalence rates in pregnant women in Haiti and Dominican republic, are much 
higher, at 8%. Surveillance is limited and data fragmented, but HIV prevalence in all countries in 
South America and the Caribbean is increasing (UNAIDS and WHO, 1998). 
1.5.5) Eastern Europe 
Although the epidemic in eastern Europe was one of the latest epidemics, levels of HIV 
prevalence are rising rapidly. Extremely low infection levels (30 000 infections) were detected in 
mass blood screening of approximately 450 million people up until the start of 1995, however newly 
diagnosed infections increased from 196 in 1995 to 4 399 in at the end of 1997. The Soviet Union 
countries of Belarus, Moldova, the Russian Federation and Ukraine have all shown explosive 
epidemics due to IVDUs. The epidemic moves into the general population after heterosexual contact 
with IVDUs and a strong overlap has been demonstrated between infected IVDUs and infected 
CSWs. Other sexually transmitted diseases (STDs) are increasing dramatically as well and indicate 
the ease with which an HIV epidemic could spread through eastern Europe (UNAIDS and WHO, 
1998). 
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1.5.6) The developed world 
Due to the HIV epidemic being measured as AIDS cases in the industrialised world, rather 
than HIV infections, with the advent of effective treatment of HIV, the numbers of AIDS cases has 
declined. There are still infections occurring, however, especially in disadvantaged populations, 
such as African Americans and in Hispanics as well as in IVDUs (UNAIDS and WHO, 1998). 
1.6) Genetic diversity and geographical distribution of HIV-1 subtypes 
Initially, HIV was classified into only two groups, "US" and "African". Currently, however, 
with the abundance of sequencing data and the ongoing global effort to characterise HIV-1, the virus 
has been reclassified into a number of groups and subtypes. HIV-1 has been divided into three 
groups; Group M (major group), Group O (outlier group) (Carr et al., 1998) and the newly identified 
Group N (Simon et al., 1998). Group M is responsible for the majority of infections to date and has 
been classified into 10 env subtypes (A-J) , with subtypes A to E being the most common (UNA IDS 
and WHO, 1998). The percentage DNA difference in the M group of this highly mutable pathogen 
ranges from approximately 15 to 30% between subtypes in the env region (Bobkov et al., 1994b), 
growing by 1% per year (UNAIDS, 1998) and between 7 and 14% in the gag region (Louwagie et al., 
1993). 
Group 0, or subtype O consists of highly divergent HIV-1 viruses that are up to 50% 
divergent from both the Group M viruses as well as from each other, hence Group 0, or outlier 
group. These viruses are too divergent to be divided into discrete subtypes as yet. (Korber et al., 
1996). In addition , isolate YBF-30 was recently identified , which led to the classification of the new 
HIV-1 virus group, Group N (Simon et al., 1998) (see section 1.2) . 
1.6.1) The variability of HIV-1 
The great genetic variability of HIV-1 is as a result of two major factors, the error-prone 
mechanism of the reverse transcriptase enzyme and recombination between viruses co-infecting a 
host cell. The reverse transcriptase enzyme introduces, on average, one error per genome per 
replication cycle, which results in approximately 1% of genetic drift each year (Balfe et al., 1990). 
Recombination, on the other hand, which occurs at a rate of about 2% per kilobase per replication 
cycle has been frequently identified amongst' tile M group of HIV-1 and selects for the most 
beneficial combinations of genes (Cornelissen et al., 1996 and Subbarao et al., 1998). 
Recombination occurs in host cells super-infected with more than one HIV virion , during replication 
of the viral genome. There are random cross-over events which occur between homologous regions 
of the two viral genomes, resulting in mosaic progeny HIV virions, with regions of the genome 
incorporated from each of the viruses infecting the host cell. Another factor resulting in the fast 
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evolution of HIV is the rapid production of virions in the host (10
9 per day) and the large number of 
replication cycles, (320 per year) (Ho, 1996). 
1.6.2) Recombinant viruses and the HIV epidemic 
Full-length genome sequences have revealed that members of certain subtype$ are 
exclusively recombinant viruses. For example, subtype E is a subtype A in the gag/pol and part of 
gp41 and subtype E in the rest of the genome. The parental subtype E virus has not been found. 
Subtype lbNG is a gag subtype A and subtype G in portions of the pol and in the L TR (Carr et al., 
1998). It was suggested that since recombinant viruses were becoming more common, the criteria 
used for classification of these recombinant subtypes be changed. Recombinant viruses such as E 
and lbNG are now classified as circulating recombinant forms (CRF) AE and AG lbNG, respectively, 
(Carr et al., 1998). It is now important to look at different regions of the genome or preferably to 
sequence the entire genome in order to designate a subtype. CRF AE and AG lbNG are established 
subtypes with widespread prevalence. CRF AE is predominant in central Africa and Asia, whereas 
CRF AG lbNG, first described in Nigeria, is prevalent throughout West and West Central Africa 
(Mastro et al., 1996; Yu et al., 1997; Carr et al., 1998; Kusagawa et al., 1998; Loue et al., 1998; 
Loussert-Ajaka et al., 1998; Paladin et al., 1998; Subbarao et al., 1998; Carr et al., 1999 and 
Mccutchan et al., 1999). The subtype A in the gag region from these two viruses is distinct from 
each other and from the non-recombinant subtype A virus, which occurs predominantly in East 
Africa. 
There are a number of new epidemic outbreaks that have occurred globally due to 
recombinant viruses, for example in China, Russia and Africa, that will be discussed later (Liitsola et 
al., 1998; Peeters et al., 1998; Renjifo et al., 1998; Shao et al., 1998 and Yu et al., 1998). Triple 
recombinants have also been identified, for example subtype I, which is an A/G/1 recombinant (Gao 
et al., 1998). Although co-infections with Group M and Group O viruses have been reported (Zekeng 
et al., 1998), no recombinant viruses have yet been identified, possibly due to the great diversity 
between these subtypes. 
1.6.3) HIV subtypes and population migration 
Although most HIV-1 strains fall into a discrete phylogenetic lineage, increasing divergence 
is becoming evident within these subtypes (Kuiken et al., 1993; Myers et al., 1995 and Rencher et 
al., 1997). In addition, recombinant viruses are being detected more frequently (Liitsola et al., 1998; 
Peeters et al., 1998; Renjifo et al., 1998 and Shao et al., 1998). 
Subtype surveillance can be used to track the HIV-1 epidemic and together with a 
knowledge of political, economical, social and cultural dynamics of spread, may allow transmission 
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patterns to be understood, future epidemic trends to be predicted and may provide information on 
the history of the HIV epidemic. This data is important for effective development of vaccines. It is 
possible that there may be a relationship between disease progression and subtype and this may 
also be investigated . In addition , the evolution of highly divergent strains must be monitored in order 
to facilitate their detection, as illustrated by the inability of many of the commercial kits for HIV to 
detect subtype O viruses when they were first identified (Schable et al., 1994). 
In many cases it is the movement of people that promotes the spread of HIV. For example 
in China, where the initial subtype C infections were shown to be due to needle sharing with IVDUs 
from India (Luo et al., 1995). It has been further determined that there are two subtypes associated 
with IVDU in China. In a recent study on IVDUs in Guangxi Province which borders Yunnan in the 
West and Vietnam in the South, subtype C was associated with IVDU in Baise city, in western China, 
whereas subtype AE has been associated ,with IVDU in Pingxiang city in southern China (Yu et al., 
1998). In addition , the recent recombinant ~ubtype B/C epidemic in China follows the drug trafficking 
route from south to west (Shao, et al., 1998). In Africa one of the major factors influencing the 
spread of the HIV epidemic is migration for socio-economic reasons (see section 1.5.2.1). Also, the 
deployment of army personnel to various countries has also resulted in the spread of subtypes to 
different countries, for example in the United States, subtypes A, D, and AE were detected in five US 
service men who were infected whilst in Uganda, Kenya or Thailand respectively (Brodine et al., 
1995). Non-B subtypes have also been spread to French military personnel (Lasky et al., 1997). In 
addition , subtype AE was detected in five out of six Uruguayan soldiers infected whilst in Cambodia 
(Artenstein et al., 1995). 
One of the largest population migrations at any one time involved the emigration of 
approximately 17 000 Jewish Ethiopians to Israel in 1991 , due to political unrest. Whereas initially 
the predominant subtype circulating in Israel and Palestine was subtype B, associated with 
homosexual transmission , a later study indicated that subtype C had entered the country and was 
associated with heterosexual transmission in Ethiopian refugees (Gehring et al. , 1997). Th~ same 
subtypes have been associated with independent introduction of HIV-1 into the homosexual (subtype 
B) and heterosexual populations (subtype C) in South Africa (Williamson et al., 1995; van Harmelen 
et al., 1997; van Harmelen et al., 1999a) (see Chapter 2) . 
Subtype AE is primarily responsible for the burgeoning heterosexual epidemic in Thailand. 
Full-length subtype AE sequences from Thailand and the Central African Republic showed similar 
mosaic patterns, indicating that the recombination event occurred prior to its introduction into 
Thailand (Gao et al., 1996b). Subtype AE is now spreading across South East Asia and has been 
detected in Myanmar, Vietnam , Japan and Malaysia (Menu et al., 1996 and Kondo et al., 1998). It 
has also been detected in certain groups in France, Sweden , England, Russia , and USA (Arnold et 
al, 1995; Brodine et al., 1995; Lukashov et a/., 1996; Simon et al, 1996; Bobkov et al., 1997; Brown 
et al., 1997 and Sonnerburg et al. , 1997). 
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1. 6. 4) Shifts in subtype distribution 
1.6.4.1) South and south-east Asia 
The importance of continual monitoring of genetic diversity is highlighted by the shift in HIV-1 
subtype distribution that occurred in Thailand . Subtype AE accounts for 95% of infections in the 
heterosexual population, followed by Thailand B' and then subtype B (Subbarao et al. , 1998 and 
Mastro et al., 1996). A significant shift in subtype distribution in intravenous drug users (IVDU) has 
been shown. From 1992 to 1995, the proportion of subtype AE in IVDUs increased from 25% to 
68% in the central region , and from 16% to 52% in the south (Mastro et al., 1996). A shift in subtype 
distribution has also been observed in IVDU in South West China (Shao et al. , 1996): from 1990 to 
1993, the proportion of prototype subtype B decreased from 90% to 40% and Thailand B' subtype 
increased from 10% to 59%. In 1995, 8 out 26 IVDU users were infected with subtype C, probably 
as a result of drug trafficking from India, where this subtype is predominant (Luo et al., 1995). 
Subtypes A, D and AE have also been identified, with subtype AE spread mostly by IVDU and 
heterosexual transmission . Subtypes A, B and AE have also been detected in India (Weniger et al, 
1994 and Tripathy et al., 1996). 
A new epidemic which has started in China , following the drug trafficking route from the 
South , through central China to the far western region is caused by a recombinant subtype B/C virus. 
Two recombinant subtypes have been identified with a breakpoint in the tat gene. The subtype B/C 
recombinant has been shown to increase in prevalence; with subtype C occurring in the South, to 
rare subtype B/C recombinants identified in central China, to common subtype 8/C recombinants 
identified in West China and finally to th~ subtype B/C recombinant being exclusively found in the far 
West region (Shao et al., 1998). 
1.6.4.2) Europe and America 
The presence of non-B subtypes in previously subtype B-restricted areas of Europe and 
North America indicate that eventually multiple subtypes will occur in most countries see fig we 1. 7. 
Recent studies in Sweden, have recorded the presence of A, B, C, D, G, H, J, and an ND 
recombinant (Letiner et al., 1995; Alaeus et al., 1996 and Sonnerberg et al., 1997). Although most of 
these infections were associated with African immigrants to Sweden, there is evidence of limited 
transmission of non-B subtypes within Sweden (Alaeus et al., 1997). In Norway, subtype C was 
identified in the heterosexual population in 1996 (Engelstad et al., 1996) and two epidemiologically-
linked cases of subtype O infection were also identified, dating back as early as 1979 (Jonassen et 
al. , 1997). In non-Dutch populations living in the Netherlands, subtypes A, B, C, D, AE, F and G 
have been identified (Lukashov et al., 1996) and subtypes A, B, C, D and AE were found in England 
(Arnold et al., 1995 and Brown et al., 1997). In a German study, 15% of new infections (three AEs 
and one C) were non-B subtypes (Dietriech et al., 1997). In addition , in France different HIV-1 
subtypes are emerging . Subtypes A to H were identified in French blood donors and in patients 
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attending a hospital in Northern Paris, including patients originating from the Central African Re
public 
(CAR), Caribbean, West Africa and South East Asia (Simon et al. , 1996 and Sarin et al., 1997). 
Figure 1.7: The global distribution of HIV-1 subtypes, indicating the prevalent subtypes occurr
ing in the western hemisphere 
in comparison to Africa and Asia. Subtype B is predominant in Europe and the United States,
 whereas this subtype is fairly 
rare in Africa . Africa has the greatest diversity of HIV subtypes, reflecting the age of the e
pidemic on this continent. In 
addition, the global prevalence of subtypes is indicated by· the circle in the left bottom cor
ner, with subtype C the most 
prevalent subtype in the world (UNAIDS, 1998). 
In Athens, Greece, a study of eighty patients from different risk groups identified 89% were 
subtype B isolates, although five subtype A, two subtype C and four subtype D viruses wer
e also 
detected (Nasioulas et al. , 1998). In addition, a subtype I virus was identified which is the 
first 
subtype I to be found outside of Cyprus where the first two subtype I viruses were ide
ntified 
(Kostrikis et al., 1995). It has recently been discovered from the full-length sequence of prov
irus 
from a Cyprus subtype I, that subtype I is a recombinant subtype A/G/1 virus. The triple recom
binant 
has more than eleven cross-over points. Segments of the subtype I clone grouped closel
y with 
2321 B (A/GI?) and MAL (A/0/?), indicating a possible African origin for subtype I (Gao et al., 199
8). 
A high degree of genetic diversity has also been observed in the former Soviet Union where 
subtypes A, B, C, D, AE, F, G and H have been identified (Bobkov et al., 1994a; Bobkov e
t al. , 
1994b; Lukashov et al., 1995; Bobkov et al., 1996a; Bobkov et al., 1996b; Bobkov et al., 1
997; 
Bobkov et al. , 1998; Liitsola et al. , 1998 and Novitsky et al. , 1998). In Russia, all of the ab
ove 
subtypes have been identified in heterosexuals, while male homosexuals were predomi
nantly 
infected with subtype B (Bobkov et al., 1996b). In Russia, Belarus and the Ukraine an explo
sive 
epidemic in the IVDU population has occurred since the early 1990s. Phylogenetic analysis sh
owed 
that a closely related subtype A epidemic had been introduced into the IVDU population (Bob
kov et 
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al. , 1998 and Novitsky et al., 1998). A new epidemic is taking hold in the IVDU's in Kalingrad in the 
Russian Federation. Out of 33 isolates from the Ukraine, Lithuania and Kalingrad 82% (all from 
Kalingrad) were subtype A/B recombinant viruses, with the gag A region derived from a subtype A 
prevalent in IVDUs in the Ukraine. Three subtype A and three subtype B viruses were also identified 
(Liitsola et al., 1998). In addition, a closely related nosocomial epidemic occurred in Russia in the 
early 1990's by subtype G (Bobkov et al., 1994a). The subtype F viruses in Romania were shown to 
be closely related , probably as a result of a founder effect, followed by spread amongst hospitalised 
children in this region . The Romanian subtype F viruses are not thought to be linked to the subtype 
F isolates from Brazil (Bandea et al., 1995). 
Non-B subtypes have been recorded in America in recent study using V3 serotyping . Out of 
a total of 40 samples from individuals attending a hospital in the Bronx, New York 15 % were from 
non-B serotypes, including 3 serotype A's 1 serotype Band 2 serotype C's (Irwin et al., 1997). In 
Brazil , subtype B is the predominant subtype associated with different modes of transmission 
(Sabino et al., 1996; Morgado et al., 1998 and Tanuri et al., 1999), although subtypes F, and to a 
lesser extent, C have also been identified (Brigido et al., 1998). In Rio de Janeiro dual infections 
(6 .5%) and recombinants (4.7%) make up an integral part of the HIV-1 epidemic. Dual infections of 
subtypes Band F, F and D, B and D and Band C were present, but only subtype B/F recombinants 
were identified (Pieniazek et al., 1998). Subtype B is also predominant subtype in the Honduras 
(Lara et al. , 1997;) Argentina (Campondonico :et al., 1998), Chile (Desgranges et al., 1998) and 
Venezuela (Quinones-Mateu et al., 1995), but subtype F, C and A have also been detected in 
Argentina (Campodonico, et al , 1998) and subtype·A in Santiago, Chile (Desgranges et al., 1998). 
1. 6. 5) Geographical distribution of subtypes in Africa 
Monitoring the shift and drift of HIV within Africa is more complicated than in regions with 
limited genetic diversity, since HIV has been circulating within Africa the longest of all the continents. 
All subtypes have been detected, or connected, to Africa with the greatest genetic diversity oc~urring 
in central Africa (see figure 1.7). A study in west and central Africa showed that up to seven 
subtypes are present in some countries, although subtypes AE, F, G and H were only identified in 
central Africa (Peeters et al., 1998). Unfortunately, the lack of representative sampling from most 
regions in Africa makes it difficult to determine the exact subtype diversity in many countries. In 
addition, seroconversion dates are often not known, thus subtyping data may not reflect the current 
subtypes circulating and the place of sampling often may not reflect the origin of the infection. 
Although subtype A is still the predominant subtype in west Africa and may be increasing in 
countries such as Kenya (Poss et al., 1997), its prevalence is decreasing in central Africa . Subtypes 
A and D are common in east Africa, and screening of a large number of samples in Uganda by 
oligonucleotide probing demonstrated a ratio of approximately 2:1 of subtypes A:D, respectively (Luo 
et al., 1998 and Rayfield et al., 1998). 
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Recombination is now playing a major role in many infections in Africa . A study by Peeters 
et al (1998) in central and west Africa identified 20% of the isolates were envlgag recombinants . In 
addition, dual infections in Cameroon have been identified in a number of samples, including subtype 
AE and subtype O dual infections. Triple infections of subtype A, subtype D and subtype O were 
also identified (Peeters et al, 1998 and Zekeng et al. , 1998), although recombinant subtype 0/Group 
M viruses have not been identified to date, possibly due to the genetic diversity between the two 
groups. In Tanzania, where subtypes A and D were prevalent from the late 1980's to early 1990's, 
subtype C is now present in 32% of samples analysed. In addition, 11 % of the isolates were 
gag!env recombinant viruses; two C/A, seven CID and two AID recombinants (Renjifo, et al., 1998). 
Subtype C is the predominant virus in Africa, occurring in more than 50% of samples 
(UNAIDS 1998) in southern Africa including Malawi, Zimbabwe, Mozambique and South Africa' 
(Engelbrecht et al., 1995; Williamson et al., 1995; van Harmelen et al., 1997; Bredell et al., 1998; van 
Harmelen et al. , 1999a and van Harmelen et al., 1999b) (see Chapters 2 and 3). This subtype is 
spreading rapidly, however and is present in 99% of 94 isolates sequenced from Ethiopia (Abebe et 
al., 1997). Subtype C was also found in more than 90% of samples from infected Ethiopian 
immigrants living in Israel (Gehring et al., 1997). In addition, it has also spread globally and is the 
most common HIV-1 subtype, making up 48% of the HIV infections world wide (UNAIDS, 1998). 
1. 6. 6) Subtype O distribution 
The highly divergent subtype O viruses appear to have originated in central Africa and 
studies have shown seroprevalences of 10.2% in Cameroon, 6% in Niger , 4.6% in Gabon and 0.5% 
in Nigeria (Peeters et al., 1994 ). The seroprevalence is given as a percentage of the total HIV 
infections in these countries. Subtype O has also been detected in Equatorial Guinea (Hunt et al., 
1997), in eight Cameroonians living in France and one French national (Charneau et al, 1994 and 
Loussert-Ajaka et al., 1994), as well as in Spain (Mas et al., 1996), USA (Rayfield et al., 1996), 
Germany (Dietrich et al., 1997), Norway (Jonassen et al., 1997) and Belgium (de Leys et al., 1990). 
1. 6. 7) Relationship between age of the epidemic and genetic diversity of HIV-1 subtypes 
In Africa, the countries bordering the equatorial belt were the first affected by the HIV-1 
epidemic. The greatest genetic diversity occurs in the central regions of Africa where almost all 
subtypes were detected (Janssens et al., 1997). Presumably, this diversity is due to the limited 
spread of the virus in isolated areas or restricted sexual networks, as well as the age of the epidemic 
(Janssens et al., 1997). In contrast to this, countries with rapidly emerging, or "explosive," epidemics 
such as South Africa, Botswana, Malawi and Zimbabwe have low subtype diversity. Over 90% of 
heterosexually infected individuals in these COLJntries are infected with subtype C viruses (Orloff et 
al., 1993; Becker et al., 1995; Williamson et al., 1995; Gao et al., 1996; Janssens et al., 1997; Shafer 
et al., 1997; van Harmelen et al., 1997; Engelbrecht et al., 1998; Novitski et al., 1999; Tien et al., 
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1999; van Harmelen et al., 1999a and van Harmelen et al., 1999b) (see Chapters 2 and 3). 
A similar effect has been seen in Europe and America as well, where subtype B accounts for 
the majority of HIV-1 infections in the homosexual population, although non-subtype B viruses have 
been identified in !VDU and heterosexual populations (see section 1.6.4.2). In addition, in south-east 
Asia, subtypes C and AE account for the majority of infections in the heterosexual populations (Ou et 
al., 1993; Grez et al., 1994; Yu, et al., 1995; Mastro et al., 1996; Tripathy et al., 1996 and Subbarao 
et al., 1998). Finally, in eastern Europe subtype A accounts for the majority of !VDU infections 
(Novitsky et al., 1998), apart from Kalingrad, where the predominant subtype is an A/B recombinant 
virus (Liitsola et al., 1998). 
1.6.8) Monitoring the HIV epidemic 
The global pattern of HIV genetic diversity is dynamic, as people move within and between 
countries, although subtypes A to AE remain predominant world-wide. Subtype C makes up 48% of 
global infections, subtype A is second, at 25%, followed by subtype B, 16% and subtypes D and AE 
at 4% each. The other subtypes make up the remaining 3% (UNAIDS 1998). It is not yet known if 
the proliferation of certain subtypes, such as A in west Africa, AE in Thailand and C in India and 
southern Africa, is due to selective advantages with respect to viral transmissibility or due to chance 
introduction and expansion in permissive social networks. 
The multiple introduction of non-B subtypes into B restricted areas has been shown to occur 
and although there is not significant spread of these non-B subtypes within these countries yet, it is 
important to monitor their progress (see section 1.6.4.2). Regions such as south and south-east 
Asia as well as eastern Europe, have illustrated the possible extent of spread after introduction of 
single subtypes into populations with high risk behaviour, such as CSWs and IVDUs (1 .6.4.1 ). 
The biological and immunological characteristics of all subtypes must be studied because 
ultimately, vaccines will be needed that are effective again all HIV subtypes. 
1.7) HIV vaccine development 
1. 7. 1) Introduction 
HIV vaccine development is beset with problems. HIV exhibits a high mutation rate, leading 
to a large degree of genetic variation. Serum antibodies from participants in the initial vaccine trials 
failed to neutralise "field" isolates, partly due to phenotypic differences between laboratory adapted, 
T-cell (SI, CXCR4) and primary (NSI, CCR5) isolates (Burton et al., 1997). It is possible that initial 
vaccines may not induce sterilising immunity. Vaccines that decrease the viral load and thus reduce 
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transmission may be acceptable, especially in developing countries that have the highest rates of 
transmission (Haynes, 1996). 
1.7.1.1) Correlates of immunity 
Both a neutralising antibody response and a cytotoxic T lymphocyte response are known fo 
be important components of the immune response to HIV. The neutralising antibody response binds 
free virus and prevents initial infection (Emini et al., 1990) and the CTL response prevents the spread 
of infection by eliminating cell-associated virus (Borrow et al., 1997 and Goulder et al., 1997). 
However, despite infected individuals mounting both a humoral and cellular response to HIV, the 
virus persists . 
Humoral response 
There are a number of mechanisms enabling HIV to foil the efforts of the antibody response 
to eliminate the virus before it is internalised within the cells of the immune system. Although 
maintained at high levels during infection, anti-Env antibodies are often only weakly neutralising 
against primary isolates (Letvin, 1998). The exposed gp120 trimer on the mature virion is only 
weakly immunogenic, due to the release of gp120 monomers and unprocessed gp160 during 
infection. Antibodies are preferentially directed against CD4, V3, V4, C1 or C5 regions on this "viral 
debris", but are unable to bind to these regions on the mature oligomer, as they are poorly 
accessible. The B-cells then inhibit the production of antibodies to the mature oligomers in a process 
which has been named the "original antigenic sin" (Burton et al., 1997 and Parren, 1997). 
The crystal structure of the gp 120 "core" from the laboratory strain HxBc2 bound to CD4 and 
17b monoclonal antibody has recently been elucidated (Kwong et al., 1998 and Wyatt et al., 1998). 
This structure mimics the HIV-CCR5/CXCR4 co-receptor binding. This new evidence from the 
crystal structure has provided valuable insight as to how the virus evades the immune response. 
The variable loops on the surface of the gp120, as well as heavy glycosylation (40-50%), 
bury and protect the conserved functional domains such as CD4 (shielded by the V1 and V2 loops) 
and the chemokine receptor binding site (shielded by the V2 and V3 loops) to which neutralising 
antibodies may be produced. The extensive glycosylation allows the regions covered to be seen as 
'self' by the immune system and thus the face of the outer domain has also been termed the "silent 
face" of gp120 (Kwong et al., 1998 and Wyatt et al., 1998). 
The conserved stem of the V1N2 stem-loop and the fourth conserved region make up what 
are known as the CD4i (inducible) epitopes yvhich are only exposed after CD4 binding. The gp120 is 
divided into two domains (inner and outer) and the inducible epitopes are part of the bridging sheet 
connecting the two domains of gp120. CD4 binding induces changes within the bridging sheet and 
between the two gp120 domains, allowing the bridging sheet to be exposed and revealing the co-
receptor binding site, thereby facilitating co-receptor binding (see figure 1.8). It is thought that the 
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charge or conformation of the V3 loop may be the factor influencing whether CCRS or CXCR4 co-












Figure 1.8: The X-ray crystal structure of the gp120 core which was derived from the HXBc2 strain of HIV-
1, subtype B, in a ternary complex with two-domain CD4 and a neutralising antibody, shown from the 
perspective of the CD4 molecule fvVyatt et al., 1998 and Kwong et al., 1998). 
Later in infection, more broadly reactive neutralising antibodies are produced, possibly due 
to the change in conformation of the T-cell adapted viruses, which have a more "open" conformation 
than the primary isolates, thus exposing neutralisation epitopes (Burton, 1997). Some of these 
antibodies, such as lgG1b12, are able to access the CD4 binding site, preventing gp120 and CD4 
binding (Moore and Trkola, 1997) whilst other antibodies, which are more rarely found, can bind to 
the CD4i epitopes, preventing binding to the co-receptor. A monoclonal antibody which is able to 
bind to the outer domain, or "silent face" of the gp120, preventing gp120-CCR5 binding, is 2G12 
(Muster et al. , 1993 and Moore and Trkola, 1997). This is unusual, since the antibody binds to the 
more conserved carbohydrate moieties on the silent face which are usually be seen as "self' (Wyatt 
and Sodroski , 1998). 
Higher neutralising antibody titres (arising after one to four years) have been found in long 
term non-progressors (LTNP's) than in rapid progressors (Carotenuto et al. , 1998), although this is 
not true in all cases (Harrer et al. , 1996b). LTNP's with high CD4 levels and efficient T-cell function 
are preferentially able to produce neutralising antibodies against heterologous isolates·. The ability to 
elicit neutralising antibodies may thus be related to the integrity of the immune system (Carotenuto et 
a/., 1998). The importance of neutralising antibodies has been illustrated by the fact that they have 
been found to protect against infection in babies born to HIV-infected mothers (Hengel et al., 1998). 
Chimpanzees have been protected from HIV infection by monoclonal antibodies to the V3 loop, or 
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gp41; SCIO mice were protected from HIV-1 infection by monoclonal antibodies to the CD4-binding 
domain and V3 loop and macaques infected with SIV had decreased morbidity and mortality when 
given immunoglobulin (Zolla-Parzner, 1997). It was recently demonstrated by Frankel et al (1998) 
that monoclonal antibodies 2G12, lgGb12 and 2F5 are able to prevent infection of mature ocrr-cell 
cultures after mucosal infection. CCR5, CXCR4 and dual tropic viruses were all blocked from 
infecting . 
Poignard et al (1998) , on the other hand, showed that hu-PBL-SCID mice infected with 
primary isolates of HIV-1 and then treated with lgG1b12 at concentrations higher than 90% in vitro 
neutralisation titres were not protected. Approximately 70% of the viruses rescued were escape 
mutants, thus antibodies to HIV-1 may play a limited role in the control of HIV-1 infection in vivo . A 
study where chimpanzees were protected against SHIV (a SIV/HIV chimera , replacing the SIV Env 
protein with HIV Env) infection by neutralising serum administered before challenge, but not after, 
indicates that neutralising antibodies may have a prophylactic role , but not a therapeutic one. This is 
due to the inability of neutralising antibodies to prevent cell-to-cell spread of the virus (Foresman et 
al., 1998). 
Cytotoxic T lymphocyte (CTL) response 
After primary infection, the suppression of HIV replication is associated with a strong CD8+ 
CTL response . A broad CTL response against multiple epitopes leads to stable, low viral load and a 
delay in disease progression (Borrow et al., 1997). The CTL response may be associated with 
protection from infection in exposed, uninfected individuals as well as in seronegative infants of 
seropositive mothers (Rowland-Jones et al., 1993; Rowland-Jones et al.,1995; Cao et al., 1997 and 
Letvin , 1998). 
HLA (human leukocyte antigen) haplotype also plays a role in the CTL response to HIV. 
Since HIV is processed in the cytoplasm, there is a vigorous HLA-restricted MHC class-I CTL 
response to the virus. Since the HLA allele frequency varies between different populations 
(Hammond , 1997 and Sette and Sidney 1998) not all HIV peptides will elicit a strong CTL response 
in all populations. It is thus important to determine HLA allele frequencies for different populations, in 
order to determine which HIV epitopes in a vaccine will give the most effective CTL response for that 
population (Brander and Walker, 1995). 
Certain regions of the HIV-1 genome have been identified as containing more broadly 
recognised CTL epitopes. For example, gp41 (position 589-598) contains epitopes presented by 
three different HLA-class I molecules, A24, 88 and 814 (Gnann et al., 1987 and Hammond et al., 
1991); reverse transcriptase (RT) (position 476-485) contains epitopes restricted by HLA-A2 and -
Bw62 (Johnson et al. , 1994) and the Nef protein contains two regions, the C-terminal end (position 
183-196) which contains HLA-A2, A52 and 835 (Hadida et al., 1995) as well as position 73-82 which 
contains epitopes restricted by HLA-A3, A 11 and 835 (Johnson et al., 1994; Brander and Walker, 
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1995). In addition, p24 contains multiple cross•reacting epitopes between different subtypes and 
different HLA haplotypes (Korber et al., 1997). 
In addition , a number of HLA-class I molecules which share similar peptide binding motifs 
have been identified and have been termed HLA-class I supertypes or superfamilies. There are four 
superfamilies which have been identified thus far; the A2-like family (del Guercio et al., 1995), 87-
like family (Sidney et al., 1995), the 844-like family and the A3-like superfamily (Sidney et al., 1996a 
and Sidney et al., 1996b). These superfamilies may make the construction of vaccines which have 
broad CTL activity easier, since vaccines could contain a limited number of epitopes and due to the 
degenerate epitope-binding of these HLA families, a large portion of the population would still elicit 
CTL responses to the vaccine (Threlkeld et al., 1997). Incorporating A2, A3 and 87 superfamily 
epitopes into a vaccine may allow a coverage of 83-89% of the population, regardless of ethnicity 
(Sette and Sidney, 1998). 
1. 7 .1.2) Cross reaction between subtypes 
HIV-1 is highly variable and the significance of genetic diversity on vaccine efficacy is not yet 
known . 
Humoral response 
Antibody cross-neutralisation between HIV ·subtypes does occur, but varies between 
isolates, and genotype does not correspond to neutralisation serotype (Moore and Trkola, 1997 and 
Nkengasong et al., 1998). Certain isolates are more easily neutralised, whereas others are difficult 
to neutralise. In addition , certain human sera may also have broader neutralising capacity than 
others (Zolla-Parzner, 1997). 
There are certain epitopes on the V3 loop of HIV-1 that share the same antigenic features 
between subtypes A, B and C. Five monoclonal antibodies (mAbs) to HIV-1 were selected using the 
V3 peptide of HIVSF and mapped to three epitopes in the hypervariable, N-terminus side of the V3 
loop. These mAbs had broad cross-reactivity, binding to four subtype A, nine subtype B and two 
subtype C laboratory adapted viruses, as well as four subtype B primary isolates. The antigenic 
relatedness was mapped to overlapping epitopes in the KSITKGP peptide region (Gorny et al., 
1997). A similar study showed that an epitope on the ~ region of the V3 loop was shared between 
subtype A, B and AE (Moore et al., 1995) and mAb, 19b, can bind to a discontinuous epitope in V3, 
cross-reacting to subtypes A, B, C, AE and F. It is thus possible that vaccines will be able to elicit 
cross-subtype humoral immunity if the correct epitopes are presented (Gorny et al., 1997). 
There are also, however, broadly resistant viruses. Four subtype B viruses (three of which 
were isolated from . paediatric patients) were recently identified which showed a high level of 
resistance to neutralisation by neutralising monoclonal antibodies, 2G12, 2F5 or lgG1b12. The same 
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isolates were also resistant to neutralisation by two sera found to be broadly neutralising against a 
diverse panel of primary isolates belonging to different subtypes. The resistance may be due to 
escc1pe from the maternal antibodies by the infecting viruses in the infants. The development of 
vaccines to elicit neutralising antibodies may thus not be effective, due to the possible evolution of 
such broadly resistant viruses (Parren et al., 1998). 
A novel approach to the induction of neutralising antibodies was recently reported , however. 
In this study, "fusion-competent" (FC) HIV immunogens were generated by capturing the envelope-
CD4-co-receptor structures which arise during HIV b!nding and fusion to the host cell. The FC 
immunogens were produced by the addition of 0.2% formaldehyde after five hours to a co-culture of 
COS-7 cells expressing the envelope of 168P (SI, CCRS and CXCR4 primary subtype B virus) and 
human U87 glioma cells (expressing CXCR4 and CCRS). The formaldehyde cross-linked the 
envelope-CD4-co-receptor structures that are produced before syncytium formation between the 
cells could occur, producing an inactivated whole cell, FC vaccine. The FC vaccine appears to target 
the exposed , highly conserved regions of the HIV envelope during the binding process and prevent 
binding of the virus to the host cell. The neutralising antibodies were able to prevent infection by 
twenty-three out of twenty-four primary virus isolates from subtypes A to AE, as well as the 
homologous 168P subtype B virus, indicating that FC immunogens may be developed in order to 
achieve a broadly neutralising vaccine to the majority of subtypes (Lacasse et al., 1999). 
Cytotoxic T lymphocyte response 
Cross-reactive cytotoxic T lymphocyte (CTL) responses have been demonstrated in a 
number of studies in both naturally infected individuals and in vaccinees. 
Gag, Env and reverse transcriptase (RT) specific CTLs were studied from individuals 
infected with subtype B in the United States and from Senegalese patients, infected with subtypes A 
(n=10), G (n=3) or C (n=1). Eight of the nine subtype B CTL clones (recognising two p17, one p24, 
two RT and four Env epitopes) which were tested against' all subtypes (A to 0) were found to be 
cross-reactive at 1 OOµg/ml peptide concentration . It was also determined that up to three nucleotide 
variations in the epitope can be tolerated . Fourteen Senegalese patients were found to have CTLs 
to at least one subtype B vaccinia virus construct expressing Gag, Env, RT, or Nef. The MHC class I 
restricted allele, A3 allowed broad cross-reactivity between subtypes in the p17 and Nef regions from 
the Senegalese patients (Cao, et al., 1997). A second study was performed by Dura Ii et al (1997), in 
which patients from France (subtype B) and Central 
1
African Republic (CAR) (subtype A and one 
subtype A/G recombinant) were studied for CTL cross-reactivity. It was found that there was 
frequent CTL cross reactivity with conserved epitopes between subtype A and B especially in the 
Gag p24, p18, the central region of Nef and in 'the integrase gene. CTL cross-reactivity was also 
demonstrated between subtype A, G and B when the A/G recombinant was studied (Durali et al., 
1998). A study examining the cross-subtype CTL recognition of subtype C infected Zambian patients 
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to autologous target cells infected with vaccinia virus (VV)-subtype B (IIIB) Gag/Env/Pol or Nef 
showed that out of eight patients, six elicited a CTL response to Gag/Env/Pol , but only three to Nef. 
Target cells infected with VV subtype B Gag, Pol or Env showed that one individual had CTL 
recognising only Gag and one recognising only Pol (Betts et al., 1997). 
The HLA background of the individuals to be vaccinated has also been studied. Out of 19 
' 
recently subtype B infected patients studied , CTL reactivity to subtype B gp120 LAI and subtype C 
gp16092sRo25 was detected in 13. Nine patients also showed CTL cross-reactivity 
to subtype A 
gp160oouGo37 • Two HLA class 1 B7 donors were able to elicit a CTL response to gp160LA1, subtype
 C 
and A, but not to gp120MN· In addition, five patients PBMCs could elicit cross-reactive CTL 
responses to subtype A GagP
55
, Pol and Nef (Wilson et al. , 1998). A recent study of the CTL 
responses to the Pol-RT, Env, Gag and Nef HIV-1 proteins from twelve Thai and nine North 
American HLA-characterised patients infected with subtype AE or B respectively, was also 
performed (Lynch et al., 1998). The Thai and North American patients had different HLA profiles and 
although cross reactive CTL responses were fairly common, they were not uniform across the two 
groups. The most frequent CTL responses from both groups of patients were to the Gag protein . It 
is thus important to determine HLA allele~ in different populations in order to prepare for global 
vaccine trials. 
The first cross-reactive CTL responses elicited in vaccinated humans was after immunisation 
with canarypox-HIV vectors. Using ALVAC-gp160MN and rgp120sF2 prime-boost protocol, or ALVAC 
vCP205 (containing the env, gag and pol from MN and LAI) alone, two different patterns of CTL 
reactivity were elicited dependant on the HLA haplotype of the volunteer. One volunteer could elicit 
broadly cross-reacting CTL response to primary isolates from subtypes A to F, but another, although 
eliciting a CTL response to the autologous T cell-adapted HIVLA1, could not elicit CTLs to any primary 
isolates. Vaccination with vCP205 increased the breadth of the CTL response and greater number 
of primary isolates were able to be recognised by CTLs from the volunteers receiving vCP205, 
regardless of their HLA haplotype (Ferrari et al., 1997). 
The type of CTL response obtained after immunisation with a monovalent vaccine of p55gag 
was studied in HIV-infected patients from the United Kingdom (UK) and Uganda. Target cells were 
infected with recombinant W expressing the p55gag protein from subtypes A, B, C and D. Five out of 
six Ugandan patients infected with diverse HIV-1 subtypes (which were not determined) had 
inducible CTL responses to subtypes A to D. · Five out of seven UK patients were infected with 
subtype B and had CTL which recognised two or more of the four HIV subtypes (McAdam, et al., 
1998) . 
The results from these studies of naturally infected and vaccinated individuals indicate that 
genetic subtype may not play a role in the CTL response to either a vaccine , or to the virus. It would 
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appear that by selecting a vaccine strain with broadly recognised CTL epitopes, a number of 
populations with different HLA haplotypes could be protected against a number of HIV subtypes. 
1. 7 .1.3) No absolute animal model 
No ideal animal model has yet been identified . High levels of neutralising antibody have 
protected chimpanzees from challenge, although m·acaques with similar levels were infected. CTL 
responses have lead to protection in certain animal models but not in others (Johnston, 1997). In 
macaques SIV is used instead of HIV as the challenge virus. In an attempt to make SIV more similar 
to HIV, SIV/HIV chimeric viruses (SH IVs) have been developed. These chimera 's have replaced the 
env, rev and tat genes of SIV with the corresponding genes from HIV-1 . Challenge of macaques 
with SH IVs leads to persistent infection and development of disease (Bogers et al., 1995; Cranage et 
al., 1997; and Shibata et al., 1997). 
An additional problem is the variability in the results obtained from animal trials due to 
differences in the animal models and challenge systems used, as well as the type of adjuvant or 
antigen . The inoculation regime and timing and the dosage of the challenge has also varied , making 
interpretation of results difficult. These factors m~st all be standardised (Kuiken and Pillai, 1997). 
1. 7 .1.4) Non-vaccine prevention of infection 
In addition to vaccines, other factors contribute towards keeping the epidemic in check. The 
use of condoms for protection against STDs and HIV as well as the treatment of STDs will reduce 
the transmission of HIV (Laga, 1995; Figueroa, et al., 1998 and Wawer et al., 1998). In addition, 
improvement of the economic conditions and hygiene may provide for better nutrition and general 
health, thereby decreasing the spread of the epidemic. In developed countries, the treatment of HIV 
positive people with drugs to decrease viral load and thus the risk of transmission may also check 
the spread of HIV. In developing countries, the short-term treatment of pregnant women with anti-
retroviral drugs may decrease the numbers of HIV-infected babies born (Marseille et al., 1998). 
Behavioural modification must also take place, such as changes in sexual behaviour 
(Robinson et al., 1995; Ngugi et al., 1996 and Jackson et al., 1997) and the empowerment of 
women. Education of mothers to prevent transmission of HIV to their babies by breast feeding and 
general education of people to inform them about prevention of transmission are also important 
(Montagnier, 1996). 
1. 7.2) Vaccine candidates 
The major types of vaccines thus far developed include: subunit vaccines, live vectors, whole 
virus (inactivated or attenuated) , DNA vaccines or mixtures of the above. These vaccines have all 
been tested in non-human primates and many have also reached clinical trials in humans. Most give 
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CD4 T-cell proliferation and a CD8+ CTL response and many elicit neutralising antibodies to T-cell 
adapted strains, but it is rare to elicit neutralising antibodies to primary isolates. 
1.7.2.1} Recombinant subunit vaccines 
Initial HIV vaccines were envelope-based, as most neutralising epitopes are found in this 
protein {Letvin, 1998) (see Tables 1.1-1.4). Baculovirus-derived recombinant gp160 was used in 
early trials, since it is a relatively cheap way to manufacture large quantities of protein. After Phase I 
testing, it was found to elicit only weakly neutralising antibodies, in part due to an altered 
glycosylation of the baculovirus-derived gp160 that did not match the natural virus (Keefer et al., 
1994). Even mammalian-derived gp120 or gp160 from T-cell adapted viruses were of low 
immunogenicity and inefficient at eliciting cross-neutralisation even between virus strains of the same 
subtype (see section 1.7.1.1 ). 
Although rare, rgp120 or rgp160 can elicit cross-neutralising antibod ies and T-cell 
proliferative responses, however. Chuenchitra et al ( 1998) presented results from a Phase I trial in 
Bangkok, Thailand, after immunisation with a Chiron rgp120sF2 (subtype B) vaccination. After one 
month the gp120sF2 (subtype B) immunisation elicited a 90% T-cell proliferation with the homologous 
protein, whereas the heterologous gp160chiang-Mai (subtype E) protein produced 53% proliferation. 
After 4 months the T-cell proliferative response had dropped to 85% for gp120sF2 and 30% for 
gp160chiang-Mai· T-cell proliferation is measured as the percentage increase in the number of T-cells 
after peptide stimulation in comparison with a mitogen stimulant which primes all T-cells, such as 
phytohaemoglutinin (PHA). 
A comparison of HIV1118 accidentally infected laboratory workers with rgp1201118 or rgp1601118 
vaccinated individuals showed that the overall antibody response, especially neutralising response, 
was higher in the naturally infected people. Three differences were found between laboratory 
infected individuals and vaccinees: antibodies were to different V3 peptide conformations, there was 
a lack of an antibody response to the V1 peptide in vaccinees and an increase in antibodies to 
gp120, blocking CD4-gp120 binding in infected workers (Pincus et al., 1997). 
A number of vaccinees participating in phase 1/11, rgp120MN subunit trials have become 
infected with breakthrough viruses. In a study by Berman et al (1997), seven out of a total of 499 
volunteers participating in phase 1/11 trials of MN-rgp120 (recombinant gp120 subunit vaccine) 
became infected with breakthrough viruses. Analysis of the infecting viruses showed that there were 
differences in neutralising epitopes in the V2 and C4 (CD4-blocking domain) domains. Some 
infecting viruses had a greater number of _glycosylation sites than the vaccinating MN strain, and 
were NSI phenotype, unlike the MN vaccine strain which is an SI virus (Berman et al. 1997). In a 
separate trial, eighteen individuals participating in phase 1/11 clinical trials for recombinant gp120 
subunit vaccine constructed from SF-2 and MN became infected with HIV-1 during the trials. No 
neutralising antibody or CTL responses were elicited . Viral burden was comparable to unvaccinated 
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of viral replication by prior vaccination with the subunit. The majority of infecting viruses were found 
to be NSI, CCRS-utilising subtype B, although two isolates were SI , one of which utilised the CCRS, 
CCR2b, CCR3 and CXCR4 co-receptors. No selective pressure for a more pathogenic virus by 
immunisation with the subunit vaccine was thus found (Connor et al., 1998). Similar results were 
shown in a study by Graham et al (1998) where twenty-three volunteers who became infected were 
selected from a total of 2099 volunteers involved in a number of phase 1/11 vaccine trials. Four of the 
twenty-three patients had received placebo's, and a further six of the volunteers had not completed 
their vaccination course before they became infected. The vaccinations included: recombinant 
proteins (gp120MN given with alum adjuvant, or with QS21 and alum, gp120sF-2 in MF59 or MPL, 
gp160MN given with alum and deoxycholate) and live recombinant vaccinia virus vector expressing 
gp160LA1, followed by a rgp160 LAI boost. There was no difference in viral load or CD4 count between 
any of the infected vaccinees and non-vaccinated controls and no major differences between the V3 
loop regions of the viruses infecting vaccinated and non-vaccinated patients. It was also established 
that although some of the isolate HIV-1 MN vaccinated volunteers had elicited high neutralising 
antibodies in vitro at the time of infection, there were no differences in the V3 loop regions of their 
infecting viruses that would have indicated immune escape from the vaccine elicited antibodies. 
None of the vaccine formulations gave significant CTL responses, even the live W recombinant 
vaccine (Graham eta/., 1998). 
Oligomeric Env is more similar to the native Env protein than monomeric Env, as the 
ol igomeric form expresses functional epitopes that can induce protection. Thus, current work now 
focuses on the use of oligomeric gp120 from both primary and T-cell adapted viruses, in an attempt 
to elicit stronger neutralising antibodies (Petry et al., 1998) (see Table 1.1). 
Apart from the conformation of the immunogen; the route of administration, number of 
immunisations and the adjuvant used all have an effect on the potency of the neutralising antibody 
response (Vancott et al. , 1997). In rare cases, even a CTL response may be induced using a 
subunit vaccine with appropriate epitopes in conjunction with adjuvant formulations favouring a Th1-
type response (see Table 1.1). 
1.7.2.2) Peptide vaccines 
It is possible that peptide or epitope vaccines may be more successful than proteins, 
especially if delivered in efficient carrier molecules, er with immune-enhancing adjuvants. These 
peptides may represent specific epitopes, targeted to be cross-neutralising, or to elicit a CTL 
response . 
More research must be undertaken to identify efficient epitopes that may be included in 
these peptide vaccines. There are currently a number of Phase 1 trials in progress for peptide 
vaccines in different formulations (Jordan report, 1998) (see Table 1.1). Recombinant protein 
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vaccines are likely to be most efficient when used in a "prime-boost" approach in combination with a 
vaccine eliciting a strong CTL response, such as live recombinant vectors or a DNA vaccine. This 
type of vaccination schedule involves an initial immunisation designated the prime, eliciting a weak, 
transient, or incomplete immune response and the subsequent vaccinations are termed boosts, 
increasing the duration of protection, the breadth of the immune response (humoral and cellular) as 
well as the strength of the immune response. 
Table 1.1: Table of subunit and peptide HIV-1 vaccine ·candidates in development and clinical trial to 
date (modified from the Jordan Report, 1998). 
Vaccine Expression system/ Adjuvant or Stage of development/Results Ref 
candidate Production method deliver~ s~stem 
Subunits 
rge160 LAI 8aculovirus/insect cell alum Phi (P), Phi, ll(T) 
1, 2 
rgp1601119 Vaccinia/monkey kidney Alum, DOC Phi (P) , Phi , ll(T) 3
, 4 
or MN cell 
rgp160 Vaccinia/mammalian cell Alum or IFA Phi (P), Phi (T) 5
, 6, 7 
MN/LAI 
rgp160 LAI Vaccinia/mammalian cell Oil , water, 3- Preclinical, chimpanzees 8 
deacyl 
monophosperyl 
Li id A 
Oligomeric 8aculovirus/insect cell Alum, MPL,IFA Preclinical, small animals, monkeys 9, 10 
r 160 LAI 
Oligomeric Mammalian cell Preclinical, elicited neutralising 11 
rgp160 1118, antibodies to a number of primary 
451 isolates in small animals 
rgp120 (Env Yeast MF59±MTP-PE Phi (P), Phi (T) 12 
2-3 SF2 
r9e120 SF2 CHO cells MF59±MTP-PE Phl,11 (P) , Phi (T) 1
3 
r9e120 1118 CHO cells alum Phi (P), Phi (T) 14, 15 
rgp120 MN CHO cells Alum or QS21 or Phi, II (P), Phi , II (T) 14, 16 
both 
rgp120 Alum, S8AS-1 Preclinical, elicited CTL, T-cell 17 
W61D (QS21 and MPL- proliferative and antibody responses 
(primary, A) or SBAS-2 in macaques, mice and chimpanzees 
dual tropic) (QS21, MPL-A 
and an emulsion) 
rgp120 S8AS-2 Phi (P), elicited antibody and cross- 18 
W61D neutralising responses, not COB CTL 
(primary, 
dual tro ic 
rgp120 Vaccinia N-linked Preclinical, broad neutralisation 19 
coupled to carbohydrate to response to usually non-neutralising 
N-linked reduce the net V1 domain epitope, antibody elicited 
carbohydrat positive charge to C 1 and CS regions in guinea pigs. 
e 
re24 LAI 8aculovirus/insect cell alum Phi (P), Phi , II (T) 20 
RT-VCG E. coli I Vibrio cholerae V. cholerae ghosts Preclinical, small animals 21 
LAI 
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Preclinical, elicited cross-reacting serum 34 
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Elicited similar response in humans, 
Ph1 P . 
Preclinical, elicited CTL response in 
small animals 
Preclinical, elicited a CTL response 
maintained up to eight months in mice 
Phi (P) 
Preclinical, small animals 






1, Keefer et al., 1994; 2, Valentine et al., 1996; 3, Belshe et al., 1993; 4, Gorse et al., 1994; 5, Pialoux et al., 1995; 6, Fleury et 
al., 1996; 7, Achour et al., 1996; 8, Bruck et al., 1994; 9, Broder et al., 1994; 10, Richardson et al., 1996; 11, Vancott et al., 
1997; 12, Keefer et al., 1996; 13, Kahn et al., 1994; 14, Berman et al., 1994; 15, Lasky et al., 1986; 16, Belshe et al., 1994; 17, 
Mooij et al., 1998; 18, Weber Cent Gardes pp287-292, 1997; 19, Garrity et al., 1997; 20, Zunich et al., 1992; 21, Eko et al., 1994; 
22, Salmon-Ceron et al., 1995; 23, Gorse et al., 1996; 24, Kelleher et al., 1997; 25, Rubinstein et al., 1995; 26, Cryz et al., 
1995; 27, Cook and Barber, 1997; 28, Ahlers et al., 1996; 29, Ahlers et al., 1997; 30, Staats et al., 1996; 31, Kalyan et al., 
1994; 32, Eckhart et al., 1996; 33, Bukawa et al., 1995; 34, Zimmer:11an et al., 1998; 35, Deprez et al., 1996; 36, Sauzet et al., 
1998; 37, Nixon et al., 1996; 38, Suzue et al., 1996; 39, Nakamura et al., 1997. 
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1.7.2.3) Live recombinant vectors 
Genes from HIV can be engineered into the genome of viruses or bacteria, in order for the 
proteins to be expressed. The live vectors will allow processing of the antigens and presentation via 
the MHC class 1 pathway thereby eliciting a CTL response. There are limitations to the technique, in 
that the recombinant organism must be non-pathogenic, stabley express the foreign genes and 
should be able to replicate at least a limited number of times in order to stimulate an adequate 
immune response. Unfortunately, the greater the capacity to replicate, the more pathogenic the 
vector tends to be (Letvin, 1998). 
Pox virus vectors 
One of the most common viral vectors used as delivery vehicles for HIV proteins are pox 
viruses. The initial vectors were constructed from v·accinia virus (VV), the live, attenuated smallpox 
vaccine, expressing either the gp120 or gp160 (Kat~ and Moss, 1997 and Letvin, 1998). Although 
W recombinants have elicited efficient CTL responses (Tartaglia, 1997), there are safety concerns 
for the use of W in potentially immunocompromised individuals, thus attenuated strains such as 
NYVAC and ALVAC have been designed for vaccine delivery. NYVAC virus strain, derived from the 
Copenhagen W had the open reading frames implicated in virulence removed, attenuating the virus; 
whereas ALVAC is derived from Kanapox, a canarypox virus and can only replicate in avian tissues. 
In addition, an attenuated vaccinia strain, Ankara MVA (modified Ankara virus) was derived from the 
serial passage of Ankara VV through chick fibroblasts 500 times, thereby changing the host range of 
the virus to avian origin only (Tartaglia, 1997). Of all the poxvirus vectors, the canarypox 
recombinant has progressed the furthest in clinical trials thus far (Jordan Report, 1998). 
Alternative live recombinant vectors for HIV vaccination 
A number of viral and bacterial vectors have also been researched as possible HIV vaccines 
(see Table 1.2). These vectors are often studied in an attempt to find a vaccine capable of eliciting a 
mucosal response, for example, BCG and Adenovirus (see section 1.7.2.7) . 
Table 1.2: Vaccine candidates and the immune response elicited in preclinical and phase 1 and 2 
trials for recombinant poxvirus vaccines (modified from the Jordan Report, 1998). 
Vaccine Expression system/ 
candidate Production method 
Wgp120 IIIB gp120 / gpB5R cytoplasmic 
transmembrane W 
chimera 
ALVAC gp160 Fowlpox and canarypox -
SF2 HIV 
vCP125 gp160 ALVAC-HIV 
vCP205 ALVAC-HIV 
gp120TM+ 




mice 11nd rabbits . 





lmmunogenisity improved by greater expression 
of gp120 on the W surface 
Increased anti-HIV antibody titre 
Ref 
Gp160 correctly expressed on the virus surface, 2,3 
T-cell proliferation and antibody response, No 
cross-neutralisation of heterologous strains 
Generates an efficient CTL response and cross 4 
neutralising response in a 'prime-boost' protocol 
Elicits a broader CTL response with additional 4 
Gag and protease proteins 
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vCP250 + separate Pol-Nef 
CTL epitopes 
vCP300 Pol and nef 
engineered into a single 
cassette resulting in 
chimeric (string-of-beads) 
Pol-Nef rotein 
E3L + WK3L leads to 





W env, gag, pol W -HIV 
NYVAC LAI MN 
Modified VV 
Ankara (MVA) 
















Elicits a broader CTL response but decreased 
replication efficiency in chick embryo fibroblasts 
Improved replicative capasity to vCP300 
Enhanced expression in human cell lines 
CTL response and neutralising antibodies 
CTL response and neutralising antibodies 
CTL response and neutralising antibodies 
CTL response and neutralising antibodies 
CTL response and neutralising antibodies 
W gp140, 30 VV-HIV Preclinical, small CTL response and neutralising antibodies 











1, Katz and Moss, 1997; 2, Radaelli et al., 1994a; 3, Radaelli et al., 1994b; 4, Tartaglia , 1997; 5, Graham et al., 1992; 6, 
Graham et al., 1993; 7, Achour et al., 1996; 8 Daniel et al. , 1994; 9, Abimiku et al., 1995; 10, Paoletti, 1996; 11, Moss et al. , 
1995; 12, Rencher et al., 1997. 
Table 1.3: Vaccine candidates and the immune response elicited in preclinical trials for live 






















Strong cellular and humeral immune 
response, protects against homologous 
SIV challenge 
Anti-Gag lgG elicited and lgA antibodies 
in vaginal washes. 




Stomatit is Virus 




VSV glycoprotein is replaced 
with HIV receptor genes in 
order to target and kill HIV-
infected cells 
BR&D (T) HIV titres in an HIV-infected T-cell line 
was decreased by 104 
3, 4 
Rabies Virus Rabies G protein is replaced BR&D (T) 5 
HIV CD4 and with HIV receptor genes to 
CXCR4 target and kill HIV-infected 
rece tors cells 
Poliovirus-HIV Recombinant BR&D Neutralising antibodies 6 
env LAI Poliovirus 
1, Berglund et al., 1997; 2, Caley, 1997; 3, Schnell et al., 1997; 4, Johnson et al., 1997; 5, Mebatsion et al., 1997; 6, Evans et 
a/. , 1989. 
1.7.2.4) Whole, inactivated viruses 
Whole , inactivated vaccines have been successfully used as poliomyelitis and influenza 
vaccines and have elicited long-lasting protection, thus were initially attractive as an HIV vaccine 
despite possible safety issues (Letvin, 1998). A number of HIV or SIV variants have been inactivated 
to form different vaccine formulations for different subtypes. SIV, inactivated by either formalin or D-
propiolactone, has been shown to protect against both intrarectal and intravenous challenge with 
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either homologous or heterologous virus (Stott et al., 1990; Cranage et al., 1992). In addtion , 
digitonin was used as an adjuvant for the p-propiolactone, binary ethylenamine and formaldehyde 
inactivated-HIV immunisation. Immunisation of rats, guinea pigs and rabbits elicited neutralising 
antibodies to both homologous and heterologous virus, as well as T-cell proliferation and a CTL 
response (Race et al., 1995). 
An inactivated vaccine which has been shown enhance the immune response in HIV-
infected patients is REMUNE™. REMUNEfM is constructed from an early HIV-1 isolate, gagG/envA from 
Zaire (HZ321), with the gp120 removed. The vaccine is completely inactivated by p-propiolactone 
and y-radiation, and the protein conformation is retained . The vaccine has been administered in 
Incomplete Freunds adjuvant (IFA) and in phase II trials has been shown to elicit a broad 
lymphoproliferative response to different HIV subtypes. Subtypes B, E, Gag G peptides have been 
recognised after immunisation , due to the conserved immunodominant gag gene of REMUNE™. 
It has also been suggested that REMUNE™ may be used to restimulate the immune response 
in HIV-infected patients who have undergone highly active antiretroviral therapy (HAART) which 
lowers the viral load and may preserve the immune functions of the patient. In addition, REMUNE™ 
stimulated the production of p-chemokines, RANTES, MIP-1 ex. and MIP-1 p that are indicative of a 
Th1 response . However, levels of proinflammatory cytokines such as TNFcx., which at high levels 
lead to a decrease in CD4+ cells, were found to decrease (Moss et al., 1998). 
The novel fusion-competent whole cell vaccine strategy (Lacasse et al., 1999) has been 
discussed in section 1. 7 .1.2. 
1.7.2.5) Virus-like particles as vaccines 
Virus-like particles (VLP's) as vaccines were considered as an alternative, in an attempt, to 
elicit a broader immune response than with subunit vaccines, but without the safety issues of whole-
killed vaccines. Most of the HIV VLP's utilise core proteins, such as p24 or the Pr55Gag precursor. 
The p24 C-terminal contains a CTL epitope which had the highest CTL precursor frequency in an 
asymptomatic patient studied and it is the most conserved region amongst all retroviruses (Harrer et 
al., 1996a). Also, escape variants to this epitope have not been found . 
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Table 1.4: Vaccine candidates and the immune response elicited in preclinical and phase 1 trials for 
virus like particles (VLP's) as vaccine vectors (modified from the Jordan Report, 1998). 
Vaccine Expression system/ 
Adjuvant or Stage of 
delivery Results Ref candidate Production method 
s stern 
development 
P17/p24 LAI P17/p24 and yeast Alum/none Ph1 (P) , *Elicited anti-p17 or p24 T-cell 1, 2, 3 
Ty-VLP transposon product Ph1 ,2(T) proliferation above baseline, 2/8 
patients had enhanced CTL 
reeonses against Gag. 
HIV-1 LAI , RF, MoMLV/mammalian cells CFA, IFA Preclinical, Antibody, CTL response 4 
others env, gag, small animals, 
pro monkeys 
seudovirions 
HIV-1 LAI env, Vaccinia/mammalian cells Alum Preclinical , Antibody, CTL response 5 
gag, pol small animals, 
eseudovirions monkeys 
Gag-V3 LAI VLP Baculovirus/insect cells Preclinical , Antibody, CTL response 6,7 
small animals 
Gag Baculovirus/insect cells none Preclinical , Neutralising antibody, CTL 8,9 Pr55- gp160 
or oligomeric small animals response 
120 
HIV LAI VLP Chimeric HIV LAI/MN in none Preclinical , Neutralising antibodies 10 
without RNA, mammalian cells small animals recognised both MN and LAI V3 
containing MN loop epitopes 
V3 loop in C2 
re ion 
HbcAg-V3 E.coli Preclinical, Antibody, CTL response 11 
earticles LAI small animals 
Tobacco mosaic Transgenic plants, V3 loop IFA, CFA Preclinica l, Neutralising antibody response in 12 
virus expressed in AIMV coat small animals mice. Possible mucosa! immune 
(TMV)/alfalfa protein response if edible vaccine is used 
mosaic virus 
(AIMV) chimera, 
V3 loo MN 
*Two of the eight patients had increased viral RNA (at greater levels than the unvaccinated control patients) similar to the 
activation phenomenon, indicating that vaccination with the VLP may be hazardous. 
1, Weber et al., 1995; 2, Veenstra et al., 1996; 3, Klein et al., 1997; 4, Rovinski et al., 1995; 5, Daniel et al., 1994; 6, Truong et 
al., 1996; 7, Brand et al., 1995; 8, Demi et al., 1997; 9, Tobin et al., 1997; 10, Rovinski et al., 1992; 11 , Grene et al. , 1997; 12, 
Yusibov et al., 1997. 
1.7.2.6) Live attenuated vaccines 
The net-attenuated vaccines were initiated after the discovery of a cohort of people infected 
by blood transfusion in Sydney, Australia who were infected with a relatively non-pathogenic Met 
HIV-1 virus which rendered the patients long term non-progressors (L TNPs) (Deacon et al., 1995). 
Follow-up on the cohort has shown increasing net deletions in the evolving progeny viruses which 
leads to decreasing replication efficiency in comparison to wild-type viruses (Rhodes et al., 1998). 
Net is necessary for HIV to replicate efficiently and, along with vpu, has been linked to pathogencity 
of the virus (see section 1.2). Both proteins down-regulate the surface expression of MHC class I 
molecules, thereby reducing the CD8+ mediated CTL response and in addition, Nef upregulates the 
expression of the Fas-ligand (Fasl) thereby increasing the binding to Fas on activated CTL's and 
initiating apoptosis. Net deletions therefore abrogate these effects and !J.net isolates are less 
pathogenic (Xu et al. , 1997). 
Vaccines from live virus which has been genetically altered in order to attenuate the 
pathogenicity have successfully been used against polio, chicken pox and measles. The immune 
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response obtained is similar and as potent as the immune response to the wild type virus (Letvin, 
1998). 
Initial studies in macaques with a net-deleted S1Vmac239 were encouraging . Attenuated 
S1Vmac239M ef was not pathogenic after immunisation and protected macaques from subsequent 
intravenous challenge with pathogenic SIV mac239 (Daniel et al., 1992). Also, immunisation of 
macaques with Mef SIVmacea or non-pathogenic SHIV89.6 (a SIV chimera containing the HIV-1 89.6 
env gene) provided protection against rectal (Cranage et al., 1997) and vaginal (Miller et al., 1997) 
challenge with pathogenic SHIV/HXB2 or S1Vmac239 respectively. Protection was associated with a 
CTL response and cervicovaginal or rectal secretions, although not neutralising antibodies. Other 
studies have also shown a lack of protection by neutralising antibodies, including Shibata et al (1997) 
where no neutralising antibodies were elicited by immunisation or after challenge. Almond et al 
(1997) showed that transfer of immune serum from protected macaques did not confer protection to 
pathogenic SIVmacJs in na'ive macaques (Almond et al., 1997). In addition, t,,nef SIV vaccines in 
macaques with wild-type SIV or SHIV intravenous, cell-free, or cell-associated challenge provided 
protection, or decreased viral infectivity substantially in a mechanism which was CD8+ CTL mediated 
(Johnson et al., 1997 and Gaudin et al., 1998). 
Live attenuated HIV vaccines pose major safety concerns and as a result no live attenuated 
vaccines have reached clinical trials in humans (Letvin, 1998). HIV mutates rapidly and it is possible 
that the attenuated virus may regain its pathogenic potential, such as SIVmacea, (Whatmore et al., 
1995). In addition, the possible long-term pathogenic effects make it difficult to perform safety trials. 
Mef strains with further deletions, such as vpr, vpx and portions of the L TR (Desrosiers et al., 1998) 
have been developed in an attempt to prevent the reversion of the live attenuated vaccine to a 
pathogenic strain. If too many genes are removed , however, the vaccine virus will lose its ability to 
replicate and at the same time its immunogenic potential. No protection from intravenous challenge 
by pathogenic strains have been elicited to these highly attenuated strains. In addition , a recent 
study by Baba et al. (1999) and earlier work by Baba et al. (1995) and Ruprecht et al. (1996) showed 
that although adult monkeys are protected from pathogenic challenge after nef-deletant 
immunisation, long term infection may eventually lead to disease. Also, neonatal monkeys 
immunised with nef-deletant strains were infected and became ill which lead to death in a number of 
cases. 
1.7.2.7) Mucosal immunity 
Since over 80% of HIV infections occur via heterosexual transmission , a vaccine to elicit 
mucosa! immunity is essential (UNAIDS and WHO, 1998) (see Table 1.5). 
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Table 1.5: Vaccine candidates tested in preclinical trials using small animals, monkeys or 







SIVmac251 lmmunogen injection into the 
rgp120, rp27, posterior wall of the pelvis , 
Pr55 and drained by the iliac lymph 
S1Vmac239 gp130 nodes (TILN). 
Peptide Vaccines 
gp120 C4N3 Synthetic peptide containing 
regions MN immunogenic epitopes for 
antibody, T-cell proliferation 
and CTL responses 
Synthetic Synthetic peptide 
multideterminan 






Synthetic peptide containing 
4 V3 peptides from different 
subtypes, 1 CD4 binding 
domain and 1 gag region 
Baculovirus/insect cells 
Live Recombinant Vaccines 




























W/monkey kidney cells 
Recombinant attenuated 
Salmonella typhimurium 











l.n., CT, boosted 
twice via rectum, 
gastric intubation, 
or vagina 
i.r., i.n., i.g. or i.d . 
with or without CT 
adjuvant 
CT, oral route 

















Protection elicited after rectal but not vaginal 
challenge with S1Vmac239 in macaques, 
although high lgG and lower lgA levels were 
produced 
Elicited anti-HIV specific vaginal lgA and lgG 2 
response, serum lgG, neutralising antibodies 
to homologous strain and T-cell proliferative 
responses in mice 
Th1 type, IL 12 and IFN-y needed for CTL 3 
response. Mice challenged with W -
gp1601110 recombinant intrarectally cleared 
the virus from their ovaries. Faecal lgG and 
lgA and serum lgG detected 
Elicited high titre gut-associated slgA able to 4 
neutralise three heterologous HIV-1 strains 
(IIIB , SF-2 and MN) in mice. High serum lgG 
antibodies and faecal slgA detected. 
Elicited systemic and mucosal lgG and lgA in 5 
rectal washes and saliva, but lgG only in 
vaginal wash* . T-cell proliferative Th1 
response also obtained 
Nasal, vaginal , salivary and rectal lgG 
detected with low lgA levels. Short-lived 
neutralising antibodies stimulated by 
baculovirus rgp160 boost in chimps 
Chimps protected from low dose HIVsF-2 
challenge and 1 year later from high dose 
challenge . Neutralising antibody response 
elicited against primary and T-cell isolates 
after low dose challenge 
Elicited lgA, long lasting systemic CTL 
response and weak T-cell proliferation, 
improved by boost in mice 






CTL response and mucosal lgA 10 
Strong CTL response, lgG neutralised 
homologous SIV in vitro , high levels of lgA to 
gp110 detected in faeces . lgA levels higher 
after oral than subcutaneous immunisation 
CTL response, mucosal lgA 
Elicited anti-Nef T cell proliferative response 
and a strong systemic and mucosal CTL 
response in mice 
Elicited antibody and mucosal CTL response 
in mice 






*Lack of lgA in the vaginal washes may have been due to the hormonal cycle of the female macaques, which can effect 
secretory lgA production in the genital tract. The low lgA production in the macaques mirrors the secretory antibody response 
in HIV-infected women. 
1, Lli et al., 1998; 2, Staats et al., 1997; 3, Belyakov et al., 1998; 4, Bukawa et al., 1995; 5, Kubota et al., 1997; 6, Lubeck et 
al., 1994; 7, Lubeck et al., 1997; 8, Brlihl et al., 1998; 9, Charbit et al., 1993; 10, Valentine et al., 1996; 11 , Lim et al., 1997; 
12, Yasutomi et al., 1993; 13, Lagranderie et al., 1997; 14, Lagranderie et al., 1998; 15, Honda et al., 1995. 
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1.8) DNA vaccination 
1.8.1). Introduction 
Naked DNA vaccines are constructed by cloning immunogenic DNA sequences into 
eukaryotic expression vectors, which are amplified in bacteria and purified (Whalen, 1997). DNA 
vaccines can be used against a wide variety of bacterial, viral and parasitic pathogens and give long 
lasting, broadly reactive responses. · Human immunodeficiency virus (HIV), Hepatitus B virus (HBV) 
and malaria DNA vaccines are in phase I trials (DNA vaccine web, 1998; MacGregor et al., 1998; 
Ugen et al. , 1998; Wang et al., 1998 and Boyer et al. , 1999). 
Usually DNA is introduced into the skin, muscle or intravenously and introduction can be by 
injection in saline, or with various adjuvants, or by gene gun bombardment with the DNA attached to 
gold particles. Expression of the DNA is under the control of an eukaryotic promotor, allowing 
expression in the hosts' transfected cells (see Chapter 4.2.4). Both a CTL response and protective 
immunity is elicited by the small amounts (nanograms) of proteins which are expressed. A long 
lasting antibody response can also be stimulated (Robinson, 1997a). 
1.8.2) Type of immune response to DNA vaccines 
DNA injected intramuscularly is expressed in skeletal muscle and when introduced into the 
skin, is expressed by keratinocytes. These cells may then present the antigen to the immune 
system. The intramuscular route elicits more of a Th1 type response, whereas the gene gun 
inoculation elicits a Th2 response. The antigen presenting cells (APCs) at the two sites are 
significantly different, but were both found to be derived from bone marrow. These bone marrow-
derived cells either obtain the antigen presented by the muscle cells and keratinocytes, or they are 
transfected directly by DNA at the inoculation site or as the DNA moves through the blood or lymph 
(Robinson , 1997a and Iwasaki et al., 1997). 
Na"fve antigen-specific T and B lymphocytes are converted to memory and effector cells in 
the lymphoid tissue and germinal centers develop where immature B-cells mature to high affinity B-
cells and antigen-antibody complexes are deposited on follicular dendritic cells. Effector B 
lymphocytes then localise in the bone marrow and produce long term antibody, whilst the memory B 
and T lymphocytes circulate, maintaining the immune response . Lymphokines such as gamma-
interferon (IFN-y) and interleukins (ILs) are also stimulated by T lymphocytes and these support the 
immune response. Intramuscular injection of DNA elicits a Th1 response with the production of IFN-
y, IL2 and IL 12. The Th1 response is complement-dependant and phagocytic, recruiting and 
activating macrophages and monocytes. Bombardment of the DNA vaccine attached to gold 
particles uses much less DNA and tends to elicit a Th2 response, where granulocyte-monocyte 
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colony stimulating factor (GM-CSF) and IL 4, 5 and 10 are produced. The response is complement-
independent and recruits eosinophils and mast cells which secrete toxins to counter pathogens (see 
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Figure 1.9: An illustration of the mechanism whereby DNA immunisation elicits an immune 
response . The DNA is initially taken up by the epithelial or muscle cells, in which the immunogen is 
expressed. The expressed antigen then travels through the blood or lymph to the lymph node or 
spleen where T- and B-cells are activated (Robinson, 1997a). 
1.8.3) Factors influencing the the immune response 
A number of factors influence the effectiveness and the type of the immune response to DNA 
vaccines: 
• the inoculation method and the DNA concentration, 
• co-factors and adjuvants used, 
• the type of host animal (genotype and age) and 
• the type of antigen (toxicity, expression level and intracellular biology). 
The gene gun gives a better Th2 response with more DNA expressed. It has been found 
that decreasing the amount of DNA administered elicits a better CTL response, whereas increasing 
the amount elicits a better antibody response. Intramuscular and intradermal immunisation uses 
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about 100-fold more DNA than the gene gun, but not as much reaches the cells due to extra-cellular 
nuclease digestion, thus less DNA is expressed and a better CTL response is obtained (Robinson, 
1997a). It is also possible that the large amount of bacterial vector DNA may act as an adjuvant, 
leading to a Th1 response (Whalen, 1996). 
Inserting an intron 5' to the gene or addition of GM-CSF increases the expression of the 
gene, thus increasing the antibody response. This is not so for toxic proteins, however, such as 
rabies, which kills the cells if expression is too high (Barry and Johnson, 1997). 
DNA vaccination with a plasmid encoding antigen-ligand fusion proteins; L-selectin or 
cytotoxic T-lymphocyte antigen 4 (CTLA4) which allows targeting to the lympoid organs and antigen 
presenting cells (APCs) respectively allowed an enhancment of both the humoral and cellular 
immune response in mice. CTLA4 is a more potent enhancer, with eight-fold higher T-cell 
proliferation and 1 O 000-fold higher antibody-binding response. The ligand acts in a similar but more 
direct way to GM-CSF, which enhances both cellular and humoral responses by recruiting APCs to 
the site of DNA vaccine expression . The CTLA4 method targets these APCs directly, increasing the 
potency of the immune response (Boyle et al., 1998). 
DNA can either be injected in saline, or complexed with various compounds. Lipids, cationic 
liposomes and microparticles have all been used for injection of DNA vaccines (Ishii et al., 1997; 
Jones et al., 1997 and Norman et al., 1997). Cationic liposomes in a number of delivery systems 
(intramuscular, intravenous, intraperitoneal and intranasal) have elicited good antibody and CTL 
responses (Ishii et al., 1997 and Norman et al., 1997) and have no side effects (Norman et al., 1997). 
Microparticles make use of poly (DL-lactide-co-glycolide) DNA complexes to elicit an antibody 
response (Jones et al., 1997). 
Vaccination schedules and the addition of co-stimulatory cytokines can be manipulated to 
induce better antibody or CTL responses. Increasing time between immunisations and fewer 
immunisations as well as a protein boost increases the antibody response (Fuller et al. , 1997). 
Cytokines like GM-CSF and IL4 can increase the antibody response whereas IL2, or IL 12, or IFN-y 
can increase the CTL response (Kim et al., 1997). 
The haplotype of the animal and the MHC epitopes recognized also effect the immune 
response. Four week mice have been found to elicit a better immune response than six to eight 
week mice when inoculated with DNA vaccines. 
1.8.4) Advantages and limitations of DNA vaccination 
The advantages of DNA vaccines are numerous: 
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• the plasmid encoding the immunogenic sequence allows the body to elicit an immune response 
close to that of a natural infection without the infectious pathogens, 
• both a humoral and cellular immune response are obtained, 
• the vaccines work efficiently in infant immune systems without interference from maternal 
antibodies, 
• a number of pathogenic antigens can be combined in a cocktail and 
• the vaccines are easy to produce, cheap and stable (Robinson, 1997b and Special conference 
issue, 1997). 
There are safety issues, however, although as yet, they have not been proven. Tolerance 
induction, an antibody response against the tissues expressing the protein or the DNA itself and the 
possibility of integration into the chromosome are concerns. Integration does not appear to occur, 
however (Special conference issue, 1997) and up to 175µg of DNA did not elicit anti-DNA antibodies 
(Liu et al. , 1997). 
Injecting a mouse with DNA vaccine plasmid and co-stimulatory cytokines such as GM-CSF 
or IL 12 does not convert non-haemopoitic cells in the muscle to APCs. This is encouraging for the 
use of DNA vaccines in humans, since APCs cannot be created from non-APCs by DNA vaccination, 
thereby possibly inducing auto-immune disease. Instead, the bone marrow-derived APCs are either 
directly transfected, or pick up the antigen from other cells which are transfected with the DNA 
vaccine (Iwasaki et al., 1997). 
1.8.5) DNA vaccine vectors 
The most common promoter in use for DNA vaccine vectors is the human cytomegalovirus 
(HCMV) immediate/early promoter that induces high expression in many cell types although Rous 
Sarcoma Virus (RSV) has also been used. It has been reported that the CMV promoter works better 
than the RSV promoter in the DNA vaccine vector for inoculation of mice with the influenza NP (Raz 
et al., 1994). Terminator sequences, bovine growth hormone poly-A (BGHpA) or simian virus 40 
poly-A (SV40pA) can be included in the vector 3' to the foreign gene, as can an intron 5' to the gene, 
increasing transcription efficiency. BGHpA is more efficient than SV40pA (Norman, 1997). 
lmmunostimulatory DNA sequences; CpG palendromic dinucleotides, also increase the effectiveness 
of transcription and give rise to a better CTL response (Sato et al., 1996). 
1.8.6) HIV-1 DNA vaccines 
Numerous HIV-1 genes have been utilised in DNA vaccines including structural, accessory 
and regulatory genes (Kim et al., 1997; Hinkula et al., 1997 and Boyer et al., 1999). Using more 
47 
genes gives a broader immune response. Both nef and gag give CTL and antibody responses 
(Hinkula et al., 1997) with a DNA vaccine. Tat, nef and rev proteins give a better antibody response 
than DNA, whereas DNA gives a better CTL response than protein (Hinkula et al., 1997). HIV DNA 
vaccines will be discussed further in section 4.1. 
1.8. 7). Infant immunisation 
Infant immunisation is limited by factors such as: neonatal immunodeficiency, immature 
neonatal immune system and the presence of maternal antibodies. As a result, there is defective B-
cell activation by bacterial polysacchrides, slow B-cell activation by protein antigens and reduced T-
cell helper activities. Neonates are thus easily infected by encapsulated bacteria and need multiple 
vaccines for their early years (Siegrist, 1997). 
Nucleic acid vaccines can overcome these limitations by helping in the identification of 
antigens and can induce a longer-lived antibody response, thus decreasing the number of 
vaccinations necessary. The vaccination process can be simplified by utilising combination DNA 
vaccines and missing cytokines can be replaced by immunising with genes expressing cytokines. 
Th1 responses can be triggered to assist in intracellular pathogen destruction and APC's can be 
transfected directly, thereby circumventing maternal antibody interference (Siegrist, 1997). 
Animal trials in infant immunisation have started. New-born mice vaccinated with murine 
leukaemia virus (Mul V) env gene were protected from challenge and had a strong CTL response. 
Immunisation with the whole genome gave a long-lasting CTL response and CDS+ cell transferral 
confers protection . The whole genome immunisation gave a higher immune response than that to 
the env gene alone (Sarzotti et al., 1997). New-born chimps were immunised on their day of birth 
against Hepatitus B surface antigen (HbsAg), boosted at six and 24 weeks, were protected against 
challenge with HBV, even though a transient antibody response to the challenge virus was found 
(Prince et al., 1997). 
1.8.8). Mucosa/ immunisation with DNA vaccines 
A good system for delivery of vaccines to mucosa! surfaces is necessary. Mucosa! 
adjuvants to enhance the immune response are also needed. It was found that intramuscular 
injection of the H1 protein of influenza virus with two boosts, protected mice against challenge and 
elicited an lgG and CTL response . Intranasal inoculation with cholera toxin adjuvant gave slight 
protection and elicited low lgA levels in the lungs (Ban et al., 1997). 
Mice have also been immunised intranasally with plasmid encoding the luciferase gene. A 
high serum lgG and low titre vaginal lgA response was elicited by immunisation with cationic 
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liposomes. The spleen and iliac lymph nodes showed a potent CTL response (Klavinskis et al., 
1997). Microparticles of poly(DL-lactide-co-glycolide) were administered orally and intraperitoneally 
with the luciferase plasmid to elicit mucosal antibodies. Good lgG, lgA and lgM responses were 
obtained with as little as 1 µg of DNA although the intra peritoneal route gave better lgG and lgM 
responses than oral. Good stool lgA levels were measured after oral immunisation, as opposed to 
intraperitoneal immunisation (Jones et al., 1997). Mucosal immunity is important for sexually 
transmitted disease prevention and intravaginal inoculation of gp160 induced lgG, secretory lgA and 
neutralising antibodies in vaginal secretions of mice (Wang et al., 1997). 
By oral immunisation immunogens are taken up by "M" cells in the intestine and transported 
to the Peyer's patch where T and 8-cell responses are elicited. Activated cells travel through the 
lymph system and elicit systemic and mucosal immunity. Cochelates are phopholipid-calcium 
precipitates that fonn scroll-like structures, which are multi-layered and exclude water, protecting the 
centre from harsh environmental conditions such as pH or lipid digesting enzymes. These 
cochelates are able to trap DNA plasmids within the lipid bilayers and peptides can be covalently 
cross-linked to the phospholipid layers, thereby producing a novel vaccine delivery system that can 
protect immunogens from the harsh environment of the gastrointestinal tract. 
Immunisation via a number of different mucosal and routes and intramuscular immunisation 
allowed the induction of a humoral and cell mediated immune response to HIV-1 11 18 env, tat and rev 
expressing plasmid. The DNA is able to enter the cell by fusion of the cochelate with the cell 
membrane, increasing the efficiency of DNA uptake (Gould-Fogerite, 1997). 
1.8.9). Non-HIV DNA vaccines 
A number of DNA vaccines are being tested in preclinical trials using different delivery 
protocols (see Table 1.6). The most promising vaccination schedule for HIV thus far appears to 'be 
the use of a prime-boost approach, however, usfng a DNA vaccine prime, followed by a recombinant 
fowl pox virus boost (Kent et al., 1998). HIV DNA vaccines will be discussed in section 4.1.1. 
Table 1.6: DNA vaccine candidates and the immune responses elicited in preclinical trials for a 
number of non-HIV DNA vaccines. 
Vaccine candidate 






HSV Glycoproteins B 
and D 
Expression system/ Adjuvant or 
Production method delivery system 
Plasmid Intramuscular, 
cardiotoxin, bupivacaine 
Fusion plasmid Intramuscularly · 
Plasmid Intramuscularly 
Results 
Elicited long-lasting humoral response 1 
and T-cell response in mice 
Elicited humoral and CTL response to 2 
HBV and HCV in mice 
Elicited humoral response and 3 
neutralising antibodies in guinea-pigs 
Ref 
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Table 1.6: continued ... 
Vaccine candidate 
Influenza NP, H1 or 
H7 




glycoprotein G (gpG) 
Rotavirus virus 
protein (VP) 4, VP6, 
VP7 genes 
Ebola nucleoprotein 
(NP) and secreted 
(sGP) or 
transmembrane (GP) 
I co rotein 
P. yoelii genes 
homologous to P. 
falciparum 
1PbTRAP and 2PbCS 
DNA vaccines 
followed by modified 
virus Ankara (MVA)-













and intravenous of 
stabley transfected , 
myoblasts transplanted 
Intramuscular 






Plasmid with Intramuscular DNA 
recombinant MVA- vaccine, followed by 
malaria boost, not vice intravenous MVA boost 
versa , however. 18 days later 
Results 
MHC class 1, CTL response with high 4 
antibody titres and protected the mice 
from cross strain challenge 
Elicited protection against genetic drift 5 
in ferrets as effective as the licensed 
vaccine homologous for the challenge 
strain 
Elicited strong antibody response with 6 
protective neutralising antibodies 
against a global spectrum of rabies 
variants in mice 
Elicited lgA and neutralising antibodies 7 
to the outer capsid proteins (VP4,VP7) 
and mice were protected against 
homologous challenge. 
Elicited a T-cell and antibody response 8 
for sGP and GP which protected 
guinea pigs against challenge 
Antibody and CTL response elicited in 9 
mice 
Elicited a potent CD8+ CTL response 
and protected BALB/c and C57BL/6 
mice from homologous P. berghei 
sporozoite challenge 
10 
DNA vaccine expressing the Plasmodia berghei thrombospondin-related adhesive protein 
2 DNA vaccine expressing the Plasmodia berghei circumsporozoite protein 
Ref 
1, Davis et al., 1997; 2, lnchauspe et al., 1997; 3, McClements et al:, 1997; 4, Fynan et al., 1993; 5, Donnelly et al., 1997; 
6, Ray et al., 1997; 7, Chen et al., 1997; 8, Xu et al., 1998; 9, Hoffman et al., 1997; 10, Schneider et al., 1998. 
1.8.10). Clinical trials 
A prophylactic vaccine for hepatitus 8 virus (HBV) is currently in Phase I clinical trials being 
conducted by PowderJect and Glaxo Wellcome. The PowderJect immunisation is by gene gun that 
bombards gold particles carrying the DNA into the epidemis using a jet of helium. The DNA enters 
the epidermal cells and detaches from the gold particles, after which it is expressed. Thus far, 
eleven out of twelve patients immunised using the PowderJect system have elicited anti-hepatitus B 
. ' 
surface antigen (HBsAg) antibodies at 10 milli-lnternational Units per millilitre, which is considered 
protective (DNA vaccine web, 1998). 
In addition, Vical's DNA vaccine with Allovectin-7, which uses a lipid-DNA complex to 
immunise against cancer cells, is in phase 11/111 testing in patients with metastatic melanoma and 
phase II in patients with head and neck cancer. Leuvectin, also a lipid-DNA complex which 
stimulates an immune response to cancer cells, is in phase II testing in patients with kidney cancer 
(DNA vaccine web, 1998). HIV clinical trials are discussed in section 4.1.1 . 
Phase I trials for a malaria DNA vaccine have started . A DNA vaccine encoding the P 
falciparum circumsporozoite protein (PfCSP) was used to immunise 20 healthy, malaria na'ive 
volunteers. Of the 20 people, 11 were able to elicit antigen-specific, CD8+ CTL responses to the 
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DNA vaccine. The CTL responses were also determined to be HLA class-I-restricted by CTL assays 
with target cells which had matched or mis-matched HLA epitopes. Mis-matched targets were not 
recognised (Wang et al., 1998). 
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1.9) Motivation for the project 
The initial objective of this study was to define the genetic diversity of the South African HIV-
1 epidemic. The only South African HIV-1 isolate which had been identified at this time was Nof, 
belonging to subtype C, which was found to be closely related to the Indian subtype C isolates 
(Dietrich et al., 1993). Knowledge of the genetic diversity of the HIV epidemic in a country can shed 
light on the origin of the subtypes circulating and may also have implications on vaccine efficacy. 
In the early 1980s, the majority of HIV infections in South Africa occurred in the male 
homosexual or bisexual populations, with very limited infections detected in the heterosexual 
population. However, by the late 1980s, there were increasing numbers of HIV infections appearing 
in the female population and by 1994, at the initiation of this project, there were more female 
infections than male infections, heralding the start of the heterosexual epidemic (see Chapter 2) . 
Since the HIV epidemic in South Africa appeared to be separated according to time course and 
mode of transmission , we wanted to define the HIV-1 subtypes in individuals infected by different 
modes of transmission. An investigation whether there was any relationship between mode of 
transmission and HIV-1 subtype was important, as the two populations may have needed to be 
targeted with different vaccine subtypes. Finally, the HIV epidemics in the different populations could 
be tracked and possible shifts in the epidemics, such as occurred in Thailand and China (see section 
1.6.4.1) could be identified. 
The initial study was performed on patient samples with known mode of transmission from 
Cape Town, a port city in the south-west province of South Africa and Bloemfontein, a central 
province in the country (see chapter 2) . To identify the subtype of a large number of samples, a 
rapid subtyping technique, heteroduplex mobility assay (HMA) (Delwart et al., 1993), was utilised. 
The second aim of the project was to determine whether similar subtypes were circulating in the 
urban heterosexual populations in the rest of South Africa (see chapter 3). To do this, HMA was 
adapted to include South African reference plasmids. Patients were selected from three major urban 
centres in geographically distinct regions in South Africa and subtypes identified were compared with 
subtypes circulating in the heterosexual population in Cape Town. 
As increasing numbers of recombinant viruses ·were being identified (Korber et al., 1997), the 
third aim of the study was to subtype HIV-1 in more than one region of the genome in order to detect 
recombinant viruses (Chapter 3) . To do this, a second rapid screening technique was successfully 
developed for subtype analysis of the gag region (see chapter 3) . Restriction fragment length 
polymorphism (RFLP) analysis in the gag region was used in conjunction with HMA in the env 
region , in order to detect any viruses recombinant in the two regions. RFLP was chosen as it is a 
simple technique to perform, allowing the identification of large numbers of isolates. 
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After establishing that subtype C was overwhelmingly responsible for the majority of HIV-1 
infections in South Africa, the second phase of the project aimed to analyse the gp120 from a 
representative South African isolate (see chapter 4). No macrophage tropic subtype C isolates from 
South Africa had been characterised at this time. The gp120 from a local macrophage tropic, 
primary subtype C isolate was thus chosen for characterisation in order to compare the envelope 
region of this isolate with other HIV isolates. In addition, the majority of vaccines at that time had 
been based on the use of gp120 from T-cell tropic subtype B viruses, whereas the predominant virus 
infecting the heterosexual population in South Africa was subtype C. Also, it had only recently been 
discovered that primary isolates were not neutralised by the initial vaccines based on T-cell adapted 
viruses due to phenotypic differences between them and the recombinant proteins utilised had failed 
to elicit effective CTL responses (Berman et al., 1997 and Connor et al., 1998). 
The final aim of this study was thus to determine the immunogenicity of the gp120 from a 
predominant South African HIV-1 subtype and to determine the potential CTL cross-reactivity 
between this isolate and a macrophage tropic subtype B isolate utilising an in vivo recombinant 
Vaccinia Virus (VV) challenge system in mice (Chapter 4) . 
In order to elicit a CTL response, a DNA vaccine vector was chosen . DNA vaccines are 
easy to construct and can be injected intramuscularly eliciting an effective immune response (Iwasaki 
et al., 1997 and Robinson, 1997a) (see section 1.8.9). The DNA vaccine was then used to immunise 
BALB/c mice in order to determine the possibility of a cross-reactive CTL response between 
subtypes 8 and C (Chapter 4) . 
A murine in vivo model, involving challenge with a recombinant VV expressing the relevant 
immunogen (subtype C gp120), was utilised for the detection of a cross-reactive CTL response in the 
DNA vaccine immunised BALB/c mice (Chapter 4). It has been established that a CTL response is 
more important than a humoral response for prevention of HIV replication (see section 1. 7.1 .2). A 
cross-reactive CTL response would prove to be valuable, since a single HIV vaccine may ' be 
developed for use in all infected populations in South Africa, regardless of the infecting HIV-1 
subtype. In addition, the DNA vaccine system may be utilised for the assessment of other potential 
HIV vaccine proteins in conjunction with the VV challenge system. The W challenge may also be 
used for determination of the optimal vaccine vector and immunisation strategy. 
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CHAPTER 2: AN INVESTIGATION OF THE ORIGIN OF HIV-1 IN SOUTH 
AFRICA AND THE RELATIONSHIP BETWEEN SUBTYPE AND MODE OF 
TRANSMISSION 
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2. 2. 1) Patient data 
2.2.2) DNA extraction 
2.2.3) Polymerase chain reaction (PCR) 
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2.1 j Introduction 
it has been estimated that there are currentiy approximateiy 3.6 miiiion HiV-positive 
persons in South Africa (Department of Heaith, i 999). The H iV-1 epidemic in South Africa has 
spiralled in recent years and fuliy half of the new southern African (including Angola, Zambia, 
Malawi, Mozambique, Zimbabwe, Botswana, Namibia, Swaziland, Lesotho and South Africa) 
infections occur here. it is estimated that there are up to 50 000 new infections occurring every 
month, with the black community in South Africa the worst affected (Department of Heaith, 1999). 
Since 1990, the South African Department of Heaith has performed an annuai survey of 
women attending antenatai ciinics of the public heaith services, whereby routine antenatal biood 
samples are coilected consecutively during October and November from over 12 000 patients. At 
the end of 1998, it was found that 22.8% of the women attending public antenatal clinics were 
infected with HIV, which is a national increase in prevalence of almost 34% since 1997 (see 
figure 2.1) (Swanevelder, 1995 and Department of Health, 1999). 





1990 1991 1992 1993 1994 1995 1996 1997 1998 
Year 
Figure 2.1: Graph indicating the increase in HIV prevalence in women attending antenatal clinics in South Africa from 
1990 to 1998 (Swanevelder, 1995 and Department of Health, 1999). 
The antenatal clinic survey is limited to women of child-bearing age, from 15 to 49 years, 
with the highest rates of infection occurring in the most sexually active age groups, from 20-24 
(26.1 % ) and 25-29 (26. 9%) years. Women who are older have lower rates of infection, at 19.1 % 
for 30-34 age group, 13.4% for the 35-39 age group, 10.5% in the 40-44 age group and 10.2% in 
women aged 45-49 years (see figure 2.2). It must be noted that since fertility decreases after 40 
years, the sample sizes in age groups over 40 are small and the percentage prevalence may not 
be accurate. In the past year, the prevalence in the youngest age group from 15-19 years has 
increased substantially from 12. 7% in 1997 to 21 .0% in 1998; a rate of increase of 65.4% 
(Department of Health, 1999). Clearly, awareness campaigns and prevention education need to 
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Figure 2.2: HIV prevalence by age group in women attending antenatal clinics in South Africa from 1997 to 1998 
(Department of Health, 1999). 
The 1997 antenatal clinic survey gave an indication of the seroprevalence in women 
attending antenatal clinics from different population groups (Department of Health, 1998). The 
highest seroprevalence was in the black population with 65% of the HIV positive women being 
black, followed by the mixed race population with 9.2% HIV positive, whites at 0.3% HIV positive 
and Asians at 0.1 % HIV positive. The remaining 25.4% of HIV positive women were of unknown 
race. The white and Asian population statistics are under-represented, however, since the 
antenatal clinic survey is from antenatal clinics of the public health services and the white and asian 
population groups tend to use private facilities (Department of Health, 1998). Reasons for the high 
HIV prevalence in the black population in South Africa have been discussed in detail in section 
1.6.2 and include social, behavioural, political and economic factors. 
The HIV epidemic in South Africa started in the early 1980s in the male homosexual 
population (Sher, 1989). This was unlike the HIV epidemic occurring in the rest of sub-Saharan 
Africa at this time, where the epidemic was predominantly spread by heterosexual transmission 
(Sher, 1989; Mccutchan et al. , 1992 and Louwagie et al. , 1995). In order to determine whether HIV 
infection had been occurring in South Africa prior to the early 1980s, 257 4 samples which had been 
collected during a pneumococcal vaccine trial in black South African mine workers from 1970-197 4, 
were screened in 1986 for HIV. Participants in the trial came from Mozambique (n=1191 ), Malawi 
(n=1080), South Africa (n=171 ), Lesotho (n=55), Botswana (n=32), Angola (n=29) and Swaziland 
(n=16). No conclusive evidence was found that there were any HIV infections in the samples 
obtained during this time period (Sher et al., 1987). This was in keeping with results obtained from 
studies by Levy et al (1986) and Lyons et al (1985). 
The first two reported cases of AIDS in South Africa, recorded in 1982, were male air 
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stewards infected by h(!mosexual transmission (Ras et al., 1983). Until 1988, the predominant 
number of AIDS cases were found to be in men infected by homosexual or bisexual mode of 
transmission (Sher, 1989). A retrospective study in Cape Town on all adult HIV-positive patients 
presenting at Somerset Hospital and Groote Schuur Hospital was performed on samples taken 
over an eleven year period (1984-1995). Somerset Hospital is the major HIV referral clinic in 
Cape Town, with a second clinic at Groote Schuur Hospital. Two patterns of infection were 
identified (see figure 2.3) . It was determined that from 1984-1989, the HIV-positive outpatient 
population at these two hospitals consisted mainly of white males, infected by homosexual mode 
of transmission. This is in contrast to 1990-1995, where there was a significant increase in the 
outpatients infected by heterosexual transmission , especially in the numbers of females and 
members of the black population (Wood et al., 1996). The second, larger epidemic, occurring in 
the heterosexual population from the late 1980's has now spread significantly and is responsible 
for the majority of HIV infections to date (WHO, 1998). 
We were interested in characterising the HIV subtype diversity within two population 
groups (homosexual/bisexual versus heterosexual) in South Africa , in order to track the epidemic. 
Determination of genetic diversity may be important for the development of vaccines since we do 
not, as yet, know which epitopes are needed for protective immunity and whether subtype-
specific proteins will have to be used (see section 1.7.1.2) . In addition , if genotype is important 
for vaccine design, it is necessary to constantly monitor circulating subtypes of HIV-1 in order to 
detect possible shifts in genetic diversity such as have been observed in other parts of the world, 
for example, Thailand and China (see section 1.6.4) . 
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Figure 2.3: Graph showing the demographics of HIV positive patients attending the HIV/AIDS clinics in Cape Town from 
1984-1995 (Wood et al., 1996). 
In addition, the movement of HIV subtypes globally must be monitored. HIV-1 subtypes 
occurring in Africa are now detected in other parts of the world where they have become 
predominant. For example, subtype Chas spread to India where it is now the prevalent virus and 
is responsible for the majority of heterosexual infections (Dietrich et al., 1993 and Grez et al., 
1994). In addition, subtype C is the predominant virus in China associated with heterosexual 
mode of transmission as well as IVDU (Shao et al., 1996; Shao et al. , 1998 and Yu et al. , 1998). 
It was speculated that the virus entered China via IVDUs from India, since the average DNA 
distance between the Indian subtype C sequences and the Chinese subtype C sequences is only 
4.5% (Luo et al. , 1995). Unlike the burgeoning epidemics in the Far East, such as in Thailand 
and China, in South Africa infection due to IVDU is rare (Sher et al., 1996 and WHO, 1998). 
In order to monitor circulating HIV subtypes within a country, a number of different 
techniques have been used. Sequencing is the most informative technique, however it is 
expensive and time consuming, thus rapid screening techniques for HIV subtype elucidation have 
been developed. For example, heteroduplex mobility assay (HMA) (Delwart et al., 1993) and V3 
serotyping (Cheingsong-Popov et al., 1993 and Cheingsong-Popov et al., 1998) have been used 
to analyse the env region of HIV-1 . 
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HMA was developed by Delwart et al (1993) as a rapid subtyping technique in order to 
identify HIV-1 env subtypes. Unknown samples of DNA are amplified by polymerase chain 
reaction (PCR) , as are reference plasmids for each subtype. The size of the fragment may vary, 
although for the HIV env genome, the 700bp V3 to VS region is most commonly used (Delwart et 
al., 1993; Bobkov et al., 1996b; van Harmelen et al, 1997; Brede II et al., 1998; van Harmelen et 
al., 1999a and van Harmelen et al., 1999b). The technique involves the formation of 
heteroduplex DNA fragments by denaturation and annealing of an equal amount of unknown 
amplified DNA with a reference subtype DNA. The denaturation separates the unknown and 
reference sample dsDNA to single strands and when cooled on ice, heteroduplexes of mixed 
reference and unknown sample· dsDNA will form along with homoduplexes of the parent strands 
that have re-annealed (Appendix A9). Due to sequence mismatches between the unknown DNA 
and reference plasmid DNA, bulges occur in the heteroduplexes. The heteroduplex fragments 
are electrophoresed through a 5% non-denaturing polyacrylamide gel. Samples that are highly 
divergent have more bulges and thus move slower through the gel than samples with high 
similarity. By creating heteroduplexes with a number of different subtype references, the 
unknown isolate can be identified as the isolate that moves the fastest after heteroduplex 
formation . 
The method also provides a means of determining quasi-species diversity within a 
sample by melting and re-annealing the unknown sample alone. Any intrasample diversity will 
cause the formation of heteroduplexes that are resolved in the polyacrylamide gel. This 
intrasample diversity is then compared with the heteroduplex patterns obtained with reference 
subtypes so that the quasi-species bands do not interfere with the identification of samples using 
the reference plasmids. 
No published data was available on the relationship of subtype to mode of transmission 
at the time of initiation of this study. The only South African subtype which had been published 
was isolate Nof subtype C (Dietrich et al., 1993) and sequence comparison of Nof by Dietrich 'et 
al (1993) showed that the sequence was genetically related to the subtype C sequences in India. 
Thus, in this study, 49 samples obtained from patients infected by different modes of 
transmission from Cape Town in the Western Cape Province and four samples from 
Bloemfontein in the Free State Province, were analysed in the V3-V5 region of the env gene by 
HMA in order to determine infecting HIV-1 subtypes. It was determined that distinct HIV-1 
subtypes were associated with either heterosexual or male homosexual modes of transmission in 
the samples analysed. 
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2.2) Materials and methods 
2. 2. 1) Patient data 
EDTA-blood was obtained from patients attending the HIV/AIDS clinic at Somerset Hospital 
(n=49) (obtained from Robin Wood, University of Cape Town, Department of Medicine). In addition, 
extracted DNA was obtained for four samples from the Bloemfontein HIV/AIDS clinic (obtained from 
Elna van der Ryst, Department of Virology, University of the Free State) . Ethical approval was 
obtained by Dr Carolyn Williamson (University of Cape Town) and blood was taken with informed 
consent. The patients were anonymous and samples were coded, with only the treating health care 
workers knowing the patient identification . Patients were not obliged to participate in the study, or to 
fill in the questionnaire. Participation in the study did not affect treatment of the patient. 
The following patient demographic data was requested: age, sex, race, place of residence, 
speculated geographical origin of infection , travel history within the previous five years and route of 
infection. In ·addition, CD4 count of the patient was obtained . When indicated as possible source of 
infection, the travel history of sexual partner was also recorded. Samples were named by year of 
isolation, country of origin and patient identification number. 
Patient clinical and demographic data from the Cape Town samples analysed (n=49) is 
shown in Table 2.1. Year of diagnosis was between 1984 and 1994. The average age of the 
Somerset Hospital patients (n=46) was 35.3 with a range of 20 to 56 years and three patients with 
unknown ages. The male to female ratio was 37:12. There were 17 white patients of which 14 were 
infected by homosexual mode of transmission, two by heterosexual mode of transmission and one 
by blood transfusion. Of the 19 mixed race patients, ten were infected by homosexual transmission, 
seven by heterosexual mode of transmission and two by unknown mode of transmission. All 13 of 
the black patients were infected by heterosexual transmission. Out of the total 49 patients studied, 
24 had CD4 counts under 200 (X106/1), with five patients having unknown CD4 counts. Five of the 
Cape Town patients infected by homosexual transmission and four infected by heterosexual 
transmission reported their speculated geographical origin of infection, due to travel within five 
years prior to the study, having been in outside of South Africa (see Table 2.6) . Four Bloemfontein 
patient samples were taken in 1994. Two of the patients were black males infected by bisexual 
transmission and two of the patients were white males infected by either homosexual or bisexual 
transmission. Only one of the patients had a CD4 count above 200 (X10
6/1) . See Table 2.3 for the 
Bloemfontein patients' demographic data. 
2.2.2) DNA extraction. 
DNA was extracted from 5 to 10ml of EDTA-blood by Maureen Lambrick, (Clinical Virology, 
UCT) as described (Kawasaki, 1990) (Appendix A1) . Briefly, 100µ1 of whole blood was 
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mixed with 0.5ml of 1XTE buffer (10mM Tris-HCI , 1mM EDTA, pH8.0) in a microfuge tube and 
centrifuged at 13 OOOg for 10 seconds. The pellet was resuspended in 0.5ml of 1XTE buffer by 
vortexing and again pelleted . This was repeated twice until a clean nuclei pellet was obtained. 
The pellet was resuspended in 100µ1 of !ysis buffer K (1XPCR buffer (Promega, Madison, WI , 
USA), 0.5% Tween 20, 1 OOµg/ml fresh proteinase K) by vortexing and then spun down before 
being incubated at 56°C for 45 minutes. The protease was inactivated at 95°C for 1 O minutes 
and the cell/nuclei lysate spun down briefly. Ten microlitres of the lysate was used for a 50µ1 
PCR master mix volume. 
2.2.3) Polymerase chain reaction (PCR) 
A 700bp and 1.2Kb DNA fragment were both amplified by nested polymerase chain 
reaction (PCR). The 700bp DNA fragment encompassing the V3-V5 region of the env gene was 
amplified by nested PCR from patient samples using outer primers EDS/12 and inner primers 
ES7/8 (NIH AIDS Research and Reference Reagent Program, USA) (see Table 2.1) as described 
(Delwart et al., 1993) (Appendix A2) . 
The 50µ1 master mixes contained : 
• 5µ1 of PCR buffer (SOOmM KCI, 100mM Tris-HCI (pH9.0), 1% Triton X-100) (Promega, 
Madison, WI, USA) , 
• 1 % DMSO, 1 % glycerol, 
• 200µM each of dNTPs, 
• 1.SmM MgCl2 (outer reaction) and 1.8mM MgCl2 (inner reaction), 
• 400nM each primer; EDS and ED12 (outer reaction) or ES7 and ESB (inner reaction), 
• 2.SU Taq DNA Polymerase (outer reaction) and 2U Taq DNA Polymerase (Promega, 
Madison, WI, USA) (outer reaction) and 
• 1 OµI patient DNA (outer reaction) or 3µ1 of.the, outer reaction PCR product (inner reaction). 
• If reference plasmids (NIH AIDS Reference and Reagent Program, USA) were amplified, 2µ1 
of plasmid DNA (20ng) was added to the inner reaction mix. 
The PCR reaction was carried out using the Techne PHC-2 PCR machine with the 
following cycling conditions: 
Outer reaction : 
• initial denaturation at 94°C for 2 minutes, 
• 94°C for 1 minute, 45°C for 1 minute and 72°C for 2 minutes (5 cycles) 
• 94°C for 20 seconds, 55°C for 45 seconds and 72°C for 1 minute (35 cycles) 
• final extension at 72°C for 6 minutes. 
Inner reaction : 
• initial denaturation at 94°C for 2 minutes, 
• 94°C for 20 seconds, ss 0 c for 45 seconds and 72°C for 1 minute (35 cycles) 
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• final extension at 72°C for 6 minutes. 
A water control and HIV-negative patient DNA was also included in order to determine 
primer specificity and to monitor for contamination. All PCR master mix reactions were made up 
in a laminar flow hood . DNA was added in a separate cubical with no DNA products allowed to 
enter the master mix flow hood . DNA was transferred to nested reactions in a third cubical in 
order to prevent contamination. Amplified product was stored at -20°C. The 700bp fragment was 
used for subtyping of patient samples by HMA. 
The 1.2Kb fragment of the env gene from seven samples (94ZA060, 94ZA061, 93ZA004, 
93ZA009, 93ZA040, 94ZA067, 93ZA034) already subtyped by HMA, was amplified using primers 
ED3/14 for the outer reaction , and EDS/12 (see Table 2.1) for the inner reaction (NIH AIDS 
Research and Reference Reagent Program, USA) as descibed (Delwart et al., 1993) (see 
Appendix A2) . Briefly, the PCR reactions for the inner and outer amplifications were were as 
above for EDS/12. Ten microlitres of patient DNA was added to the outer reaction master mix, 
and 3µ1 of the outer reaction amplified product transferred to the inner reaction for amplification 
of the final product. Water and HIV-negative patient controls were included as before. The 
product was stored at -20°C. 
PCR amplified fragments were separated by electrophoresis in a 1 % agarose gel in 
1XTAE and visualised with ethidium bromide (10ng/ml) at 256nm with UV transillumination 
(Appendix A3) . 
Table 2.1: Primers (Delwart et al. , 1993) constructed for PCR amplification of the env region for 
HMA and sequence analysis. 
Name Position Sequence 
ED3 5956bp-5985bp 5 'TT AGGCA TCTCCT A TGGCAGGAAGAAGCGG3' 
ED14 7960bp-7931 bp S'TCTTGCCTGGAGCTGTTTGA TGCCCCAGAC3' 
EDS 6556bp-6581 bp S'ATGGGATCAAAGCCT AAAGCCATGTG3' 
ED12 7822bp-7792bp 5'AGTGCTTCCTGCTGCTCCCAAGAACCCAAG3' 
ES7* 7001 bp-7020bp S'CCCGGCTGTTRAA TGGYAGYCTAGC3' 
ESB* 7667bp-67 4 7bp S'GCCGCCA T AA TTCA TTTCYCCAA TTG3' 
ED33* 7359bp-7380bp S'TT ACAGT AGAAAAA TTCCCCTC3' 
*Sequencing primers for the V3-V5 fragment. 
# Position was taken from the HIV-1 HXB2 genome (Genebank acession number K03455) 
Degenerate bases are shown using the IUPAC degenerate codes described by the DNAMAN 
Version 4, computer package (Lynnon BioSoft, 1994-1997); R = A or G and Y = C or T. 
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2.2.4) Cloning and sequencing 
The 1.2Kb (ED5/ED12) fragment of the env gene amplified from seven samples 
(94ZA060, 94ZA061 , 93ZA004, 93ZA009, 93ZA040, 94ZA067, 93ZA034) was cloned by TA 
cloning into pMos-blue T-vector polycloning site (Amersham, Buckinghamshire, UK), as 
recommended by the manufacturers (Appendix AS) . Ligated DNA was transformed into 
competent Escherischia coli strain DH5a. (Appendix A6) and white colonies containing putative 
clones screened for inserts by mini-preparation of DNA and Pstl/EcoRI double digestion 
(Appendix A4 and A7) . Digested fragments were visualised after electrophoresis in a 1 % 
agarose gel with ethidium bromide (1 Ong/ml) staining under 256nm UV light (Appendix A3). 
DNA from positive clones was purified using a commercial silica-based anion-exchange 
column DNA purification kit (Nucleobond® AX100, Machery-Nagel , Germany) according to 
manufacturers instructions (Appendix A7) . The V3-V5 region (±700bp) of the 1.2Kb env 
fragments (n=7) were sequenced in both directions with forward and reverse primers, ES7 and 
ED33 (Delwart et al., 1993) (see Table 2.2) until unambiguous, by standard dideoxy chain 
termination method (Sanger et al., 1977) using 
35S-dATP label and the Sequenase ® II kit (United 
States Biochemical Corporation , Amersham®, USA) (Appendix A8.1). 
2. 2. 5) Sequence analysis 
Sequences were initially analysed by performing a BLAST (Basic Logical Alignment 
Search Tool, http://www.ncbi.nlm.nih .gov/BLAST) search (Altschul et al., 1990) to confirm the 
HIV identity of the sequence. Sequences were aligned with reference sequences from subtypes 
A to H (see Table 2.3) using Clustal X (Thompson , 1997), with a final manual adjustment. 
Subtype J reference sequences were SE91733 and SE92809 from recent immigrants from the 
former Zaire (Democratic Republic of the Congo) residing in Sweden . Phylogenetic analysis 
generated trees based on the distance matrix' neighbour-joining method in TREE CO NW 1.0 (van 
der Peer and de Wachter, 1994). Tree top·ology was inferred using the Kimura two-parameter 
correction for multiple substitutions, ignoring insertions and deletions (Kimura, 1980). Reliability 
of the tree topology was assessed using 1000 bootstrap replicates with the SIVcpz-gab sequence 
as outgroup. No interpatient sequences were found to be identical and there was no tight 
clustering of patient sequences with reference plasmid sequences. DNA sequences were 
translated to amino acid sequences using Genepro (Version 6.10, Riverside Scientific Enterprises 
WA, USA). The seven env sequences were named by year of isolation , country of origin and 
patient identification number. The sequences have been deposited in the Genbank database 
(accession numbers AF095825 - AF095831) . 
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2.2.6) Heteroduplex mobility assay (HMA) 
Heteroduplex mobility assay (HMA) was performed on the 700bp env gene V3-V5 region 
of a total of 53 samples (Appendix A9) as described (Delwart et al. , 1993). For subtype 
designation, initial unknown samples were compared with reference plasmids representative of 
subtypes A to D, using any one subtype A, two subtype B, two subtype C and one subtype D 
reference plasmids for each isolate. The reference plasmids were supplied by the HMA kit and 
are shown in Table 2.2) (NIH AIDS Research and Reference Reagent Program, USA) . Any 
isolates which were ambiguous, or identified as a subtype A or subtype D were compared with all 
HMA reference plasmids, from subtype A to G. Prior to the use of the HMA kit, all reference 
plasmids were subjected to HMA analysis against each other and compared to a reference HMA 
gel supplied in the kit. This procedure was necessary in order to maintain that there was no 
cross-contamination between reference plasmids for each subtype. 
Table 2.2: Reference subtypes provided in the NIH AIDS Research Reference and Reagent 
Program (USA) HMA kit. 
Subtype Sequence Name Country of Origin Fragment Cloned 
A1 RW20 Rwanda gp160 
A2 IC144 Ivory Coast ED5-ED12 
A3 SF170 Rwanda gp160 
81 BR20 Brazil gp160 
82 TH14 Thailand gp160 
83 SF162 USA 6.6kb 3'end 
C1 MA959 Malawi gp160 
C2 ZM18 Zambia ED5-ED12 
C3 IN868 India ED5-ED12 
D1 UG21 Uganda gp120 
D3 UG46 Uganda gp120 
E1 TH22 Thailand gp160 
E2 TH06 Thailand gp160 
E3 CAR7 Central African ED5-ED12 
Republic 
F1 BZ162 Brazil gp120 
F2 BZ163 Brazil gp120 
G1 RU131 Russia ED5-ED12 
G3 Vl525 Gabon gp160 
H1 CA13 Cameroon ED5-ED12 
H2 Vl557 Zaire ED5-ED12 
Five sequenced isolates were used as the South African reference plasmids instead of 
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the subtype reference plasmids from the HMA kit (NIH AIDS Research and Reference Reagent 
Program, USA) (see section 2.2.4). These were ; subtype B, 93ZA004 and 93ZA009; subtype C, 
93ZA040 and 94ZA067 and subtype D, 93ZA034. In addition, one of the three subtype A isolates 
from the HMA kit (NIH AIDS Research and Reference Reagent Program, USA) was used. 
Briefly, heteroduplexes of reference strain and unknown PCR amplified DNA were 
formed in a 500µ1 eppendorf PCR tube by mixing 4.5µ1 of PCR product (approximately 100-
250ng of DNA), 4.5µ1 reference PCR plasmid (c!pproximately 100-250ng of DNA) and 1 µI 
heteroduplex annealing buffer (100mM NaCl; 10mM Tris, pH7.8; 2mM EDTA) . In order to 
determine the genetic diversity of each PCR amplified unknown sample, 4.5µ1 of sterile distilled 
water was added instead of reference plasmid DNA. The tube was heated to 94°C for 2 minutes 
in the PHC-2 PCR Techne thermocycler in order to denature the DNA strands and the tubes were 
then rapidly cooled by placing on wet ice. The heteroduplex reaction mixture was then mixed 
with 2µ1 of loading dye (0 .25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol in 
deionised water) and loaded into the wells of a 5% non-denaturing vertical polyacrylamide gel. 
The heteroduplexes were separated by electrophoresis on a Hoefer SE600, 19cm/16cm, 
1.5mm thick (Hoefer Scientific Instruments, San Francisco, USA) 5% non-denaturing 
polyacrylamide gel in 1XTBE at 200V for five hours (see Appendix A9) . The DNA fragments 
were visualised by ethidium bromide (1 Ong/ml) staining in 1 XTBE for 30 minutes and UV 
transillumination at 256nm. Although it may be necessary to dilute the patient sample prior to 
amplification if there is high quasi-species diversity, this was not necessary for any of the 
samples analysed in this study. By diluting the sample DNA to be amplified , fewer quasi-species 
are amplified which may interfere with the analysis of the heteroduplexes formed with the 
reference plasmid DNA. Samples ambiguous with the full range of HMA kit reference plasmids 
(NIH AIDS Research and Reference Reagent Program, USA) were analysed by sequence 
analysis of the V3 loop region . 
2.3) Results 
2.3. 1 Subtype designation 
HMA of the V3-V5 region of the env gene was used to subtype a total of 49 samples from 
Cape Town and four samples from Bloemfontein. Four different subtypes were identified; 
subtypes A, B, C and D (see table 2.3). In addition, five of the Cape Town isolates; 93ZA004, 
93ZA009 (subtype B) , 93ZA040, 94ZA067 (subtype C) and 93ZA034 (subtype D) were 
sequenced in the V3-V5 region of the env gene for subtype confirmation and utilised as South 
African reference plasmids for HMA. The V3-VS region of the env gene from an additional two 
samples (94ZA060 and 94ZA061) was sequenced in order to confirm subtype. 
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An initial 26 of the 53 isolates were analysed by HMA using the HMA kit reference 
plasmids (NIH AIDS Research Reference and Reagent Program, USA) as described in the 
methods, section 2.2.3. However, South African subtype reference isolates were postulated to be 
more similar to the unknown South African samples being studied than the reference isolates 
from the HMA kit (NIH AIDS Research Reference and Reagent Program, USA) . Five South 
African reference plasmids were thus constructed , in order to increase the specificity of the HMA 
technique. The five isolates were selected as South African reference plasmids after 
identification by HMA using the HMA kit reference plasmids, from subtype A to G (NIH AIDS 
Research Reference and Reagent Program, USA): subtype B (93ZA004, 93ZA009) , C (93ZA040, 
94ZA067) and D (93ZA034) . Subtype identity was subsequently confirmed by sequence analysis 
of the V3-V5 region of the env gene (see section 2.3.2). The remaining 27 samples were thus 
identified using these South African reference plasmids. Although Delwart et al (1993) reported 
that it was possible to calculate DNA distances based on the mobility of unknown samples, we 
found that the technique was unreliable. This was partly due to samples not migrating according 
to their DNA distances, but also because we did not have sufficient numbers of reference 
plasmids to accurately determine the DNA distance standard curve . 
When used for HMA analysis, it was found that although the South African reference 
plasmids did not increase the mobility shift between subtypes for South African unknown samples 
in comparison to the reference plasmids, all but two of the samples studied were still able to be 
successfully identified. Isolates not subtyped as B or C were rare, (n=4) and were further 
analysed using the NIH AIDS Research Reference and Reagent Program (USA) HMA kit 
reference plasmids. 
Patient 94ZA050 had a speculated origin of infection in Thailand . After unsuccessful 
HMA identification using the South African reference plasmids, the isolate was analysed using 
subtype A (RW20), subtype B (BR20 and TH14), subtype C (MA959), subtype D (UG21) and 
subtype E (TH06) from the HMA kit (NIH AIDS Research Reference and Reagent Program, 
USA) . The heteroduplex formed with the Thailand subtype B reference plasmid, TH14, migrated 
the fastest (see figure 2.4) , identifying the isolate as a subtype B. 
The isolate from patient 94ZA061 gave anomalous results, using the South African 
reference plasmids, thus a more detailed analysis was performed on the isolate, using the 
reference plasmids from subtype A to F in the HMA kit (see Table 2.3). The heteroduplexes 
formed between isolate 94ZA061 and subtype E reference plasmids (TH22 and TH06) migrated 
similar distances as heteroduplexes formed with subtype A reference plasmids (RW20 and 
SF170) (see figure 2.5) , although the fastest migration occurred with subtype E plasmid TH22 
(Thailand) . In order to clarify the HMA results, a second sample was obtained for both patient 
94ZA061 and his wife, 94ZA060. Both samples were analysed by HMA using the reference 
plasmids from the HMA kit , including all of the subtype A (RW20, SF170 and IC144) and all of 
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the subtype E plasmids (TH06, TH22 and CAR7). Isolate 94ZA060 was identified as a 
subtype A by HMA, migrating fastest with the subtype A reference plasmids. No 
heteroduplex shifts were observed with any of the subtype E reference plasmids. Isolate 
94ZA061 , however, again shifted both with the subtype E reference plasmids as well as the 
subtype A reference plasmids. The fastest migration was observed with TH22, the subtype E 
Thailand isolate, as before. To confirm the sequence identity of both isolates, they were 
sequenced in the V3 to V5 region of the env gene and it was determined that both patients 
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VI 
Figure 2.4: HMA gel of two subtype B 
isolates, 93ZA008 and 94ZA050. The 
faster mobility of the heteroduplexes 
when annealed to a subtype B reference 
isolate is clearly shown. He 
(heteroduplexes) , Ho (homoduplexes) , A 
(RW20), B1(BR20) , B2 (TH14), C1 
(MA959) , C2 (ZAM18) , D (UG21) and E 
(TH06). MW VI (Boehringer Mannheim, 
Hamburg, Germany). 
Figure 2.5: HMA gel of 94ZA061 , showing 
the dual shift with subtype A and subtype E 
reference plasmids. Subsequent sequence 
analysis confirmed that the isolate was a 
subtype A. He (heteroduplexes) , Ho 
(homoduplexes), A1 (RW20) , A2 (SF170) , 
81 (BR20) , 82 (TH14) , C1 (MA959), C2 
(ZAM18) , C3 (1868), D1 (UG21) , D2 
(UG46) , E1 (TH06) , E2 (TH22) , E3 
(CAR?), F (82162), MW VI (Boehringer 
Mannheim, Hamberg, Germany). 
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Table 2.3: Demographic and patient clinical data according to mode of transmission for the 
patient samples studied from Somerset Hospital in Cape Town in the Western Cape Province and 
from the HIV/AIDS clinic in Bloemfontein in the Free State Province. 
Sample Age Sex Race CD4 count Origin of Origin of Subtype 




93ZA006 30 male white 342 RSA C 
93ZA010 41 female black 530 RSA C 
93ZA020 33 female mixed race 5 Zambia Zambia C 
93ZA023 48 male black 169 RSA C 
93ZA024 41 male black 200 RSA Namibia C 
93ZA029 29 female black 172 RSA C 
93ZA031 31 male black 154 Zimbabwe C 
93ZA032 34 female black 72 RSA C 
93ZA035 52 male mixed race 140 RSA C 
93ZA037 32 male mixed race 418 RSA C 
93ZA040 34 female black 269 RSA C 
93ZA042 27 male mixed race 54 RSA C 
93ZA043 32 female mixed race 443 RSA C 
93ZA046 21 female black 404 RSA C 
93ZA047 24 male black 373 RSA C 
93ZA048 40 male black 111 RSA C 
93ZA049 20 female black 517 RSA C 
94ZA058 37 female white 357 RSA D 
#94ZA060 42 female mixed race 421 RSA A 
94ZA061 33 male black 138 RSA A 
94ZA063 24 male mixed race ND RSA C 
94ZA067 30 female black ND RSA C 
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Table 2.3 continued ... 
Sample Age Sex Race CD4 count Origin of Origin of Subtype 
name (years) (X10
8/I) infection infection of 
partner 
Homosexual Transmission 
93ZA001 37 male white 504 RSA B 
93ZA002 35 male white 52 RSA B 
93ZA003 32 male white 84 Unknown B 
93ZA004 30 male white 564 USNEurope B 
93ZA005 42 male mixed race 231 RSA USA/Europe B 
93ZA007 41 male white 0 RSA Europe B 
93ZA009 31 male mixed race 499 RSA B 
93ZA011 25 male mixed race 481 RSA B 
93ZA017 25 male white 8 RSA B 
93ZA021 44 male mixed race 245 RSA B 
93ZA022 49 male white 69 RSNAus B 
93ZA033 36 male white 374 Aus/USA B 
93ZA034 42 male white 21 RSA D 
93ZA039 37 male mixed race 748 RSA B 
93ZA041 30 male mixed race 54 RSA B 
93ZA044 48 male white 208 RSA B 
93ZA045 26 male mixed race 397 RSA B 
94ZA050 39 male mixed race 32 RSA Thailand B 
94ZA059 55 male mixed race 77 RSA B 
94ZA073 47 male white 23 RSA B 
94ZA076 ND male white ND RSA B 
94ZA077 ND male mixed race ND Thailand B 
Bisexual Transmission 
93ZA038 38 male white 0 RSA B 
94ZA072 56 male white 45 RSA B 
Other Transmission 
*93ZA008 28 female white 6 B 
594ZA074 42 male mixed race 11 B 
594ZA078 ND male mixed race ND B 
Bloemfontein 
Homosexual transmission 
95ZA25FS 38 Male White 10 RSA B 
Bisexual transmission 
95ZA06FS 22 Male Black 130 RSA C 
95ZA14FS 22 Male Black 240 RSA B 
95ZA17FS 30 Male White 120 RSA B 
ND, not determined 
*Patient infected by blood transfusion 
# Isolate sequenced in the env region 
5 Patients infected whilst incarcerated in Pollsmoor prison 
RSA, Republic of South Africa; USA, United States of America; UK, United Kingdom; Aus, 
Australia. 
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2. 3. 2) Sequence analysis of the env V3-VS region 
The V3-V5 (700bp) region from isolates 94ZA060, 94ZA061, 93ZA004, 93ZA009, 
93ZA040, 94ZA067 and 93ZA034 were sequenced using the Sanger dideoxy termination method 
(Sanger et al., 1977) and subjected to phylogenetic analysis with reference sequences from 
subtypes A to J with SIVcpz-gab as the root (see figure 2.6). All of the subtypes designated by 
HMA were found to cluster with their expected reference subtype sequences, with both 
intrasubtype and intersubtype DNA distances shown in Table 2.4. 
Table 2.4: The intrasubtype and intersubtype DNA distance percentages for South African 











































































































































In our comparison of the V3 loop region frorn subtypes A to AE (figure 2.7), including 
our reference plasmid sequences (HIV sequence database, 1998), the V3 loop of all South 
African isolates, except 93ZA034 (subtype D) was 35 amino acids in length. Isolate 93ZA034 
had a V3 loop of 36 amino acids. 
Both of the subtype B viruses had the characteristic GPGR tetrapeptide crown. The 
two subtype A, two subtype C viruses and one subtype D virus had the GPGQ tetrapeptide 
crown motif. Both of the subtype C isolates sequenced in this study, as well as all of the 
reference subtype C isolates were missing the N-linked glycosylation site at position 265-267, 
proximal to the start cycteine of the V3 loop, that is usually absent in subtype C isolates 
(Korber et al., 1997 and Abebe et al., 1997). The argenine substitutions at positions 276, 290 
and 297 that result in an increased positive charge and are indicative of a syncitium-inducing 
phenotype was only present in sample 94ZA067 (Fouchier et al., 1992 and De Wolf et al., 
1994). Unfortunately, the CD4 count for this patient was not available, thus the disease stage 
could not be determined. The second V3 loop glycosylation site at position 271-273 was 
present in all subtype C isolates. 
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Figure 2.6: Phylogenetic tree of the V3 to VS region of the env gene for isolates 94ZA060, 94ZA061 , 93ZA004, 93ZA009, 
93ZA040, 94ZA067 and 93ZA034 in comparison to at least two reference sequences from subtypes A to J . Isolates 
94ZA060 and 94ZA061 cluster with the subtype A sequences with a bootstrap value of 100%; isolates 93ZA004 and 
93ZA009 group with the subtype B sequences with a bootstrap value of 97%; isolates 93ZA040 and 94ZA067 belong to 
subtype C, clustering with the subtype C isolates with a bootsrap value of 100%; and isolate 93ZA034 clusters with the 
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Figure 2.7: An alignment of the V3 loop for subtypes A to AE. The top sequence is a consensus sequence for the subtype taken from 
Myers et al (1 996). Potential N-linked glycosylation sites are shown in blue with carets (A) above, the conserved cysteine residues are 
indicated with asterisks (*) and the V3 crown tetrapeptide is shown in red. The arginine residue at position 276, indicative a SI phenotype is 
indicated in green (Fouchier et al., 1992 and De Wolf et al. , 1994). 
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2.3.3) HIV-1 subtype in South Africa according to mode of transmission 
The HIV-1 subtypes in South Africa were found to segregate according to mode of 
transmission , with subtype C the prevalent virus in the heterosexual population and subtype B 
responsible for the majority of homosexual and bisexual infections. 
2.3.3.1) Heterosexual Transmission 
Of the 22 patients infected by heterosexual transmission , 17 were infected with subtype 
C, two with subtype A, two with subtype B and one with a subtype D virus (see figure 2.8) . The 
majority of the patients infected with subtype C in this study were black (n=11) , although four 
patients were of mixed race an_d two patients were white . The single subtype D-infected patient 
was a woman , residing in South Africa, with no record of travel history to any other country within 
the last five years before sampling . 
2.3.3.2) Homosexual transmission 
Of the 24 male patients analysed frorn Cape Town, infected by homosexual or bisexual 
transmission, 23 were infected with subtype .B and one with a subtype D virus (see figure 2.4). 
The majority of men infected by homosexual or bisexual transmission (n=24) were white males 
(n=14) , although 10 males of mixed race were also infected. In the Cape Town study, no men 
infected by homosexual or bisexual transmission were infected with a subtype C virus, the 
subtype predominant in the heterosexual population . The single subtype D virus was detected in 
a white male residing in South Africa who had no travel history to a country where subtype D was 
prevalent, within the last five years prior to the study. 
In Bloemfontein two white males infected by homosexual and bisexual mode of 
transmission and one black male infected by bisexual mode of transmission were infected with 
subtype B. The remaining sample, taken from a black male infected by bisexual transmission 
was found to be infected with the first subtype C virus identified in the bisexual/homosexual 
population. 
2.3.3.3) Other modes of transmission 
Three additional subtype B viruses were identified; two transmitted by unknown route in 
men currently incarcerated at Pollsmoor prison and one transmitted to a woman by blood 
transfusion (see figure 2.8) . 
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Figure 2.8: A graph indicating the relationship between subtype and mode of transmission. The predominant subtype 
infecting the heterosexual population is subtype C and the predominant subtype infecting the homosexual population is 
subtype B. 
2.3.3.4) The relationship of HIV-1 subtype to speculated origin of infection 
Although the patients involved in the study all resided in South Africa, a number of 
patients from the Cape Town study reported having had sexual contact outside of the country, or 
their partners had had sexual contact abroad within five years prior to sampling (see section 
2.2.1 ). All of these individuals infected by homosexual transmission were infected with subtype 
B viruses, including 93ZA004, 93ZA005 and 93ZA033 (presumed origin of infection, USA); 
93ZA004 and 93ZA007 (Europe}, 93ZA022, 93ZA033 (Australia) and 94ZA050 and 94ZA077 
(Thailand). In addition, a number of Cape Town patients infected by heterosexual contact 
speculated that their origin of infection was in a nearby Southern African country, or the patients 
had previously resided in these countries. These include 93ZA020 (presumed origin of infection 
Zambia}, 93ZA024 (Namibia) and 93ZA031 (Zimbabwe). All of these individuals were infected 
heterosexually with subtype C viruses (see Table 2.5). 
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Table 2.5: The HIV subtype identified in each patient according to race group and speculated 
origin of infection of the patients or their'sexual partner within five years of sampling . 




White 108, 1D 
Black 18, 1C 








3C, 28, 1A 












* Predicted geographical origin of infection for either the patient or their partner. In addition, two 
mixed race , male patients were infected whilst in Pollsmoor prison and one white female was 
infected by blood transfusion , all with subtype 8 viruses. 
a Note: patients may have a speculated origin of infection in more than one country. 
2.4) Discussion 
I 
A comparison of the number of AIDS cases occurring in men and women from the early 
1980's until the present indicates that there were two separate patterns of HIV infection in South 
Africa . In the early 1980s, HIV was predominantly detected in white or mixed race homosexual 
men , whereas HIV infection in women was rare (Sher, 1989 and Wood et al. , 1996). A 1983 
study performed in Johannesburg showed that the majority of homosexual infections were as a 
result of sexual contact with men abroad in Europe or the USA (Sher et al., 1985). However, 
many (23 out of 35) of patients infected homosexually in our study, in the mid- to late 1980~. 
reported that they had not had sexual contact whilst abroad , or with any partners who had been 
abroad five years prior to sampling for this study. 
The numbers of HIV infected women started rising by 1988 and in 1992, the number of 
infected females was approximately equivalent to the number of infected males (Sher et al., 
1989; Swanevelder, 1995 and Wood et al., 1996). By 1994, the number of female AIDS cases in 
South Africa was higher than AIDS cases in men with large numbers of infections in the sexually 
active female population (see figure 2.2) (Swanevelder, 1995). 
In order to understand the epidemic occurring in South Africa , the global HIV epidemic 
must be taken into consideration . HIV-1 subtype 8 was first identified in men infected by 
homosexual transmission in the United States and countries in Europe and is now the 
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predominant virus in these countries. Subtype B is, however, rarely detected in Africans residing 
on the African continent. Although all of the subtypes are present in Africa, subtypes A, C and D 
are the prevalent viruses. Subtype A is common in west Africa (Poss et al., 1997), subtypes A 
and D in central and east Africa (Luo et al., 1998; Rayfield et al., 1998) and subtype C in southern 
and north Africa (Abebe et al., 1997; Bjorndal et al., 1999; Novitski et al., 1999 and Tien et al., 
1999). The predominant mode of transmission is heterosexual (MAP, 1997 and WHO, 1998). 
In this study, four subtypes were identified in the 53 samples analysed in the env region of 
the HIV-1 genome, including two subtype A, 31 subtype B, 18 subtype C and two subtype D 
viruses. The subtypes segregated according to mode of transmission, with 92.9% (26 out of 28) 
of the male homosexual/bisexual group infected with subtype B viruses and 77.2% (17 out of 22) 
of the heterosexual group infected with subtype C viruses. Three patients were infected by 
unknown node of transmission. There is a significant association between subtype and mode of 
transmission (p=<0.0001 ), which suggests that the origin of the second, heterosexual epidemic is 
mostly independent to the first wave of infections. 
The genetic diversity of two South African subtype B reference isolates, 93ZA004 and 
93ZA009 were investigated by sequence analysis of an approximately 700bp region of the env 
gene, incorporating the V3 loop. It was determined that the intrasubtype DNA distance between 
the reference sequence from the United States (SF162) was equal to (93ZA004, 13.2%) or less 
than (93ZA009, 8.9%) the DNA distance between the two South African subtypes (13.2%)(see 
Table 2.4). This is in comparison to the DNA distance (9.6%) between the reference sequence 
from the United States (SF162) and from Thailand (TH14). The South African subtype B isolates 
were thus as divergent from each other as from at least one of the HMA kit (NIH AIDS Research 
Reference and Reagent Program, USA) reference subtype B isolates. This high genetic diversity 
may be an indication as to why the South African reference plasmids were not more efficient in 
the identification of South African subtype B samples than the kit reference subtypes. 
Although the predominant subtype infecting the homosexual population in our study was 
subtype B, subtype D was also identified. An earlier study on fourteen samples from Tygerberg 
Hospital, obtained between 1984 and 1989 by Engelbrecht et al (1995) reported on the 
identification of subtype D in five men infected by homosexual or bisexual mode of transmission. 
The subtype D isolates may have epidemiological linkage, with an intrasubtype DNA distance of 
only 4.6% to 6.5% in the V3 loop of the env gene. This is in comparison to a maximum 
intrasubtype DNA distance of 13.9% when the Zairean reference sequence, ELI, was included. 
However, in our study, out of 28 male homosexual patients diagnosed in the late-1980's to early-
1990's (up to seven years after the Tygerberg patients) only one was infected with a subtype D 
virus. It would thus appear that the subtype D epidemic has failed to proliferate in the homosexual 
population. 
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Subtype C was identified as the predominant virus infecting the heterosexual population 
in Cape Town by HMA. Results from a concurrent study on the p17 region of the gag gene from 
Cape Town patient isolates gave an indication of the DNA distances and genetic diversity 
between Cape Town subtype C isolates (Williamson et al., 1995 and van Harmelen et al., 1997). 
The high intrasubtype DNA distance in the gag region (6 .8%), together with the recent 
introduction of subtype C into the country indicated the multiple entry of this subtype at different 
times (Williamson et al., 1995 and van Harmelen et al., 1997). These results were confirmed by 
a more recent study, performed by Bredell et al (1998) on 43 mine workers working in the 
Gauteng Province gold mines. Mine workers included migrant workers from Lesotho, Botswana, 
Mozambique and Swaziland, as well as South African men. The average intrasubtype DNA 
distance between subtype C isolates sequenced in the V3 to VS region was over ten percent 
(Bredell et al., 1998). 
Epidemiological data supports the hypothesis that subtype C was introduced into the 
heterosexual population in South Africa on a number of different occasions from neighbouring 
countries. Some of the patients in this study reported having had sexual contact in Zambia, or 
Zimbabwe, where subtype C is commonly found (Mccutchan et al., 1992 and Tien et al., 1999). 
It would thus appear that the later epidemic was as a result of the regional spread of the HIV-1 
from neighbouring countries into South Africa. Due to the close socio-economic ties between 
South Africa and its neighbouring countries as well as the extensive migrant labour, there is a 
constant movement of people, facilitating the spread of HIV-1 to South Africa. 
The two South African subtype C reference isolates sequenced in the V3-V5 region were 
only 4.5% divergent, in comparison to the Zambian and Malawian subtype C sequences to which 
they were at least 8.1 % divergent (93ZA040 and ZM18 or MA959) and at most 9.1 % divergent 
(94ZA067 and MA959) . The low DNA difference between the two subtype C isolates is not 
representative of the subtype C epidemic in South Africa, however, as illustrated in the gag an'd 
env regions (see Chapter 3) (Williamson ef al., 1995; van Harmelen et al., 1997 and Brede II et 
al., 1998). The low genetic diversity of the South African reference plasmids, in comparison to 
the majority of highly divergent subtype C isolates may explain why the reference plasmids did 
not yield greater mobility shifts by HMA with unknown South African samples than the kit subtype 
C reference plasmids from Zambia and Malawi. The genetic diversity of subtype C in South 
Africa and factors influencing the spread of the heterosexual epidemic will be discussed in more 
detail in Chapter 3. 
The heterosexual population in Cape Town had the highest diversity of HIV subtypes, 
with subtypes A, B and D also identified . Although subtype B was the subtype associated with 
the initial homosexual epidemic, it failed to spread significantly within the heterosexual 
population in Cape Town, where only two patients were found to be infected with subtype B. 
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The two subtype A viruses, 94ZA060 and 94ZA061, were sequenced in the V3-V5 region 
of the env gene. Although they had a fairly high DNA distance (9 .1 %), the two sequences 
grouped together in the phylogenetic tree, with a bootstrap value of 100%. The average DNA 
distance of 94ZA060 and 94ZA061 was 12.5% in comparison to the two reference subtype A 
samples, RW20 and SF170. The migration of isolate 94ZA061 with TH22, the Thailand 
reference plasmid, by HMA could not be explained by the DNA distance (21.1 %) between the 
sequences. The gag region of these isolates was also sequenced and will be discussed in 
Chapter 3. 
In addition, subtype D was identified in a white female infected by heterosexual 
transmission. There is no indication as to where the patient may have been infected, since the 
patient resided in South Africa, with no reported travel, or contact with a sexual partner who had 
travelled to central or east Africa, where subtype D is common. 
There is an association between subtype and mode of transmission in a number of other 
countries; including China, India, Thailand and Russia (Dietrich et al., 1993; Ou et al., 1993; Luo 
et al., 1995; Wasi et al., 1995; Lukashov et al., 1997 and Liitsola et al., 1998; Shao et al., 1998) 
(see detailed discussion in section 1.7.4). It is necessary to maintain surveillance over the 
prevalent subtypes, since genetic shifts between subtypes have been identified (see section 
1.6.4) . In South Africa , the first subtype C virus infecting the bisexual population was identified 
in the Bloemfontein study. This could be an indication of the beginning of a shift in the subtypes 
infecting the homosexual/bisexual population, with subtype C now entering this population. The 
limited sample numbers make an accurate analysis impossible, and a larger study of men 
infected by homosexual/bisexual transmission should be performed in order to monitor the 
possible spread of subtype C within this population. 
Although it is possible that certain subtypes may have a selective advantage in 
transmission , in South Africa, however, it is more probable that social and cultural reasons 
influence the segregation of subtype with mode of transmission. Besides mode of transmission, 
there may be other segregating factors between the two epidemics. The early homosexual 
epidemic started during the years when apartheid was still the political policy in South Africa and 
it is possible that the forced racial segregation played a role in the segregation between the two 
epidemics. However, our study was not designed to investigate this. 
In conclusion, the initial homosexual epidemic in South Africa was at least in .part, a 
result of the introduction of HIV-1 into South Africa from other continents, such as North America 
and Europe. Molecular evidence confirms this, whereby the predominant subtype infecting the 
homosexual population is subtype B, which is common in Europe and the United States, but rare 
in Africa . The heterosexual epidemic, on the other hand, is predominantly caused by subtype C 
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infections. This devastating epidemic appears to have been introduced into South Africa on a 
number of occasions and at different times, and probably originated from neighbouring countries 
where subtype C is known to be prevalent (Bredell et al., 1998; Engelbrecht et al., 1998; Novitski 
et al., 1999 and Tien et al., 1999). The genetic diversity of the heterosexual epidemic in South 
Africa will be discussed in detail in the following chapter. 
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CHAPTER 3: THE GEOGRAPHICAL DISTRIBUTION OF HIV-1 SUBTYPES 
IN SOUTH AFRICA 
3.1) Introduction 
3.2) Materials and methods 
3. 2. 1) Patient data 
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3.1) Introduction 
Until December 1988 only 166 AIDS cases were reported in South Africa. The majority 
of these cases were in the homosexual/bisexual population (75.3%), although there were a small 
number of cases in the heterosexual population (14.5%). In addition, 8.4% of the cases were by 
infection with HIV-contaminated blood product and 1.8% of cases were in babies infected by 
vertical transmission (Sher, 1989). 1988 was a pivotal year, however, and in an analysis of over 
700 000 blood donor samples collected up until October, 244 tested positive for HIV antibodies, 
of which 101 were women and 143 were men (Sher, 1989). This increase in the numbers of 
female HIV infections was indicative of the heterosexual epidemic to come, which was 
subsequently documented by the annual antenatal clinic surveys, initiated in 1990 (Swanevelder, 
1995). There was a steady rise in the numbers of AIDS cases in women, starting in 1987 and 
increasing until 1994 where more females than males were diagnosed ( see figure 3.1) 
(Swanevelder, 1995). 
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Figure 3.1: The number of AIDS cases reported by year of diagnosis in South Africa from 1982-1994 illustrating 
the increase in AIDS cases in the female population from 1987 until 1994 (Swanevelder, 1995). 
The first epidemic occurred in the homosexual population, as described by Sher et al. in 
the early Johannesburg study in 1985, as well as in the Cape Town study by Wood et al. in 1996. 
These provinces, Gauteng and Western Cape respectively, had the highest numbers of AIDS 
cases in 1988. As AIDS is not a notifiable disease, the number of AIDS cases are not a good 
representation of HIV prevalence, however the numbers do give an indication of the epidemic in 
different regions. As the second, heterosexual epidemic started, seroprevalence in provinces 
such as KwaZulu/Natal, Mpumalanga, Free State and Gauteng increased (Dusheiko et al., 1989). 
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There is geographical variation in the timing and severity of the heterosexual epidemic in the 
country. The annual antenatal clinic survey shows that by 1991 KwaZulu/Natal Province had the 
highest HIV prevalence at 2.87%, whereas Transvaal and Cape Provinces had 1.11 % and 
0.37%, respectively. It is not possible to directly compare provincial figures from this time to 
current figures, due to changes in provincial boundaries in 1994. The most recent antenatal 
clinic survey (performed in 1998), illustrated in Table 3.1, indicates that the Western Cape 
Province, the only province with a decrease in HIV prevalence, still has the lowest HIV 
prevalence at 5.2%, although this may be an under-representation. KwaZulu/Natal Province still 
has the highest prevalence at 32.5% (see figure 3.2) (Department of Health, 1999). 
Table 3.1 : The annual antenatal clinic survey of HIV-positive women attending public health 
services antenatal clinics from 1997-1998 (Department of Health, 1999). 
Province HIV+ (95%CI) 1997 HIV+ (95%CI) 1998 
Western Cape 6.3 (5 .2-7.5) 5.2 (3 .2-7.2) 
Northern Cape 8.6 (6.4-11.3) 9.9 (6.4-13.4) 
Northern Province 8.2 (6.9-9 .7) 11.5 (9.2-13.7) 
Eastern Cape 12.6 (11 .0-14.4) 15.9 (11.8-20.0) 
North West 18.1 (16.2-20.1) 21 .3 (19.1-23.4) 
Gauteng 17.1 05.1-19.2) 22.5 (19.2-25. 7) 
Free State 20.0 (17 .1-22.2) 22.8 (20.2-25.3) 
Mpumalanga 22.6 (20.5-24.8) 30.0 (24.3-35.8) 
KwaZulu/Natal 26.9 (24.9-29.0) 32.5 (29.3-35.7) 
National 17.04 22.8 
The HIV-1 epidemic in sub-Saharan Africa is influenced by a number of factors; 
including economic, social, cultural and political factors as was discussed in detail in section 
1.6.2. The same factors play a role in the spread of the heterosexual epidemic in South Africa . 
Migration between countries on the African continent is frequent and has been occurring for 
many generations. Migration plays a major role in the spread of HIV by the movement of people 
throughout the African continent. Since many countries in Africa are poverty stricken , or plagued 
by continual civil wars, migrant workers and refugees are constantly on the move in search of 
work or asylum (Quinn, 1996). 
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15.9% 
Dept. of Health, 1999 
Figure 3.2: The percentage prevalence of HIV positive women attending antenatal clinics at the end of 1998 for 
each of the nine Provinces in South Africa (Department of Health, 1999). 
In South Africa, the mining industry has played a major role in the movement of people 
from rural to urban areas. Whilst working on the mines, the majority of migrants reside away from 
their families, in single sex hostels which are often serviced by commercial sex workers (CSWs). 
In Carltonville, Gauteng Province, an area where 88 000 mine workers are resident, serviced by 
400-500 CSWs, there is an HIV prevalence of 22% (UNAIDS, 1998). The large numbers of 
concurrent sexual partners allows a rapid spread of the HIV epidemic in the migrant mine worker 
population which is then spread to the rural areas when the men return home. The migrant 
workers on the mines are mostly men from neighbouring countries such as Lesotho, Botswana, 
Mozambique and up until the late 1990's, Malawi, as well as South African men (Williams and 
Campbell, 1996). The spread of HIV into South Africa, may thus have been facilitated by migrants 
from these neighbouring countries. Evidence of this was illustrated in 1986 by Sher where the HIV 
prevalence in migrant mine workers was 3.71% in Malawians and 0.07% in Mozambicans, a time 
when the majority of South African infections were occurring in the homosexual population (Sher, 
1989). 
In addition to migrant labourers who enter the country for work, there are also large 
numbers of illegal immigrants who enter the country from Lesotho, Mozambique, Swaziland and 
Zimbabwe, as well as further afield such as Zaireans, Ugandans and Zambians (van Haldenwang, 
1996). Although the figures are rough estimates, it was suggested that in 1994 from two to eight 
million illegal immigrants entered the country, with Gauteng and KwaZulu/Natal Provinces having 
the highest numbers of illegal immigrants (van Haldenwang, 1996). 
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In the previous chapter we established that the HIV epidemic is segregated according to 
mode of transmission, with subtype B primarily associated with homosexual or bisexual mode of 
transmission and subtype C with heterosexual transmission. A concurrent study performed in 
Cape Town , based on gag p17 gene sequences (Williamson et al., 1995), indicated that 
according to the age of the HIV epidemic .(approximately four to six years at the time of 
sampling) and the DNA distance between subtype C gag sequences (6.8%) , there appear to 
have been multiple introductions of subtype C into the country. 
Rapid screening techniques for subtype elucidation often utilise the env region for 
subtype analysis. These techniques include heteroduplex mobility assay (HMA) and V3 loop 
serotyping. The env region represents less than 10% of genome however, and it is important to 
define subtypes using more than one region in order to detect recombinant viruses. 
Restriction fragment length polymorphism (RFLP) analysis involves the identification of 
unique cutting restriction endonucleases that are able to distinguish between subtypes or strains. 
The unknown sample DNA is amplified by polymerase chain reaction after which the DNA is 
digested using the selected restriction endonucleases. The fragments produced are separated 
by agarose or polyacrylamide gel electrophoresis in order to visualise the patterns specific for 
each subtype or strain. A number of different virus strains have successfully been differentiated 
using this technique, including ; dengue virus (Vorndam et al., 1994), infectious bursal disease 
virus (Liu et al., 1994) as well as HIV-1 in the protease gene (Pieniazek et al. , 1995, Heyndrickx 
et al., 1996 and Janini et al. , 1996) and p24 region (Janini et al., 1996). No radioactive labelling 
is required as for 
35S sequencing and the technique is faster and easier to perform than HMA. 
In this study, in order to assess the geographical distribution of HIV-1 subtypes within 
South Africa , 83 samples from Johannesburg and Pretoria (in the Gauteng Province), 
Bloemfontein (in the Free State Province) and Durban (in the KwaZulu/Natal Province) were 
analysed by heteroduplex mobility assay (HMA) in the env region. Thirty-nine of these samples 
were also analysed in the gag region by restriction fragment length polymorphism (RFLP) 
analysis. In addition, 47 samples from Cape Town and four samples from Bloemfontein that had 
been analysed in the V3-V5 region of the env gene (see Chapter 2), sequenced in the p17 region 
of the gag gene (Williamson et al., 1995 and van Harmelen et al., 1997), or subtyped in both 
regions, were analysed by RFLP analysis of the gag gene. Samples subtyped in the env and 
gag regions were then compared in order to determine the presence of recombinant viruses in 
the regions studied. 
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A phylogenetic study taking into account all published Southern African subtype C 
sequences would give an indication of the genetic diversity within the South African heterosexual 
epidemic, as well as whether there is any subclustering with a country of origin. In this work, we 
thus phylogenetically compared all published South African subtype C V3 loop sequences with 
sequences from other southern African countries as well as at least two reference sequences 
from each subtype from A to Hand J. 
3.2) Materials and methods 
3. 2. 1) Patient data 
Convenience samples were collected between 1994 and 1996. Extracted proviral DNA 
was obtained from 83 samples collected in three geographically distinct urban centres in South 
Africa : Johannesburg (n=34) (obtained from Sue Lyons, National Institute of Virology, 
Johannesburg) and Pretoria (n=S) (obtained from Elna van der Ryst, University of the Free 
State) in Gauteng Province; Bloemfontein (n=24) (obtained from Elna van der Ryst, University of 
the Free State) in Free State Province; and Durban (n=20) (obtained from Dennis York, 
University of Natal) in KwaZulu/Natal Province. Samples from Johannesburg and Durban were 
obtained from women attending antenatal clinics, whereas the Bloemfontein samples were taken 
from individuals attending an HIV/AIDS clinic. Ethical approval was obtained by each institute 







Figure 3.3: Map of South Africa, showing the five cities in distinct geographical locales sampled for 
subtyping. 
We obtained demographic data for the analysed samples including : age, sex, race, date 
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of first serodiagnosis, CD4 count and sexual orientation (see Table 3.7) . Demographic data from 
the Cape Town samples were reported previously in Chapter 2. The ages of the Johannesburg 
and Pretoria women were not recorded. Out of the 34 women from Johannesburg, 30 women 
were black and four were of Asian descent and all five of the Pretoria women were black. The 
Durban women were between the ages of 20 and 35 years, except for one baby that was born to 
an HIV positive mother who had attended the antenatal clinic. Of the 20 patients, 18 were black, 
one was of mixed race and one was Asian . The Bloemfontein samples were from both men and 
women at a ratio of 5:19 men to women, all infected by heterosexual transmission. All of the 
patients were black, except one woman who was of mixed race . The average age was 24 years 
with a range of 15-4 7 years. Eighteen out of the 24 patients had a CD4 count above 200 
(X106/1) . In addition, four Bloemfontein samp!es were infected by homosexual of bisexual mode 
of transmission (94ZA06FS, 94ZA14FS, 92Z.A,17FS and 91ZA25FS; analysed by HMA in the env 
region in Chapter 2) . Samples were numbered by ·date of diagnosis, country of residence and 
sample number. 
In addition, 5-10ml of EDTA-blood was collected from 47 patients attending the 
HIV/AIDS clinic at Somerset Hospital in Cape Town (n=42) and five patients sampled in the 
routine diagnostic laboratory at Groote Schuur hospital in Cape Town. We had previously 
subtyped twenty-one of the samples by both HMA in the V3-V5 region of the env gene (see 
Chapter 2) and by sequence analysis in the p17 region of the gag gene (Williamson et al., 1995 
and van Harmelen et al., 1997) (see Chapter 2) . In addition , we had analysed 16 samples by 
HMA alone in the env region and 10 samples by sequence analysis alone in the p17 region (van 
Harmelen et al. , 1997) (see Chapter 2) . 
Out of ten Cape Town patients previously subtyped by sequence analysis (van Harmelen 
et al., 1997) and analysed by RFLP in the gag region in this study, eight reported their presumed 
origin of transmission due to travel or residence within five years prior to sampling, to be in 
South Africa . However, patient 93ZA019, a white male, infected by homosexual transmission 
reported having a possible origin of infection in Europe. Patient 93ZA030, a black male infected 
by heterosexual transmission, reported a presumed origin of infection in Zambia . 
3. 2. 2) DNA extraction 
DNA was extracted from peripheral blood mononucleocytes for the Johannesburg and 
Pretoria samples (n=39) or directly from blood in the Cape Town (n=47) , Bloemfontein (n=28) 
/ 
and Durban (n=20) samples. DNA was isolated from Cape Town (Maureen Lambrick, 
Department of Clinical Virology, UCT Medical School) and Bloemfontein (Elna van der Ryst, 
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Department of Virology, University of the Free State) samples as described (Kawasaki, 1990 and 
Appendix A1) . Johannesburg samples were extracted using Ficoll (Sigma, St Louis MO, USA) 
gradient separation and Proteinase K digestion in lysis buffer (TE lysis buffer, 1 OmM Tris-HCI 
pH7.5, 1 mM EDTA, 0.5% Triton X-100, 1 % Tween 20) (Sue Lyons, National Institute of Virology, 
Johannesburg and Appendix A1) . Durban sample proviral DNA was extracted from 300µ1 of 
whole blood containing EDTA, using the Genomix extraction kit (Talent, SRL, Italy) (Savathree 
Madurai and Dennis York, Department of Virology, University of Natal and Appendix A1). 
3.2.3) Polymerase chain reaction (PCR) amplification of patient samples for HMA analysis 
For HMA analysis in this study, a 700bp V3 to VS fragment of the env gene was 
amplified by nested polymerase chain reaction (PCR) using primers EDS/12 for the outer 
reaction and ES?/8 (NIH AIDS Research and Reference Reagent Program, Rockville MD, USA) 
for the inner reaction as described in Chapter 2 (section 2.2.3 and Appendix A2) . Ten microlitres 
of patient DNA was added to the outer reaction, except for the Durban samples, which were 
more concentrated, where 5µ1 was added. For the inner reaction of the nested PCR, 3µ1 of the 
outer PCR was tranferred to the inner master mix (Delwart et al., 1993). All PCRs were 
performed with the appropriate controls for contamination (see section 2.2.3) ; a water control as 
well as a sample from a HIV-negative patient. PCR amplified samples were electrophoresed on 
a 1 % agarose gel in order to detect positive samples. The DNA was stained with ethidium 
bromide (1 Ong/ml) and visualised under a 256nm UV transilluminator (Appendix A3) . 
3.2.4) Heteroduplex mobility assay (HMA) of env sequences 
Heteroduplex mobility assay (HMA) was performed on amplified DNA from all 83 
samples (Delwart et al., 1993, see Appendix A9) in this study. Unknown isolates were compared 
with South African reference plasmids developed (two subtype B, two subtype C and one 
subtype D, see chapter 2) as well as one subtype A reference plasmid from the NIH AIDS 
Research Reference and Reagent Program (USA) (see section 2.2.6) . Any ambiguous isolates 
would have been compared with the full range of HMA reference plasmids, from subtype A to G 
(NIH AIDS Research and Reference Reagent Program, USA). The plasmids are shown in Table 
2.5 (see Chapter 2). Samples still unidentified would have been subjected to sequence analysis. 
Heteroduplexes were subjected to non-denaturing polyacrylamide gel electrophoresis at 200V for 
five hours through the 5%, 19cm/16cm, 1.5mm thick (Hoefer SE600, Hoefer Scientific 
Instruments, San Francisco, USA) gel (see section 2.2.6) . Gels were stained for 30 minutes with 
1 Ong/ml ethidium bromide and visualised with 256nm UV transillumination (Appendix A9). 
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3.2.5) Polymerase chain reaction (PCR) amplification of patient samples for RFLP analysis 
In this study, two fragments from the gag region of HIV-1 (400bp and 650bp respectively) 
were amplified for RFLP analysis . The 400bp fragment contained the complete p17 gene coding 
for the matrix protein of HIV-1. The 650bp fragment contained the p17 gene as well as part of the 
p24 gene coding for the viral capsid protein. A total of 86 patient samples were amplified for 
RFLP analysis (Cape Town n=47, Johannesburg n=20, Bloemfontein n=17 and Durban n=2). 
PCR conditions are recorded in detail in Appendix A2 . 
Proviral DNA was amplified using nested PCR primers; L TRu5 and Pol2 (van Harmelen et 
al., 1999) as outer primers to amplify a 1.5Kb fragment and L TR310j (van Harmelen et al., 1999) 
and SK431 (Lynch et al., 1992) (650bp fragment) or L TR31 Oj and gag778 (van Harmelen et al., 
1999) (400bp fragment) (see Table 3.2) . In addition, a 400bp fragment from cloned , previously 
sequenced, p17 gag sequences (Williamson et al., 1995) was amplified using the inner primers 
only (L TR31 Oj/gag778) in order to determine the reliability of the RFLP technique. 
Table 3.2: Primers for PCR amplification of the gag reg ion for RFLP analysis . 
Name #Position *Sequence 
LTRu5 608bp-630bp 5'ATCTCTAGCAGTGGCGCCCGAAC3' 
Pol2 2265bp-2279bp 5'CGGAATTCAGGGTCGTIGCCAAAG'3 
LTR310j 753bp-773bp 5TAGTCGACGACTAGCGGAGGCTAGAAG3' 
SK431 14 72bp-1499bp 5'TGCTATGTCAGTICCCCTIGGTICTCT3' 
gag778 1232bp-1255bp 5'CACCT AGAACTTI[A/G]AA[T /C]GCATGGG3' 
#Sequence positions were taken from HXB2 (Genebank acession number K03455) 
*Bold letters represent restriction enzyme sites, EcoR1 and Sal I that could be used for cloning 
purposes. · 
The PCR master mixes (50µ1) contained: 
• 5µ1 1 OX PCR (500mM KCI, 100mM Tris-HCI (pH9.0), 1 % Triton X-100) (Promega, Madison, 
WI, USA), 
• 1 % DMSO, 1 % glycerol, 
• 200µM each of dNTPs, 
• 1.5mM MgCl2, (outer reaction) and 1.8mM MgCl2 , (inner reaction), 
• 400nM each primer; LTRu5 and Pol2 (outer reaction) and LTR310j and SK431 or gag778 
(inner reaction), 
• 2.5U Taq DNA Polymerase (outer . reaction) and 2U Taq DNA Polymerase (Promega, 
Madison, WI, USA) (inner reaction) and 
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• 1 OµI of patient DNA (outer reaction) or 3µ1 of outer PCR reaction (inner reaction). 
If cloned and already sequenced reference gag plasmid DNA was used, 20ng of DNA was 
added. 
The PCR amplification was performed using the Techne PHC-2 thermocycler under the 
following conditions: 
Outer reaction : 
• initial denaturation at 94°C for 2 minutes, 
• 94°c for 1 minute, 45°C for 1 minute and 72°C for 2 minutes (5 cycles) 
• 94°C for 20 seconds, 55°C for 45 seconds and 72°C for 1 minute (30 cycles) 
• final extension at 72°C for 6 minutes. 
Inner reaction : 
• initial denaturation at 94°C for 2 minutes, 
• 94°c for 20 seconds, 55°C for 45 seconds and 12°c for 1 minute (30 cycles) 
• final extension at 72°C for 6 minutes. 
A water control, as well as an HIV-negative patient DNA control, was included for all 
PCR reactions in order to monitor for possible contamination and all necessary precautions were 
taken in order to avoid contamination (see section 2.2.3) . PCR amplified DNA was 
electrophoresed in a 1 % agarose gel in 1 XTAE and visualised with ethidium bromide (1 Ong/ml) 
at 256nm with UV transillumination (Appendix A3). 
3. 2. 6) Restriction endonuc/ease site analysis (RESA) of HIV-1 gag sequences 
In order to determine unique cutting restriction endonucleases for RFLP analysis of HIV-
1 subtypes, we obtained gag HIV-1 consensus sequences for subtypes A, B, C and D from the 
HIV sequence database (http://hiv-web.lanl.gov/) . The unique restriction sites and predicted 
product length for each subtype was determined using a computer program (Genepro Version 
6.1, Riverside Scientific Enterprises, WA, USA). I have named the process of determining 
unique cutting restriction endonuclease sites using Genepro restriction endonuclease site 
analysis (RESA) . 
In addition , the following published full length gag sequences (n=25) from the HIV 
sequence database were analysed with Genepro to determine RESA patterns for this study: 
subtype A, Vl32 (Gabon), 92UG037.1, U455 (Uganda) and K89 (Kenya) ; subtype B, JRFL, 
HXB2, RF (USA) and OYI (Gabon) ; subtype C, Nof, Kon (South Africa), DJ259 (Djibouti) , 
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I , 
ETH2220 (Ethiopia) , LBV10-5, Vl1313 (Gabon) , SM145 (Somalia) , UG268 (Uganda), ZAM18, 
ZAM19, ZAM20, ZAM716-17 (Zambia) and 92BR025 (Brazil), and subtype D, 94UG114.1 
(Uganda), ELI, Z2Z6 and NDK (Democratic Republic of Congo, formerly Zaire) . 
South African sequences of the p17 gag region (Williamson et al., 1995) (n=31) and the 
sequences from isolates 94ZA060 and 94ZA061 were also analysed using Genepro to determine 
RESA patterns for our study: subtype A, 94ZA060, 94ZA061 ; subtype B, 88ZA001 , 93ZA008, 
91ZA011, 90ZA012, 89ZA017, 87ZA019, 91ZA021, 93ZA022, 92ZA025, 93ZA037, 92ZA045, 
93ZA051 , subtype C, 93ZA006, 93ZA010, 92ZA023, 93ZA029, 91ZA030, 93ZA032, 93ZA035, 
92ZA036, 90ZA040, 93ZA046, 93ZA048, 94ZA063, 93ZA200, 93ZA201 , 92ZA202, 93ZA204, 
92ZA205, 93ZA207 and subtype D, 91ZA034. 
3.2. 7) Restriction fragment length polymorphism (RFLP) analysis of gag sequences 
In this study, the amplified gag fragment from a total of 86 samples was analysed by 
RFLP analysis. Eight microlitres of amplified PCR product were digested with with 1 OU of 
restriction endonuclease (Boehringer Mannheim, Hamburg, Germany) for two hours at 37°C 
(Appendix A4) . All subtype C isolates were confirmed by Accl digestion, since Accl is able to 
digest subtype B, but not subtype C. Tracking dye (2µ1, 0.25% bromophenol blue, 0.25% xylene 
cynol FF and 30% glycerol in water) was then added and the sample was electrophoresed in a 
4% agarose (MetaPhore, USA) horizontal gel at 5 Volts/cm using TAE buffer (40mM Tris-
acetate, 1 OmM EDTA, pH8.0) (Appendix A3). Molecular weight markers VI and VIII (Boehringer 
Mannheim, Hamburg, Germany) were used as DNA fragment size markers. The gels were 
stained with 1 Ong/ml of ethidium bromide and the DNA fragments visualised at 256nm with UV 
transillumination. 
3.2.8) Cloning and sequencing of the gag sequences 
The 650bp gag fragment from two isolates, 94ZA060 and 94ZA061, a husband and wife 
pair were amplified by PCR (see section 3.2.5) and cloned the gag fragments into the pMos-blue 
T-vector polycloning site (Amersham, Buckinghamshire, UK) by TA cloning , as recommended by 
the manufacturers (Appendix AS) . Ligated DNA was transformed into competent Escherischia 
coli strain DHSa. (Appendix A6) and white . colonies containing putative clones screened for 
inserts by minipreparation of DNA and Pstl!EcoRI double digestion (Appendix A4 and A7) . DNA 
fragment electrophoresis was performed in a 3% agarose gel containing ethidium bromide 
(1 Ong/ml) and visualised by UV transillumination at 256nm (Appendix A3) . 
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The two 650bp gag fragments (94ZA060 and 94ZA061) were sequenced in both 
directions until unambiguous using forward and reverse primers T7 
(5'AATACGACTCACTATAGGG3') and U19 (5'ACGTCGTGACTGGGAAAACC3') (pMOS-blue-T vector, 
Amersham , Buckinghamshire, UK) respectively, by the Pharmacia™ ALFexpress® automated 
sequencer using fluorescent Cy5-labelled primers (Appendix A8.2) . DNA sequences were 
translated to amino acid sequences for V3 loop analysis using Genepro (Version 6.10, Riverside 
Scientific Enterprises WA, USA) . 
3.2.9) Sequence analysis of the env V3 region 
Thirty-nine subtype C reference isolate V3 sequences from African countries, India and 
Brazil were obtained from the HIV sequence database (http://hiv-web.lanl.gov/) for comparison 
with the South African sequences (see Table 3.3) . Seventy-eight South African V3 sequences 
included those taken from studies in Gauteng Province (Bredell et al., 1998) (n=43) , 
KwaZulu/Natal Province (Moodley et al., 1998) (n=22) and Western Cape Province (n=7) 
' 
(Becker et al., 1995 and Engelbrecht et al., 1995). 
Table 3.3: Subtype C reference sequences obtained from the HIV sequence database, 1998 for 
phylogenetic comparison with all published South African subtype C sequences, according to 
subtype and country of origin . 
Country 
ZW ZM MW MZ BW ZR 
No. 4 4 9 8 1 1 
DJ 
2 
UG SO SN 





Zimbabwe (ZW), Zambia (ZM), Malawi (MW), Mozambique (MZ), Botswana (BW), Zaire (ZR), Djibouti (DJ) , Uganda (UG), 
Somalia (SO) , Senegal (SN) , India (IN) , Brazil (BR) and South Africa (ZA). Number of sequences, No. 
The seven V3 loop sequences from subtypes A to D from our study in Chapter 2 were 
included for comparison , as were five subtype C mother-baby sequences from Mr Shayne 
Loubser (Department of Medical Microbiology, UCT) (Genbank numbers, AF095834 - AF095838) 
and sequence 97ZA347TS (Genbank number; AF095831) , which will be discussed in more detail 
in Chapter 4. Two reference V3 sequences for each subtype from A, B, D to H and J were taken 
from the NIH AIDS Reference and Reagent Program kit (USA) (subtypes A, B and D to H) and 
the HIV sequence database (1998) (subtype J). The names of the reference sequences from 
subtypes A, B and D to H are illustrated in Table 2.5. Subtype J is represented by sequences 
SE91733 and SE92809 from former Zairean individuals residing in Sweden. In addition, a single 
subtype A and subtype B sequence from South Africa was included in the phylogenetic analysis 
(Moodley et al., 1998) (see figure 3.7) . 
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All 140 V3 sequences were aligned using Clustal X (Thompson , 1997) and final 
adjustments were made manually. The distance matrix neighbour joining method was used to 
generate the phylogenetic tree with insertions and deletions ignored. The tree topology was 
inferred using the Kimura two-parameter algorithm (Kimura, 1980) and the reliability of the tree 
topology was assessed by doing 100 bootstrap replicates in TREECONW (van der Peer and de 
Wachter, 1994). The phylogenetic tree was drawn using the TreeView program (Page, 1996) 
with the SIVcpz-gab sequence as the outgroup. All 117 subtype C V3 loop DNA sequences were 
translated into amino acid sequences using Genepro (Version 6.10, Riverside Scientific 
Enterprises, WA, USA). 
3.2.10) Sequence analysis of the gag 650bp fragments from 94ZA060 and 94ZA061 
The 650bp sequences obtained from the husband and wife samples, 94ZA060 and 
94ZA061 in this study were aligned with at least two reference sequences from subtypes A to H 
and J, using Clustal X (Thompson, 1997) and final adjustments were made manually. Reference 
sequences are shown in table 3.4. The phylogenetic tree was constructed using the distance 
matrix neighbour joining method and insertions and deletions were ignored. The topology of the 
phylogenetic tree was inferred using the Kimura two-parameter algorithm (Kimura, 1990) and 
' 
1000 bootstrap replicates were performed to assess the reliability of the tree topology using the 
TREECONW program (van der Peer and de Wachter, 1994). The phylogenetic tree was drawn 
using TREECONW (van der Peer and de Wachter, 1994) with the SIVcpz-gab sequence as the 
outgroup. 
3.3) Results 
In this study, a total of 83 samples taken from heterosexually infected individuals from 
Johannesburg , Bloemfontein and Durban were subtyped using heteroduplex mobility assay 
(HMA) in the env V3-V5 region, identifying 77 subtype C and six subtype B viruses. RFLP 
analysis was developed as a tool for the rapid identification of gag subtypes. Thirty-nine of the 
above eighty-three samples were analysed in the p17 region of the gag gene. A further 47 
samples from patients infected by heterosexual or homosexual transmission in Cape Town were 
also analysed by RFLP in the p17 region of the gag gene. These samples had either been 
previously subtyped in the env region by HMA (see Chapter 2), sequenced in the gag p17 region 
(Williamson et al. , 1995 and van Harmelen et al., 1997), or both . Out of the total 86 isolates 
subtyped by RFLP in the gag region , two belonged subtype A, 25 to subtype 8 , 58 to subtype C 
and one to subtype D. Finally, the phylogenetic relationship between 117 subtype C sequences 
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was also investigated . 
Table 3.4: Reference sequences obtained from the HIV sequence database, 1998 for 
phylogenetic comparison with sequences from isolates 94ZA060 and 94ZA061 from Cape 
Town. 
Name of sequence Country of origin 
U455 Uganda 
92UG037 Uganda 
subtype A K89 Kenya 
Vl32 Ivory Coast 
RF Haiti 
subtype B HXB2 United States 






subtype C DJ259 Djibouti 
SM145 Somalia 
Vl1313 Gabon 
Nof South Africa 
Kon South Africa 
NDK DRC, formerly Zaire 
subtype D Z2Z6 DRC, formerly Zaire 
· ELI DRC, formerly Zaire 
CM240 Thailand 
subtype AE 93TH253 Thailand 
90CF402 Central African Republic 
9382162 Brazil 
subtype F 93BR020 Brazil 
Vl69 Bel ium 
SE6165 Sweden 




subtype H 90CF056 Central African Republic 
Vl557 DRC, formerly Zaire 
SE92809 Sweden 
SE91733 Sweden Subtype J 
DRC, Democratic Republic of the Congo 
3.3.1) Computer aided restriction endonuctease site analysis (RESA) of HIV-1 gag sequences 
Four restriction endonucleases that would generate unique fragment patterns for each 
subtype were identified by RESA of the gag gene consensus sequences for subtypes A to D (HIV 
sequence database, 1998). Restriction endonucleases; Swal, Accl , Alul and Xmnl were 
predicted to distinguish subtypes A, B, C and D respectively (see figure 3.4). 
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Figure 3.4 : The restriction endonuclease site analysis (RESA) of the partial gag consensus sequences for 
subtypes A, B, C and D in this study, showing where the identifying restriction endonucleases digested and the 
fragment sizes in base pairs which are produced. 
3.3.3) Determination of endonuc/ease sites in published gag sequences 
In order to determine the reproducibility of the technique, 33 South African p17 gag 
sequences (Will iamson et al., 1995 and unpublished data) were analysed using RESA to 
determine the fragment sizes which would be produced after digestion with A/ul , Accl , Swal an._d 
Xmnl respectively. Samples included 18 subtype C isolates, 12 subtype B isolates, two subtype 
A isolates and one subtype D isolate. All of the sequences were correctly subtyped using the 
four restriction endonucleases. 
In addition, to determine whether the RFLP strategy would identify isolates from outside 
of South Africa , twenty-five published international sequences (HIV sequence database, 1998) 
were analysed by RESA (see section 3.2.6) . Samples included thirteen subtype C full-length gag 
sequences and RESA analysis determined that the 400bp fragment was more reliable than the 
650bp fragment for subtype C detection . Twelve out of the thirteen subtype C sequences would 
have been correctly identified by Alul digestion in the 400bp p17 fragment. The remaining 
subtype C isolate (LBV10-5 originating from Libreville) contained an additional Alul site, 
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producing a restriction fragment pattern similar to subtypes A, B and D, but did not have the 
specific restriction sites for the identification of the other subtypes and was classified as non-
typable . 
Subtype B isolates (n=4) would be detected using either the 400bp or 650bp fragments 
after Acct digestion. The four subtype A sequences, however, would be detected by Swal 
digestion in the 650bp fragment only. 
Finally, only three of the four subtype D isolates would have been correctly identified 
using Xmnl restriction endonuclease in either the 400bp or 650bp fragments, since one of the 
subtype D isolates (Z2Z6) contained an Accl site incorrectly identifying the sample as a subtype 
B. Such a sample would be identified as a 8/D isolate. The remaining three isolates were 
correctly identified as subtype D since Xmnl alone and not Accl would be able to digest the 
isolates. The single subtype D isolate sequenced from South Africa was correctly identified as a 
subtype D by RESA using either the 400bp or 650bp fragment since no Acct site was present. 
3.3.4) Restriction fragment length polymorphism (RFLP) strategy for subtype identification 
Since the majority of isolates from South Africa identified at the time of the study were 
subtype C (Williamson et al. , 1995; van Harmelen et al., 1997 and Bredell et al., 1998), a 
strategy for identification of local isolates was developed based on the predicted restriction 
endonuclease sites by RESA (see figure 3.5) . 
A total of 86 isolates from Johannesburg (n=20), Bloemfontein (n=17) , Durban 
(n=2) and Cape Town (n=4 7) were analysed by RFLP in the p17 (400bp) or p17, partial p24 
region (650bp) of the gag gene in this study. PCR amplified 400bp fragments would be initially 
' 
digested with Alu I in order to detect subtype C. Samples identified as subtype C would then be 
re-amplified and digested with Ace I that is able to digest subtype B, but not subtype C, as 
confirmation of subtype. A 400bp or 650bp fragment would then be amplified from any 
unidentified samples, and digested with Ace I in order to detect subtype B. Remaining 
unidentified isolates would be reamplified and the 650bp fragment subjected to Swa I 
amplifi cation in order to detect subtype A. Finally, unidentified samples would be PCR amplified 
and either the 400bp or 650bp fragment digested with Xmn I for the identification of subtype (see 
figure 3.5) . 
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Figure 3.5: The RFLP strategy developed in this study, starting with digestion of the 400bp gag PCR 
product with Alu I, to detect subtype C's, followed by amplification of a 650bp fragment and digestion with 
Accl, to detect subtype B's, Swa I to detect subtype A's and finally Xmnl to detect subtype D's, which are 
digested with Xmnl , but not Acct. The predicted fragments from the consensus sequence analysis are 
shown in brackets. 
Initially, 31 of the 33 previously sequenced HIV-1 p17 isolates analysed by RESA 
(Williamson et al., 1995 and unpublished data) were subtyped by RFLP in a blinded fashion in 
this study, in order to determine the reliability of the technique (see Table 3.5). Two were 
subtype A, 11 were subtype B, 17 were subtype C and one was a subtype D. No subtype C 
isolates were digested with Accl, confirming their identity. Figure 3.6 shows the RFLP patterns 
obtained using Accl to detect subtype B (see figure 3.6a) and A/ul to detect subtype C (see figure 
3.6b) in unknown samples. Figure 3.6 shows the RFLP patterns obtained using Accl to detect 
subtype B (see figure 3.6a) and A/ul to detect subtype C (see figure 3.6b) in unknown samples. 
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a) b) 
Figure 3.6: RFLP gels showing the unique restriction fragment patterns produced by digestion of the gag p1
7 
fragment with Accl (a) and A/ul (b). a) Three subtype B isolates identified by Accl which only digests subtype B. Fo
ur 
subtype C isolates identified by A/ul digestion are confirmed as subtype C by Accl digestion, which does not dige
st 
subtype C. The variations in size and fragment number are caused by insertions and deletions in the gag gen
e, but 
do not hinder subtype designation. b) Six subtype C isolates identified by A/ul digestion which results in only tw
o 
visible fragments for subtype C, but multiple smaller fragments for subtypes A to D (see figure 3.4). Molecular 
weight 
markers are MWVI and MWVIII (Boehringer Mannheim, Hamburg, Germany). 
Table 3.5: Gag subtype designation by RFLP analysis and RESA compared to the genetic 





ND, Not determined 
NT, Not typable 















3.3.5) Subtype designation by restriction fragment length polymorphism (RFLP) of the gag 
gene 
Once the reliability of the RFLP technique had been determined, 16 Cape Town 
samples that had been subtyped by HMA in the env region in the previous chapter were 
analysed by RFLP. Analysis of the 400bp gag fragment identified four subtype C isolates. In 
addition, 12 subtype 8 isolates were identified using the 650bp fragment. No subtype C 
samples were digested by Accl, confirming their subtype. Although all subtypes could be 
successfully identified using the four restriction endonucleases, minor variations in the 
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fragment sizes between samples of the same subtype were observed due to insertions and 
deletions. 
In addition, 39 patient samples from Johannesburg , Bloemfontein and Durban, identified 
by HMA in the env region (see section 3.3.6) were subtyped by RFLP of the partial gag gene 
fragment. The majority of these samples belonged to subtype C (37 out of 39) , including one 
male Bloemfontein patient infected by bisexual transmission , although two male Bloemfontein 
patients infected by homosexual/bisexual transmission (92ZA 17FS and 91 ZA25FS) were 
identified as being infected with a subtype B virus. The homosexual/bisexual Bloemfontein 
patients subtyped by HMA were analysed in Chapter 2 and the results used for comparison with 
RFLP subtyping in this chapter. 
3.3.6) Subtype identification by heteroduplex mobility assay (HMA) of the env gene 
It was established in this study that subtype C predominated in the three major urban 
centres in South Africa where an average of 92.8% of the 83 isolates (n=77) analysed by HMA 
were classified as subtype C (see figure 3.7). The patients were specifically selected as having 
been infected by heterosexual transmission in order to determine the genetic diversity of HIV in 
the urban heterosexual populations in South Africa . A total of 7.2% of the samples tested: two of 
the 34 samples from Johannesburg (94ZA267J and 94ZA263J) , one of the 24 samples from 
Bloemfontein (94ZA20FS) and three of the 20 samples from Durban (94ZA025DBN, 
94ZA065DBN, 94ZA115DBN) were infected with subtype B viruses (see figure 3.7) . 
All of the samples could be subtyped using the South African reference plasmids, 
93ZA004, 93ZA009 (subtype B), 93ZA040, 94ZA067 (subtype C) and 93ZA034 (subtype D) , as 
well as one of the three subtype A reference plasmids (RW20, IC144, or SF170) from the HMA 
kit (NIH AIDS Research Reference and Reagent Program, USA). None of the amplified samples 
needed to be analysed against additional plasmids, in order to successfully identify them. 
There were no discrepancies in subtype designation between the env and gag regions 
using HMA or RFLP in these isolates, indicating no recombinant viruses in the regions studied 
(see Table 3.6) . 
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Figure 3.7: Graph illustrating the genetic diversity within the heterosexual urban populations in four major cities in South Africa , 
as determined in this study. Cape Town data from the previous chapter has been included for comparitive purposes. Similar 
subtype distribution between subtypes B and C occurs in all four cities in the heterosexual population, with subtype C making up 
77% to 96% of the samples (Cape Town to Bloemfontein) and subtype B only 4% to 15% of the samples (Bloemfontein to 
Durban) . Greater subtype diversity occurs in Cape Town with subtypes A , 8 , C and D present in the heterosexual population. 
Table 3.6: A comparison of the subtype obtained by RFLP in the gag region and HMA in the env 
region for samples from Johannesburg (n=20), Durban (n=2), Bloemfontein (n=17) and Cape Town 
(n=38), indicating no discrepancies were found between subtype designation in the env and gag 
regions studied. 
envHMA 
Johannesburg Durban 118 loemfontein ;;11Ca12e Town 
Subtype C C B C A B C D 
A 2 
gag B 2 21 
RFLP C 20 2 15 14 
D 1 
* An additional ten samples were analysed by RFLP in the gag region from Cape Town samples 
which had been previously sequenced in the p17 region . 
# A number of samples from Bloemfontein and Cape Town were analysed in Chapter 2. 
3. 3. 7) Genotypic analysis of the V3 loop region of the env gene 
In order to determine the genetic diversity within South African subtype C sequences and 
to determine whether there was any clustering of South African sequences with a southern 
African country of origin, all published Southern African subtype C sequences were 
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phylogenetically compared. Phylogenetic analysis of the 105 subtype C sequences (see figure 
3.8) from southern African countries gave no indication of clustering with a country of origin, 
however. Only a small number of subtype C samples grouped together with bootstrap values of 
over 70%. The average intrasubtype DNA difference for the South African subtype C's was 
14.06%, which was similar to the average intrasubtype DNA distance of 13.97% for all 117 of the 
subtype C sequences analysed . The South African sequences are thus as divergent from each 
other as they are from the remaining subtype C isolates from southern Africa and the rest of the 
world . 
The V3 loop amino acid sequence that was generated for all 117 of the subtype C 
sequences analysed in this study was found to be 35 amino acids in length for 111/117 of the 
isolates (see figure 3.9) . In 16 samples a single amino acid deletion had occurred at different 
positions in the V3 loop, resulting in a V3 loop of 34 amino acids. In three samples; 92BR025 
(Brazil), 93MW960 and 93MW956 (Malawi) there was an insertion of isoleucine at position 280 
and an amino acid deletion at position 291, maintaining the V3 loop 35 amino acid length. Out 
of the 117 isolates, 114 maintained the characteristic GPGQ tetrapeptide crown. One South 
African isolate (95ZA961 ZA) had a GPGR tetra peptide crown and one South African isolate 
(95ZA742ZA) and one Zimbabwean isolate (SE9337) had a RPGQ crown motif. The octameric 
tip was predominantly RIGPGQTF, followed by RIGPGQAF, although a small number of other 
variations were identified. Positively charged argenines in positions 276, 290 and 297 are 
associated with a syncitia-forming phenotype (Fouchier et al., 1992 and De Wolf et al., 1994). 
Position 276 had an argenine substitution present in only two of the southern African subtype C 
isolates, NOF and 89ZA067. No data was available on the stage of disease for either of these 
isolates. 
Subtype C viruses characteristically lack the first glycosylation site proximal to the start 
cysteine of the V3 loop at position 265-267 and only 17 of the 117 isolates retained this 
glycosylation site (Abebe et al., 1997 and Korber et al., 1997). In the remaining isolates, valine 
was the most common substitution. Eleven of these isolates were from the KwaZulu/Natal 
Province of South Africa . The first glycosylation site within the V3 loop, at positions 271-273 was 
absent in five isolates, all originating from South Africa . No additional glycosylation sites were 
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Figure 3.8: Phylogenetic tree of all published southern African V3 loop sequences showing no South African subclusters. 
The South African sequences are in bold and isolates sequenced in our laboratory are indicated in blocks. The DNA distance 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3.8) Phylogenetic analysis of the 650bp gag region of94ZA060 and 94ZA061 
Isolates 94ZA060 and 94ZA061 that were analysed in the gag region were found to group 
together with a bootstrap value of 96%. In addition, the two sequences group with the subtype A 
reference sequences, U455, 92UG037, K89 and Vl32, as well as the subtype AE reference 
sequences, CM240, 93TH253 and 90CF402 with a bootstrap value of 100%. The subtype AE 
sequences form their own sub-cluster with a bootstrap value of 100% (see figure 3.10). The 
average intrasubtype DNA distance of the South African subtype A sequences with the reference 
subtype A sequences determined in this study, is 9.57%, with a range of 6.4% (94ZA061 and 
92UG037) to 11.0% (94ZA060 and U455). 
3.4) Discussion 
The HIV epidemic in South Africa was shown to segregate according to mode of 
transmission in the previous study (see Chapter 2) . The heterosexual epidemic started later than 
the homosexual epidemic and is now responsible for the majority of infections occurring monthly 
in South Africa (Swanevelder, 1995; WHO, 1998 and Department of Health, 1999). The current 
study involved the sampling of females attending antenatal clinics in Johannesburg, Pretoria and 
Durban, in an attempt to select samples specifically from heterosexually infected patients. In 
addition, male and female patients infected heterosexually were sampled from a Bloemfontein 
HIV/AIDS clinic and heterosexually infected patients from the Cape Town study (see Chapter 2) 
were all analysed in order to identify the predominant subtype(s) causing the overwhelming 
heterosexual epidemic in South African urban centres . 
Out of a total of 109 isolates ta)<en from heterosexually infected patients from four major 
urban centres in South Africa; Johannesburg and Pretoria (Gauteng Province), Bloemfontein 
(Free State Province), Durban (KwaZulu/Natal Province) and Cape Town (Western Cape 
Province) and analysed in the env region, gag region, or both, the majority of individuals {92%) 
were found to be infected with subtype C. The results from this study are similar to results from 
our Cape Town study reported in the previous chapter, where subtype C was responsible for the 
majority (77.2%) of the heterosexual infections and subtype B for only 9%. A greater subtype 
diversity was detected in Cape Town, with two subtype A and one subtype D viruses detected in 
the heterosexual population (see figure 3.7 and Table 3.6). However, a greater number of 
samples were analysed, thus it was more likely that low prevalence subtypes would be 
detected. Subtypes A and D, the most common subtypes in Central and East Africa, were not 
detected outside of Cape Town, although subtype A has subsequently been reported in 
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Figure 3.10 : Phylogenetic analysis of 94ZA060 and 94ZA061 , indicating their subtype and their relationship to at least two 
reference sequences from each subtype from A to H and J as determined by this study. The two sequences, from a husband 
and wife pair group together on the phylogenetic tree with a bootstrap value of 96%, as well as with the subtype A lineage, 
clustering with a bootstrap value of 100% with the subtype A sequences from Uganda, Kenya and the Ivory Coast, as well as 
three subtype AE sequences from Thailand and the Central African Republic. 
was associated with the initial homosexual epidemic in South Africa (Engelbrecht et al. , 1995; 
Williamson et al. , 1995 and van Harmelen et al. , 1997) it has failed to proliferate significantly in 
the subsequent heterosexual epidemic. This is illustrated by the low percentage of subtype B 
105 
infections (8%), a total of nine subtype B viruses; two from Johannesburg, one from 
Bloemfontein, three from Durban and three from Cape Town patients. 
Table 3.7: Collective demographic and patient clinical data for this study, as well as subtype 






































































































































































































Table 3.7: Continued .. . 
Age CD4 count 
Sample name Sex Race (x108/I) 
Subtype 
(years) 
98ZAUN01GP 20-40 ND Black <200
 C 
98ZAUN02GP 20-40 ND Black <200 
C 




98ZAUN04GP 20-40 ND Black <200 
C 
98ZAUN05GP 20-40 ND Black <200 
C 
98ZAUN06GP 20-40 ND Black <200 
C 
98ZAUN07GP 20-40 ND Black <200 
C 




90ZA01 FS 37 Female Black 150 C 
91ZA02FS 31 Female Black 260 C 
94ZA03FS 24 Male Black 600 C 
94ZA04FS 27 Male Black 370 C 
93ZA05FS 47 Male Black 110 C 
94ZA07FS 23 Female Black 600 C 
94ZA08FS 17 Female Black 430 C 
93Z09FSA 25 Female Black 260 C 
90ZA10FS 23 Female Black 110 C 
93ZA11 FS 20 Female Black 210 C 
92ZA12FS 35 Female Black 40 C 
94ZA13FS 26 Female Mixed race 280 C 
91ZA15 FS 38 Female Black 100 C 
94ZA16FS 39 Male Black 180 C 
94ZA18FS 25 Female Black 660 C 
94ZA19FS 28 Female Black 200 C 
94ZA20FS 15 Female Black 600 B 
94ZA21FS 31 Male Black 460 C 
94ZA22FS 25 Female Black 340 C 
Homosexual transmission 
95ZA25FS 38 Male White 10 B 
Bisexual transmission 
95ZA06FS 22 Male Black 130 C 
95ZA14FS 22 Male Black 240 B 
95ZA17FS 30 Male White 120 B 
Durban 
Heterosexual Transmission 
95ZA008DBN 20-35 Female Black ND C 
95ZA009DBN 20-35 Female Black ND C 
95ZA014DBN 20-35 Female Black ND C 
95ZA015DBN 20-35 Female Asian ND C 
95ZA022DBN 20-35 Female Black ND C 
95ZA023DBN 20-35 Female Black ND C 
95ZA025DBN 20-35 Female Black ND B 
95ZA031DBN 20-35 Female Black ND C 
95ZA033DBN 20-35 Female Black ND C 
95ZA048DBN <0.1 ND Black ND C 
95ZA049DBN 20-35 Female Black ND C 
95ZA052DBN 20-35 Female Black ND C 
95ZA056DBN 20-35 Female Black ND C 
95ZA058DBN 20-35 Female Mixed race ND C 
95ZA059DBN 20-35 Female Black ND C 
95ZA065DBN 20-35 Female Black ND B 
94ZA115DBN 20-35 Female Black ND B 
94ZA116DBN 20-35 Female Black ND C 
94ZA117DBN 20-35 Female Black ND C 
94ZA118DBN 20-35 Female Black ND C 
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Table 3.7: Continued ... 
Age CD4count 





93ZA006 30 Male White 342 C 
93ZA010 41 Female Black 530 C 
93ZA020 33 Female Mixed race 5 C 
93ZA023 48 Male Black 169 C 
93ZA024 41 Male Black 200 C 
93ZA025 24 Female Mixed race 375 B 
93ZA029 29 Female Black 172 C 
93ZA030 58 male Black 154 C 
93ZA031 31 Male Black 154 C 
93ZA032 34 Female Black 72 C 
93ZA035 52 Male Mixed race 140 C 
93ZA036 42 male Black 625 C 
93ZA037 32 Male Mixed race 418 C 
93ZA040 34 Female Black 269 C 
93ZA042 27 Male Mixed race 54 C 
93ZA043 32 Female Mixed race 443 C 
93ZA046 21 Female ~lack 404 C 
93ZA047 24 Male Black 373 C 
93ZA048 40 Male Black 111 C 
93ZA049 20 Female Black 517 C 
94ZA058 37 Female White 357 D 
94ZA060 42 Female Mixed race 421 A 
94ZA061 33 Male Black 138 A 
94ZA063 24 Male Mixed race ND C 
94ZA067 30 Female Black ND C 
94ZA201 38 Female Mixed race ND C 
94ZA202 44 Female Black ND C 
94ZA204 0.1 Male Black ND C 
94ZA205 21 Female Black ND C 
94ZA207 1 Unknown Black ND C 
Homosexual Transmission 
93ZA001 37 Male While 504 B 
93ZA002 35 Male While 52 B 
93ZA003 32 Male White 84 B 
93ZA004 30 Male White 564 B 
93ZA005 42 Male Mixed race 231 B 
93ZA007 41 Male White 0 B 
93ZA009 31 Male Mixed race 499 B 
93ZA011 25 Male Mixed race 481 B 
93ZA017 25 Male White 8 B 
93ZA021 44 Male Mixed race 245 B 
93ZA022 49 Male White 69 B 
93ZA033 36 Male White 374 B 
93ZA034 42 Male White 21 D 
93ZA039 37 Male Mixed race 746 B 
93ZA041 30 Male Mixed race 54 B 
93ZA044 48 Male While 208 B 
93ZA045 26 Male Mixed race 397 B 
94ZA050 39 Male Mixed race 32 B 
94ZA059 55 Male Mixed race 77 B 
94ZA073 47 Male White 23 B 
94ZA076 ND Male While ND B 
94ZA077 ND Male Mixed race ND B 
93ZA012 26 Male Mixed race 550 B 
93ZA019 40 Male While 534 B 
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The epidemiological data suggests that migrant labour and illegal immigrants play a role 
in the introduction of HIV into the country (Sher, 1989; Williams and Campbell, 1996 and 
van 
Haldenwang, 1996). Neighbouring southern African countries have some of the most explo
sive 
HIV epidemics within sub-Saharan Africa , with HIV prevalence ranging from 25% to over 40%
 in 
women attending some antenatal clinics in 1998 (MAP, 1997). Within South Africa, the spr
ead 
of the virus is rapid due to both economic and behavioural factors (see section 1.6.4). 
Our molecular data supports the epidemiological inference that the heterosexual 
epidemic in South Africa was as a result of regional spread of HIV from neighbouring countr
ies. 
Subtyping studies in Malawi (Orloff et al. , 1993 and Gao et al., 1996a), Zimbabwe (Shafer et al
., 
1997 and Tien et al., 1999), Botswana (Novitski et al., 1999) and Mozambique (Engelbrecht e
t 
al., 1998) have shown that subtype C is predominant in these countries. In addition, a stud
y 
performed on 43 mine workers in Gauteng Province of South Africa identified only subtype 
C in 
migrant labourers from Botswana and Lesotho, although it is not certain that these men w
ere 
infected in their country of origin, or within South Africa (Bredell et al., 1998). Isolates from
 
these countries were included in the 117 subtype C sequences phylogenetically compared in
 the 
V3 loop in this study. No subclusters with a country of origin were identified, in this stu
dy, 
however. This is in contrast to 93 sequences analysed in the V3 region of the env gene f
rom 
Addis Ababa in Ethiopia , where a subcluster of 32 isolates were identified with an average 7
.4% 
DNA distance, in comparison to the remaining 61 isolates which were on average 11
.5% 
divergent (Abebe et al., 1997). 
In addition , the high DNA distance demonstrated in this study between the southern 
African V3 loop sequences is an indication that the HIV subtype C epidemic in South Africa is
 not 
a clonal epidemic and it is probable that HIV entered the country on a number of occasions f
rom 
different countries of origin. As was indicated in the previous chapter (see section 2.3.3.4
), a 
number of the patients infected with subtype C reported having a possible origin of infection 
in a 
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neighbouring country where subtype C is known to occur. Multiple subtype C introductions into 
South Africa have also been indicated by sequencing results of isolates taken from mine workers 
in the Gauteng province, mentioned above (Bredell et al., 1998). In these isolates the env V3-V5 
region had an intrasubtype genetic diversity of 11 %. In addition, high intrasubtype DNA 
distances for subtype C were also determined in a study of the p17 region of the gag gene from 
Cape Town isolates sampled during the start of the epidemic (Williamson et al., 1995 and van 
Harmelen et al., 1997), providing evidence of multiple subtype C introductions into the country. 
Here, intrasubtype DNA distances from the subtype C isolates analysed in the gag gene were 
6.8% divergent, with a range of 1 to 11 .8%. 
High genetic diversity within subtype C isolates has also recently been reported by 
Novitsky et al. (1999). In a phylogenetic analysis of eight full length subtype C isolates from 
Botswana, an interpatient DNA distance of 9.1 % was determined. The DNA distance in the 
envelope gene was higher, at 12.4%. This group give a number of reasons as to why there is 
such high genetic diversity within the subtype C lineage, including that the viral load in patients 
infected with subtype C may be higher and that there may be faster viral transcription and 
replication within subtype C viruses (Neilson et al., 1998 and Novitski et al. , 1999). They also do 
not discount the possibility that multiple introductions of subtype C into Botswana may account 
for the great genetic diversity within the subtype. 
The South African epidemic (and Botswana epidemic) can be contrasted to subtype C 
epidemics in India and China that have much less genetic diversity. It has been suggested that 
the Indian epidemic was started by a single ancestor virus that then spread throughout India. 
The greatest DNA distance recorded in the Indian epidemic is 6.8% in the env region in Indian 
patients in Bombay (Grez et al., 1994). The Chinese subtype C epidemic was traced back to 
Chinese IVDUs sharing needles with Indian IVDU's (Shao et al., 1996) and an analysis of the 
sequence diversity of the Chinese subtype C isolates and Indian subtype C isolates indicated 
only 4.5% distance between the viruses iri the env region (Luo et al., 1995). lntrasubtype 
sequence diversity of subtype C isolates from China show an average DNA distance of only 
2.25% (Shao et al., 1996) to 2.6% (Luo et al., 1995). 
It has recently been shown by a number of studies that subtype C viruses rarely evolve 
to utilise the CXCR4 co-receptor (Doms and Moore, 1997; Tscherning et al., 1998 and Bjorndal 
et al., 1999). An indication of the phenotype of the isolate can be obtained from the V3 loop 
where more basic (positively charged) arginine residues at positions 276, 290 and 297 (see 
figure 3.8) are indicative of a fasUhigh, SI virus. A recent study of nine Ethiopian AIDS patients 
showed that all isolates were CCR5-restricted (Bjorndal et al., 1999). The results from our study 
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of 117 southern African subtype C isolates also only shows two isolates to have one of the 
arginine substitutions indicative of an SI phenotype, NOF and 94ZA067. Unfortunately no 
information on the disease stage of the patient was available for the isolates. 
Recently, the number of reports of re(;ombinant viruses has been increasing , especially 
in central Africa where there many different subtypes circulating (Liitsola et al., 1998; Peeters et 
al., 1998; and Renjifo et al., 1998) (see section 1.6.2) and it no longer sufficient to subtype only 
one region of the viral genome. The only way to identify complete recombinant viruses is by 
sequence analysis of the entire genome. However, sequencing is both time consuming and 
costly, thus rapid methods are needed for subtyping different regions of the genome to allow a 
general screening of large numbers of samples, in order to identify potential recombinant 
viruses, which can then be characterised . 
Restriction fragment length polymorphism (RFLP) analysis is a rapid method of 
subtyping that has been used in the protease and p24 regions of HIV genome. A useful strategy 
to ensure the reliability of the technique, and simultaneously screen for recombinants, would be 
to analyse different regions of the genome by RFLP, including p17, p24 and protease encoding 
regions and to combine this with V3 serotyping , or HMA of the env gene. RFLP analysis of the 
highly variable HIV env region was not possible, since analysis of the 700bp V3-V5 env region 
gave discrepant results in comparison to env HMA subtypes. V3 serotyping has also not proved 
as reliable as HMA in the identification of subtype B isolates in the South African epidemic, 
however. A 1998 study reported that 15 out of 119 samples, including 4 7 of the Cape Town 
isolates identified by HMA in the envelope region in this study, were not able to be typed using 
the V3 serotyping technique. In addition, three out of 26 subtype B samples were incorrectly 
serotyped as A/C (n=1), or C (n=2) and two subtype C samples were incorrectly serotyped as A, 
or A/C. It is possible, however, that with the use of alternative peptides the specificity of the 
technique may be improved (Cheingsong-Popov et al., 1998). 
In this study RFLP analysis was used in the HIV-1 gag p17 region in order to identify the 
gag subtype of South African isolates. In combination with HMA in the env region, a rapid 
screening of large numbers of samples would allow the detection of recombinant viruses in the 
gag and env regions and strengthen our knowledge of virus diversity. Although RFLP analysis is 
cheaper and easier to perform than sequence analysis on large numbers of samples, the 
technique does have some limitations, since HIV is a rapidly evolving virus and identification is 
based on the analysis of a limited number of informative sites. Even so, all 33 of the Cape Town 
samples of known sequence analysed by restriction endonuclease site analysis (RESA) in this 
study were correctly identified and 16 Cape Town isolates subtyped by RFLP analysis in a 
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blinded fashion were all correctly identified. In addition, when 25 sequences from other regions 
of Africa and the world were analysed by RESA, only two samples were problematic: a subtype 
C from Gabon was, which was untypable and a subtype D from the Democratic Republic of 
Congo which was inaccurately typed as a subtype B. It has been shown in a number of studies 
(Engelbrecht et al., 1995; Williamson et al., 1995; va_n Harmelen et al., 1997; Bredell et al. , 1998; 
Moodley et al., 1998; van Harmelen et al., 199_9a and van Harmelen et al., 1999b) that at present 
there is limited subtype diversity in South Africa, although there is high variability within subtype 
C and RFLP analysis has proven to be reliable in this setting . 
No discordance in subtype designation was identified in 77 samples from Johannesburg 
(n=20), Bloemfontein (n=17), Durban (n=2) and Cape Town (n=38) subtyped in both the gag 
gene (by RFLP) and env gene (by HMA) (see Table 3.6), indicating that no recombinants were 
identified in the regions of the genome analysed . In South Africa the greatest numbers of HIV-1 
infections are in the heterosexual population, with over 90% of the viruses to date being subtype 
C, although subtypes A, B and D have also been rarely identified (van Harmelen et al., 1997 and 
Bredell et al., 1998). The homosexual epidemic is almost exclusively subtype B (Williamson et 
al., 1995 and van Harmelen et al., 1997). Reco'mbinant viruses are thus not common, as 
opposed to Uganda, for example, where subtypes A and D co-circulate, leading to frequent co-
infection and recombinant formation (European Commission and UNAIDS Workshop Report, 
1997). 
It has not been determined why there is a predominance of subtype C in South Africa, 
India and China; whether it is by selective advantage of the virus due to phenotypic differences, 
allowing enhanced transmission , or due to increased transmissibility of the virus, or whether it is 
merely chance. Thus far, the only report of selection for growth of subtype C (and AE) was in 
Langerhans' cells (Soto-Ramirez et al., 1996 and Essex et al., 1997), but has since been refuted 
(Dittmar et al., 1997 and Pope et al., 1997). In addition, disease progression and survival rate 
was found to be similar between African and non-African HIV-positive individuals tested at an 
HIV/AIDS clinic in London (del Amo, 1996). However, a recent study of CSWs in Senegal 
reported that there may be faster disease progression in women infected with non-A subtypes of 
HIV-1 than subtype A infected women. The study was small , but suggests that further work may 
be warranted in order to investigate the possible relationship between subtype and pathogenicity 
(Kanki et al., 1999). 
Subtype C has spread throughout Africa to as far north as Ethiopia, Senegal and Djibouti 
(Louwagie et al., 1995; Abebe et al., 1997 and Bjorndal et al., 1999). In addition, subtype Chas 
spread globally, reaching epidemic proportions in India (Dietrich et al., 1993 and Grez et al., 
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1994) and China (Luo et al., 1995; Shao et al. , 1998 and Yu et al., 1998) and can now be found 
in every continent (European Commission (EC) and the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) , 1998). 
In this study it has thus been shown that subtype C is the predominant virus infecting the 
heterosexual population in South Africa and although subtypes A, B and D have been identified , 
the distribution of these subtypes is limited. Since South Africa is a potential site for vaccine 
trials (International AIDS Vaccine Initiative (IAVI Report, 1998), however, it is important to 
continually monitor genetic diversity within the country. 
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As was established in Chapters 2 and 3, the predominant HIV-1 subtype infecting the 
heterosexual population in South Africa is subtype C, and subtype B is prevalent in the 
homosexual population (Engelbrecht et al., 1995; Williamson et al., 1995; van Harmelen et al., 
1997; Bredell et al., 1998; Moodly et al. , 1998; van Harmelen et al., 1999a and van Harmelen et 
al., 1999b). Since South Africa is actively involved in HIV vaccine trials (IAVI Report, 1998), it 
would be beneficial if studies pertaining to the effect of virus diversity on vaccine design could be 
done on South African isolates. It has been shown by a number of studies that a cellular immune 
response is more important than a humoral response in limiting the spread of HIV in the body 
(Pantaleo et al., 1995; Rinaldo et al., 1995; Rowland-Jones et al., 1995 and Harrer et al., 1996). It 
is possible that for the most effective cytotoxic T lymphocyte (CTL) response, the vaccine should 
be constructed from virus subtypes endemic to the region. This is because the most conservation 
between CTL epitopes is within a subtype, although some CTL cross-reaction between subtypes 
has been shown (see sections 1. 7 .1.1 and 1. 7 .1.2). 
4. 1. 1) DNA vaccines 
A vaccine simple to construct and efficient at eliciting a CTL response would be ideal for 
the determination of immunogenicity of potential HIV vaccine proteins. DNA vaccines are known 
to elicit a potent CTL response to a number of foreign genes incorporated into DNA vaccine 
vectors (see Table 4.1 ). HIV-1 structural, accessory and regulatory genes have all been included 
in DNA vaccines (Kim et al., 1997, Boyer et al., 1997 and Hinkula et al., 1997). See section 1.8 
for a detailed description of DNA vaccines. 
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Table 4.1: A survey of the published results of DNA vaccines containing HIV antigens in order to 
elicit an immune response in non-human primates and small animals. Advantages and 
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A number of animal trials have been performed demonstrating the efficiency of DNA 
vaccines in eliciting both a humoral and cellular immune response (see Table 4.1). In addition, 
HIV DNA vaccines have entered clinical trials. In a phase I study of nine HIV-infected, but 
symptom-free patients, DNA vaccines containing the nef, rev or tat regulatory genes of HIV were 
injected intramuscularly into the patients' deltoid muscle. Although the patients had low or no 
CTL or antibody reaction to these HIV regulatory proteins before DNA immunisation, eight 
patients elicited MHC class-I restricted CD8+ CTLs to the protein expressed by the DNA 
vaccine. CTLs to regulatory proteins, which are produced early in the replication cycle of HIV, 
may eliminate infected cells before progeny virus is released (Calarota et al., 1998). 
Phase I clinical trials are ongoing with a therapeutic envlrev DNA vaccine (APL 400-003) 
to determine the safety and effectiveness of this vaccine. No anti-DNA antibodies, muscle 
enzyme elevations, or local or systemic reactions to the vaccine have been recorded, indicating 
the safety of the vaccine. Fifteen asymptomatic HIV infected patients were divided into three 
groups, immunised with three doses at ten week periods: 30µg, 100µg, or 300µg of DNA vaccine 
and all five of the patients in the 1 OOµg and 300µg groups elicited anti-gp120 antibodies great~r 
than double their baseline antibody level after 21 weeks. None of the patients in the 30µg group 
were able to elicit an antibody response greater than their baseline level to gp120, however. 
CTLs were obtained in 2/3 patients analysed from the 1 OOµg group, although no CTL response 
was detected in any of the other patients (n=7) tested from the other groups. All patients tested 
for T-cell proliferation showed an increase in stimulation index (SI), however, which was not 
dose-related. The vaccine thus appears to be safe and potentially immunogenic, encouraging 
further studies (MacGregor et al., 1998). 
DNA vaccines would thus provide a useful model for determination of the 
immunogenicity of potential HIV vaccine proteins. The effective CTL response elicited may be 
used in studies to determine CTL cross-reactivity between HIV subtypes. 
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4.1.2) The in vivo Vaccinia Virus challenge system: a critical review 
In order to evaluate the possibility of a cross-reactive CTL response to predominant 
South African HIV-1 subtypes, an in vivo recombinant vaccinia virus (VV) murine challenge 
system was utilised . A number of papers have reported on the use of this murine challenge 
system in order to determine the in vivo CTL response to different vaccine formulations (Doherty 
et al. , 1989; Binder and Ki.indig, 1991; Bachmann et al., 1994, Belyakov et al., 1998; and Kent et 
al., 1998). Here, the pertinent literature on this challenge model is critically appraised. 
In mice, the primary infection by VV is controlled by the CD8+ CTL response, whereas 
antibodies play a role in assisting the CTL response in the complete clearance of the virus as 
well as preventing the spread of the virus in a secondary infection (Hirsch et al., 1968). The 
recombinant W progeny is produced within the cytoplasm of the infected cell and the 
endogenously expressed proteins can thus enter the MHC class 1 pathway and be expressed on 
the surface of the cells, eliciting the CD8+ CTL response (Binns and Smith, 1992). It has been 
shown that after vaccination of mice with a specific antigen, followed by challenge with a similar 
antigen expressed by the W recombinant, if the mice are depleted of CD8+ T cells, the virus is 
able to initiate an infection equivalent to that in unimmunised mice. Depleting the challenged 
mice of CD4+ T cells, however, has no effect and the immunised mice are able to clear the 
recombinant VV infection (Binder and Ki.indig , 1991, Bachmann et al., 1994; Belaykov et al., 
1998 and Kent et al., 1998). 
Since the CD8+ CTL response to the recombinant VV allows the mouse to eliminate the 
recombinant VV (Hirsch et al., 1968; Binder and Ki.indig, 1991; Bachmann et al., 1994; Belyakov 
et al., 1998 and Kent et al., 1998), the challenge system gives an in vivo indication of the CD8+ 
CTL response in the mouse to the immunogenic protein. 
Vaccinated mice have been challenged with recombinant vaccinia virus (VV) expressing 
foreign genes from the vaccine strain via a number of different inoculation routes including; 
intraperitoneal (Bachmann et al., 1994), intrarectal (Belyakov et al., 1998), intracranial (Doherty 
et al., 1989) or intravenous (Binder and Ki.indig, 1991 and Kent et al., 1998). The earliest paper 
studied the susceptibility (as the percentage mortality) of BALB/c, CBA/H and C57B1 mice to 
recombinant W expressing the influenza virus nucleoprotein and haemagglutanin proteins after 
intracranial challenge. It was established that male and older female mice were more resistant 
to the recombinant W, as were C57B1 mice (Doherty et al., 1989). 
A second study investigated the recombinant VV titres in C57BU6 mouse organs 
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(spleen, liver, lung, thymus, ovaries and brains) after intravenous challenge with a W 
expressing the nucleoprotein of vesicular stomatitis virus Indiana, Mudd-Summer isolate (VV-
IND-NP) , showing the highest titres to be in the mouse ovaries after three to seven days. Mice 
challenged with recombinant W-IND-NP after priming with VSV were shown to have over 5 log10 
lower titres of W-IND-NP in their ovaries in comparison to mice immunised with unrelated 
influenza virus PR8 (Binder and Kundig, 1991 ). Recombinant VV clearance and the level of the 
CTL response can thus be determined by calculating the W titres in the mouse ovaries and 
comparing the titres to those in unimmunised, control mice. 
A further three studies have used the murine W challenge model to detect CTLs. The 
first group (Bachmann et al. , 1994) used the technique in order to illustrate that a CTL response 
was elicited to their VSV N (nucleoprotein) vaccine. The group were able to show that 
immunisation of mice with recombinant viral proteins from VSV Indiana produced in a 
baculovirus system elicited a CD8+ CTL response after intraperitoneal challenge with 
recombinant VV-VSV-N. The CTL response was measured as a 5.6 log10 decrease in W-VSV-N 
titres twenty-five days after immunisation in the mouse ovaries in comparison to the control, 
unimmunised mice. A second study used the in vivo challenge model in order to compare the 
effectiveness of different inoculation routes, followed by recombinant W challenge. Similar 
levels of protection to Bachmann's group were obtained after intrarectal challenge with 
recombinant VV expressing HIV-1 1119 gp160 in BALB/c mice immunised intrarectally with a HIV-1 
peptide vaccine, PCLUS3-18111B (Belyakov et al., 1998). The recombinant challenge technique 
has also been used to determine the most effective vaccination strategy, using a prime-boost 
protocol. Intramuscular immunisation with a DNA vaccine expressing the gag and env proteins 
of HIV-1sF2, followed by a fowlpox-HIV-1 5Frgag/pol boost, completely protected CBNH mice 
from challenge with a W expressing the Gag and Pol proteins of HIV-1sF2. The protection was 
measured as a decrease in recombinant W titre from 6.8 log10 to undetectable levels (<2 log10) 
(Kent et al., 1998). 
The murine recombinant W challenge technique thus gives an indirect measurement of 
the in vivo CD8+ CTL response to the immunogenic proteins in the vaccinated mice. 
4.1.3) Objectives of this study 
At the time of initiation of this study, the gp120 of HIV was widely used in vaccine design 
(see section 1.7). Limited studies had been performed on the identification of CTL epitopes in 
HIV proteins or on CTL cross-protection between subtypes (see section 1. 7) . The gp120 from 
two HIV-1 isolates belonging to subtypes B and C were thus chosen for genotypic 
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characterisation and immunogenicity studies, since the two subtypes predominate · in the 
homosexual male and heterosexual populations in South Africa respectively (see Chapters 2 and 
3) . Subtype C was also chosen , as at the time of initiation of the study, vaccine development 
had mostly been based on T-cell tropic, subtype 8 isolates (IAVI , 1998). The gp120 from a NSI, 
CCR5-restricted, primary subtype B reference isolate, SF162 (USA) and subtype C from a 
macrophage tropic, primary virus isolate, 97ZA347TS, from South Africa were selected . To 
determine the immunogenicity of the gp120 from the two subtypes, the gp120 protein from each 
was cloned into pcDNA3.1/Zeo DNA vaccine vectors (lnvitrogen, USA). In addition, the CTL 
cross-reactivity between the subtype 8 and subtype C gp120s was determined using the in vivo 
murine W challenge system. 
4.2) Materials and Methods 
4.2.1) Source of the gp120 
The gp120 from a NSI reference plasmid , SF162, from the United States of America 
(USA) (obtained from NIH AIDS Research Reference and Reagent Program, USA) was used for 
the subtype 8 DNA vaccine. In addition , the gp120 from a local subtype C isolate was selected 
for the subtype C DNA vaccine. The subtype C isolate, 97ZA347TS, was cultured from an 
individual who had been working on a mine in the Gauteng Province (obtained from Sue Lyons, 
National Institute of Virology, Johannesburg). The isolate was shown to be non-syncitium 
inducing and macrophage tropic, unable to grow in U-937 or MT-2 cell lines (Sue Lyons, 
personal communication) . 
4.2.2) DNA extraction of 97ZA347TS and PCR amplification of 97ZA347TS, SF170 and SF162 
Proviral DNA was extracted from the cultured 97ZA347TS isolate as in described 
(Kawasaki , 1990 and Appendix A1) . The gp120 from 97ZA347TS was amplified by nested PCR 
using primers ED3/14, (Delwart et al., 1993), in the outer reaction and envJ/envB (Gao et al., 
1994) as the inner primers as described (Appendix A2) . The gp120 from the reference plasmid, 
SF162, was amplified by the inner primers only. Briefly, the 2.5Kb outer reaction and 1.6Kb 
inner reaction fragments were amplified by nested PCR amplification with 50µ1 master mixes 
containing: 
• 5µ1 10X PCR buffer (Promega , Madison, WI ,' USA), (500mM KCI , 100mM Tris-HCI (pH9.0) , 
1% Triton X-100) , 
• 1.5mM MgCl2, 
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• 1% DMSO, 1% glycerol , 
• 200µM each of dNTP's, 
• 400nM each of ED3/ED14 (outer reaction) and envB!envJ (inner reaction) and 
• 2.SU Taq DNA Polymerase (outer reaction) and 2U Taq DNA Polymerase (inner reaction) 
The outer reaction mixes were made up to 40µ1 and the inner reactions to 47µ1 with 
sterile, deionised water and were overlayed with 30µ1 of mineral oil. Ten microlitres of DNA 
isolated from viral culture was added to the outer reaction and 3µ1 of the outer reaction product 
was transferred to the inner reaction mix. For amplification of the plasmid DNA, 2µ1 of plasmid 
DNA was added to the inner reaction mix. Negative controls included HIV negative patient DNA 
and sterile distilled water in order to monitor contamination. The amplification conditions in the 
Techne PHC-2 PCR thermocycler for the outer reactions were: 
• Initial denaturation at 94°C for 2 minutes, 
• 94°C for 1 minute, 45°C for 1 minute and 72°C for 2 minutes (5 cycles), 
• 94°C for 20 seconds, 55°C for 45 seconds and 72°C for 1 minute (35 cycles) and 
• Final extension at 72°C for 6 minutes. 
Amplification conditions for the inner reactions were: 
• Initial denaturation at 94°C for 2 minutes, 
• 94°C for 20 seconds, 55°C for 45 seconds and 72°C for 1 minute (35 cycles) and 
• Final extension at 72°C for 6 minutes. 
The amplified product was stored at -20°C before cloning into the pMOS-blue vector 
(Amersham, Buckinghamshire, UK) . 
4.2.3) Cloning and sequencing of the gp120 from subtypes Band C 
The amplified gp120 was cloned into the pMOS-blue (Amersham, Buckinghamshire, UK) 
vector by TA cloning according to manufa·cturers' instructions (Appendix AS). The ligated 
plasmids were transformed into competent E. coli, strain DHa (Appendix A6) and DNA from 
putative clones extracted by mini-preparation (Appendix A7) . The clones were then screened by 
restriction endonuclease digestion with Hincll (subtype B) and Hindlll (Boehringer Mannheim, 
Hamburg, Germany) (subtype C) in order to determine the correct orientation for sub-cloning into 
pcDNA3.1/Zeo (lnvitrogen , USA) (Appendix A4). 
The ATG start codon of the gp120 from the isolates had to be adjacent to the EcoRI site 
of pMOS-blue (Amersham, Buckinghamshire, UK) for directional cloning into the 
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pcDNA3.1/Zeo+ vector (lnvitrogen, USA) (see figure 4.1). However, for cloning of the subtype C 
isolate into the pSC65 VV vector (obtained from Bernard Moss, NIH, USA), the ATG start codon 
had to be in the opposite orientation. Two pMOS-blue plasmid vectors for 97ZA347TS were thus 
constructed, one in each orientation (see figure 4.1). The digested fragments were 
electrophoresed through a 1 % TAE agarose gel and stained with ethidium bromide (1 Ong/ml) 
(Appendix A3) in order to visualise the fragments using the UVP transilluminator at 256nm. 
The pMOS-97ZA347TS plasmid DNA was extracted by maxi-preparation using the 
Nucleobond® AX100 anion-exchange kit (Machery-Nagel , Germany) according to manufacturers 
instructions (Appendix A 7) and sequenced using forward and reverse primers, T7 
(5'AA TACGACTCACT AT AGGG3') and U-19 (5'ACGTCGTGACTGGGAAAACC3') respectively (pMOS-
blue-T vector, Amersham, Buckinghamshire, UK), as well as internal primers, E135 and E155 
(Myers et al., 1995), shown in Table 4.2. Sequencing was performed using the Pharmacia™ 
ALFexpress® automated sequencer using fluorescent Cy5-labelled primers (Appendix A8.1) with 
both strands sequenced until unambiguous. 
Table 4.2: Sequencing primers for the HiV-1 env gene used for internal sequencing of the 










Nucleotide position is indicated on the 5' end of the primer and is taken from the reference 
isolate HXB2 (Genbank accession number, K03455) . Reverse primers are indicated by"«". 
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Figure 4.1: An illustration of the restriction endonucleases used and the expected fragment sizes for identification of 
pMOS-blue clones containing the inserted gp120 from subtype B (SF162) and C (97ZA347TS). Clones in the correct 
orientation, indicated by a tick, were used for subcloning into pcDNA 3.1/Zeo and pSC65. 
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Phylogenetic analysis of the gp120 from 97ZA347TS was performed with at least two 
reference sequences each, from subtypes A to J, using Clustal X (Thompson, 1997) to align 
sequences, with additional manual alignment. The tree was drawn using TREECONW (van der 
Peer and de Wachter, 1994) using the distance matrix neighbour joining method, ignoring 
insertions and deletions. The Kimura two-parameter algorithm (Kimura, 1990) was used to infer 
tree topology and the reliability of the tree topology was assessed by doing 1000 bootstrap 
replicates with the SIVcpz-gab sequence as the outgroup in TREECONW (van der Peer and de 
Wachter, 1994) (see section .2.9). The entire gp120 sequence was translated using the computer 
programme, Genepro (Version 6.10 Riverside Scientific Enterprises WA, USA). Variable loop 
regions, conserved cysteines and N-linked glycosylation sites were determined and compared with 
reference sequences belonging to subtype A, B, C, D and AE (HIV sequence database, 1998) (see 
section 4.3.1 ). 
4.2.4) Directional cloning of the gp120 into pcDNA3.1/Zeo 
The DNA vaccine vector, pcDNA3.1 /Zeo+ (lnvitrogen, USA) is a 5.0Kb plasmid with a 
polycloning site containing restriction endonuclease sites for 16 enzymes (See Appendix C.1 for 
the pcDNA3.1 /Zeo+ map). The foreign gene is inserted with the start ATG codon downstream of 
a human cytomegalovirus (HCMV) immediate/early promoter. Downstream of the foreign gene is 
the bovine growth hormone polyA terminator sequence (BGHpA), which has been shown to 
increase transcription efficiency (Norman, 1997). The vector contains a zeocin resistance gene 
for selection of stable transfectants, upstream of a simian virus 40 (SV40) origin of replication, and 
downstream of a SV40pA sequence. The plasmid also contains a ColE1 origin of replication for 
growth in E coli, as well as an ampicillin resistance gene for selection of recombinant bacteria. 
The subtype B and C gp120 fragments and digested pcDNA3.1/Zeo (lnvitrogen, USA) 
vectors were ligated overnight at 16°C using T4 DNA ligase (Boehringer Mannheim, Hamburg, 
Germany) (Appendix A5) and the ligated product was used to transform competent E. coli strain 
DH( cells (Appendix A6) with the appropriate controls. Putative clones were screened by miniprep 
DNA purification (Appendix A7) and restriction endonuclease analysis with EcoRI and Xbal 
(Appendix A4). Incorporation of gp120 was also detected by PCR analysis with env V3-V5 
primers, ES7and ESB, as performed in section 2.2 (Appendix A2). See figure 4.2 for a graphic 
representation of the cloning protocol. 
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4.2.5) Transfection of HeLa cells with pcDNA- SF162 and-97ZA437TS 
In order to determine whether the gp120 proteins from the two DNA vaccines were 
expressed, immunofluorescent detection of the gp120 was performed after transfection of the 
DNA vaccines into Hela cells. 
The pcDNA3.1-HIV subtype Band C vectors were amplified by growth in E. coli DHa cells 
and the DNA purified by maxi-preparation using the Nucleobond® AX100 anion-exchange kit 
(Machery-Nagel Germany) according to manufacturers' instructions {Appendix A7). DNA was 
further purified by ethanol precipitation (Appendix A4) and purity and concentration measured by 
spectrophotometric analysis using the Beckman DU-40 spectrophotometer scanning from 220nm 
to 310nm wavelengths. Purified DNA at a 2601280nm ratio of between 1.7 and 2 was stored in 
aliquots at -20°C (Appendix A7). 
Hela cell stocks {obtained from the American Type Culture Collection, Rockville, MA, 
USA) frozen in liquid nitrogen were thawed and centrifuged at 1 000 rpm for five minutes to 
remove DMSO (Appendix B1 ). The cell pellet was re-suspended in 5ml of Dulbecco's Modified 
Eagle's Medium (DMEM) medium containing 10% fetal calf serum (FCS}, penicillin, streptomycin 
(PS) and Fungizone (F) (GibcoBRL, Paisley, UK) (Appendix B 1 ). The He La cell culture was then 
incubated at 37°C with 5-10% CO2 , and the cell culture was split when the cells had reached 
100% confluency (Appendix B1 ). 
Ten micrograms each of pcDNA3.1sF162 (subtype B) and pcDNA3.197ZA346rs (subtype C) 
was transfected separately into 60-70%. confluent Hela cells in a six-well plate containing a glass 
microscope cover-slip in each well, using 30µ1 of the DOTAP (Boehringer Mannheim, Hamburg, 
Germany) transfection reagent according to manufacturers instructions (Appendix B2). The cells 
were able to grow on the cover-slip, which was then removed for immunofluorescence 
detection. Two microlitres of positive control eukaryotic expression plasmid containing the ~-D 
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galactosidase gene, pSVNeo-pgal (Stratagene, La Jolla, CA, USA), was also added, since the 
pcDNA3.1 /Zea vector does not have the p-D galactosidase marker gene, allowing detection of 
transfected cells by 5-bromo-4-chloro-indolyl P-D-galactoside (X-gal) staining. After a six hour 
incubation at 37°C with 5-10% CO2, the 2ml of medium containing the DOTAP and DNA mixture was 
removed and 2ml of fresh DMEM (10% FCS, PS and F) media added. 




clone into pMOS-blue t 








Figure 4.2: Flow diagram illustrating the method used for construction of the DNA vaccines. The gp120 (shown in blue) 
was cloned into pMOS-blue (Amersham, Buckinghamshire, UK) in the correct orientation (see figure 4.1). The gp120 
was then excised and directionally cloned into pcDNA3.1 /Zeo (lnvitrogen, USA) using EcoRI and Xbal restriction 
endonucleases. The technique was repeated for subtypes B and C. 
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4. 2. 6) lmmunofluorescent detection of the gp120 protein 
The transfected cells were incubated for a further 24-48 hours after which the medium 
and cover-slips were removed and the remaining cells in the six well plate were fixed with 4% 
para-formaldehyde for five minutes at room temperature . At the same time the cover-slips were 
submerged in acetone at 4°C for ten minutes for fixation of the cells to the glass, after which they 
were allowed to dry at room temperature. The cells remaining in the six well plate were stained 
with X-gal stain (Appendix 85) and the number of blue cells counted to give an indication of the 
effectiveness of the transfection protocol. The cover-slips were subjected to immunofluorescent 
detection (Appendix 86) using a goat anti-HIV gp120 (8iogenesis, Poole, England) , followed by a 
rabbit anti-sheep FITC conjugate (DAKO, Glostrup, Denmark). lmmunofluorecent cells 
expressing the gp120 were visualised using the SM-LUX fluorescent microscope (Leitz-Wetzlar, 
GM8L, Germany) with a tungsten halogen lamp (1 OOW, 12V) at 450-490nm wavelength and 
photographed. 
4.2. 7) Immunisation of BALB/c mice with DNA vaccine and antibody detection 
Six to eight week male 8AL8/c mice (H-Z) were obtained from the UCT animal unit 
after approval of the study by the UCT ethics committee (ethical approval number 97/026). Mice 
were divided into three groups, with five mice in each group (see Table 4.3) . 
Table 4.3: The DNA vaccine and gp120 subtype which was inoculated into the five mice in each 
group. 
Mouse Group 
Group 1 (5 mice) 
Group 2 (5 mice) 




pcDNA3.1 /Zeo alone 
Subtype 
Subtype 8 gp120 
Subtype C gp120 
Negative control 
For immunisation, the mice were immunised with 100µ1 of 0.25% bupivacaine-HCI 
(Adcock Ingram Pharmaceuticals) into each tibia/is anterior muscle, 48 hours prior to the DNA 
vaccine immunisation (Kim et al., 1997). The bupivacaine-HCI is a local anaesthetic that causes 
the localised muscle tissue to necrotise. After approximately 48 hours, the muscle fibres begin 
to regenerate and allow a more efficient uptake of the naked DNA. Fifty micrograms of the 
relevant DNA vaccine diluted to a concentratjon of 1,µg/µI in sterile 1XP8S for immunisation, was 
thus injected intramuscularly into the regenerating muscle at the same position (1 OOµg per 
mouse) (Whalen, 1997) (Appendix 87). Mice were immunised on weeks 0, 2, 4 and 8 and 200µ1 
of blood was taken prior to the first immunisation, prior to each bupivacaine-HCI injection and a 
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final 200µ1 was obtained nine days after the final DNA immunisation. Blood was allowed to clot 
at 4°c overnight and then microfuged at 8 OOOrpm for one minute to remove red blood cells. 
The serum was transferred to a fresh eppendorf tube and stored at -20°C until antibody 
detection. 
Antibodies to the expressed gp120 were detected using an enzyme-linked 
immunosorbant assay (ELISA) with a rabbit anti-mouse HRP (horseradish peroxidase) conjugate 
(Dako, Glostrup, Denmark) (Appendix B8). Briefly, ninety-six well microtitre plates (Nunc-
lmmuno(, Delta, Denmark) were coated overnight at 4°C with 2µg of HIV111s gp120 protein 
(obtained from the National Institute for Biological Standards and Control (NIBSC), Hertfordshire, 
UK) . After blocking with ELITE® milk powder, the mouse serum diluted 1/50 in 1XPBS 
containing 0.05% Tween-2o""' was added. The plate was incubated at 37(C for an hour, followed 
by incubation with the rabbit anti-mouse HRP conjugate diluted 1/600 in blocking solution 
(1XPBS, 0.05% Tween-20"', 1 % ELITE® (milk powder) for an hour. The plate was washed with 
1X PBS containing 0.05% Tween-20"' between each incubation and before the addition of the 
substrate. After the addition of freshly made up OPD substrate (DAKO, Glostrup, Denmark), the 
ELISA plate was read on the Anthos ELISA plate reader (Labtech Instruments) at 492nm OD 
with a filter of 620nm. 
4.2.8) 97ZA347TS gp120 subcloning into pSC65 
The pSC65 shuttle vector (obtained from Bernard Moss, NIH, USA) is a vector for the 
construction of recombinant Ws containing foreign genes. The shuttle vector contains a 
polycloning site consisting of seven restriction endonuclease sites, which is downstream of the 
synthetic early/late poxvirus promoter (See Appendix C.2 for the pSC65 map). The vector also 
contains a (~-D galactosidase (LacZ) gene, which is under the control of the poxvirus early/late 
P7.5 promoter. Poxvirus promoters must be used in poxvirus vectors, as cellular promoters will 
not be recognised by poxvirus transcriptional enzymes (Binns and Smith , 1992). The foreign 
gene and Lacz gene are flanked by regions of the poxvirus thymidine kinase (TK) gene in order 
to allow homologous recombination with the wild type W. The TK gene interruption by these 
inserts also provides a selection mechanism for the recombinant poxviruses. This is due to the 
TK gene being involved in the recycling of nucleotides needed for the replication of the dsDNA 
poxvirus genome. In vitro, TK competent virus.es allow the phosphorylation of BUdR (5-
bromodeoxyuridine), which is lethally incorporated into the virus genome. After interruption of 
the TK gene in recombinant VVs, addition of BudR has no effect and only the recombinant TK. 
viruses will survive (Chakrabarti et al., 1985 and Binns and Smith , 1992). The pSC65 vector 
also contains a ColE1 origin of replication for growth in E. coli, as well as an ampicillin resistance 
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gene for selection of E. coli clones. 
In order to construct the pSC6597ZA34ns recombinant vector containing the gp120 from 
isolate 97ZA34 7TS, the gp120 with the ATG start codon adjacent to the Sal I site (see figure 
4.1), was excised from pMOS-blue (Amersham, Buckinghamshire, UK) using the restriction 
endonuclease, Sma I (Boehringer Mannheim, Hamburg , Germany) (Appendix A4) . The DNA 
was purified by ethanol precipitation (Appendix A4) . The pMOS-blue-gp120 vector was then 
digested with Sa/ I in a different buffer (Boehringer Mannheim, Hamburg, Germany) in order to 
release the gp120 fragment with one sticky and one blunt end (Appendix A4) . The pSC65 vector 
was digested in the same manner in order to release the stuffer fragment with complementary 
sticky/blunt ends. The vector and gp120 fragments were gel purified by excision from 1 % TAE 
gel after electrophoresis as in section 4.3.2.1 (Appendix A3) and extracted by phenol squeeze 
(Append ix AS) . The vector and gp120 fragment was ligated overnight at 16°C using Boehringer 
Mannheim (Hamburg, Germany) T4 DNA ligase (Appendix AS) and the ligation mix was used to 
transform competent E. coli strain DH( cells (Appendix A6) with the appropriate controls. 
Putative clones were screened by mini prep DNA purification (Appendix A 7) and restriction 
endonuclease analysis with EcoRI and Xbal to release the gp120 fragment (Appendix A4) . The 
gp120 was also detected by PCR analysis with env V3-V5 primers, ES7and ESB, as performed 
in section 2.2.3 (Appendix A2) . See figure 4.3 for a flow diagram of the cloning protocol utilised 
in th is study. 
4. 2. 9) Recombinant VV97ZA347TS selection 
Two cell types were used in the formation of recombinant W 97ZA3ms: CV1 and 1438 
(TK). Cell stocks (American Type Culture Collection, Rockville, MA, USA, Appendix 81) stored 
in liquid nitrogen, were thawed and washed as before (see section 4.2.5). Cells were incubate_d 
at 37°C with 5-10% CO2 until 100% confluent after which they were split and fresh medium 
added every two days. 
VV-infected CV1 cells were the initial cells used for transfection of the pSC6597ZA34n s 
plasmid (Appendix 83). Briefly, the cells were grown to 60-80% confluence in a six well plate 
and then infected with 105 plaque forming units (pfu) of wild-type Wwr, (W strain western 
reserve) (obtained from John Williamson, St Mary's Hospital , London) in 500µ1 of virus diluent 
(DMEM, 1% 10mM HEPES) for one hour, with shaking every 30 minutes. The virus was 
removed and 2ml of DMEM (10%FCS, PS and F) containing 3µg of Sea I linearised 
pSC6591ZA347Ts DNA and 4µ1 of FuGene 6 {Boehringer Mannheim, Hamburg, Germany) were 
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added according to manufacturers' instructions (Appendix 82). The infected CV1 cells were 
incubated for two to three days, until cytopathic effect (cpe) was detectable. The CV1 cells were 
then scraped from the six well plate using a rubber policeman, transferred to Nunc cryotubes (Delta, 
Denmark) and freeze/thawed three times. The cells were frozen by plunging them into an ethanol, 
dry ice bath and thawed at 37°C. The infected cells were then diluted 1/2 in virus diluent for 
infection of 70-80% confluent 1438 (TK) cells for one hour, shaking every 30 minutes. 
97ZA347TS-gp120 




Figure 4.3: Flow diagram illustrating the method used for construction of the recombinant W vector, pSC65 
containing the 97ZA347TS isolate gp120 (pSC6597ZAi4ns). The gp120 gene was excised from pMos"..blue 
(Amersham, Buckinghamshire, UK) using Smal and San restriction endonucleases (see figure 4.1) and directionally 
cloned into pSC65 (obtained from Bernard Moss, NIH, USA). 
TK cells, lacking the thymidine kinase gene are used in the selection of recombinant Ws. 
Selection medium consisting of BUdR (5-bromodeoxyuridine) (5mg/ml) incorporated into 2ml of 
DMEM medium at 1 /200 (25µg/ml) concentration was added to the TK cells after removal of the 
virus. After two to three days, the medium was removed and stored at -70°C, and a 2% agarose 
overlay, containing 25(g/ml BUdR and 250(g/ml X-gal in 2XDMEM at 42°C, was added. Blue 
plaques indicative of recombinant W 97ZA34rrs were picked, resuspended in 200µ1 of virus diluent 
and freeze/thawed as before. A 1/5 dilution of virus in diluent was used to infect TK cells 
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and fresh selection medium containing 25µg/ml BUdR was added. The infected TK- cells were 
incubated for two days until cpe had formed and then overlayed with agarose as before 
(Appendix 83). The recombinant viruses were passaged a total of 13 times before pure 
recombinant VV97ZA347TS was obtained . 
A pure VV97ZA34ns stock was grown on the amniotic membrane of (five to ten day) 
fertilised eggs at 37°C (Appendix 84) . Three days after infection of the membranes, the 
W 97ZA3m s was harvested (Appendix 84) . The virus titre was determined by serial dilution of 
virus from 10-3 to 10-9 in virus diluent and infection of 70% confiuent CV1 cells (Appendix 84) . 
The virus was grown for three days at 37°C until plaques had formed and then pfus were counted 
after Ziehl Neelson Carbol Fuchsin staining. The VV97ZA3ms stock was stored in aliquots at -
70°C in Mcllvaine's buffer. Purified VV97ZA3ms was confirmed by immunofluorescence of 
infected cells using goat anti-HIV gp120 (Biogenesis, Poole, England) and a rabbit anti-sheep 
FITC conjugate (DAKO Glostrup, Denmark) as in section 4.2.3.3. 
4.2. 10) Challenge of DNA vaccine-immunised female BALB/c mice with recombinant VV972A34ns 
A preliminary study to confirm that the recombinant W 97ZA34ns would replicate in the 
mouse ovaries was performed . Eight female BALB/c mice (six to eight weeks) were injected 
intraperitoneally with 100µ1 of: PBS; 5X106 pfu ; 5X107 pfu; and 1X108 pfu (two mice per group) of 
virus. After five days, the mice were sacrificed and their ovaries removed . The ovaries were 
ground up in Mcllvaine's buffer (10(1/mg of mouse ovary) using ten-broek grinders (Appendix 
89) . The virus titre was measured by serial dilution from 10-3 to 10-9 in virus diluent, infection of 
70% confluent CV1 cells and detection of virus plaques after three days as above (Appendix 84). 
Once it was determined that the recombinant VV97ZA34n s was able to grow in BALB/c 
' ' 
mouse ovaries, two experiments were performed . In both , female BALB/c mice (six to eight 
weeks) were divided into three groups with two mice in each group. Group 1 contained two mice 
immunised with pcDNA3.1 sF162, group 2 contained two mice immunised with pcDNA3.197ZA346rs 
and the final group contained two mice that were immunised with the pcDNA3.1 (lnvitrogen, 
USA) vector alone. Mice were only given one DNA vaccine immunisation as described in 
section 4.2.4. (Appendix 87) and nine days later challenged intraperitoneally (Appendix 87) . For 
the first experiment, 100µ1 of 1X107 pfu of VV97ZA347rs was delivered as the challenge dose and 
for the second experiment 5X107 pfu of VV97ZA3ms was delivered . Mice receiving 1X10
7 pfu of 
virus (low challenge dose) were sacrificed eight days later and their ovaries removed. Mice 
receiving 5X107 pfu of VV97ZA3ms (high challenge dose) were sacrificed after five days and their 
ovaries removed . Ovaries from both mice in each group were pooled and ground up in 
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Mcllvaine's solution as above (Appendix 89) . Virus titres were determined as above (Appendix 
84) and the level of virus in each group was compared to the negative control , pcDNA3.1 
immunised mice. 
4.3) Results 
As subtype C was demonstrated to be the predominant subtype in South Africa in the 
previous chapter, we aimed to characterise the gp120 in more detail. An isolate that was 
macrophage tropic and NSI was selected (97ZA346TS) as it was considered to be more closely 
related to the sexually transmitted phenotype. Co-receptor usage was not available at this time 
and is therefore unknown. For comparative purposes, a parallel study utilising the gp120 from a 
NSI , CCR5-restricted subtype B isolate (SF162) was undertaken. In order to determine the 
immunogenicity of the gp120, the genes were cloned and expressed by the pcDNA3.1/Zeo DNA 
vaccine (pcDNA3.1 sF162 and pcDNA3.191ZA346rs) and used to immunise BALB/c mice. The in vivo 
CTL cross-reactivity obtained in BALB/c mice between subtypes B and C was also investigated, 
using the murine in vivo challenge system (Binder and Kundig , 1991, Bachmann et al., 1994; 
Belyakov et al., 1998 and Kent et al., 1998), utilising the VV-HIV recombinant, W 97ZA34ns, as the 
challenge virus. 
4.3.1) Characterisation of the gp120 from 97ZA347TS 
The DNA sequence encoding the complete gp120 (and 5' end of the gp41) of 
97ZA347TS is shown in figure 4.4. Phylogenetic analysis of 97ZA347TS in figure 4.5 shows that 
the sequence clusters within the subtype C lineage with a bootstrap value of 100%. The average 
intrasubtype DNA distance between 97ZA347TS and the nine reference subtype C sequences is 
10.1 % with a range of 8.5% to 10.8% (see Table 4.4) . No South African sequences of the 
complete gp120 were available for comparison and the South African sequence, 97ZA347TS, 
was found to be most related to ZAM18, from Zambia with a DNA difference of 8:5%. 
The gp120 amino acid divergence between the two isolates being immunogenically 
compared, 97ZA347TS and SF162, was also determined. In addition, the gp120 amino acid 
sequence of ZAM18 was included for comparison . The amino acid divergence between SF162 
and 97ZA347TS is 24% and 25% between SF162 and ZAM18, whereas ZAM18 is 15% divergent 
from 97ZA347TS. 
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97ZA347TS DNA sequence 
ATGAGAGTGAGGGGGATACGGAAGAATTGTCAACAATGGTGGATATGGGGCATCTTAGGC 















,l.. V3 loop start 
CAACTTAATGGGTCTGTAGAAATTGTGTGTACAAGACCCAGCAATAATACAAGAAAAAGT 
ATAAGGATAGGACCAGGACAAGCATTCTATGCAACAGGTGACATAATAGGTAACATAAGG 















Figure 4.4: The complete gp120 DNA sequence and 5' end of the gp41 for the macrophage tropic, primary subtype C isolate, 
97ZA347TS indicating the start and end of the gp120 as well as the V3 loop sequence. 
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Table 4.4: The percentage DNA distance between subtype C, 97ZA347TS and reference 
sequences from subtypes A to AE, including nine subtype C reference sequences from 
southern Africa (n=4) and globally (n=5). No full length gp120 subtype C sequences from 
South Africa have been published and could thus not be included. 
A B C1 C2 C3 C4 cs C6 C7 ca C9 C10 D AE 
C1 16.5 16.1 0 10.5 10.6 10.4 8.5 10.8 10.4 10.0 10.0 10.0 17.1 17.7 
C2 17.3 17.6 10.5 0 10.7 10.5 10.0 11 .3 11.3 10.2 9.9 9.9 18.0 18.3 
C3 17.1 16.8 10.6 10.7 0 10.4 9.8 12.3 11 .0 9.0 8.3 9.4 18.1 18.3 
C4 16.8 16.5 10.4 10.5 10.4 0 9.3 11 .0 10.0 9.4 8.3 9.6 17.3 17.7 
cs 16.3 17.0 8.5 10.0 9.8 9.3 0 19.7 9.4 7.7 7.4 9.1 17.6 18.2 
C6 16.5 16.6 10.8 11.3 12.3 11 .0 10.7 0 9.9 11.2 10.7 8.5 17.1 18.4 
C7 16.5 16.5 10.4 11.3 11 .0 10.0 9.4 9.9 0 10.3 9.6 9.1 17.5 17.5 
cs 16.8 16.7 10.0 10.2 9.0 9.4 7.7 11 .2 10.3 0 5.8 9.5 17.9 17.7 
C9 17.0 16.5 10.0 9.9 8.3 8.3 7.4 10.7 9.6 5.8 0 8.6 17.6 17.9 
C10 15.3 15.8 10.0 9.9 9.4 9.6 9.1 8.5 9.1 9.5 8.6 0 17.1 16.9 
A - K89, SF170; B - OYI, LAI, SF162; C1 - 97ZA347TS; C2 - 96BW0408; C3 -
96BW0502; 
IN.11246; 
C4 - 96BW01 B22 C5- ZAM18; C6 - ETH2220; C7 - 92BR025; CB -
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Figure 4.5: Phylogenetic tree of the gp120 and 5' portion of the gp41 from isolate 97ZA347TS in comparison with 
reference sequences from subtypes A to J . The sequence from macrophage tropic isolate SF162 was also included for 




A . KE . K89 MRVMGTQR-NCQHL-LRWGTM----ILGMII IC-----SAA-ENLWVTVY 50 
A.RW.SF1703 MRVMGIQM-NCQNL-LRWGTM----ILGMLII C-----SAT- SKLWVTVY 
B.FR.HXB2 MRVKE----KYQHL-WRWGWRWGTMLLGMLMIC-----SAT-EKLWVTVY 
B.FR . LAI MRVKE----KYQHL-WRWGWKWGTMLLGILMIC-----SAT-EKLWVTVY 
B.US.SF162 MRVKGIRK- NYQHL-WRGGTL----LLGMLMIC-----SAV-EKLWVTVY 
C.BR.92BR025 MRVEGIQR-NWKQW-WIWGIL----GFWMVMIY-----NVR-GNLWVTVY 
C.ET . ETH2220 MKVMGIQR-NCQQW-WIWGIL----GFWMLMIC-----NGM-GNLWVTVY 
C.ZA.97ZA347TS MRVRGIRK-NCQQW-WIWGIL----GFWMLMIC-----NGE-G-LWVTVY 
C .BW.96BW0502 MRVMGILK-NYQQW-WMWGIL----GFWMLIIS-----SVV-GNLWVTVY 
C.ZM.ZAM18 MRVREILR-NWQQW-WIWGIL----GFWMVMNY-----NVV-GDNLWVTY 
C.IN.D1 024 MRVRGILR-NYQQW-GIWGIL----GFWMLMIC-----NVV-GNLWVTVY 
D.ZR.NDK MRAREKER-NCQNL-WKWGIM----LLGMLMTC-----SAA-EDLWVTVY 
D.ZR.ELI MRARGIER-NCQNW-WKWGIM----LLGILMTC-----SAA-DNLWVTVY 
AE.CF.90CR402 MRVKGTRR-NWPNL-WKWGTL--- - ILGLVIIC-----SAS-DNLWVTVY 
AE.TH.KH03 MRVKETQM-NWPNL-WKWGTL----I LGLVIIC-----SAS-DNLWVTVY 
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Vl loop --> <--
A. KE.K89 AT-------------------SGTTHGGRGRMKNCS YNITTELRDRRQKV 200 
A.RW.SF1703 HN-------------- IT TNNPNITKYMEGEI KNCSYNMTTELRDKKQKV 
B.FR.HXB2 TN------- --------TNSSSGRMIMEKGEIKNCS FNIS TSIRGKVQKE 
B.FR.LAI TN----------TNSSNTNSS SGEMMMEKGEI KNCS FNIS TSIRGKVQKE 
B. US .SF1 62 TN------- --- TKSSN------WKEMDRGEIKNCS FKVTTSIRNKMQKE 
C.BR.92BR025 YN--------------------NRTDNMGGEI KNCS FNMTTEVRDKREKV 
C. ET . ETH2220 TK---- ------- ------VTNNS INSANDEMKNCS FNITTELRDKKRKA 
C.ZA.97ZA347TS VD-----------------TVDNDTMS--GGMKNCSFNITTDLRDKRKKE 
C. BW . 96BW0502 NN-- -------------- - INSMIDNSNKGEMKNCS FNVTTELRDRKQEV 
C.ZM . ZAM18 HE-----------------------NSTKGEMKNCS FNATTELKDKKQRV 
C.IN.Dl 024 NI--------------- - ------- TNNGEEI KNCS FNATTEIRDRKQTV 
D.ZR.NDK SK-------------------GNGKVEEEEKRKNCS FNVR----DKREQV 
D. ZR . ELI NG----------------- TMGNNVTTEEKGMKNCS FNVTTVLKDKKQQV 
AE.CF.90CR402 NA-------------------TSDRIKMEDAVRNCS FNMTTELQDKKQEV 
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YALFYRLDIVPLDS-----------NNKS ----KYRLINCNTSAI - TQAC 
YALFYKLDIVPIDN-----------NNRTNST -NYRLINCDTSTI -TQAC 
YALFYRLDIVPIDN-----------DSSTNST-NYRLINCNTSAI - TQAC 
HALFYTSDVVQISS--SVQNNNNSNTSGQNNSHKFRLIHCNTSVI - KQAC 
YALFYKLDIVPIEH- --------KNNSS -----EYRLITCNTSVI - KQAC 
* * * 
PKVTFE-PIPIHYCAPAGFAILKCKDKKFNGTGPCTNVS T-VQCTHGIKP 
PKVSFE-PIPIHYCAPAGFAILKCNDAEFNGTGPCKNVST- VQCTHGIRP 
PKVSFE-PIPIHYCAPAGFAILKCNNKT FNGTGPCTNVS T-VQCTHGIRP 
PKVSFE-PIPIHYCAPAGFAILKCNNKT FNGTGPCTNVS T- VQCTHGIRP 















* A.KE.K89 VVSTQLLLNGS LAE-GEVMIRSENIT-NNAKNI IVQFAEPVKI NCTRPNN 350 A.RW.SF1703 VISTQLLLNGSLAE-GRVKIRSENIT-NNAKTIIVQLNKTVEI NCTRPNN B.FR.HXB2 VVSTQLLLNGSLAE-EEVVIRSVNFT- DNAKTIIVQLNTSVEI NCTRPNN B.FR.LAI VVSTQLLLNGS LAE-EEVVIRSANFT-DNAKTIIVQLNQSVEI NCTRPNN B. US.SF162 VVSTQLLLNGSLAE-EGVVIRSENFT-DNAKTIIVQLKESVEI NCTRPNN C.BR. 92BR025 VVSTQLLLNGSLAE-EEIIIRSKNLT - DNVKTIIVHLNESVEI NCTRPNN C.ET .ETH2220 VVSTQLLLNGS IAE-GETIIRFENLT-NNAKIIIVQLNESVEITCTRPSN C.ZA.97ZA347TS VVSTQLLLNGSLAE-EEIIISSENLT-DNAKPILVQLNGSVE IVCTRPSN C.BW. 96BW0502 VVSTQLLLNGSVAK-GEIIIRSENLT-NNAKIIIVQLNKPVKIVCVRPNN C.ZM. ZAM18 VVSTQLLLNGSLAE-EEIIIRSENLT-NNAKTIIVHLNESVE IVCTRPSN C. IN.D1024 VVSTQLLLNGS LAE-GEIIIRSENLT- NNVKTIIVHLNQS VEIVCTRPNN D.ZR . NDK VVSTQLLLNGSLAE - EEIIIRSENLT-NNVKTIIVQLNAS IVI NCTRPYK D.ZR . ELI VVSTQLLLNGSLAE-EEVIIRSENLT-NNAKNIIAHLNESVKITCARPYQ AE.CF.90CR402 VVSTQLLLNGS LAE-EEIIIRSEDLT-DNAKTIIVHLNKS IEINCTRPFK AE.TH.KH03 VVSTQLLLNGSLAE-GEIIIRSENLT - NNAKTIIVHLNKSVEI NCTRPSD 
V3 loop --> 
* 
A.KE.K89 NTRMSIRI ---GPGQAFYATGD----IIGNIRQAHCNVS RAEWN- TTLQK 400 A. RW.SF1703 NTRKSVRI ---GPGQAFYATGD----IIGDIRQAYCNVS RADWN- KT LQG B.FR.HXB2 NTRKRIRI - QRGPGRAFVTIGK----- IGNMRQAHCNISRAKWN- NT LKQ B.FR . LAI NTRKSIRI - QRGPGRAFVTIGK-----IGNMRQAHCNISRAKWN- ATLKQ B.US.SF162 NTRKSITI---GPGRAFYATGD----IIGDIRQAHCNIS GEKWN- NT LKQ C.BR.92BR025 NTRKSIRI ---GPGQAFYATGE----IIGDIRQAHCNISRTAWN- KT LQE C.ET.ETH222 0 NTRESIRI---GPGQTFYATGD----IIGDIRQAHCNIS EEKWN- KT LQK C.ZA.97ZA347TS NTRKSIRI---GPGQAFYATGD---- IIGNIRQAYCNISEE KWN- ETLQE C.BW.9 6BW0502 NTRKSVRI---GPGQTFYATGE----IIGDIRQAYCIINKTEWN- STLQG C.ZM.ZAM1 8 NTRKSIRI-- -GPGQAFYATGG----IIGNIRQAHCNISKENWN- KT LQK C.IN.D1024 NTRKSIRI--- GPGQTFYATGD---- IIGDIRRAYCNISEDKWN- ETLQR D. ZR . NDK YTRQRTSI ---GLRQSLYTITG-KKKKTGYIGQAHCKISRAEWN-KALQQ D. ZR.ELI NTRQRTPI---GLGQSLYTTR-----SRSIIGQAHCNISRAQWS-KTLQQ AE . CF . 90CR402 KVRISARI ---GPGRVFHTTGN----INGDIRKAYCEI NKTKWK- ETLKQ AE.TH . KH03 RMRTPMRI---GPGRVFYKTGN----IMGDRRTAYCEINGTKWN- RVLKQ 
CD4 
I I * 
<--
A.KE.K89 VV---TKLREYFGN-NKT IKFANSSGGDLEITTH--SFNCGGEFFYCNSS 450 A.RW.SF1703 VA---NQLKSYFSN-- KT IIFASSSGGDLEITTH--SFNCGGEFFYCDTS B.FR.HXB2 IA---SKLREQFGN- NKT IIFKQSSGGDPEIVTH--SFNCGGEFFYCNST B.FR.LAI IA---SKLREQFGN- NKT IIFKQSSGGDPEIVTH--SFNCGGEFFYCNST B.US.SF162 IV---TKLQAQFGN--KT IVFKQSSGGDPEIVMH--SFNCGGEFFYCNST C.BR. 92BR025 VG---KKLAEHFPN--KAIKFAKHSGGDLEITTH--SFNCRGEFFYCNTS C.ET.ETH2220 VK---EKLQKHFPN--KT IEFKPSSGGDLEITTH--SFNCGGEFFYCNTS C. ZA . 97ZA347TS VV---KKLKEYFQQ--KTIILNHHSGGDLEIPTH--SFNRRGEFFYCNTS C.BW . 96BW0502 vs---KKLEEHFSK--KAIKCEPSSGGDLEITTH--SFNCRGEFFYCDTS C.ZM.ZAM18 VG---KKLAEHFPN--KT IKFDQHSGGDLEITTH--SFNCRGEFFYCNTS C.IN. D1024 VG---KKLAEHFPN--KT INFASSSGGDLEITTH- - SFNCRGEFFYCNTS D. ZR . NDK VA---TKLGNLLNK--TTITFKPSSGGDPEITSH--MLNCGGDFFYCNTS D.ZR . ELI VA- --RKLGTLLNK--TIIKFKPSSGGDPEITTH- - SFNCGGEFFYCNTS AE.CF . 90CR402 VT ---RKLREHLNG- TMTISFRPSSGGDPEITMH--HFNCRGEFFYCNTT AE . TH . KH03 VM- --GKLKEHFNN--KT ITFQPPSGGDLEITMH--HFNCRGEFFYCNTT 
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A. KE . K89 
A. RW . SF1703 
B. FR . HXB2 
B. FR . LAI 
B. US . SF162 
C. BR . 92BR025 
C . ET . ETH2220 
C. ZA . 97ZA34 7TS 
C . BW . 96BW0502 
C . ZM . ZAM18 
C. IN . Dl024 
D. ZR . NDK 
D. ZR . ELI 
AE . CF . 90CR402 
AE . TH . KH03 
A . KE . K89 
A . RW . SFl 703 
B . FR . HXB2 
B . FR . LAI 
B . US . SF162 
C. BR . 92BR025 
C. ET . ETH2220 
C. ZA. 97ZA34 7TS 
C.BW.96BW0502 
C. ZM . ZAM18 
C. IN . Dl024 
D. ZR . NDK 
D. ZR . ELI 
AE . CF . 90CR402 
AE . TH . KH03 
A . KE . K89 
A . RW . SF1703 
B. FR . HXB2 
B. FR . LAI 
B. US . SF162 
C. BR . 92BR025 
C. ET . ETH2220 
C. ZA . 97ZA347TS 
C. BW . 96BW0502 
C. ZM . ZAM18 
C. IN . Dl024 
D. ZR . NDK 
D. ZR . ELI 
AE . CF . 90CR402 
AE . TH . KH03 
V4 loop --> 
* 
GLFNSTW-- -TNMQESNSTES N--- - ----DT ITLPCRIK- IINMWQR- A 
GLFNSTW---GGNSTDSIQES NSTESN-- - DT IILPCRIKQIINMWQR- V 
QLFNSTW- -F--NSTWSTEGS NNTEGS---DTITLPCRIKQIINMWQK- V 
QLFNSTW--F--NSTWSTEGS NNTEGS---DTITLPCRIKQFINMWQE- V 
QLFNSTW---- - NNT IGPNNTN------- - GT ITLPCRIKQIINRWQE- V 
SLFNSTY--TPNSTENITGTEN- -- - - - - - SIITIPCRIKQIINMWQG- V 
NLFNSTK------LELFNSS TN- - ------LNITLQCRIKQIINMWQG- V 
KLFKGTY-------DTNGTESNSS------STIILPCRINQIINMWQG-V 
QLFNSTY---SPSFNGTENKLN---- - ---GT ITITCRIKQIINMWQK- V 
NLFNSTY-------KPNDTNSTYNPN----DT ITLPCRIKQIINMWQG- V 
NLFNSTY-------MPNGTKSNS N------STITILCSIKQIVNMWQE- V 
RLFNSTW------NQTNSTGFNN-------GTVTLPCRIKQIVNLWQR- V 
GLFNSTW--NISA- WNNITESNNSTN----TNITLQCRIKQIIKMV- A- G 
ALFNSTW-- I NGT----MQEVNGTNS----GNITLPCRIKQIVNMWQE - V 
RLFNNTCIGNETKEGCN--------- - ---GT ITLPCKIKQIIKMWQG-V 
CD4 
* 
GQAMYAPPIQGIIKCVS - NITGLILTRDGGDN---N----SESETFRPGG 
GQAMYAPPIQGVIKCIS - NITGLLLTRDGGDN---N- ---SANETFRPTG 
GKAMYAPPISGQIRCSS - NITGLLLTRDGGNS---N----NESEIFRPGG 
GKAMYAPPISGQ I RCSS - NITGLLLTRDGGNN-- -N----NGSEIFRPGG 
GKAMYAPPIRGQIRCSS - NITGLLLTRDGGKE--- I ---SNTTEIFRPGG 
GRAMYAPPIEGILTCRS - NITGLLLTRDGGTG-------MHDTEIFRPEG 
GRAMYAPPIEGIIMCRS - NITGLLLTRDGAKE---- - - PHSTKEIFRPEG 
GRAMYAPPIAGNlTCKS-NITGLLLTRDGGGYGNN----TTTTEIFRPGG 
GRAMYAPPIAGNLTCES-DITGLLLTRDGGKT---- - -GPNDTEIFRPGG 
GQAMYAPPIAGNlTCKS-NITGLLLTRDGGSN-- - -- - DTTNTETFRPGG 
GRAMYAPPIEc.NlTCKS - NITGLLLVRDGGTESN- ----- - TTETFRPGG 
GKAMYAPPIEGLIKCSS - NITGLLLTRDGGAN- N--- - -- SSHETIRPGG 
RKAIYAPPIERNILCSS - NITGLLLTRDGGI N---N---- STNET FRPGG 
GRAMYAPPISEVINCVS-NITGILLTRDGGIN- - - Q- NQTNKNET FRPGG 
GQAMYAPPISGIINCLS - NITGILLTRDGGPN-N- -- - --MTNET FRPGG 
<- fusion 
gp120/gp41 
GDMRDNWRSELYKYKVVKIEPLGVAPT - KAKR----RVVE - REKRAVG- I 
GNMRDNWRSELYKYKVVKIEPLGVAPT - PAKR----RVVQ- REKRAVG- I 
GDMRDNWRSELYKYKVVKIEPLGVAPT - KAKR----RVVQ- REKRAVG- I 
GDMRDNWRSELYKYKVVKIEPLGVAPT - KAKR----RVVQ- REKRAVG- I 
GDMRDNWRSELYKYKVVKIEPLGVAPT- KAKR----RVVQ- REKRAVT - L 
GDMRDNWRSELYKYKVVEIKPLGIAPT - KAKR----RVVE - REKRAVG- I 
GDMRDNWRSELYKYKVVEIKPLGVAPT- KPKR----RVVE - REKRAA--L 
GDMRDNWRSELYKYKVVEIKPLGVVPT-KAKR----RVVE-REKRAVG-I 
GDMRDNWRNELYKYKVVEIKPLGVAPT-EAKR----RVVE - REKRAVG- I 
GDMRDNWRSELYKYKVVEIKPLGIAPT- AAKR----RVVETREKRAVG- I 
GDMRNNWRS ELYKYKVVEIKPLGVAPT - AAKR----RVVE- REKRAVG- I 
GDMRDNWRS ELYKYKVVKIEPIGVAPT - KARR----RVVE - REKRAIG- L 
GDMRDNWRS ELYKYKVVQIEPLGVAPT- RAKR----RVVE - REKRAIG- L 
_GNIKDNWRSELYKYKVVQIEPLGIAPT - KARR----RVVE - REKRAVG- I 





peptide - > 
A. KE . K89 GAVFLG-FLGAAGSTMGAASITLTV 625 
A. RW . SF1703 GAVFIG-FLGAAGSTMGAASITLTV 
B.FR . HXB2 GALFLG-FLGAAGSTMGAASMTLTV 
B. FR . LAI GALFLG- FLGAAGS TMGARSMTLTV 
B. US . SF162 GAMFLG- FLGAAGSTMGARSLTLTV 
C . BR . 92BR025 GAVFLG-FLGAAGS TMGAAS I TLTV 
C . ET . ETH2220 GALFLG-FLGAAGSTMGAAS I TLTV 
C. ZA . 97ZA34 7TS GAVFLG-FLGAAGSTMGAASTTLTV 
C. BW . 96BW0502 GAVFLG-FLGAAGS TMGAASITLTV 
C . ZM . ZAM18 GAVFLG- FLGAAGS TMGAAS ITLTA 
C . IN . D1024 GAVFLG- FLGAAGS TMGAAS I TLTV 
D. ZR . NDK GAVFLG- FLGAAGS TMGAASVTLTV 
D. ZR . ELI GAMFLG- FLGAAGSTMGARSVTLTV 
AE . CF . 90CR40 2 GAMIFG- FLGAAGS TMGAAS I TLTV 
AE . TH.KH 03 GAMIFG- FLGAAGS TMGAASITLTV 
Figure 4.6: The alignment of amino acids making up the gp120 and part of gp41 from the South African, macrophage 
tropic, primary isolate, 97ZA347TS (in bold type) sequenced in this study compared with two reference subtypes from A to 
AE (HIV sequence database, 1998), Also, the amino acid sequence from SF162, the NSI reference subtype 8 isolate 
included in the DNA vaccine study has been included for comparative purposes. Conserved cysteine residues are indicated 
with an asterisk(*), whilst potential N-linked glycosyfation sites are shown in pink (conserved potential N-linked glycosyfation 
sites indicated with carets ["]). The tetrapeptide crown is shown bold and in blue. The amino acid positions are also shown 
(starting from zero at the start of the gp120), as are the variable loop positions and CD4 binding domains. 
Figure 4.6 shows an alignment of the amino acids making up the gp120 and partial gp41 
from 97ZA347TS as well as reference subtypes from subtypes A to AE (HIV sequence database, 
1998) indicating conserved cysteine residues, N-linked glycosylation sites, variable loop regions 
and CD4 binding regions. The South African isolate 97ZA347TS gp120 contains 22 potential N-
linked glycosylation sites, in comparison to an average of 24 in five macrophage tropic subtype C 
isolates analysed, 23 in macrophage tropic subtype B isolates (n=5), 28 in T-cell tropic subtype C 
isolates (n=2) and 26 in T-cell tropic subtype 6 isolates (n=6) (HIV sequence database, 1998 and 
' Doms and Moore, 1997). In two positions, at 285 and 440, the usually conserved cysteine residue 
is replaced with an arginine residue (shown in red). The characteristic loss of a glycosylation site 
at position 344-346 in subtype C viruses was present in 97ZA347TS, with a valine replacing the 
asparagine residue at position 344 (shown in green). In addition, an extra N-linked glycosylation 
site, shown in bold maroon, common in subtype C isolates, was present at position 512 in 
97ZA347TS. The molecular weight of the gp120 from 97ZA347TS is 56 303 (499 amino acids) 
and has a net charge of +6 with 51 acidic and 57 basic residues. No arginine residues, indicative 
of a syncitium inducing phenotype (Fouchier et al. , 1992 and De Wolf et al., 1994), were present at 
positions 355, 369 or 376 (shown in turquoise) in isolate 97ZA347TS, although the arginine 




4.3.2) lmmunonuorescent detection of the expressed gp120 protein 
In order to determine the expression of gp120 from both pcDNA3.1sF1s2 an
d 
pcDNA3.197ZA34ns, immunofluorescent staining of the gp1
20 was performed. 
lmmunofluorescent detection showed gp120 expressed by the DNA vaccines in
 the cell 
cytoplasm in Hela cells after 24 hours, but not after 48 hours. The same p
attern of 
fluorescence was detected for the gp120 proteins of both subtypes. No fluoresce
nce was 
observed in cells that were transfected with pcDNA3.1/Zeo alone. 
The gp120 from 97ZA347TS cloned into pSC65 was transfected into W-infecte
d 
CV1 cells and the recombinant VV expressing gp12097ZA347TS selected by serial pa
ssage in 
TK" cells. After thirteen passages in TK. cells, the gp120, stabley expressed by rec
ombinant 
W 91ZA34ns, was detected by immunofluorescence, showing the 
fluorescent labelled gp120 
both in the cell cytoplasm and on the cell membranes of TK" cells (see figure 
4.7a). No 
fluorescence was observed in the TK" cells infected with wild-type W (see figure 4.7
b). 
a) b} 
Figure 4.7: lmmunofluorescent staining of TK. cells ·infected with W 97ZA34ns (a) or 
Wwr (b) at 40X magnification. a) 
TK cells infected with VVmA347TS are stained fluorescent yellow-green by the a
nti-HIV gp120 FITC conjugate which 
binds to the gp120 expressed in the cell cytoplasm by the recombinant W 97ZA34
7TS as_ well as on the cell membranes. 
b) Negative control of TK cells infected with Wwr. The virus plaque is visibl
e , and no fluorescent staining can be 
observed. 
4.3.3) DNA immunisation of BALB/c mice 
DNA vaccines expressing the gp120 from SF162 and 97ZA347TS were inoculated into 
BALB /c mice in order to determine the immune response. The BALB/c mice were immunised 
intramuscularly into the TA muscle with the DNA vaccine ( 1 OOµg per mouse), followed by three 
intramuscular boosts, one every two weeks. The antibody response to gp120 in mice 
immunised with pcDNA3.1 sF162 (subtype B) and pcDNA3.197ZA346rs (subtype C), as well as 
pcDNA3.1 /Zea alone, was determined by indirect ELISA with gp120 from laboratory isolate, 
HIV1118 , as the capture antigen. Peak antibody levels were reached 2 weeks after the first 
immunisation in mice immunised with pcDNA3.197ZA346rs , an increase of seven-fold above the 
levels detected in mice immunised with pcDNA3.1/Zeo plasmid alone (negative control mice) 
(see figure 4.8). The antibody levels then dropped to three-fold above negative control mice, 
remaining stable throughout the two subsequent boost immunisations. The mice immunised 
with pcDNA3.1 sF162 had slowly increasing antibody levels from three-fold to almost five-fold 
above the negative control mice, from the start of the immunisation regimen until the final 
immunisation. The pre-bleed serum was non-reactive, with an 00492 of 0.001 and mice 
immunised with the pcDNA3.1/Zeo plasmid alone had antibody levels of 0.028 00492. Mice 
with antibody levels greater than two-fold that of the pcDNA3.1/Zeo immunised mice were 
considered to have a positive antibody response. 
Mouse antibody levels after DNA vaccine immunisation 
0.2 
0.15 







Figure 4.8: Antibody levels obtained in SALB /c mice in our study after immunisation with DNA vaccine : pcDNA-8 ; 
pcDNA-C; or pcDNA3.1/Zeo. The immunisation times are indicated with arrows (weeks 0, 2, 4 and 6) and blood was 
taken prior to each immunisation as well as two weeks after the final immunisation. 
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4.3.3) Determination of a cross-reactive in vivd CTL response to subtype Band C DNA vaccines 
It was previously established that unimmunised SALB /c mice were not protected from 
Wwr and the vi rus was able to replicate to a titre of 9 to 10 log 10 pfu per mouse (see section 
4.2.1 O) . The unimmunised SALB /c mice challenged with VV972A347TS did not have as high viral 
ovarian titres, since the recombinant W is attenuated, with the gp120 interrupting the TK- gene. 
In order to determine the possible CTL cross-reaction obtained between subtype Band C gp120, 
SALB /c mice inoculated once with a DNA vaccine expressing either subtype B, or subtype C 
gp120, were challenged nine days later with recombinant W expressing the gp120 from the 
homologous subtype C isolate. 
Table 4.5 shows the VV97ZA347rs titres in the ovaries of two female SALB /c mice 
immunised once with either pcDNA3.1sF162 (subtype B) , pcDNA3.197ZA346Ts (subtype C) or 
pcDNA3.1/Zeo (negative control). The CTL response was measured as the decrease in 
W 97ZA3ms titre (log10 of the pfu) in the subtype B and C immunised mouse ovaries, in 
comparison to the titres obtained in the negative control mice (see figure 4.9) . As the negative 
control mice had not been immunised , there was limited protection against the W 91ZA347TS 
challenge and these mice had higher ovarian titres of VV. 
Two experiments were performed . In the first experiment, mice immunised with 
pcDNA3.1sF162 and pcDNA97ZA347rs were given an intraperitoneal challenge of 1X10
7 pfu in 100(1 
of sterile 1XPBS and sacrificed after eight days. The negative control mice had a titre of 6.58 
log10 per mouse, in comparison to the mice immunised with the homologous subtype C gp120, 
pcDNA3.191ZA346Ts, which had a 1.9 log10 decrease in viral titre per mouse. The subtype B DNA 
vaccine (pcDNA3.1 sF162) , on the other hand, elicited a 1.4 log10 pfu decrease. This was 
approximately 0.5 log10 higher titre than in mice vaccinated with the homologous subtype C DNA 
vaccine (see Table 4.5 and figure 4.9) . 
In the second experiment , a higher challenge titre (5X10
7 pfu) was used and the mice 
were sacrificed after five days. The ovaries from the negative control mice in this experiment 
had a higher titre of recombinant W 97ZA347rs' (8. 70 log10), than in the first experiment, due to the 
higher initial titre infecting the mice. The levels of protection , on the other hand, were also 
greater than in the first experiment, possibly because the timing of the second experiment lead 
to a more efficient CTL response being detected than in the first experiment. Mice immunised 
with the homologous subtype C DNA vaccine (pcDNA3.197ZA346rs) had a viral t itre of 6.10 log10 
pfu per mouse, which was 2.6 log10 pfu lower than for the negative control mice. The subtype B 
(pcDNA3.1 sF162) immunised mice had a virus titre 2.0 log10 lower than the negative control mice 
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(see figure 4.9). 
Table 4.5: The cross-reactive in vivo CTL response as measured by W 97ZA34rrs titres in mouse 
ovaries. BALB /c mice were immunised with DNA vaccines expressing the gp120 from 
subtypes B, C, or the DNA vaccine alone (negative control) , followed by challenge with the 
recombinant W 97ZA34rrs- The CTL response was measured as a decrease in W 97ZA34rrs titres 
in the mouse ovaries* between immunised and negative control mice. 
DNA vaccine Ovary weight 1Titre/ml Titre/mouse 
ExQeriment 1 
2pcDNA3.1 sF162 50mg/0.5ml 1.8X105 pfu 1.5X105 pfu 
3pcDNA3.197ZA346Ts 50mg/0.5ml 2X105 pfu 4.5X104 pfu 
pcDNA3.1/Zeo 50mg/0.5ml 1.5X107 pfu 3.8X106 pfu 
ExQeriment 2 
2 pcDNA3.1 sF162 90mg/0.9ml 1X107 pfu 5X106 pfu 
3 pcDNA3.197ZA346Ts 70mg/0.7ml 5X106 pfu 1.25X106 pfu 
pcDNA3.1 /Zeo 90mg/0.9ml 2X109 pfu 5X108 pfu 
The minimal level of detection was 100pfu. 
2
•












• subtype B 
OSubtype C 
C pcDNA3.1/Zeo 
Figure 4.9: The cross-reactive CTL response between subtypes Band C measured as the decrease in W97ZA347TS in 
the mouse ovaries between subtype B and C immunised mice and negative control mice. 
The human and murine gp120 epitopes for consensus subtype B and C isolates were 
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compared (Korber et al. , 1997). In addition, the gp120 epitopes from the macrophage tropic 
South African isolate 97ZA347TS, and the NSI subtype B reference isolate, SF162 were 
deduced and compared with the gp120 epitopes in the subtype B and C consensus sequences 
(see figure 4.10). Unfortunately, only a limited number of murine CTL epitopes were available 
for the HIV gp120 protein. The only murine SALB /c H-i' epitope recorded from gp120 was 
epitope 40, KQFINMWQEVGKAMYA, which had two amino acid mismatches in the sequence 
from isolate SF162 and four in the sequence from isolate 97ZA347TS. CTL epitopes with 
greater than two mismatches are unlikely to be functional (Cao et al., 1997). It is thus unlikely 
that 97ZA347TS would have elicited a CTL response to epitope 40 in the SALB /c mice, 
however other CTL epitopes which have not yet been identified may have played a role in the 
murine CTL response. 
A better indication of the possibility of cross-reactive CTL epitopes is obtained by a 
determination of the amino acid distance between isolates 97ZA347TS and SF162 (see 
section 4.3.1 ). Isolate SF162 is 24% divergent from 97ZA347TS. This divergence is reflected 
in the gp120 CTL epitopes for the two isolates, where twenty-two of the identified forty-two 
gp120 epitopes (Korber et al. , 1997) are conserved in isolate SF162, whereas only five of the 
gp120 epitopes are conserved in isolate 97ZA347TS. 
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Gp120 Epitope 3 (32-41) 
Epitope/HLA :KLWVTVYYGV /A2 
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Subtype C .n---------
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Gp120 Epitope 7-8 (41-51) 
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Gp120 Epitope 19-21 (256-264) 
Epitope: RPVVSTQLLLNGSLAEEEVV/B7 
Epitope/HLA:SVEINCTRPNNNTRKSI/A2 
/HLA RPVVSTQLL / B35, 8*3501 
RPNNNTRKSI/B7,? 








Gp120 Epitope 15 (160-169) 
Epitope /HLA :NCSFNISTSI /Cw8 
Subtype B :nc sfnittsi 
SF162 .----KV----
Subtype c :-----a--el 
97ZA347TS :------T-DL 










Gp120 Epitope 22-24 (295-311) 
Subtype B: rpvvstqlllNGSlaeeevv 
SF162 . -----------------G--
Subtype C . k-----------------ii 
Subtype B : sveinCtRpnnntrksi 
SF162 · -----------------
Subtype c .----v------------
97ZA347TS:K-----------------DI 97ZA347TS . ----V----S-------













/A2 . l ,A2 
/A2 , A3,All 
/B27 




IGPGRAFYTT /H-2 Dd , Dd 
RGPGRAFVTI /Dd ,Ld,D,H- 2d,p, u 
IGPGRJ\.FHT /H-2Dd 
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Gp120 Epitope 38-40 (417-436) 















KQIINMWQEVGKAMYA/ H-2a,b , f 
Gp120 Epitope 41 (422-437) 
Epitope/HLA : KQIINMWQEVGKAMYA /A2 
Subtype B : kqiinmwQevgkamya 





. N- ----- - G--R----
MYAPPIGGQI/H-2Kd 






:VKIEPLGVAPTKAKRRVVQR / A2 
: vki e plgvAptk . akrRvvqr 
·------------ ----- ---. . 
. -e-k--------.------e-
.-E-K- -- - V- --.------E-
Key 
RED: Conserved 
BLUE: 1 mismatch 
GREEN: 2 Mismatches 
Black: >2 Mismatches 
Figure 4.10: An alignment of the gp120 CTL epitopes, taken from the HIV Molecular Immunology Database (Korber et al., 
1997) is illustrated. The epitope number and amino acid site in the gp120 protein is shown above each alignment, followed by 
the epitope amino acid sequence and the human HLA allele for that epitope. The subtype 8 and C consensus amino acid 
sequences for each epitope are also shown. In addition, the gp120 epitopes for the two DNA vaccine isolates in this study 
(97ZA347TS and SF162) are included for comparative purposes. Dashes indicate regions of conservation with the consensus 
subtype 8 epitope, dots indicate amino acid deletions and question marks indicate stop codons in the consensus sequence. The 
level of conservation with the human epitope is indicated by the colour of the amino acid sequences. Red indicates conservation 
with the epitope, blue indicates a single amino acid mismatch to the epitope and green indicates two amino acid mismatches in 
comparison with the epitope. The equivalent murine gp120 epitopes are also included for comparison. 
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4.4) Discussion 
Isolate 97ZA347TS is the first South African, known macrophage tropic isolate to be 
genotypically characterised in the complete gp120. The only published South African subtype C 
gp120 was NOF (Dietrich et al., 1993), but this sequence lacks the first approximately 500bp of 
the gp120. Although there is an arginine substitution at position 276 in the V3 loop that has been 
demonstrated to be indicative of a syncitium inducing phenotype (Fouchier et al., 1992 and De 
Wolf et al., 1994), the disease stage of the infected patient and phenotype of isolate NOF was 
not published. At the time of initiation of this study, little work had been performed to identify 
cross-reactive CTL epitopes in HIV and the majority of vaccines were based on the envelope 
region of HIV-1 (see section 1.7.2). The gp120 protein from isolate 97ZA347TS was thus 
selected as the protein to be analysed for vaccine design. 
It is possible that the most effective CTL response will be elicited by a vaccine 
I 
representative of the circulating subtypes in the area, although cross-reaction between different 
subtypes has been demonstrated (see section 1.7.1 .2) . The complete gp120 from 97ZA347TS 
was thus phylogenetically compared with other subtype C isolates, as well as a number of 
reference sequences, from subtypes A to J and SIVcpz-gab. The average DNA distance 
between isolate 97ZA34 7TS and the other subtype C isolates was 10.2%, however the subtype C 
sequences clustered together in the phylogenetic tree with a bootstrap value of 100%. The high 
genetic diversity of subtype C within South African isolates has been discussed in Chapter 3. 
The number of potential N-linked glycosylation sites in the macrophage tropic isolate, 
97ZA347TS was also determined, since the great degree of glycosylation in the envelope region 
makes the HIV gp120 less immunogenic (Kwong, 1998 and Wyatt, 1998). This is due to the 
glycosylated areas being seen as "self' by the immune system. The macrophage tropic subtype 
C isolate from South Africa, 97ZA347TS, contains 22 potential N-linked glycosylation sites in its 
gp120, which is below the average number of N-linked glycosylation sites (24 potential sites) in 
I 
other macrophage tropic subtype C isolates studied from the HIV sequence database (1999). It 
has been postulated (Graziosi et al., 1998) that a lack of glycosylation in certain regions of the 
gp120, such as the C2 and V2, as well as a decrease in the total number of potential N-linked 
glycosylation sites may correlate with the ability of the patient to neutralise the infecting virus. 
Out of three patients analysed, two infected with ~iruses having fewer glycosylation sites (23 and 
24) were able to develop a neutralising response to autologous virus as well as T-cell adapted 
strains in vitro . On the other hand, the patient infected with a virus containing 27 N-linked 
glycosylation sites in the gp120 did not elicit a neutralising response. It may thus be important 
that the isolate chosen for vaccine development have a low degree of N-linked glycosylation, 
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especially in the V2 and C2 regions. 
Isolate 9ZA347TS also had the GPGQ V3 loop crown sequence characteristic of subtype 
C viruses and the asparagine replacement at position 344 with valine, common in subtype C 
isolates. This results in the loss of the potential N-linked glycosylation site just downstream of 
the V3 loop. The characteristic addition of · an N-linked glycosylation site at position 512 in 
subtype C isolates was also present in 97ZA347TS. It is possible that this additional glycosylation 
site , which is within the CD4 binding site (Myers et al., 1996), may have an effect on binding 
affinity or antigenicity. The argenine substitutions at positions 355, 369 or 376 (see figure 4.6) 
resulting in an increased positive charge and indicative of a syncitium-inducing phenotype were 
not present in isolate 97ZA347TS (Fouchier et al., 1992; De Wolf et al., 1994). This is to be 
expected, since the isolate is a primary, macrophage tropic isolate. As was discussed in chapter 
3, this substitution was only detected in 2 out of 117 southern African subtype C isolates 
analysed , NOF and 94ZA067. It has been documented that subtype C isolates rarely evolve to 
CXCR4, syncitium inducing isolates (Doms and Moore, 1997; Korber et al., 1997; Tscherning et 
al., 1998 and Bjorndal et al. , 1999) 
The pcDNA3.1 sF162 and pcDNA3.197ZA3ms immunised SALB /c mice elicited an anti-
gp120 antibody response. Peak antibody levels of between five- (pcDNA3.1 sm2) and seven-fold 
(pcDNA3.1 97ZA34ns) greater than the negative control mice were detected . Similar antibody 
levels were documented by Wang et al (1993), where SALB /c mice were immunised with gp160 
from a T-cell isolate, HXB2. A strong humoral response was not expected from the mice 
immunised intramuscularly with the DNA vaccine. It is known that intramuscular immunisation 
with DNA yields a predominantly Th1 type immune response with subsequent inhibition of the 
Th2 response and lower antibody levels (Robinson , 1997a). Although not the aim of this study, it 
is possible to enhance the antibody response in the mice by using alternative methods of 
inoculation, for example with a gene gun (Lu et al., 1995 and Lu et al., 1998), or with the addition 
of co-stimulatory cytokines such as GM-CSF, that will induce a stronger humoral immune 
response . However, a drawback of these strategies is that the cellular response will be down-
regulated. 
The DNA vaccine system with intramuscular immunisation was chosen in order to induce 
the Th1 response in mice which would allow CTL c'ross-reactivity between subtypes B and C to 
be elucidated . In this study, the cross-reactive CTL response elicited to the two subtypes was 
determined in two experiments, with recombinant VV97ZA346rs (subtype C) as the challenge virus. 
Our study is the first utilising the in vivo challenge technique in order to determine the CTL cross-
reactivity between subtypes. 
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Mice inoculated with the pcDNA3.1 /Zeo plasmid alone were used as the control mice 
since they were not protected from the W 97ZA346rs challenge. These mice were found to have 
increased replication of the challenge virus in thei~ ovaries, with viral titres of 6.58 and 8.70 10910 
pfus per mouse in the two experiments, respectively. The subtype B and C immunised mice, 
however, were able to clear the W 97ZA346rs infection by at least 50-fold and at most over 500-fold 
in comparison to the negative control mice (see figure 4.9) , indicating a cross-reactive CTL 
response (Binder and KOndig, 1991; Bachmann et al., 1994; Belyakov et al., 1998 and Kent et 
al., 1998). This cross-reactive CTL response was obtained with only a single DNA vaccine 
immunisation . 
The initial experiment was performed with a lower intraperitoneal W 97ZA346Ts challenge 
dose of 1X107 pfu, which resulted in lower ' viral titres in the mouse ovaries. The second 
experiment used 5X107 pfu of W 97ZA346rs as the intra peritoneal challenge dose. In the first 
experiment, the difference in W 97ZA346rs' viral· titre ·between the control, pcDNA3.1/Zeo-
immunised mice and the homologous pcDNA3.197ZA346rs-immunised mice was only 1.9 IOQ10, 
whereas in the second experiment with the higher challenge titre, the difference was 2.6 log10. 
Similar results were seen in mice immunised with the heterologous subtype B DNA vaccine, 
where in the first challenge experiment, there was a 1.4 log10 decrease in viral titre compared to 
the negative control mice and in the second experiment, a 2 log10 decrease in titre . Although the 
heterologous subtype B DNA vaccine was not able to elicit as effective a CTL response as the 
homologous subtype C DNA vaccine, possibly due to differences in the CTL epitopes between 
the two viruses (see figure 4.10), we were still able to demonstrate CTL cross-reaction using the 
in vivo challenge system (see figure 4.9). 
The levels of protection elicited by the single DNA vaccine immunisation in our study 
were lower than those reported in other studies where a decrease in recombinant W titre of 
between 5 and 7 log10 per mouse were reported . It must be noted that in the other studies, the 
challenge technique was used after an optimal vaccination regimen in order to determine the 
effectiveness of the vaccination strategy or different routes of inoculation. In our study, however, 
the technique was used in order to determine the extent of CTL cross-reactivity between 
subtypes B and C, which was achieved. 
In hindsight, the gp120 may not be the optimal reg ion for eliciting a broadly cross-
reactive CTL response , possibly due to the high variability in the region (HIV sequence database, 
1998). It was determined in a study by Lole et al. (1999) , that CTL epitope conservation in 
subtype C viruses is less in the env region than other regions, such as the Gag, Pol and Nef, and 
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these more conserved regions are likely to elicit strong, broadly cross-reactive CTL responses. 
Future studies should involve the construction of DNA vaccines expressing these alternative 
proteins as well as recombinant VVs expressing the corresponding proteins in order to 
characterise the in vivo CTL cross-reactivity. 
The high genetic variability within South African subtype C isolates was discussed in the 
previous chapter and was confirmed in studies by Williamson et al (1995) and Bredell et al 
(1998) . The CTL epitopes, within the gp120, for the subtype C isolate used in our study were 
thus identified for all human leucocyte antigen (HLA) haplotypes. The gp120 epitopes were 
compared for isolate 97ZA347TS, SF162 and the consensus sequence epitopes for subtypes B 
and C. The results confirm that the envelope region is not the optimal region for the induction of 
a CTL response (see figure 4.10). 
Out of the fourty-two human CTL epitopes identified for the gp120, isolate SF162 has 
twenty-two conserved epitopes and thirty-three with up to a two amino acid mismatch. In 
addition , only five of the epitopes are conserved in isolate 97ZA347TS and thirteen have up to a 
two amino acid mismatch. It is important to note that the gp120 epitopes that have been 
identified were based on a subtype B isolate and as the CTL epitopes for subtype C gp120 have 
not been defined, it may be more pertinent to look at the amino acid difference between isolates 
SF162 and 97ZA347TS as an indication of potential CTL epitope conservation . It was 
determined that the two isolates are 24% divergent, in comparison with only 15% divergence 
between isolate 97ZA347TS and the closest related sequence available, ZAM18, from Zambia. 
This high divergence between isolates SF162 and 97ZA347TS is a possible indication why the 
CTL response elicited in the BALB/c mice was not strongly cross-reactive between the two 
subtypes. 
The mice used in our study were inbred BALB/c mice (H-z>) defined murine MHC 
(murine histocompatability complex) class I molecules and it is questionable how relevant the in 
vivo CTL detection technique is to the CTL response elicited in outbred humans. Unfortunately, 
only limited data is available on murine CTL epitopes for the gp120 of HIV (see figure 4.10) 
(Korber et al., 1997). Preliminary studies have started to identify common HLA haplotypes in 
indigenous South African populations, in order to determine the best CTL epitopes for eliciting a 
broad and effective CTL response . Studies based on the Xhosa population in South Africa 
(Brain and Hammond, 1972 and Omar et al., 1984) have been performed . The distribution of 
HLA showed that the most common HLA-class I, HLA-A alleles are A30, A28, A2 and A23 
respectively. HLA-B alleles screened showed that the most common alleles are Bw58, Bw70, 
Bw42 and B7, with B27 being extremely rare. The most frequently detected Cw alleles were 
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Cw7, Cw6, Cw2 and Cw4 (du Toit et al., 1988 and Hammond et al., 1997). If the gp120 epitopes 
recognised by these alleles are determined from figure 4.10, it can be seen that the allele which 
has the broadest recognition gp120 epitopes for both SF162 and 97ZA347TS is A2. It must be 
noted, however, that the A2 haplotype has been the most characterised. Only six of the gp120 
CTL epitopes in 97ZA347TS would potentially be recognised in indigenous populations in South 
Africa based on the gp120 epitopes identified and the alleles identified thus far. Thirteen of the 
gp120 CTL epitopes from isolate SF162 would be recognised . More human HLA genotypes 
need to be analysed in order to broaden our knowledge of what will be needed for an efficient, 
broadly cross-reactive CTL response . 
For future studies, DNA vaccines should be constructed containing other HIV proteins 
such as Gag, RT, and Nef in order to determine which will el icit a strong and broadly cross-
reactive CTL response. The in vivo murine CTL model used in this study can be used to 
determine the immunogenicity of these potential vaccine proteins as well as to assess alternative 
vaccine types and regimens. In this way, the best proteins to elicit a strong, broadly cross-
reactive CTL response can be identified and utilised in an HIV vaccine. 
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CHAPTER 5: CONCLUSIONS AND FUTURE STUDIES 
This thesis presents a study of HIV-1 genetic diversity according to different modes of 
transmission and geographical distribution of HIV-1 subtypes in South Africa . The complete 
gp120 from a macrophage tropic, NSI isolate, representative of the predominant subtype 
infecting the heterosexual population in South Africa was genotypically characterised. In 
addition, the immunogenicity of the gp120 was determined by DNA vaccine immunisation and 
CTL cross-reactivity investigated using a recombinant vaccinia virus challenge system in 
BALB/c mice. 
5.1) The association of HIV-1 subtype with mode of transmission in South Africa 
Although the HIV epidemic in Africa is the oldest, with all of the HIV-1 subtypes 
occurring on this continent, the majority of infections are caused by viruses belonging to 
subtypes A, C and D (Orloff et al., 1993; Williamson et al., 1995; Abebe et al., 1997; Poss et 
al., 1997; Shafer et al., 1997; van Harmelen et al., 1997; Bredell et al., 1998; Engelbrecht et 
al., 1998; Luo et al., 1998; Rayfield et al., 1998; Novitski et al., 1999; Tien et al., 1999; van 
Harmelen et al., 1999). Subtype B, although the predominant subtype detected in Europe 
and the United States, is rarely identified on the African continent. At the time of initiation of 
this study, in 1994, only one isolate from South Africa had been genetically characterised. 
Although based on a limited number of samples, epidemiological data showed two 
modes of transmission in the South African HIV-1 epidemic, male homosexual and 
heterosexual. It was also reported that the majority of men infected by homosexual or 
bisexual transmission during the early stages of the epidemic (early 1980s) had had sexual 
contact with men whilst abroad in the ,United States or Europe {Sher et al., 1985). It was thus 
not surprising that in our initial study of patients infected by homosexual or bisexual mode of 
transmission from Cape Town and Bloemfontein, 92.9% (26 out of 28) of the isolates 
identified by HMA in the env region belonged to subtype B (see chapter 2). The subtype B 
epidemic was not limited to men who reported having had homosexual contact abroad, 
however, as 22 of the 28 patients in the study reported no sexual contact abroad, or with a 
sexual partner who had been abroad, up to five years prior to the study. The homosexual, 
subtype B epidemic had thus continued to spread within the homosexual population in South 
Africa. 
In addition to subtype B, a single env subtype D virus was identified in the 
homosexual population from the Cape Town/Bloemfontein study. Subtype D was also 
identified in a separate study by Engelbrecht et al, (1995) in five homosexually or bisexually 
infected men attending Tygerberg hospital, who were infected between 1984 and 1989. The 
subtype D epidemic does not appear to have spread, however, since out of 28 male 
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homosexual patients in our study (with patients diagnosed up to seven years after the 
Tygerberg patients), only one, 93ZA034, was infected with a subtype D virus. 
By 1994, at the start of this study, there were more AIDS cases reported in women 
than in men (Swanevelder, 1995), which was indicative of t~e increase in numbers of 
heterosexual infections. Although subtype B was identified as the predominant virus infecting 
the homosexual and bisexual populations, subtype C was identified by HMA in 77.2% (17 out 
of 22) of the heterosexual infections in Cape Town and Bloemfontein patients sampled. The 
origin of the subtype C epidemic was probably regional, supported by patient epidemiological 
data, whereby a number of patients infected by heterosexual transmission reported having 
sexual contact whilst in neighbouring countries such as Zambia, or Zimbabwe, where subtype 
C is common (Mccutchan et al., 1992; Korber et al., 1997; Shafer et al., 1997 and Tien et al., 
1999). Subtypes A and D were rarely detected in South Africa . 
The heterosexual population in Cape Town had the greatest HIV-1 subtype diversity, 
with subtypes A, B and D identified, as well as the major subtype, C. Subtype B, associated 
with the initial homosexual epidemic, failed to spread significantly within the heterosexual 
population in Cape Town, where only two patients were found to be infected with subtype B. 
It must be noted, however, that one of the patients from the Bloemfontein cohort, a bisexual 
male, was infected with a subtype C isolate. This is the first subtype C isolate reported to be 
transmitted via homosexual or bisexual contact. 
A significant association between subtype and mode of transmission (p=<0.0001), 
was identified, suggesting that the two epidemics in South Africa are indeed independent of 
each other and related to mode of transmission. The distribution of subtypes in all 
populations must continue to be monitored , however, as genetic shifts in subtype may occur. 
5.2) The genetic diversity and geographical distribution of HIV-1 in the heterosexual 
population of South Africa 
The second part of this study was to identify the predominant subtype responsible for 
the heterosexual epidemic in the rest of the country and to determine the genetic diversity of 
HIV-1 in South Africa. 
As in the initial Cape Town/Bloemfontein study, the majority (92%) of isolates 
analysed by HMA (out of a total of 109) from four major urban centres in South Africa 
belonged to subtype C (see Chaper 3) . Only 8% of the heterosexual patients sampled from 
these centres were infected by subtype B. Subtype A and subtype D, detected in the 
heterosexual population in Cape Town were not identified in any of the four cities sampled in 
this study, even though a greater number of samples were analysed, making it more likely 
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that low prevalence subtypes would be detected. Subtype A has subsequently been reported 
in Durban, however (Moodley et al., 1998). 
To detennine the genetic diversity within subtype C, 117 published subtype C V3 loop 
sequences (up until 1998), including 78 from South Africa were obtained from HIV sequence 
database (1998) and these sequences were phylogenetically compared. 
The South African subtype C sequences were as divergent to each other as they 
were to subtype C isolates from countries further North in Africa, and subtype C from other 
continents, with an average DNA distance of 14.06% and no subclusters within South Africa, 
or with a country of origin were detected . Similarly high DNA distances have been reported in 
a Gauteng Province study by Bredell et al (1998) , where HIV isolates from 43 mine workers 
were found to be 11 % divergent in the V3-V5 region of the env gene. A recent study by 
Novitski et al (1999) in Botswana compared the DNA distance in the complete genome 
between subtype C isolates in Botswana with subtype B isolates. The study indicates that 
there is a greater degree of divergence within t~e subtype C lineage (12.4% in the envelope 
region) in Botswana than between isolates belonging to subtype B. 
The high DNA distance demonstrated in the V3 loop sequences in our study is an 
indication that the HIV subtype C epidemic in South Africa is not a clonal epidemic and it is 
probable that HIV entered the country on multiple occasions. As was determined in the initial 
Cape Town study, where patients infected with subtype C reported sexual contact in 
neighbouring countries, Bredell et al (1998) also reported that a number of the mine workers 
infected with subtype C in their study were residents of neighbouring countries where this 
subtype has been identified. 
It has been shown by a number of studies that subtype C viruses are usually 
restricted to the use of the CCR5 co-receptor and remain NSI, despite being able to cause the, 
patient to progress to AIDS (Doms and Moore, 1997; Tscherning et al., 1998 and Bjorndal et 
al., 1999). An indication of the phenotype of the isolate can be obtained from the V3 loop 
where more basic (positively charged) arginine residues at positions 276, 290 and 297 
indicate a SI phenotype. The 117 subtype C isolates analysed in our study also shows that 
the arginine substitutions indicative of an SI phenotype are rare, only being identified in two 
isolates, NOF and 94ZA067. 
Increasing numbers of recombinant viruses are being reported, especially in central 
Africa where there many different subtypes circulating (Peeters et al., 1998 and Renjifo et al., 
1998) (see section 1.6.2) and it is now necessary to sequence more than just one region of 
the viral genome. Although the entire genome of the virus should be sequenced, this 
technique is expensive and time consuming, thus methods are needed for rapid screening of 
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a number of different regions of the genome, in order to identify recombinant viruses, which 
can then be characterised by sequence analysis. 
Seventy-seven samples from Johannesburg, Bloemfontein, Durban and Cape Town 
which had been subtyped in the env gene by HMA, were thus subtyped in the gag gene by 
RFLP. No discordance was identified between subtype designation in the gag region in 
comparison to the env region, indicating that none of the viruses were recombinants in the 
regions analysed . It will be necessary to continue to screen for recombinant viruses, even 
through there is a segregation of subtype with mode of transmission . In China, for example, it 
has recently been reported that there is a new epidemic in the IVDU population caused by a 
subtype B/C recombinant (Shao et al., 1998) and in Russia, another IVDU epidemic has been 
caused by a subtype A/B recombinant (Liitsola et al., 1998). 
Although it has not been established why subtype C is the predominant HIV-1 
subtype world wide, with 48% of infection caused by this subtype, some suggestions have 
been put forward . A number of studies have shown that there may be a relationship between 
subtype and viral pathogenicity (Kanki et al., 1999 and Neilson et al., 1999), with certain 
subtypes associated with faster disease progression than others, although this has been 
disputed by others (Aleus et al., 1999 and Hu et al., 1999). Thus far, the only report of 
phenotypic selection for subtype C (and AE) was in Langerhans' cells (Soto-Ramirez et al., 
1996 and Essex et al., 1997), but was subsequently refuted by a number of studies (Dittmar 
et al., 1997 and Pope et al., 1997). Although there have been multiple introductions of HIV 
into the country, the majority of the viruses belong to subtype C. Whether this subtype has a 
selective advantage allowing easier transmission than other subtypes, or whether it is merely 
the predominance of this virus in southern Africa which has led to its almost exclusive 
entrance into South Africa , is not certain. 
It was thus shown in this part of our study that subtype C is the predominant virus , 
infecting the heterosexual population throughout South Africa and although subtypes A, B and 
D have been identified, the distribution and numbers of these subtypes are limited . South 
Africa is actively involved in vaccine trials '(International AIDS Vaccine Initiative (IAVI) Report, 
1998) and it is essential to constantly monitor the genetic diversity of HIV-1 subtypes 
circulating within the country. 
5.3) Characterisation of the macrophage tropic South African subtype C gp120 and a 
determination of the immunogenicity of the gp120 protein 
The majority of vaccines being developed at the time of initiation of this study were 
based on the envelope region of T-cell tropic subtype B isolates and little work had been 
performed to characterise cross-reactive CTL epitopes. In addition, the only South African 
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gp120 sequence that had been published was isolate NOF and this sequence did not include 
the complete gp120. We thus set out to characterise the complete gp120 of a macrophage 
tropic subtype C isolate from South Africa in order to determine the immunogenicity of this 
isolate in comparison with a macrophage tropic subtype B isolate (see Chapter 4). 
Isolate 97ZA347TS is the first to be genotypically characterised from a known 
macrophage tropic South African isolate and clustered within the subtype C lineage, with an 
average DNA distance of 10.2%. The amino acid sequence for isolate 97ZA347TS was 
generated and the macrophage tropic isolate was found to lack any of the arginine 
substitutions in the V3 loop increasing the positive charge and indicative of a SI phenotype, 
suggesting that the isolate is NSI (Fouchier et al., 1992; De Wolf et al., 1994), which was 
expected. Isolate 97ZA347TS contains 22 N-linked glycosylation sites, including an 
additional site in the CD4 binding region at position 512, common in subtype C isolates, which 
may influence CD4 binding affinity or antigenicity (Myers et al., 1996). 
The immunogenicity of the gp120 from isolate 97ZA347TS (subtype C) and the 
reference isolate, SF162 (subtype 8) was determ·ned in BALB/c mice. As the vaccination 
was intramuscular by DNA vaccine, a predominantly Th1 type response was expected 
(Robinson, 1997a) and antibody levels peaked at'between five- (pcDNA3.1 sF162) and seven 
times (pcDNA3.191ZA34ns) greater than the negative control mice. 
BALB/c mice immunised once with the DNA vaccine and challenged with W 97ZA346Ts 
showed a decrease in ovarian titre of 100 to over 500 fold in mice immunised with the 
homologous subtype C DNA vaccine, whereas the mice immunised with the heterologous 
subtype B DNA vaccine had a 50 to 100 fold decrease in ovarian W 97ZA346Ts titre. This is the 
first study utilising an in vivo technique in order to determine the cross-reactive CTL response 
between different subtypes, although other studies have shown cross-reactive CTL responses 
by conventional in vitro methods. 
The difference in efficiencies between the two DNA vaccines to elicit an in vivo CTL 
response to W91ZAJms in the BALB/c mice is probably due to the differences in their CTL 
epitopes. It is assumed that greater than two amino acid mismatches in the CTL epitope of 
the virus will not be recognised by the host (Cao et al. , 1997) ,' although it also depends where 
the amino acid mismatch occurs in the epitope. In this study, a comparison of the identified 
fourty-two human CTL epitopes in the gp120'with the gp120 from isolate 97ZA347TS showed 
that only 11 . 9% of the gp120 epitopes were conserved, indicating that the gp120 may not be 
the optimal region for the induction of a CTL response. 
As the CTL epitopes for subtype C have not been determined, a better indication of 
the possibility of CTL cross-reactivity between isolates 97ZA347TS and SF162 may be the 
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amino acid divergence between the two isolate gp120s. The amino acid similarity between 
the two isolates should be a reflection of the similarity between potential CTL epitopes as 
well. The two isolates are highly divergent, with almost a quarter of the amino acids making 
up the gp120 protein differing between them . Even ZAM18 is 15% divergent from 
97ZA347TS and it is possible that a broader CTL response will be obtained using a more 
conserved region for an HIV vaccine. 
5.4) Future investigations 
Although subtype C is currently the predominant HIV-1 subtype circulating within the 
heterosexual population of South Africa, with subtypes A, B and D rarely detected or with 
limited distribution (subtypes A and D), it is essential to continue to monitor the South African 
epidemic for emerging subtypes. Seroconvertors from high risk groups may be good sentinel 
populations to monitor. Since the African continent has all of the HIV-1 subtypes present, as 
well as HIV-2, and with a constant traffic of people from one country to another for reasons 
such as work, famine or war (see section 1.5.2,. 1) it is highly likely that additional subtypes 
may be introduced into the country. In addition, recombinant viruses are becoming more 
prevalent and are responsible for some of the burgeoning epidemics in China, Russia and 
Tanzania (Shao et al., 1998; Liitsola et al., 1998 and Renjifo et al., 1998). Although at 
present there is limited subtype diversity in South Africa , it is possible that recombinant 
viruses may enter the country, or may form between the subtype B and C viruses circulating 
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in regions or populations where both subtypes have been identified. 
The first man infected by bisexual transmission with a subtype C virus was identified 
in this study The bisexual population should be monitored, as it is possible that greater 
numbers of subtype C infections may enter the bisexual and homosexual populations. Shifts 
in subtype distribution according to mode of trahsmission have been reported in Thailand 
(Mastro et al., 1996) and China (Shao et al., 1996) and it is important to continue monitoring , 
possible "transition populations" in order to detect similar shifts in South Africa . 
The genetic diversity of the prevalent subtypes circulating within South Africa may 
have an effect on vaccine design for the country. As South Africa is involved in developing 
vaccine trial sites (IAVI Report, 1998) it is important to keep abreast with the HIV subtypes 
circulating within the country and the genetic diversity within these subtypes as they may 
influence vaccine efficacy. This study has laid down a basis for the investigation of subtype C 
isolates from different centres in South Africa . Regions other than the Env and Gag must be 
analysed , in order to determine the diversity between South African subtype C isolates in the 
whole HIV genome. For future studies, alternative regions with more conserved CTL epitopes 
such as Gag, Pol or Nef, may be used in a DNA vaccine system in order to determine which 
will elicit a strong and broad CTL response . The· in vivo murine CTL challenge model can 
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then be used to determine the immunogenicity of these potential vaccine proteins. This 
model may also be used to compare vaccines and immunisation schedules, in order to 
determine their efficacy in eliciting a CTL response , as has been utilised in a number of other 
studies (Binder and KUndig, 1991; Bachmann et al., 1994; Belyakov et al., 1998 and Kent et 
a/., 1998). In this way, the best vaccine schedule to elicit a strong, broadly cross-reactive 
CTL response will be identified prior to testing in more expensive primate models. 
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APPENDIX A: DNA TECHNIQUES 
A1 DNA extraction 
Cape Town and Bloemfontein samples: 
DNA was extracted from 5-10ml of blood as described (Kawasaki, 1990) by Maureen Lambrick, 
Clinical Virology, UCT and Elna van der Ryst, Department of Virology, University of the Free State). 100µ1 
of whole blood was mixed with 0.5ml of 1XTE buffer (10mM Tris-HCI, 1mM EDTA, pHB.O) in a microfuge 
eppendorf tube and centrifuged at 13 OOOg for 10 seconds. The pellet was resuspended in 0.5ml of 1XTE 
buffer by vortexing and again pelleted by microfugation. The process was repeated twice until a clean nuclei 
pellet was obtained. The pellet was resuspended in 100µ1 of lysis buffer K [1XPCR buffer (Promega, 
Madison, WI , USA), 0.5% Tween-20, 1 OOµg/ml fresh proteinase K) by vortexing and then spun down by 
microfugation before being incubated at 56°C for 45 minutes. The protease was inactivated at 95°C for 10 
minutes and the cell/nuclei lysate spun down briefly. Ten microlitres of the lysate was used for a 50µ1 PCR 
master mix volume. 
Johannesburg samples : 
Samples were collected and DNA extracted by Sue Lyons (National Institute of Virology, 
Johannesburg). Peripheral blood mononucleocytes were purified on a Ficoll gradient (Sigma, St Louis, 
USA) after which cells were pelleted by centrifugation and washed 2-4 times with 1X phosphate buffered 
saline (PBS). PBS (pH7.2) is made by adding 17.2g of KH2P04 (solution A) and 104.4g of Na2HP04·12H20 
(solution B) to 1000ml of distilled water. The cells were then lysed using ammonium chloride to remove the 
red blood cells if necessary and re-suspended in 100 µI lysis buffer (TE lysis buffer; 10mM Tris HCI pH 7.5, 
1mM EDTA, 0.5% Triton X-100, 1% Tween 20™) and 6µ1 Proteinase K (stock 20mg/ml). The tube was then 
incubated at 56°C for three hours ( or overnight) , followed by 95°C for 15 min, then stored until use at -70°C. 
Durban samples: 
HIV positive samples were collected and provira! DNA was extracted directly from 300µ1 of whole 
EDTA-blood using the Genomix extraction kit (Talent, SRL, Italy) by Savathree Madurai and Dennis York 
(Department of Virology, University of Natal). The protocol was as described by the manufacturer but with 
the following addition: the final pelleted DNA (100µ1) was re-precipitated with 255µ1 absolute ethanol and 
10µ1 3M sodium acetate (pH5.2) and washed with 70% ethanol. The pellet was re-suspended in 50µ1 of 
distilled water and stored at -70°C until use. 
A2 Polymerase chain reactions (PCR) 
V3-V5 region : 
The V3 loop was amplified by nested PCR of 1.2Kb and 700bp fragments respectively using 
primers ED5/12 for the outer reaction and ES?/8 for the inner reaction (Delwart et al., 1993). 
The outer reaction master mixes (50µ1) contained : 
• 5µ1 10X PCR buffer (Promega, Madison, WI, USA), (500mM KCI, 100mM Tris-HCI (pH9.0), 1% Triton 
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X-100), 1.5mM MgCb, 
• 1 % DMSO, 1 % glycerol, 
• 200µM each of dNTP's, 
• 400nM each EDS and ED12 and 
• 2.5U Taq DNA Polymerase (Promega, Madison, WI, USA) 
The reaction mixes were made up to 40µ1 with sterile, distilled water and overlayed with 30µ1 of mineral oil 
and 10µ1 of patient DNA (or 5µ1 of patient DNA for Durban samples, topped up with 5µ1 of sterile, deionised 
water) was added. Samples were amplified using the following amplification conditions in the Techne PHC-
2 PCR thermocycler: 
• Initial denaturation at 94°C for 2 minutes, 
• 94°c for 1 minute, 45°C for 1 minute and 72°C for 2 minutes (five cycles), 
• 94°C for 20 seconds, 55°C for 45 seconds and 72°C for 1 minute (35 cycles) and 
• Final extension at 72°C for 6 minutes. 
The inner reaction master mixes (50µ1) contained: 
• 5µ1 10X PCR buffer (Promega, Madison, WI , USA), (500mM KCI, 100mM Tris-HCI (pH9.0), 1% Triton 
X-100), 1.8mM MgCl2, 
• 1% DMSO, 1% glycerol, 
• 200µM each of dNTP's, 
• 400nM each ES? and ESB and 
• 2U Taq DNA Polymerase (Promega, Madison, WI, USA) 
The PCR reaction mixes were made up to 47µ1 with sterile, distilled water and overlayed with 30µ1 of mineral 
oil. For the inner reaction, 3µ1 of outer reaction DNA was transferred, or 2µ1 of plasmid DNA was added. 
Amplification conditions using the Techne PHC-2 PCR thermocycler were: 
• Initial denaturation at 94°C for 2 minutes, 
• 94°C for 20 seconds, 55°C for 45 seconds and 72°C for 1 minute (35 cycles) and 
• Final extension at 72°C for 6 minutes. 
Gag p17 and partial p24 region 
The gag p17 region and partial p24 and p17 region were amplified by nested PCR for RFLP 
analysis. Primers used are shown in Table 3.2. The nested PCR ampl ified 1.5Kb and 400bp or 650bp 
fragments respectively, using primers L TRu51Pol2 (van Harmelen et al., 1999a) for the outer reaction and 
L TR31 Oj (van Harm el en et al., 1999a)/SK431 (Lynch et al., 1992) or gag778 (van Harmelen et al., 1999a) for 
the inner reactions. PCR master mixes (50µ1) contained: 
• 5µ110X PCR (500mM KCI , 100mM Tris-HCI (pH9.0), 1% Triton X-100) (Promega, Madison, WI, USA), 
• 1% DMSO, 1% glycerol, 
• 200µM each of dNTP's, 
• 1.5mM MgCb, (outer reaction) and 1.8mM MgCl2, (inner reaction), 
• 400nM each primer; LTRu5 and Pol2 (outer reaction) and LTR310j and SK431 or gag778 (inner 
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reaction) and 
• 2.5U Taq DNA Polymerase (outer reaction) and 2U Taq DNA Polymerase (Promega, Madison, WI, 
USA) (inner reaction). 
The reaction mixes were made up to 40µ1 (outer reaction), or 47µ1 (inner reaction) with sterile deionised 
water and overlayed with 30µ1 of mineral oil. 1 OµI of patient DNA was added to the outer reaction. For the 
inner reaction, 3µ1 of outer PCR product was transferred to the outer reaction mix. If cloned and already 
sequenced reference gag plasmid DNA was used, 20ng of DNA was added. Amplification conditions for the 
outer reaction using the Techne PHC-2 PCR thermocycler were: 
• Initial denaturation at 94°C for 2 minutes, 
• 94°C for 1 minute, 45°C for 1 minute and 72°C for 2 minutes (5 cycles), 
• 94°C for 20 seconds, 55°C for 45 seconds and ?2°C for 1 minute (30 cycles) and 
• Final extension at 72°C for 6 minutes. 
For the inner reaction, PCR condit ions were: 
• Initial denaturation at 94°C for 2 minutes, 
• 94°C for 20 seconds, 55°C for 45 seconds and 72°C for 1 minute (30 cycles) and 
• Final extension at 72°C for 6 minutes. 
gp120 fragment: 
The gp120 was amplified from a primary, macrophage tropic isolate belonging to subtype C 
(97ZA347TS) in order to characterise the gp120. Primers ED3/ED14 were taken from Delwart et al (1993) 
and envB/env J from Gao et al (1994) and used to amplify a 2.5Kb outer reaction and 1.6Kb inner reaction 
by nested PCR amplification. The PCR master mixes (50µ1) contained the following : 
• 5µ1 10X PCR buffer (Promega, Madison, WI, USA), (500mM KCI, 100mM Tris-HCI (pH9.0), 1% Triton 
X-100), 
• 1.5mM MgC'2, 
• 1% DMSO, 1% glycerol, 
• 200µM each of dNTP's, 
• 400nM each of ED3/ED14 (outer reaction) and envB/envJ (inner reaction) and 
• 2.5U Taq DNA Polymerase (outer reaction) and 2U Taq DNA Polymerase (Promega, Madison, WI, 
USA) 
The reaction mixes were made up to 40µ1 (outer reaction) or 47µ1 (inner reaction) with sterile, deionised 
water and overlayed with 30µ1 of mineral oil. 1 Oµl of cultured isolate proviral DNA was added to the outer 
reaction and 3µ1 of the outer reaction product was transferred to the inner reaction mix. Negative controls 
included HIV negative patient DNA and sterile distilled water in order to monitor contamination. The 
amplification conditions in the Techne PHC-2 PCR thermocycler for the outer reactions were: 
• Initial denaturation at 94°C for 2 minutes, 
• 94°C for 1 minute, 45°C for 1 minute and 72°C for 2 minutes (5 cycles) , 
• 94°C for 20 seconds, 55°C for 45 seconds and 72°C for 1 minute (35 cycles) and 
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• Final extension at 72°C for 6 minutes. 
Amplification conditions for the inner reactions were: 
• Initial denaturation at 94°C for 2 minutes, 
• 94°C for 20 seconds, 55°C for 45 seconds and 72°C for 1 minute (35 cycles) and 
• Final extension at ?2°C for 6 minutes. 
All samples were stored at -20°C after amplification and the appropriate controls (HIV negative patient DNA 
and sterile distilled water) were included in order to detect possible contamination. 
Samples were stored at -20°C after amplification. 
A3 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed using horizontal gel apparatus (Hoefer Scientific 
Instruments, San Francisco, USA) as described in Sambrook et al (Sambrook, 1989). The agarose powder 
was melted with frequent swirling to prevent clumping in 1XTAE (50XTAE/liter; 242g Tris base, 57.1ml 
glacial acetic acid, 100ml 0.5M EDTA, pH 8.0) at concentrations of 1 to 4%, depending on the size of the 
DNA fragments to be separated. Once melted, ethidium bromide (10mg/ml) stain was added to a final 
concentration of 1µg/100ml of agarose. The agarose gel ·slabs were allowed to set at room temperature for 
30 minutes after which the well combs were removed. Samples were mixed with 1/5 their volume of loading 
dye (0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol in deionised water) and added to the 
1XTAE submerged wells . The agarose gel was electrophoresed at 5V/cm until the relevant fragments were 
separated. The DNA fragments were then visualised using the UVP transilluminator at 256nm wavelength 
and photographed either with a M645 1000S polaroid camera or with the UVP computerised gel imager. 
Molecular weight markers were used to determine DNA fragment sizes; including Marker VI and VIII 
(Boehringer Mannheim, Hamburg, Germany) and the 1 Kb ladder (Promega, Madison, WI , USA). 
A4 Restriction endonuclease digestion 
Restriction digests were carried out using the 1 OX buffer supplied by the manufacturer (Boehringer 
Mannheim, Hamburg, Germany). Two restriction enzymes were combined in a single digest if their buffers 
were compatible. If not, the digestion was done sequentially and the DNA was purified to remove the first 
buffer using ethanol precipitation, before addition of the second enzyme and buffer. The restriction enzyme 
digests were performed as described in Sambrook et al ( 1989). Most of the restriction endonucleases 
digested at 37°C, except Sma I that had an optimal temperature of 25°C. The restriction endonucleases 
were all suppl ied at 10U/µI (Boehringer Mannheim, Hamburg, Germany). Fragments were electrophoresed 
in a 1 % agarose gel for detection and/or ligation purification. For a single digestion reaction, the following 
reaction components were included in a 1 OµI reaction mix: 
1 µI 1 OX restriction endonuclease buffer 
8µ1 of PCR product or 1 µg/8µ1 of plasmid DNA 
1 µI 1 OU/µI restriction endonuclease 
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Ethanol precipitation 
The reaction volume was made up to 90µ1 with TE pH 8.0 (10mM Tris·CI pH 8.0; 1mM EDTA, pH 
8.0) in an eppendorf tube. One volume of phenol was added and the solution emulsified by shaking, 
followed by centrifugation in a benchtop microfuge at 14 OOOrpm for 2 minutes. The upper phase was 
transferred to a fresh eppendorf tube. This process was repeated and then one volume of 
chloroformlisoamyl alcohol (24: 1) was added and the solution emulsified by shaking . The upper aqueous 
phase was recovered by centrifugation as before. 1110 the volume of 3M sodium acetate pH 4.8 and 2.5 
volumes of absolute alcohol was added, the solution mixed and incubated on dry ice for 10 minutes. The 
DNA pellet was collected by centrifugation at 14 OOOrpm for 20 minutes, washed with 70% ethanol and 




TA ligation was performed as per manufacturers' instructions using the pMOS-blue TA cloning kit 
(Amersham, Buckinghamshire, UK). The ligation mix contained: 
1µ1 1 OX DNA ligase buffer 
0.5µ1 100mM OTT 
0.5µ1 10mM ATP 
1µ1 50nglµI pMOS vector 
2-3µ1 PCR product 
0.5µ1 T4 DNA ligase 
Made up to 1 OµI with nuclease-free water. 
The ligation mix was incubated at 16°C for 2 hours, 1 µI of ligation mix was transformed into 100µ1 of 
competent OHa cells and 350µ1 was plated onto 2XYT agar (Appendix A6). 
Subcloning 
The restriction endonuclease digested vectors were electrophoresed in 1 % low melting pq_int 
agarose to separate out the gp120 and stuffer fragments as described by Sambrook et al (1989). The 
relevant fragments were excised from the gel visualised under low intensity UV light. The agarose was 
removed using the phenol freeze method (modified from Sambrook et al., 1989). The vector and inserts 
were mixed together at 3: 1 ratios and the following was added to a total of 60µ1: 
6µ1 1 OX DNA ligase buffer (Boehringer Mannheim, Hamburg, Germany) 
2. 5µ1 100mM OTT (Amersham, Buckinghamshire, UK ) 
2.5µ1 10mM ATP (Amersham, Buckinghamshire, UK) 
2µ1 (1U) DNA ligase (Boehringer Mannheim, Hamburg,·Germany) 
Made up to 60µ1 with nuclease free water (Amersham, Buckinghamshire, UK) 
The ligation mix was incubated at 16°C overnight and 5 volumes of ice cold 0.1 M CaCl2 added. 
Twenty microlitres were used to transform DHa cells and 350µ1 was plated onto 2XYT agar (Appendix A6). 
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Phenol freeze 
The relevant DNA fragments were excised from the low melting point agarose gel, transferred to an 
eppendorf and finely chopped up with a scalpel. One volume of phenol was added, the solution mixed and 
frozen at -70°C for 10 minutes, followed by centrifugation in a microfuge for 10 minutes at 14 OOOrpm. The 
upper aqueous phase was transferred to a fresh eppendorf tube and 1 volume of phenol and 1 volume of 
chloroform:isoamyl alcohol (24: 1) added. The solution was emulsified by mixing and microfuged as before. 
The upper aqueous phase was again transferred to a new eppendorf and 1.5 volumes of absolute ethanol 
and 1/10 the volume of sodium acetate (3M, pH4.8) added to precipitate the DNA. The tube was placed on 
dry ice for 10 minutes followed by centrifugation for 20 minutes at 14 OOOrpm to pellet the DNA. The DNA 
was then washed with 70% ethanol and re-suspended in an appropriate volume of distilled, deionised water. 
A6 Transformation of DNA into competent E. coli cells 
CaCl2 shock procedure (Oagert and Ehrlich, 1979) 
E coli strain DHa was used for manufacture qt competent cells. Five milililtres of DHa bacteria 
were grown overnight at 37°C in 2xYT broth, pH7.0 (Per liter, 900ml deionised water, 16g bacto-tryptone 10g 
bacto-yeast extract, 5g NaCl) in a McCartney bottle placed flat on the shaker for good aeration of the culture. 
The bacterial culture was then diluted 1/100 to 1/200 in 50 or 100ml 2xYT broth in a flask five to ten times 
the culture volume. The bacterial culture were grown to early log phase (ODsoo 0.2-0.4) and the cells were 
harvested by centrifugation at 4 000-5 OOOrpm for 5 minutes at 4°C in the Beckman J2-21 centrifuge. The 
cell pellet was re-suspended in 1 /2 the culture volume of 0.1 M ice cold CaCl2 and then placed on ice for 1 to 
2 hours. The cells were collected by centrifugation as before and then re-suspended in 1/10 the original 
culture volume of 0.1 M ice cold CaCl2. The competent cells were then al iquoted in 100µ1 aliquots into ice 
cold eppendorf tubes and 10% (v/v) ice-cold sterile glycerol was added. The cells were mixed and left on ice 
for 30 minutes and then stored at -70°C. 
Transformation of CaC/2 competent cells 
The relevant plasmid DNA (1-10ng) containing ampicillin resistance was mixed with 100µ1 of 
competent DHa cells and the mixture swirled to mix and left on ice for 30 minutes. The bacteria were then 
heat-shocked at 42°C for 2 minutes. The cells were removed and 900µ1 of 37°C 2xYT broth was added after 
which the cells were incubated at 30 to 60 minutes to allow plasmid ampicillin resistance gene, P-lactamase 
expression before plating. The transformed bacteria were plated on 2xYT agarose (2xYT broth with 15g 
bacto-agar added before autoclaving) plates containing 0.5ml of X-gal (5ml DMSO, 0.4g X-gal , mixed and 
5ml of distilled water added), 50µ1 of IPTG (10ml distilled water, 0.24g IPTG) and ampicilin (100µg/ml) per 
100ml of agar. Colonies were grown overnight at 37°C and transformed bacteria identified (Appendix A2, 
A4, A7). 
If the marker gene, /acZ was present on the plasmid transformed into the bacteria (pMOS-blue and 
pSC65) the transformed bacteria appeared blue. The defective /acZ gene in the plasmid and the defective 
Lacz gene in the bacteria complement each other, allowing the expression of p-galactosidase, induced by 
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the IPTG in the medium. The p-galactosidase is able to ''metabolise X-gal, a chromogenic substrate, thus 
producing blue colonies. Selection of recombinant clones can occur if the multiple cloning site is within the 
Lacz gene of the plasmid, disrupting it. The recombinant bacteria are therefore not able to express P-
galactosidase and the colonies are white. The recombinant pMOS-blue vectors were identified in this way. 
Controls were also run for all ligation and transformation experiments. Negative control , non-
transformed bacteria were unable to grow, since they did not contain the plasmid-carried ampicillin 
resistance gene. Positive control, non-recombinant pMOS-blue was plated in order to determine the 
transformation efficacy. In addition, digested, non-ligated vector (pMOS-blue, pcDNA, or pSC65) was 
transformed and plated to ensure that the vector had not re-circularised; re-ligated vector (pMOS-blue) was 
added in order to determine that the T4 ligase (Boehringer Mannheim, Hamburg, Germany) was efficient; 
and digested, DNA fragments were ligated and transformed to ensure that no plasmid DNA was present. 
Putative clones were identified by restriction endonuclease digestion (Appendix A4) of miniprepped clones, 
followed by agarose gel electrophoresis, as well as V3-V5 PCR using primers ES? and ESB (Appendix A2). 
A7 Plasmid DNA extraction 
Plasmid DNA minipreperation 
The protocol was based on Sambrook et al. (1989). The selected recombinant bacteria were 
inoculated into 3-5ml of 2xYT broth containing 1 OOµglml ampicillin and grown overnight at 37°C with 
shaking. Two mil ilitres of culture was transferred to a 2ml -eppendorf tube and centrifuged at 14 OOOrpm for 
2 minutes in a microfuge. The supernatant was removed and the pellet re-suspended in 100µ1 of Buffer 1 
(50mM glucose, 10mM EDTA, 25mM Tris-CJ, pH8.0). After re-suspension, 400µ1 of Buffer 2 (8.8ml distilled 
water, 0.2ml 10M NaOH, 1ml 10% SOS) was added and the tube placed on ice for 5 minutes after gentle 
mixing. The protein and genomic DNA was then precipitated by the addition 300µ1 of Buffer 3 (3M KAc and 
1.3M formic acid) and placed on ice for 30 minutes. The flocculant was removed by centrifugation at 14 000 
rpm for 15 minutes in a micro-centrifuge and the clear supernatant transferred to a fresh eppendorf tube. 
The DNA was further purified by the addition of 200µ1 of phenol and vortexed to emulsify, followed by the 
addition of 400µ1 of chloroform:isoamyl alcohol (24: 1 ). The solution was vortexed and then centrifuged for 2 
minutes. The upper aqueous phase was transferred to a new eppendorf and 500µ1 of absolute ethanol was 
added. The solution was mixed and placed on dry ir.e for 10 minutes. Precipitated plasmid ONA was 
pelleted by centrifugation in a microfuge at 14 OOOrpm for, 20 minutes and washed with 70% ethanol. The 
DNA pellet was re-suspended in an appropriate amount of TE (pH 7.6) or sterile, distilled water. 
Plasmid DNA maxipreperation 
For amplification of up to 100µg of plasmid, th.e Nucleobond® AX PC-Kit 100 (Machery-Nagel, 
Germany) was used according to manufacturers' instructions. The AX100 column is a silica-based, anion-
exchange column for purification of plasmid DNA from 10 to 100ml of broth. The desired transformed 
bacterial cells were grown in 50ml of 2xYT broth contain ing 1 OOµg/ml of ampicillin overnight at 37°C with 
' < 
shaking. The bacterial cells were then pelleted at 5 OOOrpm for 5 minutes at 4°C using the Beckmann J2-21 
centrifuge. The supernatant was removed and .the bacterial pellet carefully re-suspended in 4ml of 4°C 
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buffer S1 (50mM Tris/HCI, 10mM EDTA, 100µg Rnase A/ml, pH8.0). The re-suspended bacteria were then 
gently mixed with 4ml of room temperature buffer S2 (200mM NaOH, 1%SDS) and incubated at room 
temperature for exactly 5 minutes. Buffer 3 (2.8M KAc, pH5.2) (4ml) at 4°C was then added and the 
suspension mixed gently by inverting the tube 6 to 8 times, until a homogeneous suspension was formed . 
The suspension was incubated for 5 to 1 O minutes on ice and then centrifuged in a Beckmann J2-21 
centrifuge at 11 OOOrpm for 25 minutes at 4°C. The supernatant was carefully removed from the white 
precipitate and loaded onto the AX 100 column, equilibrated with 2ml of buffer N2 (100mM Tris/H3P04, 15% 
ethanol, 900mM KCI, pH6.3). Once the supernatant had run through, the column was washed with 2x 4ml 
of buffer N3 (1 OOmM Tris/H3P04, 15% ethanol, 11 SOmM KCI, pH6.3). The purified plasmid DNA was then 
eluted from the column with 2ml of buffer NS (1 OOmM Tris/H3P04, 15% ethanol, 1 OOOmM KCI, pH8.5), 
although one bed volume (0.35ml) was discarded at the beginning to reduce the volume containing the 
plasmid. The eluted plasmid DNA was then precipitated with 0.8 volumes of room temperature isopropanol 
and immediately centrifuged in a micro-centrifuge at 14 OOOrpm in a microfuge for 10 minutes. The pellet 
was washed with 70% ethanol and re-suspended in an appropriate volume of TE (pH?.8). The DNA was 
then further purified by ethanol precipitation (Appendix /l.4 ), or for pcDNA vaccine purification, by addition of 
2.5 volumes of absolute ethanol and 1/10 volume of 3M sodium acetate. The tube was then incubated at -
20°C overnight, or on dry ice for 5 minutes to precipitate the DNA and centrifuged at 14 OOOrpm in a 
microfuge for 20 minutes. The DNA pellet was washed and re-suspended in sterile 1X PBS (pH 7.2) and 
stored at -20°C. 
Determination of DNA purity and concentration 
The re-suspended DNA was diluted one in one hundred in distilled water and scanned using the 
Beckman DU-40 spectrophotometer from 310nm to 220nm wavelengths. The spectrophotometer was 
blanked against distilled water after which the samples were read. To determine the purity of the DNA, the 
260nm peak (DNA) was divided by the 280nm (protein) value and if the ratio was between 1.7 and 2.0 the 
DNA was deemed pure. The DNA concentration was determined by multiplication of the A260 by 50 (the 
factor for double stranded DNA) multiplied by one hundred, the dilution factor. 
AS Sequence analysis 
AB.1 Radioactive DNA sequencing 
The five reference plasmids and two subtype A isolates from Cape Town were sequenced in the V3 
to VS region of the env gene using the Sanger dideoxy termination method (Sanger et al., 1977) with primers 
ES?, ES8 and ED33 shown in Table 2.2. The Sequenase® Version 2.0 DNA Sequencing Kit was used as 
per manufacturers' instructions (United States Biochemical Corporation (USB™) Amersham, Illinois, USA). 
The kit was stored at -20°C. 
Alkaline denaturation of the dsDNA template 
Nucleobond columns were used to purify the DNA for sequencing (Appendix A?), after which the 
pellet was further purified by ethanol precipitation (Appen.dix A4 ). Approximately 10-1 Sµg of purified DNA 
was added to 18µ1 of deionised MilliQ® water in a 0.5ml eppendorf tube. Two microlitres of 2M NaOH was 
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added and the eppendorf incubated at 37°C for 30 minutes. The denatured DNA in the eppendorf was then 
placed on ice and 3µ1 of 3M sodium acetate and 100µ1 of absolute ethanol was added to precipitate the DNA. 
The tube was placed at -70°C for 5 minutes after which the DNA was pelleted in a microfuge at 14 OOOrpm 
for 20 minutes. The supernatant was removed and the DNA pellet washed with 70% ethanol, after which it 
was air-dried. 
Annealing reaction 
The denatured DNA pellet was resuspended in 7µ1 of deionised MilliQ® water and the following 
added: 
2µ1 5X Reaction Buffer (suppl ied by kit) 
2µ1 primer (20ng/µI or 2 pmol) 
The DNA was then annealed by heating at 65°C for 2 minutes, then cooled slowly to <35°C over 15 
to 30 minutes. The DNA was pelleted by microfugation and placed on ice. 
Note: 5X Reaction Buffer (1.0ml): 200mM Tris-HCI, pH 7.5, 100mM MgC'2, 250mM NaCl 
While cooling, 1.0ml eppendorf tubes were labelled and filled with 2.5µ1 of each Termination 
mixture, ddGTP, ddATP, ddTTP and ddCTP, respectively. The tubes were then pre-warmed to 37°C. 
Termination mixes contain 80µM dGTP, 80µM dATP, 80µM dCTP, 80µM dTTP, 50mM NaCl and: 
ddG termination mix (250µ1): 8µM ddGTP 
ddA termination mix (250µ1): 8µM ddATP 
ddT termination mix (250µ1): 8µM ddTTP 
ddC termination mix (250µ1): 8µM ddCTP 
The Labelling mix (7.5µM dGTP, dCTP and dTTP) was diluted 5-fold to the working concentration, typically: 
2µ1 dGTP 
8µ1 deionised MilliQ® water 
Labelling reaction 
To the ice-cold annealed DNA mixture (1 OµI) was added: 
1µ1 OTT (0.1M) 
2µ1 Diluted Labelling mix 
0.5µ1 (35S) dATP 
2µ1 diluted T7 DNA polymerase (d iluted freshly 1 :8 in ice cold Enzyme Dilution Buffer) 
The total 15.5µ1 was incubated at room temperature for 2-5 minutes after thorough mixing, avoiding 
bubbles. 
Note: Enzyme Dilution Buffer (1.0ml): 10mM Tris-HCI, pH?.5, 5mM OTT, 0.5mg/ml BSA 
Sequenase Version 2.0 T7 DNA Polymerase (2qµI ; 13 units/µ!) in: 20mM KP04, pH7.4, 1mM OTT, 
0.1 mM EDT A and 50% glycerol. 
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Termination reactions 
3.5µ1 of labelling reaction was added to each termination tube (G, A, T and C) and mixed after 
which the eppendorf tubes were incubated at 37°C for a further 5 minutes. The reactions were then stopped 
by adding 4µ1 of Stop Solution. The samples were heated to 75°C for two minutes immediately before 
loading onto the sequencing gel. 2-3µ1 was loaded onto each well. 
Note: Stop Solution (2X 1.25ml): 95% formamide, 20mM EDTA, 0.05% bromophenol blue, 0.05% xylene 
cynol FF. 
Preparation of the 6% non-denaturing polyacrylamide gel 
Two glass plates, one notched, were washed thoroughly in warm water using a soft wash cloth and 
non-scratch detergent. The surface of one glass plate was made hydrophobic using silane in order to 
facilitate separation of the gel. The insides of the plates were wiped with ethanol in order to remove dust 
particles and the plates were placed on top of each other with 0.5mm spacers along both sides and the 
bottom of the plates. The plates were clamped together using ' bulldog paper clamps" making sure that 
there were no gaps between the spacers. 
40% acrylamide stock solution was made by dissolving 38g of acrylamide and 2g N', N'-methylene 
bis-acrylamide in 100ml of distilled deionised water. The 6% acrylamide was made by mixing: 
• 15ml 40% acrylamide 
• 50ml 10XTBE (88mM Tris-borate, 89mM Boric acid . 2mM EDTA) 
• 
• 46g molecular grade urea 
• made up to 100ml with distilled deionised water 
The mix was heated to 37°C in order to allow the gel to set more rapidly and just prior to pouring 
the gel the following was added: 
• 100µ1 aliquot of ammonium persulphate 
• 50µ1 N,N,N',N'-tetramethyl-1,2-diaminoethane (TEMED) 
The clamped glass plates were held slightly upright and the acrylamide gel was poured between the 
glass plates, making sure that no bubbles were trapped between the plates, maintaining a steady flow. 
Once the gel casting apparatus was filled, it was rested with the open end slightly raised to prevent leakage 
and the ' sharks-tooth" comb inserted backwards approximately 5mm into the gel in order to seal the open 
end. The gel was then clamped over the comb to prevent leakage and the gel left for 30 minutes one hour to 
set. If left overnight, Gladwrap® was used to seal the gel to prevent evaporation and drying. 
Polyacrylamide gel electrophoresis of the sequencing reactions 
The Gladwrap®, "Bulldog clamps" and the spacer at the bottom of the gel were removed. The 
polymerised gel was then transferred to the electrophoresis tank with the notched plate at the back, facing 
the upper buffer chamber. The electrophoresis tanks were filled with 0.5XTBE in the upper tank and 1XTBE 
in the lower tank. The ' shark's tooth" comb was then removed carefully and inserted evenly with the teeth 
0.5-1 mm in the gel surface. Before loading the sequencing reactions, the DNA was denatured at 95°C for 5 
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minutes and then placed on ice. The wells were washed using buffer from the upper electrophoresis tank 
and a 20ml syringe with a needle in order to remove any diffuse urea that would lead to uneven band 
formation. A P20 PIPETMAN Gilson® micropipette (Gilson Medical Electronics, France) was used to layer 3µ1 
of denatured sequencing reaction onto each well. Each template is run in four wells, ending in A, C, G and 
T). The DNA was then electrophoresed at 30V/cm. The power supply was set at 2000-2300V, 30-35mA and 
80-85W for 1.5-2 hours for 100-200bp to be read and 3.5-4 hours for 150-400bp to be read. 
Gel drying and autoradiography 
After electrophorsis, the gel apparatus was dismantled and the plates pried apart using a thin 
wedge. The gel remained on the un-notched plate, due to the silane coating of the notched plate. The 
electrophoresis buffer containing radioactive waste was disposed of as recommended by the laboratory 
radioactive safety manual. Whatman 3MM chromatography paper was cut to the size of the gel and was 
lowered onto the polyacrylamide gel, pressing carefully to ensure that the entire gel was in contact with the 
absorbent paper. The gel was lifted from the glass plate by removal of the paper and covered in Gladwrap®. 
The gel was dried on a 70°C gel drier (make) attached to a vacuum pump for 1-2 hours after which the 
Gladwrap® was removed and the gel placed on top of Agfa Curix P1 X-ray film (Agfa-GevaertTM), in a dark 
room. The X-ray film was exposed for 1-4 days, depending on the strength of the 35S used. The X-ray film 
was then removed and developed by submerging for 3 minutes in developer (1 part Novolith™Liquid A to 3 
parts water mixed with an equal volume of 1 part Novolith™ Liquid B to 3 parts water) (May and Baker, 
Essex, UK), followed by 1 minute in stop solution (2% acetic acid) and then 3 minutes in fixative (Agfa 
G334C (Bayer, RSA) 1 part solution A to four parts water, mixed with 1 part solution B to 20 parts water). 
After a water rinse the developed X-ray was air-dried and the A, C, T and G lanes for each template were 
read manually and recorded for analysis. 
AB.2 Automated sequencing 
Automated sequencing was performed on the 650bp gag p17, partial p24 regions of 94ZA060 and 
94ZA061 as well as on the entire gp120 from the primary, macrophage tropic isolate, 97ZA347TS. The 
Pharmacia™ ALFexpress® sequencer was used to detect fluorescently labelled dideoxy chain terminated 
fragments after electrophoresis. Sequencing was performed by Di James (Department of Microbiology, 
UCT). The sequencing reaction is based on the detection of non-radioactive Cy5-labelled primers in Thermo 
Sequenase® cycle sequencing reactions (see Pharmacia ALF Express manual and the Thermo Sequenase 
fluorescent-labelled primer cycle sequencing kit) . The primers used were U19 
(5'ACGTCGTGACTGGGAAAACC3')and T7 (5'MTACGACTCACTATAGGG3') (pMOS-blue-T vector, 
Amersham, Buckinghamshire, UK) in the outer gag and gp120 sequencing reactions and internal primers, 
E135 and E155 (Myers et al., 1995), shown in Table 4.2. The primers were labelled with Cy5 amidite using 
an oligonucleotide synthesiser. Thermo Sequenase is an exonuclease-free thermostable DNA polymerase 
that was engineered for cycle sequencing. 
Thermo Sequenase cycle sequencing using the fluorescent dye-labelled primer 
5µg of template DNA was added to 20µ1 of sterile MilliQ water in an eppendorf tube. The reaction 
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mix contained : 
• 1 µI Methyl violet-labelled primer (1-2pmol/µI) 
• 5µ1 Template DNA 
• 2µ1 A, C, G or T reagent (Tris-HCI (pH9.5, MgCl2, TweenT"'20, Nonidet™ P-40, 2-mercaptoethanol, 
dATP, dCTP, dTTP, dGTP and ddATP, thermostable pyrophosphatase and Thermo Sequenase DNA 
polymerase in addition to the respective ddATP, ddCTP, ddGTP or ddTTP) suppl ied by kit. 
The reaction was mixed by pipetting up and down twice after which the following thermocycler condit ions 
were used: 
• Initial denaturation at 98°C for 5 minutes, 
• 98°C for 30 seconds, 60°C for 30 seconds and 72°C for 40 seconds (25-30 cycles) and 
• Final extension at 72°C for 40 seconds. 
The DNA was then ethanol precipitated by addition of 1/10 volume of 3M sodium acetate, pH5.2 and 2.5 
volumes of absolute ethanol and mixed. The DNA was pelleted at 12 OOOrpm for 10 minutes at room 
temperature and the pellet washed with 70% ethanol. After air-drying, the pellets were re-suspended in 
formamide loading dye (formamide, EDTA and methyl violet) supplied by the kit and DNA denatured at 90°C 
for 2 minutes before gel electrophoresis. 
Electrophoresis and detection 
A vertical gel cassette was used for electropRoresis. The temperature was controlled by water 
circulat ion through the ALFexpress automated sequencer thermoplate. Samples were loaded onto wells at 
the top of the gel. Detection is by a fixed laser beam that passes through the glass spacer located between 
the glass and thermoplate of the gel cassette. The beam passes through the gel perpendicular to the 
direction of band migration and exits the fluorescently-labelled DNA bands. The light emitted is detected by 
photodetectors which are behind the gel. Signals are collected, digitised and stored on a computer for 
processing. The raw data was displayed as a chromogram on a computer monitor during electrophoresis. 
The ALF Express software, AM V.O stores the data during electrophoresis and performs a post-
electrophoresis evaluation of the sequencing data. 
A9 Heteroduplex Mobility Assay (HMA) 
Heteroduplex formation (De/wart et al., 1993) 
In order to form heteroduplexes of reference strain and unknown PCR amplified DNA the following 
was mixed in a 500µ1 eppendorf PCR tube: 
4.5µ1 PCR product (approximately 100-250ng of DNA), 
4.5µ1 reference PCR plasmid (approximately 100-250ng of DNA) and 
1 µI heteroduplex annealing buffer (100mM NaCl; 10mM Tris, pH7.8; 2mM EDTA). 
In order to determine the genetic diversity of each PCR amplified unknown sample, 4.5µ1 of sterile 
distilled water was added instead of reference plasmid DNA. The tube was heated to 94°C for 2 minutes in 
the Techne PHC-2 PCR thermocycler in order to denature the DNA strands and the tubes were then rapidly 
cooled by placing on wet ice. The rapid cooling is important for facilitating stable heteroduplex formation 
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between highly divergent sequences, although not as important for more closely related sequences. The 
heteroduplex reaction mixture was then mixed with 2µ1 of loading dye (0.25% bromophenol blue, 0.25% 
xylene cyanol FF, 30% glycerol in deionised water) and loaded onto the wells of a 5% non-denaturing 
vertical polyacrylamide gel. 
Polyacrylamide gel electrophoresis 
Polyacrylamide gel (5%)was mixed (per 50ml): 
8.3ml 30% acrylamide stock (1% bis-acrylamide) 
5ml 10X TBE (88mM Tris-borate, 89mM Boric acid, 2mM EDTA) 
36.7ml distilled water 
50mg ammonium persulphate 
33µ1 TEMED 
The 5% polyacrylamide gel was poured into the 190mm/160mm, 1.5mm thick Hoefer SE600 
vertical gel casting tray (Hoefer Scientific Instruments, San Francisco, USA) to set at 37°C for 30 minutes. 
The set polyacrylamide gel was . then transferred to the electrophoresis apparatus containing 1 X TBE (1 OX, 
108g Tris-HCI, 55g boric acid, 20ml of 0.5M EDTA ma.de up to a litre) for electrophoresis of the samples. 
The heteroduplexes were electrophoresed at 200V for 5 hours at room temperature. DNA was visualised by 
ethidium bromide (1 ng/ml) staining and visualisation on a 254nm wavelength UVP transilluminator. 
'· 
173 
APPENDIX B: TISSUE CULTURE TECHNIQUES 
B1 Mammalian cell propagation 
Three different mammalian cell lines were obtained from American Type Tissue Culture Collection 
(Rockville, MA, USA); Hela (a human cervical epitheloid carcinoma cell line), CV1 (African Green monkey 
[Cercopithecus aethiops] kidney cell line) and 1438 cells (human osteosarcoma cells, resistant to 5-bromo-
2'-deoxyuridine, due to defective a thymidine kinase gene)'. Frozen stocks were thawed from liquid nitrogen 
storage by melting the cells in a 37°C water bath. The cells were pelleted by centrifugation at 1 OOOrpm for 5 
minutes and the storage medium containing 10% DMSO was removed. The cells were washed twice with 
1XDMEM (Dulbecco's Modified Eagle's Medium) (Dulbecco et al. , 1959) (Highveld Biological, South Africa) 
containing 10% fetal calf serum (FCS), penicillin (P), streptomycin (S) and Fungizone (F) (GibcoBRL, 
Paisely, UK) and then re-suspended in a 25ml flask (Nunclon , Nunc, Delta, Denmark) in 5ml of DMEM with 
10% FCS and PSF. The cells were then incubated at 37°C with 5-10% CO2 atmosphere for two to three 
days, until the cells formed a confluent layer. Cells were split by adding trypsin to lift them for 5 minutes at 
37°C and then diluting them 1/5 in fresh DMEM with 10% FCS and PSF. The trypsin working solution was 
made by mixing 1 ml of 5% trypsin with 10ml of 1 OX Trypsin base, in 89ml of sterile distilled water. 
The 10 trypsin base was made by adding 30g NaCl, 2g KCI, 1.2g Na2HP04 and 5g glucose to 
700ml of sterile distilled water. Two grams of EDTA was added, followed by 25ml of 0.4% phenol red and 
the solution stirred. The trypsin base was adjusted to a pH of 7.8 with 1 N NaOH and the solution made up 
to 11. The trypsin base was then filtered through a 0.2 micron _Cameo 25AS pore filter (Westboro Medical, 
USA) and stored at -20°C. 
The 5% trypsin solution was made by adding rnml of trypsin base to 90ml of sterile distilled water 
and 0.5ml of PSF. 1 N HCI was added drop-wise until the solution turned bright yellow and the solution was 
then heated to 37°C for 2 minutes. The trypsin powder (5g) was then sprinkled slowly on top of the solution 
and swirled gently to dissolve it, without stirring . The solution was left at room temperature for 1-4 hours to 
dissolve the trypsin completely and then filtered through a 0.2 micron pore filter. The 5% trypsin solution 
was stored at -20°C. 
Cell stocks were prepared by trypsinising a 10ml culture of confluent cells and centrifuging at 1 
OOOrpm for 5 minutes to remove additional trypsin. The cell pellet was re-suspended in 800µ1 of FCS with 
10µ1 of DMEM. The Nunc cryotubes (Nunc, Delta , Denmark) of cells were placed on ice and 10µ1 of DMSO 
was immediately added. The cryotubes were then thickly wrapped in paper towel and placed at -70°C for 2 
to 3 days, after which they were transferred to liquid nitrogen for storage. 
B2 Transfection using DOTAP and Fugene6 
Hela cells were grown in a Nunc six well plate (Delta, Denmark) until they were 60-80% confluent. 
The cells were transfected with 30µ1 of DOT AP (Boehringer Mannheim, Hamburg Germany), 2µ1 of pSVNeo-
pgal (Stratagene La Jolla, CA, USA) and 1 OµI of either pcDNA3.1sF1s2 or pcDNA3.1g72A346Ts, according to 
manufacturers' instructions. The pSVNeo-pgal plasmid expresses p-galactosidase. The DOTAP was 
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incubated for 5 minutes at room temperature in HEPES buffer making up a total of 100µ1. The pSVNeo-pgal 
and DNA vaccines were also added to HEPES buffer, made up to 50µ1 and the DNA and DOTAP mixed by 
gently tapping the tube and incubated at RT for 10-15 minutes. The pSVNeo-pgal and DNA vaccine, DOTAP 
mixture was added to the HeLa cells growing in 2ml of fresh DMEM with 10% FCS and PSF and the 
transfected cells were incubated at 37°C with 5-10% CO2 overnight. The DOTAP, DNA mixture was then 
removed and 2ml of DMEM with 10% FCS and PSF added. The cells were incubated at 37°C with 5-10% 
CO2 for two days and X-gal stained (Appendix 85). 
83 Recombinant formation 
CV1 cells were grown to 60-80% confluence in a six well plate. The vaccinia virus (VV) western 
reserve (wr) stock (obtained from John Williamson, St Mary's Hospital, London) was diluted to 3X105 
viruses/ml in virus diluent (DMEM and 1% 1M HEPES) and 0.5ml added to each well. The infected cells 
were incubated at 37°C with 5-10% CO2 for 1 hour with occasional shaking. Instead of DOT AP, FuGene6 
was used as the transfection reagent. Four microlitres of Fugene6 was added to 97µ1 of serum-free medium 
and incubated at room temperature for 5 minutes. Three microl itres of Sea I linearised pSC6591zA347TS 
plasmid, expressing the HIV gp120 gene, was added to the FuGene6 transfection reagent and incubated at 
room temperature for 15 minutes. The VVwr in diluent was removed from the wells and the transfection mix 
was added in 2ml fresh DMEM with 10% FCS and PSF. The transfected, infected cells were incubated at 
37°C with 5-10% CO2 for two to three days until cytopathic effect (cpe) were detected. After cpe were 
detected, the cells were scraped off the plate with a rubber policeman and re-suspended in 200µ1 of virus 
diluent in cryotubes (Nunc, Delta, Denmark). 
The infected cells were frozen in dry ice and ethanol and thawed at 37°C three times to lyse the 
cells and release the virus. The virus was then diluted 1/2 in 500µ1 of virus diluent and added to 80% 
confluent TK. cells. The cells were incubated at 37°C with CO2 for 1 hour with occasional shaking as before 
and the virus removed. 25µg/ml BUdR selection medium (Sigma, St Louis, USA) in 2ml DMEM with 10% 
FCS and PSF was added and the cells incubated for 2 to 3 days until cpe were evident. The medium was 
removed and the infected cells overlayed with 2% low 111elting point agarose at 42°C containing 25µgtml 
BudR and 250µg/ml X-gal to detect recombinant plaques. The agarose mixture was set at RT and the cells 
incubated overnight at 37°C with 5-10% CO2. 
Blue recombinant plaques were picked using a Pasteur pipette with a bulb and added to 200µ1 of 
virus diluent. The infected cells were freeze/thawed as before, diluted 50µ1 into 500µ1 virus diluent and used 
to infect a second plate of 80% confluent TK. cells (Passage 2). The recombinant virus, VV97zA34ns was 
passaged until purely blue recombinant plaques were detected (11 passages) and then used to infect eggs 
for the production of large quantities of virus (see Appendix 84). After virus from eggs was extracted, wild 
type VVwr revertants were detected, thus the virus was passaged a further two times and the virus re-grown 
in eggs. Pure VV91zA347TS was obtained and confirmed by immunofluorescence (see Appendix 86). 
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84 Vaccinia virus propagation in eggs 
Infection of eggs with VV 
A 25ml flask of TK- cells in 5ml of DMEM with 10% FCS and PSF was grown until the cells were 
80% confluent. The cells were infected with 5X105pfu/ml of VV91zA34ns recombinant and incubated for 3 
days, or till cpe were evident. The infected cells were scraped off the bottom of the flask with a rubber 
policeman and saved in the supernatant. The infected cells in supernatant were freeze/thawed three times, 
as before, to release the virus and stored at -70°C. 
In order to infect the eggs, the virus was diluted Yi, 1/5 and 1/10 in 1X PBS and 5 day to 10 day old 
eggs used for infection. The eggs were placed on a rack and marked, using 6 eggs per dilution factor. The 
virus is inoculated onto the amniotic membrane of the egg and to determine where the inoculation site was, 
the eggs were held to a light bulb in the dark. The air sac on round side was identified and marked with a 
pencil. It is best to inoculate near a vein, thus a vein on the top of the egg was also marked with a cross. 
The eggs were returned to the rack and a small hole made in the cross on top of the egg, being careful not 
to break the membrane. A hole was also made in the air sac. The air sac hole was opened with a sterile, 
sharp fountain pen. A drop of sterile 1XPBS containing PS was placed onto the top hole using a Pasteur 
pipette and a drop of melted wax was placed above the hole. The top membrane was loosened with a 
curved, sterile fountain pen to let the PBS run in . The eggs were again looked at over a light and a rubber 
bulb used to suck at the air sac hole making the top membrane drop. The PBS should run onto the top 
amniotic membrane inoculation site. The eggs are incubated for 1. 5 hours in order for the chick to settle. 
600µ1 of recombinant VV91zA347Ts of each dilution factor was sucked into a MODRI 1 ml syringe with a s1ocoR 
25 gauge needle (Disposmedicor, South Africa) and 100µ1 per egg injected into top hole just below surface 
without puncturing the membrane. The wax was scraped over the hole to seal the egg, the eggs were 
swirled slowly to disperse the virus and then replaced in the 37°C incubator for 3 days. 
Extraction of virus 
The desk was lined with a paper towel and sterile forceps and scissors, a petri dish and two bottles 
(100ml each) of physiolog ical saline placed on top. Mcllvaine's buffer and Arklone® (AECI , South Africa) 
were placed on ice. Mcllvaine's buffer was made by adding 1.83ml of solution A (0.1 M citric acid) and 
18.17ml of solution B (0.2M Na2HP04•12H20) to 800ml of sterile distilled water. The pH was adjusted to 7.4 
with the two solutions and made up to 11 with distilled water. The solution was then autoclaved and stored at 
4°C. In addition, 4 McCartney bottles were filled with glass beads up to 2cm from the bottom of the bottle 
and the bottles placed on ice. A metal bucket was lined with a bio-waste bag and placed next to the paper 
towel. 
The pair of scissors was used to cut around sides of the egg from air sac hole, working over the 
bucket. The shell was flapped up and the chick and bottom half of the egg cut away. The dropped 
membrane should be visible with the poxes seen as white dots. The egg shell around the dropped 
membrane was cut away and discarded. The infected membrane was removed with sterile forceps and 
dropped into the first bottle of saline to rinse, followed by a second rinse in the second bottle of saline. The 
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infected membrane was placed in the McCartney bottle with glass beads, using one bottle for 4 membranes. 
One millilitre of Mcllvaine's and 250µ1 of Arklone® per membrane was added. The McCartney bottle lids 
were tightened and the bottles wrapped in paper towel in case of leakage. The bottles were shaken 
vigorously for two minutes to disrupt the infected membrane. 
The disrupted membranes were centrifuged at 1 OOOrpm for 10mins at 4°C and the supernatant 
transferred to 2 fresh McCartney bottles on ice. Four milli litres of Mcllvaine's buffer was added to the glass 
beads and debris and the bottles shaken again for 2 m·nutes. The membranes were re-centrifuged as 
before. The supernatant was again transferred to the McCartney bottles on ice and the supernatant 
incubated on ice for 1.5 hours. The two McCartney bottles were then centrifuged at 2 OOOrpm for 15 minutes 
to remove debris and the supernatant transferred to Beckman® centrifuge bottles. Slowly, 500µ1 of 36% 
sucrose was allowed to run down the side of the tube to form a layer at the bottom and the virus was then 
centrifuged at 11 OOOrpm for 1 hour in the Beckman J2-21 rotor. The supernatant was removed and the 
pellet re-suspended gently overnight in 1 ml Mcllvaine's buffer at 4°C. The re-suspended virus was diluted 
10-3 to 10-9 in virus diluent for virus titration in triplicate. 
Virus titration 
The re-suspended virus diluted 10-3 to 10-9 was used to infect a 24 well plate (Nunc, Delta , 
Denmark) of 80% confluent CV1 cells. 200µ1 of diluted virus was added to each well , using three wells per 
dilution factor. The cells were incubated for 1 hour with occasional shaking at 37°C after which the virus 
was removed and 1 ml of fresh DMEM with 10% FCS and PSF was added. The infected cells were 
incubated at 37°C with 5-10% CO2 for two to three days until cpe was visible after which they were stained 
with Ziehl Neelson Carbol Fuchsin stain for one minute, and the plaques counted. The number of plaques 
was multiplied by 5 to obtain a value per 1 ml. 
B5 X-gal stain 
Transfected cells were incubated for 2 days at 37°C with 5-10% CO2 after which the medium was 
removed and the cells washed in 1X PBS. 1 ml cf 4% para-formaldehyde was added to each well for : 0 
minutes at room temperature to fix the cells. The para-formaldehyde was removed and 1 ml of the X-gal 
stain (working solution in 10mls; 9.2ml 1X PBS, 0.2ml of 50mg/ml X-gal, 0.2ml of 200mM ferricyanide, 
0.2ml of 200mM ferrocyanide and 0.2ml of 200mM MgCl2) was added. The cells were incubated at 37°C 
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overnight and the number of blue cells counted . 
B6 lmmunofluorescence 
Transfected or infected cells were grown on a glass cover-sl ip in a 6 well plate for 2 to 3 days. The 
cells were fixed to the cover-slip with acetone at 4°C for 10 minutes and the cover-slip air dried and washed 
with 1X PBS. 2% ovalbumin was added as blocking reagent for 20 minutes at RT with shaking and then the 
cover-sl ips were washed twice with 1X PBS for 10 minutes each. A 1/300 dilution of the anti-HIV gp120 
goat polyclonal antibody (Biogenetics, Poole, England) containing 1.5% BSA in 1X PBS was added and the 
cells incubated for 1 hour at 37°C. The cover-slip was washed twice with 1X PBS for 10min each and 1/40 
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dilution of rabbit anti-sheep FITC conjugate (DAKO, Glostrup, Denmark) and 200µ1 of Evan's blue counter 
stain in 1X PBS was added and the cover-slip incubated for 1 hour at 37°C. The cells were washed twice 
with 1X PBS for 10 minutes each, rinsed in distilled water and allowed to air dry. The cover-slips were then 
mounted cells down on a slide for fluorescent microscopy using the SM-LUX (Leitz-Wetzlar, Germany) 
fluorescent microscope at 450-490nm wavelength and 40X magnification. Photographs were taken using 
Fug i® Sensia II IL400 film with a 2-3 minute exposure. 
87 Immunisation and challenge of mice 
Direct gene transfer to the tibia/is anterior muscle in mice 
Six to eight week BALB/c males were used for antibody detection, whilst 6-8 week female BALB/c 
mice were used for the in vivo CTL experiment. Forty-eight hours prior to the DNA vaccine immunisation the 
mice were injected with 100µ1 of 0.25% bupivacaine-HCI (Adcock Ingram Pharmaceuticals) using a MODRI 
1 ml syringe with a BIOCOR 25 gauge needle (Disposmedicor, South Africa) with a collar to limit penetration to 
2mm into the tibia/is anterior (TA) muscle, causing localised necrotisation of the muscle. 
After 48 hours, the muscle was regenerating which facilitates uptake of the DNA injected into the 
same site. Mice were anaesthetised using an ether nose-cone, since awake mice contract their muscles and 
squeeze the DNA solution out. Once the mice were asleep, the DNA prepared in endotoxin-free injectable 
1X PBS at 1 mg/ml was injected. Fifty microlitres was injected into each TA muscle using the MODRI 1 ml 
syringe with BIOCOR 25 gauge needle (Disposmedicor, South Africa). The injection was 3mm lateral to the 
anterior tibial tuberos ity (half way between the knee and the ankle), keeping the needle almost perpendicular 
to the tibia. Once the needle was in place, the DNA was injected slowly, over approximately 10 seconds, the 
needle held in place for another 5-10 seconds and then removed slowly. 
Recombinant VV91ZAJ47TS challenge of the mice 
Mice immunised once with DNA vaccine were challenged after nine days with the recombinant 
VV97ZA3ms. The mice were injected with 100µ1 of either 1X107 or 5X107 pfu/ml of virus intraperitoneally 
using the MODRI 1 ml syringe with a BIOCOR 25 gauge needl~ (Disposmedicor, South Africa). After 5 to 8 days 
the mice were sacrificed by lethal inhalation of ether and their necks were broken. Their ovaries were 
removed and extracted (see Appendix 89). 
88 Detection of mouse antibodies 
ELISA plate (Nunc-lmmuno™, Delta, Denmark) wells were coated with 50µ1 of 2µg/ml of HIV1118 gp120 
protein (obtained from the National Institute for Biological Standards and Control (NIBSC) AIDS Reagent 
Project, Hertfordshire, UK) in 0.1 M, pH 7.6 carbonate buffer (sodium carbonate, 1.36 g; sodium 
bicarbonate, 7.35 g and distilled water, 950 ml) overnight at 4°C. The wells were washed with 1X PBS 
contain ing 0.05% Tween-20® and blocked for 1 hour at 37°C in blocking solution (1% Elite® milk powder, 
0.05% Tween-20® in 1X PBS made up fresh weekly) , filling the wells to the top. The plate was then washed 
3 times using LP55 Sanofi plate washer (Pasteur Diagnostics, Paris, France) with 10 second waits in 
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washing buffer (1XPBS with 0.05% Tween-20®). Fifty microlitres of mouse serum diluted to 1/50 in 1X PBS 
was added to duplicate wells and the plate was incubated covered at 37°C in a water bath for 1 hour. 
Controls consisted of coated wells with no serum, and non-coated wells with serum. The plate was washed 
as before using the plate washer. Fifty microlitres of rabbit anti-mouse-HRP conjugate (DAKO, Glostrup, 
Denmark) diluted to 1/600 in blocking solution was added to the wells, including the control wells, in order to 
detect background or contamination. The plate was incubated for 1 hour at 37°C in a water bath and then 
washed as before in the plate washer. Fifty microlitres of freshly made up substrate (DAKO, Glostrup, 
Denmark) (12ml distilled water, 4 OPD tablets and 5µ1 H20 2) was added to each sample well, and to two 
non-coated, empty wells and the plate was incubated at room temperature for 25 to 30 minutes in the dark. 
Fifty microlitres of 1 N H2S04 was added to stop the reaction and the plate was read using the Anthos ELISA 
plate reader (Labtech Instruments) at 492nm with a 620nm filter. 
B9 VV91zA347TS extraction from mouse ovaries 
The two ovaries from each mouse were pooled and weighed once all fat had been removed. The 
ovaries were then placed in a petri dish and finely chopped using a sterile scalpel. The chopped ovaries were 
transferred to a ten broek grinder in Mcllvaine's buffer, using 10µ1 of buffer per 1 mg of mouse ovary tissue 
and subjected to 30 strokes with the grinder. The ground ovary solution was transferred to a 2ml eppendorf 
tube and the ovary extract freeze/thawed three times to lyse any cells which may have remained whole. The 
ovary cell extract was then centrifuged on a benchtop microfuge for 1 minute to remove debris and the 
supernatant transferred to a fresh eppendorf. The VV91zA34TTs recombinant was titrated as before (see 
Appendix 84) and the stock virus stored in aliquotes at -:70°C in Mcllvaine's buffer. 
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APPENDIX D1: AMINO ACID CODE 
Alanine Ala A Leucine Leu L 
Arginine Arg R Lysine Lys K 
Asparagine Asn N Methionine Met M 
Aspartic acid Asp D Phenylalanine Phe F 
Cysteine Cys C Praline Pro p 
Glutamine Gin Q Serine Ser s 
Glutamic acid Glu E Threonine Thr T 
Glycine Gly G Tryptophan Trp w 
Histidine His H Tyrosine Tyr y 
lsoleucine lie I Val ine Val V 
APPENDIX D2: CODONS 
Codon Amino Codon Amino Codon Amino Codon Amino 
Acid Acid Acid Acid 
AAA K CAA Q GAA E TAA * 
AAC N CAC H GAC D TAC y 
AAG K CAG Q GAG E TAG * 
AAT N CAT H GAT D TAT y 
ACA T CCA p GCA A TCA s 
ACC T CCC p GCC A TCC s 
ACG T CCG p GCG A TCG s 
ACT T CCT p GCT A TCT s 
AGA R CGA R GGA G TGA * 
AGC s CGC R GGC G TGC C 
AGG R CGG R GGG G TGG w 
AGT s CGT R GGT G TGT C 
ATA I CTA L GTA V TTA L 
ATC I CTC L GTC V TTC F 
ATG M CTG L GTG V TTG L 
ATT I CTT L GTT V TTT F 
182 
REFERENCES 
Abebe, A. , Kuiken, C.L., Goudsmit, J., Valk, M., Messele, T., Sahlu, T., Yeneneh, H., Fontanet, A., 
de Wolf, F. and Rinke de Wet, T.F. (1997). HIV Type 1 subtype C in Addis Abbaba, 
Ethiopia. AIDS Res. Hum. Retroviruses, 13(12):1071-1075. 
Abimiku, A.G ., Franchini, G., Tartaglia, J., Aldrich, K., Myagkikh , M., Markham, P.O., Chong, P., 
Klein, M., Kieny, M.P., Paoletti , E., et al. (1995). HIV-1 recombinant poxvirus vaccine 
induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med, 1(4):321-
9. 
Achour, A., Bex, F., Hermans, P., Burny, A. and Zagury, D. (1996). Induction of anti-gp160 
cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human 
immunodeficiency virus type 1 envelope-immunized individuals. J Viral, 70(10):6741-50. 
Agadjanyan, M.G. , Trivedi, N.N ., Kudchodkar, S., Bennett, M., Levine, W., Lin , A. , Boyer, J., Levy, 
D., Ugen, K.E., Kim, J.J. and Weiner, D.B. (1997). An HIV type 2 DNA vaccine induces 
cross-reactive immune responses against HIV type 2 and SIV. AIDS Res. Hum. 
Retroviruses, 13(18):1561-72. 
Ahlers, J.D., Dunlop, N., Pendleton, C.D., Newman, M., Nara, P.L. and Berzofsky, J.A. (1996). 
Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit 
type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same , 
adjuvant immunization. AIDS Res Hum Retroviruses, 12(4):259-72. 
Ahlers, J.D., Dunlop, N., Alling , D.W., Nara, P.L. and Berzofsky, J.A. (1997). Cytokine-in-adjuvant 
steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-
macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance 
induction of cytotoxic T lymphocytes. J lmmunol, 158(8):394 7-58. 
Alaeus, A., Leitner, T., Lidman, K. and Albert, J. (1997). Most HIV-1 genetic subtypes have 
entered Sweden. AIDS, 11 (2):199-202. 
Alaeus , A., Lidman, K., Bjorkman, A., Giesecke, J. and Albert, J. (1999). Similar rate of disease 
progression among individuals infected with HIV-1 genetic subtypes A-0. AIDS, 13(8):901-
7. 
Alkhatib, G., Combadiere, C., Broder, C.C., Feng, Y., Kennedy, P.E., Murphy, P.M. , Berger, E.A. 
(1996). CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for 
macrophage-tropic HIV-1 . Science, 272(5270):1955-8. 
Almond, N., Rose, J., Sangster, R. , Silvera, P., Stebbings, R., Walker, B., Stott, E.J. (1997). 
Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. 
Protection cannot be transferred with immune serum. J Gen Viral, 78(8):1919-22. 
Altschul, S.F. , Gish, W., Miller, W., Myers, E.W. and Lipman, D.J. (1990) . Basic local alignment 
search tool. J Mot Biol, 215(3):403-10. 
Arnold, C. , Barlow, K.L., Parry, J.V., Clewley, J.P. (1995). At least five HIV-1 sequence subtypes 
(A, B, C, D, A/E) occur in England . AIDS Res Hum Retroviruses, 11 (3):427-9. 
Artenstein , A.W., Coppola, J., Brown, A.E., Carr, J.K. , Sanders-Buell , E., Galbarini, E., Mascola, 
J.R., Vancott, T.C., Schonbrood, P., and Mccutchan, F.E. (1995). Multiple introductions 
of HIV-1 subtype E into the western hemisphere. Lancet, 346(8984):1197-8. 
Published erratum appears in Lancet, (1995) 346(8986):1376. 
183 
Baba, T.W., Jeong, Y.S., Pennick, D., Bronson, R., Greene, M.F., and Ruprecht, R.M. (1995). 
Pathogenicity of live, attenuated SIV after mucosa! infection of neonatal macaques. 
Science, 267(5205): 1820-5. 
Baba, T.W., Liska, V., Khimani, A.H., Ray, N.B., Dailey, P.J., Penninck, D., Bronson, R., Greene, 
M.F., McClure, H.M., Martin, L.N ., Ruprecht, R.M . (1999). Live attenuated, multiply deleted 
simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med, 
5(2):194-203. 
Bachmann, M.F., KUndig , T.M., Freer, G., Li, Y., Kang, C.Y. , Bishop, D.H., Hengartner, H. and 
Zinkernagel , R.M . (1994 ). Induction of protective cytotoxic T cells with viral proteins. Eur J 
lmmunol, 24:2128-36. 
Balfe, P., Simmonds, P., Ludlam, C.A., Bishop, J.O., Brown, A.J . (1990). Concurrent evolution of 
human immunodeficiency virus type 1 in patients infected from the same source: rate of 
sequence change and low frequency of inactivating mutations. J Viral, 64(12):6221 -33. 
Balter, M. (1998). Chemokine mutation slows progression. Science, 279(5349):327. 
Ban, E.M., van Ginkel, F.W., Simecka, J.W., Kiyono, H., Robinson, H.L. and McGhee, J.R. (1997). 
Mucosa! immunization with DNA encoding influenza hemagglutinin. Vaccine , 15(8):811-3. 
Bandea, C.I., Ramos, A. , Pieniazek, D., Pascu, R. , Tanuri , A. , Schochetman, G. and Rayfield, 
M.A. ( 1995). Epidemiologic and evolutionary relationships between Romanian and 
Brazilian HIV-subtype F strains. Emerg Infect Dis, 1 (3):91-3. 
Sarin, F., Courouce, A.M., Pillonel, J. and Buzelay, L. (1997). Increasing diversity of HIV-1 M 
serotypes in French blood donors over a 10-year period (1985-1995). Retrovirus Study 
Group of the French Society of Blood Transfusion. A/OS, 11 (12):1503-8. 
Barre-Sinoussi, F., Chermann, J.C., Rey, F., Nugeyre, M.T., Chamaret, S., Gruest, J., Dauguet, 
C., Axler-Blin, C. , Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W., Montagnier, L. (1983). 
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune 
deficiency syndrome (AIDS). Science, 220(4599):868-71 . 
Barre-Sinoussi, F. (1996) HIV as the cause of AIDS. Lancet, 348(9019):31-35 (review). 
Barry, M.A. , Johnston, S.A. (1997). Biological features of genetic immunization. Vaccine , 
15(8):788-91 . 
Becker, M.L., De Jager, G. , Becker, W.B. (1995). Analysis of partial gag and env gene sequences 
of HIV type 1 strains from southern Africa . A/OS Res Hum Retroviruses, 11(10):1265-7. 
Belshe, R.B., Clements, M.L., Dolin, R., Graham, S.S., McElrath, J., Gorse, G.J., Schwartz, D., 
Keefer, M.C., Wright, P., Corey, L., et al. (1993). Safety and immunogenicity of a fully 
glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects 
at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine 
Evaluation Group Network. J Infect Dis, 168(6): 1387-95. 
Belshe, R.B., Graham, S.S., Keefer, M.C., Gorse, G.J. , Wright, P., Dolin, R., Matthews, T., 
Weinhold , K., Bolognesi, D.P., Sposto, R. , et al. (1994). Neutralizing antibodies to HIV-1 in 
seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1 . 
NIAID AIDS Vaccine Clinical Trials Network. JAMA, 272(6):475-80. 
Belyakov, I.M., Wyatt, L.S., Ahlers, J.D., Earl , P. , Pendleton, C.D., Kelsall, B.L., Strober, W., 
Moss, B., Berzofsky, J.A. (1998). Induction of a mucosa! cytotoxic T-lymphocyte response 
184 
by intrarectal immunization with a replication-deficient recombinant vaccinia virus 
expressing human immunodeficiency virus 89.6 envelope protein. J Viral, 72(10):8264-72. 
Berger, E.A., Dams, R.W., Fenyo, E.M., Korber, B.T., Littman, D.R., Moore, J.P., Sattentau, Q.J., 
Schuitemaker, H., Sodroski, J., and Weiss, R.A. (1998). A new classification for HIV-1. 
Nature, 391 (6664 ):240. 
Berglund, P., Quesada-Rolander, M., Putkonen, P., Biberfeld, G., Thorstensson, R., Liljestrom, P. 
(1997). Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest 
virus encoding human immunodeficiency virus type 1 envelope protein and challenge with 
a high dose of SHIV-4 virus. A/OS Res Hum Retroviruses, 13(17):1487-95. 
Berman, P.W., Gray, A.M., Wrin, T., Vennari, J.C., Eastman, D.J., Nakamura, G.R., Francis, D.P., 
Gorse, G., Schwartz, D.H. (1997). Genetic and immunologic characterization of viruses 
infecting MN-rgp120-vaccinated volunteers. J Infect Dis, 176(2):384-97. 
Betts, M.R., Krowka, J., Santamaria, C., Balsamo, K., Gao, F., Mulundu, G., Luo, C., N'Gandu, N., 
Sheppard, H., Hahn, B.H., Allen , S. and Frelinger, J.A. (1997). Cross-clade human 
immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected 
Zambians. J Viral, 71 (11 ):8908-11. 
Binder, D. and KOndig, T.M. (1991 ). Antiviral protection by CD8+ versus CD4+ T cells: CD8+ T 
cells correlating with cytolytic activity in vitro are more efficient in antivaccinia virus 
protection than CD4-dependent IL. J lmmunol, 146(12):4301-7. 
Binns, M.M. and Smith G.L. Eds. (1992). Recombinant poxviruses. CRC Press, Boca Raton, Ann 
Arbor, London and Tokyo. 
Bjorndal, A., Sonnerborg, A., Tscherning, C., Albert, J. and Fenyo, E.M. (1999). Phenotypic 
charactersitics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian 
AIDS patients. A/OS Res Hum Retroviruses, 15(7):647-53. 
aBobkov, A., Cheingsong-Popov, R., Garaev, M., Rzhaninova, A., Kaleebu, P., Beddows, S., 
Bachmann, M.H., Mullins, J.I., Louwagie, J., Janssens, W., van der Groen, G., Mccutchan, 
F. and Webber, J. (1994). Identification of an env G subtype and hetergeneity of HIV-1 
strains in the Russian Federation and Belarus. A/OS, 8:1649-55. 
bBobkov, A., Garaev, M.M., Rzhaninova, A., Kaleebu, P., Pitman, R., Weber, J.N., Cheingsong-
Popov, R. (1994). Molecular epidemiology of HIV-1 in the former Soviet Union: analysis of 
env V3 sequences and their correlation with epidemiologic data. A/OS, 8(5):619-24. 
aBobkov, A. , Cheingsong-Popov, R., Karasyova, N., Selimova, L., Kravchenko, A., Bochkova, M., 
Kazennova, E., Ladnaya, N., Pokrovsky, V. and Weber, J. (1996). Sequence analysis of 
the glycoprotein 120 coding region of a new human immunodeficiency virus type 1 subtype 
G strain from Russia. A/OS Res Hum Retroviruses, 12(14):1385-8. 
bBobkov, A., Cheingsong-Popov, R., Selimova, L., Kazennova, E., Karasyova, N., Kravchenko, 
A., Ladnaya, N. , Pokrovsky, V. and Weber, J. (1996). Genetic heterogeneity of HIV type 1 
in Russia: identification of H variants and relationship with epidemiological data. A/OS Res 
Hum Retroviruses, 12(18):1687-90. 
Bobkov, A., Cheingsong-Popov, R., Selimova, L., Ladnaya, N., Kazennova, E., Kravchenko, A., 
Pokrovsky, V. and Weber, J. (1997) HIV type 1 subtype E in Russia. A/OS Res Hum 
Retroviruses, 13(8):725-7. 
185 
Bobkov, A., Kazennova, E., Selimova, L., Bobkova, M., Khanina, T. , Ladnaya, N., Kravchenko, A., 
Pokrovsky, V., Cheingsong-Popov, R. and Weber, J. (1998). A sudden epidemic of HIV 
type 1 among injecting drug users in the former Soviet Union: identification of subtype A, 
subtype B, and novel gagA/envB recombinants. A/OS Res Hum Retroviruses, 14(8):669-
76. 
Bogers, W.M., Niphuis, H., ten Haaft, P., Laman, J.D., Koornstra, W., Heeney, J.L. (1995) . 
Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in 
rhesus macaques infected with attenuated SIV: consequences of challenge. A/OS, 12:F13-
8. 
Borrow, P. , Lewicki, H., Wei, X., Horwitz, M.S., Peffer, N., Meyers, H., Nelson, J.A., Gairin, J.E., 
Hahn, B.H., Oldstone, M.B., Shaw, G.M. (1997). Antiviral pressure exerted by HIV-1-
specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid 
selection of CTL escape virus. Nat Med, 3(2):205-11 . 
Boyer, J.D., Ugen, K.E. , Wang, B., Agadjanyan , M., Gilbert, L., Bagarazzi, M.L., Chattergoon, M., 
Frost, P. , Javadian, A., Williams, W.V., Refaeli , Y., Ciccarelli, R.B., McCallus, D., Coney, L. 
and Weiner, D.B. (1997). Protection of chimpanzees from high-dose heterologous HIV-1 
challenge by DNA vaccination . Nat Med, 3(5):526-32. 
Boyer, J.D., Chatergoon, M.A., Ugen, K.E., Shah, A., Bennet, M., Cohen , A., Nyland, S., Lacy, 
K.E., Bagarazzi, M.L. , Higgins, M.L., Baine, T.J., Ciccarelli, R.B., Ginsberg, R.S., 
MacGregor, R.R. and Weiner, D.B. (1999). Enhancement of cellular immune response in 
HIV-1 seropositive individuals: A DNA-based Trial. Clinical Immunology, 90:100-7. 
Boyle JS, Brady, J.L. and Lew, A.M . (1998). Enhanced responses to a DNA vaccine encoding a 
fusion antigen that is directed to sites of immune induction . Nature, 392(6674):408-11 . 
Braaten, D., Franke, E.K and Luban, J. (1996). Cyclophilin A is required for the replication of 
group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus 
SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses . J Viral, 
70(7):4220-7. 
Brain, P. and Hammond, M.G. (1972). Frequency of HLA antigens in South African Bantu, Indians 
and Caucasians. In Histocompatibility Testing, Eds. Dausset, J. and Colombani, J. , 
Munksgaard, Copenhagen. pp433-439. 
Brander, C and Walker B.D. (1995). The HLA-class 1 restricted CTL response in HIV-1 infection : 
identification of optimal epitopes. In Human Retroviruses and AIDS: A Compilation and 
Analysis of Nucleic Acid and Amino Acid Sequences. Eds. Myers, G., Korber, B., Hahn, 
B.H., Jeang, K.T., Mellors, J.W., Mccutchan, F.E., Henderson, L.E. and Pavlakis, G.N. 
Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, 
New Mexico. 
Brand, D., Mallet, F. , Truong, C., Roingeard, P., Goudeau, A. and Barin , F. (1995). A simple 
procedure to generate chimeric Pr55gag virus-like particles expressing the principal 
neutralization domain of human immunodeficiency virus type 1. J Viral Methods, 51 (2-
3):153-68. 
Bredell, H., Williamson, C., Sonnenberg, P., Martin, D.J. and Morris, L. (1998). Genetic 
Characterization of HIV Type 1 from Migrant Workers in Three South African Gold Mines. 
AIDS Res Hum Retroviruses, 14(8):677-84. 
Brigida, L.F.M., Rossini, M., Santos, I., Santana, C. and Oliviera, C. (1998). HIV-1 subtypes 
circulating in Sao Paulo Brazil. 12th World AIDS Conference, Geneva, abs 13162. 
186 
Broder, C.C., Earl, P.L., Long, D., Abedon, S.T., Moss, B. and Dams, R.W. (1994). Antigenic 
implications of human immunodeficiency virus type 1 envelope quaternary structure: 
oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci U S A, 
91 (24):11699-703. 
Brodine, S.K., Mascola, J.R., Weiss, P.J. , Ito, S.I., Porter, K.R., Artenstein, A.W., Garland, F.C. , 
Mccutchan, F.E and Burke, D.S. (1995). Detection of diverse HIV-1 genetic subtypes in 
the USA. Lancet, 346(8984):1198-9. 
Brown, A.J ., Lobidel, D., Wade, C.M., Rebus, S., Phillips, A.N ., Brettle, R.P ., France, A.J ., Leen, 
C.S., McMenamin, J., McMillan, A., Maw, R.D., Mulcahy, F., Robertson, J.R., Sankar, K.N., 
Scott, G., Wyld, R. and Peutherer, J.F. (1997). The molecular epidemiology of human 
immunodeficiency virus type 1 in six cities in Britain and Ireland. Virology, 235(1):166-77. 
Bruck, C., Thiriart, C., Fabry, L., Francotte, M., Pala, P., van Opstal, 0 ., Culp, J., Rosenberg, M., 
De Wilde, M., Heidt. P., et al. (1994). HIV-1 envelope-elicited neutralizing antibody titres 
correlate with protection and virus load in chimpanzees. Vaccine, 12(12):1141-8. 
BrUhl , P., Kerschbaum, A., Eibl, M.M., Mannhalter, J.W. (1998). An experimental prime-boost 
regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice. 
AIDS Res Hum Retroviruses, 14(5):401-7. 
Bukawa, H., Sekigawa, K., Hamajima, K., Fukushima, J., Yamada, Y., Kiyono, H., Okuda, K. 
(1995). Neutralization of HIV-1 by secretory lgA induced by oral immunization with a new 
macromolecular multicomponent peptide vaccine candidate. Nat Med, 1 (7):681-5. 
Burton, D.R. (1997) A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci US A, 
94(19):10018-23. 
Calarota, S., Bratt, G. , Nordlund, S., Hinkula, J., Leandersson, A.C. , Sandstrom, E. and Wahren, 
B. (1998) . Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected 
patients. Lancet, 351 (9112):1320-5. 
Caley, I.J., Betts, M.R., lrlbeck, D.M., Davis, N.L., Swanstrom, R. , Frelinger, J.A. and Johnston, 
R.E. (1997). Humoral, mucosal, and cellular immunity in response to a human 
immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine 
encephalitis virus vaccine vector. J Viral, 71(4):3031-8. 
Campondonico, M., Fay, F., Taborda, M. and Fay, 0 . (1998). At least four genotypes circulate in 
Rosario, Argentina. 12 World AIDS Conference, Geneva, abs 13175. 
Cannon, P.M., Matthews, S., Clark, N., Byles, E.D. , lourin, 0 ., Hockley, D.J., Kingsman, S.M., 
Kingsman, A.J . (1997). Structure-function studies of the human immunodeficiency virus 
type 1 matrix protein , p17. J Viral, 71(5):3474-83. 
Cao, H., Kanki, P., Sankale, J.L., Dieng-Sarr, A., Mazzara, G.P., Kalams, S.A., Korber, B., Mboup, 
S., Walker, B.D. (1997). Cytotoxic T-lymphocyte cross-reactivity among different human 
immunodeficiency virus type 1 clades: implications for vaccine development. J Viral, 
71 (11 ):8615-23. 
Carotenuto, P., Looij, D., Keldermans, L., de Wolf, F., Goudsmit, J. (1998). Neutralizing antibodies 
are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-
free infection. AIDS, 12(13):1591-600. 
187 
aCarr, J.K., Foley, B.T., Leitner, T., Korber, B. and Mccutchan. F. (1998). Reference Sequences 
Representing the Principal Genetic Diversity of HIV-1 in the Pandemic. HIV sequence 
database. http://hiv-web.lanl .gov/HTML/reviews/reviews.html 
bCarr, J.K., Salminen, M.O., Albert, J., Sanders-Buell, E., Gotte, D., Birx, D.L. , Mccutchan, F.E. 
(1998). Full genome sequences of human immunodeficiency virus type 1 subtypes G and 
A/G intersubtype recombinants. Virology, 247(1 ):22-31. 
Carr, J.K., Laukkanen , T., Salminen, M.O., Albert, J., Alaeus, A., Kim, B., Sanders-Buell, E., Birx, 
D.L., Mccutchan, F.E. (1999). Characterization of subtype A HIV-1 from Africa by full 
genome sequencing. A/OS, 13(14):1819-26. 
Chakrabarti, S., Brechling, K. and Moss, B. (1985). Vaccinia virus expression vector: 
coexpression of beta-galactosidase provides visual screening of recombinant virus 
plaques. Mo/ Cell Biol, 5(12):3403-9. 
Chan, D.C., Fass, D., Berger, J.M., Kim, P.S. (1997). Core structure of gp41 from the HIV 
envelope glycoprotein. Ce//, 89(2):263-73. 
Charneau, P., Borman, A.M., Quillent, C., Guetard, D. , Chamaret, S., Cohen, J., Remy, G., 
Montagnier, L., and Clave!, F. (1994). Isolation and envelope sequence of a highly 
divergent HIV-1 isolate:definition of a new HIV-1 group. Virology, 205:247-253. 
Charbit, A., Martineau, P., Ronco, J., Leclerc, C., Lo-Man, R., Michel, V. , O'Callaghan, D. and 
Hofnung, M. (1993). Expression and immunogenicity of the V3 loop from the envelope of 
human immunodeficiency virus type 1 in an attenuated aroA strain of Salmonella 
typhimurium upon genetic coupling to two Escherichia coli carrier proteins. Vaccine, 
11(12):1221-8. 
Cheingsong-Popov, R., Bobkov, A., Garaev, M.M., Kaleebu, P., Callow, D., Rzhiminova, A., 
Saukhat, S.R., Burdajev, N.P., Kolomijets, N.D. and Weber, J.N. (1993). Identification of 
human immunodeficiency virus type 1 subtypes and their distribution in the Commonwealth 
of Independent States (Former Soviet Union) by serologic V3 peptide-binding assays and 
V3 sequence analysis. J Infect Dis, 168(2):292-7. 
Cheingsong-Popov, R., Williamson, C., Lister, S., Morris, L., van Harmelen, J., Bredell, H., Wood, 
R. Sonnenberg, P., Van der Ryst, E., Martin, D. and Weber, J. (1998). Usefulness of HIV-1 
V3 serotyping in studying the HIV-1 epidimic in South Africa. A/OS 12(8):949-966. 
Chen, B.K., Gandhi, R.T. and Baltimore, D. (1996). CD4 down-modulation during infection of 
human T cells with human immunodeficiency virus type 1 involves independent activities of 
vpu, env, and nef. J Viral, 70(9):6044-53. 
Chen, S.C., Fynan, E.F., Robinson, H.L., Lu, S., Greenberg, H.B., Santoro, J.C. and Herrmann, 
J.E. (1997). Protective immunity induced by rotavirus DNA vaccines. Vaccine , 15(8):899-
902. 
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.O., Wu, L., Mackay, C.R., 
LaRosa, G., Newman, W., Gerard, N., Gerard, C. and Sodroski, J. (1996). The beta-
chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Ce//, 
85:1135-48. 
Christodoulou, C., Poullikas, M., Neumann, A.U., Kostrikis, LG. (1997). Low frequency of CCR5 
delta32 allele among Greeks in Cyprus. AIDS Res Hum Retroviruses, 13(16):1373-4. 
188 
Chuenchitra, T., Ratto-Kim, S., De Souza, M., Rungruengthanakit, K., Nitayaphan, S., 
Khamboonruang, C., Chuenchitra, C., Michael, R.A. , Sinangil, F., Duliege, A.M., McNeil , 
J.G. and Birx, D.L. (1998). HIV-1 cross-clade lymphoproliferative responses following 
immunisation with recombinant gp120 SF2. 12th World AIDS Conference, Geneva, abs 
21201 . 
Churdboonchart, V., Moss, R.B., Sirawaraporn, W., Smutharaks, B., Sutthent, R., Jensen, F.C., 
Vacharak, P. , Grimes, J., Theofan, G., Carlo, D.J. (1998). Effect of HIV-specific immune-
based therapy in subjects infected with HIV-1 subtype E in Thailand . AIDS, 12(12):1521-7. 
Coffin, J., Haase, A., Levy, J.A., Montagnier, L., Oroszlan, S., Teich, N., Temin, H., Toyoshima, 
K., Varmus, H. and Vogt, P. et al. (1986). Human immunodeficiency viruses. Science, 
232(4 751 ):697. 
Connor, R.I., Korber, B.T., Graham, B.S., Hahn, B.H., Ho, D.D., Walker, B.D., Neumann, A.U ., 
Vermund, S.H., Mestecky, J., Jackson, S., Fenamore, E., Cao, Y., Gao, F., Kalams, S., 
Kunstman, K.J ., McDonald, D., McWilliams, N., Trkola, A., Moore, J.P.and Wolinsky, S.M. 
(1998). Immunological and virological analyses of persons infected by human 
immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit 
vaccines. J Viral, 72(2):1552-76. 
Cook, J. , and Barber, B.H. (1997). Recombinant antibodies with conformationally constrained HIV 
type 1 epitope inserts elicit glycoprotein 160-specific antibody responses in vivo. AIDS Res 
Hum Retroviruses, 13(6):449-60. 
Cornelissen, M., Kampinga, G., Zorgdrager, F., Goudsmit, J. (1996). Human immunodeficiency 
virus type 1 subtypes defined by env show high frequency of recombinant gag genes. The 
UNAIDS Network for HIV Isolation and Characterization. J Viral, 70(11):8209-12. 
Cranage, M.P., Baskerville, A., Ashworth, L.A., Dennis, M., Cook, N., Sharpe, S., Farrari, G., 
Rose, J., Kitchin , P.A., Greenaway, P.J. (1992). lntrarectal challenge of macaques 
vaccinated with formalin-inactivated simian immunodeficiency virus. Lancet, 
339(8788):273-4. 
Cranage, M.P., Whatmore, A.M., Sharpe, S.A., Cook, N., Polyanskaya, N., Leech, S., Smith, J.D., 
Rud, E.W., Dennis, M.J . and Hall, G.A. (1997). Macaques infected with live attenuated 
SIVmac are protected against superinfection via the rectal mucosa. Virology, 229(1 ):143-
54. 
Cryz, S.J. Jr, Goldstein, H., Pettoello-Mantovani , M., Kim, A. , Furer, E., Que, J.U., Hasler, T. and 
Rubinstein, A. (1995). Human immunodeficiency virus-1 principal neutralizing domain 
peptide-toxin A conjugate vaccine. Vaccine, 13(1 ):67-71 . 
Csillag, C. (1994). HIV-1 subtype C in Brazil. Lancet, 344(8933):1354 (letter) . 
Dagert, M. and Ehrlich, S.D. (1979). Prolonged incubation in calcium chloride improves the 
competence of Escherichia coli cells . Gene, 6(1 ):23-8. 
Daniel , M.D., Kirchhoff, F., Czajak, S.C., Sehgal , P.K. and Desrosiers, R.C. (1992). Protective 
effects of a live attenuated SIV vaccine with a deletion in thenef gene. Science, 
258(5090):1938-41 . 
Daniel , M.D., Mazzara, G.P., Simon, M.A., Sehgal, P.K., Kodama, T., Panicali, D.L. and 
Desrosiers, R.C. (1994). High-titer immune responses elicited by recombinant vaccinia 
virus priming and particle boosting are ineffective in preventing virulent SIV infection . AIDS 
Res Hum Retroviruses, 10(7):839-51 . 
189 
Davis, H.L., Brazolot, Millan, C.L., Mancini, M., McCluskie, M.J., Hadchouel, M., Comanita, L. , 
Tiollais, P., Whalen, R.G. and Michel, M.L. (1997) . DNA-based immunization against 
hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice. Vaccine, 
15(8):849-52. 
Deacon NJ , Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, 
Greenway AL, Ellett A, Chatfield C, et al. (1995). Genomic structure of an attenuated quasi 
species of HIV-1 from a blood transfusion donor and recipients. Science 270(5238):988-
91 . 
Dean, M., Carrington, M., Winkler, C., Huttley, G.A., Smith, M.W., Allikmets, R., Goedert, J.J., 
Buchbinder, S.P., Vittinghoff, E., Gomperts, E., Danfield, S., Vlahov, D., Kaslow, R., Saah, 
A., Rinaldo, C., Detels, R. and O'Brien, S.J. (1996). Genetic restriction of HIV-1 infection 
and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia 
Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia 
Cohort Study, San Francisco City Cohort, ALIVE Study. Science, 273(5283):1856-62 
Published erratum appears in Science, (1996) 274(5290):1069. 
de Francesco, M.A., Caruso, A., Fallacara, F., Canaris, AD., Dima, F. , Poiesi, C., Licenziati, S., 
Corulli, M., Martinelli, F., Fiorentini, S. and Turano, A. (1998). HIV p17 enhances 
lymphocyte proliferation and HIV-1 replication after binding to a human serum factor. AIDS, 
12(3):245-52. 
Decasas, J., Kane, F., Anarfi, J.K., Sodji , K.D. and Wagner, H.U. (1995). Migration and AIDS. 
Lancet, 346(8978):826-8. 
del Amo, J., Petruckevitch, A., Phillips , A.N ., Johnson, A.M ., Stephenson, J.M., Desmond, N., 
Hanscheid, T. , Low, N., Newell , A. , Obasi, A., Paine, K., Pym, A. , Theodore, C.M., De 
Cock, K.M. (1996). Spectrum of disease in Africans with AIDS in London . AIDS, 
10(13):1563-9. 
De Leys, R. , Vanderborght, B., vanden Haesevelde, M., Heyndrickx,L., van Geel A., Wauters, C., 
Bernaerts, R., Saman, E., Nijs, P., Willems, B., Taelman, H., van der Groen, G., piot, P., 
Tersmette, T., Huisman, J.G. and van Heuverswyn, H. (1990). Isolation and partial 
characterisation of an unusual human inmmunodeficiency retrovirus from two persons of 
west-central African origin . J. Viral, 64:1207-90. 
del Guercio, M.F., Sidney, J., Hermanson, G., Perez, C., Grey, H.M., Kubo, R.T., Sette, A. 
(1995). Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like 
supertype. J lmmunol, 154(2):685-93. 
Delwart, E.L., Shpaer, E.G., Louwagie, J., Mccutchan, F.E., Grez, M., Rubsamen-Waigmann, H. 
and Mullins, J.I. (1993). Genetic relationships determined by a DNA heteroduplex mobility 
assay: analysis of HIV-1 env genes. Science, 262(5137):1257-61. 
Demi, L., Schirmbeck, R. , Reimann, J., Wolf, H. and Wagner, R. (1997). Recombinant human 
immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins 
induce cytotoxic T-cells and neutralizing antibodies. Virology, 235(1 ):26-39. 
Deng, H.K., Unutmaz, D., Kewal Ramani, V.N. and Littman, D.R. (1997). Expression cloning of 
new receptors used by simian and human immunodeficiency viruses. Nature, 
388(6639) :296-300. 
190 
Department of Health, Republic of South Africa. (1998). Eighth National HIV survey of women 
attending antenatal clinics of the Public Health Services, October/November 1997. Health 
systems research and epidemiology. 
Department of Health, Republic of South Africa. (1999). Ninth National HIV survey of women 
attending antenatal clinics of the Public Health Services, October 1998. Health systems 
research and epidemiology. 
Deprez, B., Sauzet, J.P., Boutillon, C., Martinon, F., Tartar, A., Sergheraert, C., Guillet, J.G., 
Gomard, E. and Gras-Masse, H. (1996). Comparative efficiency of simple lipopeptide 
constructs for in vivo induction of virus-specific CTL. Vaccine, 14(5):375-82. 
de Rocquigny, H., Petitjean, P., Tanchou, V., Decimo, D., Drouot, L., Delaunay, T., Darlix, J.L. 
and Roques, B.P. (1997). The zinc fingers of HIV nucleocapsid protein NCp7 direct 
interactions with the viral regulatory protein Vpr. J Biol Chem, 272(49):30753-9. 
de Roda Husman, A.M. and Schuitemaker, H. (1998). Chemokine receptors and the clinical 
course of HIV-1 infection. Trends Microbial, 6(6):244-9. 
Desgranges, C., Filion, S., Letourneur, F., Buzelay, L., Sepulveda, C., Guzman, M.A., Afani, A., 
Barin, F and Saragosti, S. (1998). HIV-1 subtypes in Santiago, Chile. AIDS, 12(12):1563-5. 
Desrosiers, R.C. , Lifson, J.D., Gibbs, J.S., Czajak, S.C., Howe, A.Y., Arthur, L.O. and Johnson, 
R.P. (1998). Identification of highly attenuated mutants of simian immunodeficiency virus. J 
Viral, 72(2):1431-7. 
de Wolf, F., Hogervorst, E., Goudsmit, J., Fenyo, E.M., Rubsamen-Waigmann, H., Holmes, H., 
Galvao-Castro, B., Karita, E., Wasi , C. and Sempala, S.D., et al. (1994). Syncytium-
inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 
subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV 
Isolation and Characterization. AIDS Res Hum Retroviruses, 10(11):1387-400. 
Dietrich, U., Grez, M., van Briesen, H., Panhans, B., Geissendorfer, M. , Kuhnel , H., Maniar, J., 
Mahambre, G., Becker, W.B. and Becker, M.L., et al. (1993). HIV-1 strains from India are 
highly divergent from prototypic African and US/European strains, but are linked to a South 
African isolate. AIDS, 7(1):23-7. 
Dietrich, U., Ruppach, H., Gehring, S., Knechten, H., Knickmann, M., Jager, H., Wolf, E., Husak, 
R., Orfanos, C.E., Brede, H.D., Rubsamen-Waigmann, H. and van Briesen, H. (1997). 
Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance 
mutations among German seroconvertors. AIDS, 11 (12):1532-3. 
Dittmar, M.T., Simmons, G., Hibbitts, S., O'Hare, M., Louisirirotchanakul, S., Beddows, S., Weber, 
J. , Clapham, P.R. and Weiss, R.A. (1997). Langerhans cell tropism of human 
immunodeficiency virus type 1 subtype A through F isolates derived from different 
transmission groups. J Viral, 71(10):8008-13. 
Doherty, P.C., Allan, W., Boyle, D.B., Coupar, B.E.H. and Andrew, M.E. (1989). Recombinant 
vaccinia viruses and the development of immunisation strategies using influenza virus . J 
Infect Dis, 159(6): 1119-21 . 
Dams, R.W. and Moore, J.P. (1997). HIV-1 Co-receptor Use: A molecular window into viral 
tropism. Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and 
Amino Acid Sequences. Eds. Korber, B., Hahn, B., Foley, B., Mellors, J.W., Leitner, T., 
Myers, G., Mccutchan, F. and Kuiken, C.L. Theoretical Biology and Biophysics Group, Los 
Alamos National Laboratory, Los Alamos, New Mexico. pplll 1-12. 
191 
Donnelly, J.J ., Friedman, A. , Ulmer, J.B. and Liu, M.A. (1997). Further protection against antigenic 
drift of influenza virus in a ferret model by DNA vaccination . Vaccine 15(8):865-8. 
Doranz, B.J ., Rucker, J., Yi, Y., Smyth, R.J., Samson, M., Peiper, S.C., Parmentier, M., Collman, 
R.G. and Doms, R.W. (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the 
beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Ce//, 
85(7):1149-58. 
Dorfman, T., Mammano, F., Haseltine, W.A. and Gottlinger, H.G. (1994). Role of the matrix 
protein in the virion association of the human immunodeficiency virus type 1 envelope 
glycoprotein. J Viral, 68(3):1689-96. 
Dunn, D.T., Newell, M.L., Ades, A.E. and Peckham, C.S. (1992). Risk of human 
immunodeficiency virus type 1 transmission through breastfeeding. Lancet, 340(8819):585-
8. 
Durali , D. , Morvan, J., Letourneur, F., Schmitt, D. , Guegan, N., Dalod, M., Saragosti, S., Sicard, 
D., Levy, J.P. and Gomard, E. (1998). Cross-reactions between the cytotoxic T-lymphocyte 
responses of human immunodeficiency virus-infected African and European patients. J 
Viral, 72(5):354 7-53. 
Dusheiko, G.M ., Brink, B.A., Conradie, J.D. , Marimuthu, T. and Sher, R. (1989). Regional 
prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern 
Africa: a large population survey. Am J Epidemiol, 129( 1 ): 138-45. 
Du Toit, E.D., MacGregor, K.J., Taljaard, D.G. and Oudshoorn, M. (1998). HLA-A, B, C, DR and 
DQ polymorphisms in three South African popultion groups: South African Negros, Cape 
Coloureds and South African Caucasoids. Tissue Antigens, 31 : 109-125. 
Dybul , M., Weissman, D., Rubbert, A., Machado, E., Cohn, M., Ehler, L. , O'Callahan, M., Mizell, S. 
and Fauci, A.S. (1998). The role of dendritic cells in the infection of CD4+ T cells with the 
human immunodeficiency virus: use of dendritic cells from individuals homozygous for the 
delta32CCR5 allele as a model. AIDS Res Hum Retroviruses, 14(13):1109-13. 
Eckhart, L., Raffelsberger, W. , Ferko, B., Klima, A., Purtscher, M., Katinger, H. and Ruker, F. 
(1996). lmmunogenic presentation of a conserved gp41 epitope of human 
immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen 
Viral, 77(9):2001-8. 
Eko, F.O., Szostak, M.P., Wanner, G. and Lubitz, W. (1994). Production of Vibrio cholerae ghosts 
(VCG) by expression of a cloned phase lysis gene: potential for vaccine development. 
Vaccine , 12:1231 -1237. 
Emini , E.A. , Nara, P.L. , Schleif, W.A. , Lewis, J.A., Davide, J.P., Lee, D.R., Kessler, J., Conley, S., 
Matsushita, S. and Putney, S.D. (1990). Antibody-mediated in vitro neutralization of human 
immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Viral, 64(8):3674-8. 
Engelbrecht, S., Laten, J.D., Smith, T.L. , and van Rensburg , E.J. (1995). Identification of env 
subtypes in fourteen HIV type 1 isolates from South Africa. AIDS Res Hum Retroviruses, 
11(10):1269-1271 . 
Engelbrecht, S. , Koulinska, I., Smith, T.L., Barreto, J. and van Rensburg , E.J. (1998). Variation in 
HIV type 1 V3 region env sequences from Mozambique. AIDS Research and Human 
Retroviruses, 14(9):803-805. 
192 
Engelstad, M. (1996) Genetic diversity of env V3 loop sequences in HIV type 1-infected 
homosexuals, heterosexuals, intravenous drug users, and hemophilia patients in norway: 
high prevalence of subtype B and detection of subtype C. A/OS Res Hum Retroviruses, 
12(18):1733-8. 
Essex, M., Soto-Ramirez, L.E., Renjifo, E., Wang, W.K. and Lee, T.H. (1997). Genetic variation 
within human immunodeficiency viruses generates rapid changes in tropism, virulence, 
and transmission. Leukemia, Suppl 3:93-4. 
European Commision, (DG XII, INCO DC) and Joint United Nations Programme on HIV/AIDS 
Workshop Report, EC/UNAIDS. (1997). HIV-1 subtypes: implications for epidemiology, 
pathogenicity, vaccines and diganostics. A/OS, 11 :UNAIDS 17-36. 
Evans, D.J ., McKeating, J., Meredith, J.M., Burke, K.L., Katrak, K., John, A., Ferguson, M., Minor, 
P.O., Weiss, R.A. and Almond, J.W. (1989). An engineered poliovirus chimaera elicits 
broadly reactive HIV-1 neutralizing antibodies. Nature, 339(6223):385-8, 340. 
Farzan, M., Choe, H., Martin, K., Marcon, L., Hofmann, W., Karlsson, G., Sun, Y., Barrett, P., 
March, N., Sullivan, N., Gerard, N., Gerard, C. and Sodroski, J. (1997). Two orphan seven-
transmembrane segment receptors which are expressed in CD4-positive cells support 
simian immunodeficiency virus infection. J Exp Med, 186(3):405-11. 
Feng, Y., Broder, C.C., Kennedy, P.E. and Berger, E.A. (1996). HIV-1 entry cofactor: functional 
cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 
272(5263):872-7. 
Fenyo, E.M., Schuitemaker, H., Asjo, B., McKeating, J., Sattentau, Q. and the EC Concerted 
Action HIV Variability. (1997). The History of HIV-1 Biological Phenotypes Past, Present 
and Future. Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid 
and Amino Acid Sequences. Eds. Korber, B., Hahn, B., Foley, B., Mellors, J.W., Leitner, T., 
Myers, G., Mccutchan, F. and Kuiken, C.L. Theoretical Biology and Biophysics Group, Los 
Alamos National Laboratory, Los Alamos, New Mexico. pplll 13-18. 
Ferrari, G., Humphrey, W., McElrath, M.J., Excler, J.L., Duliege, A.M., Clements, M.L., Corey, 
L.C., Bolognesi, D.P. and Weinhold, K.J. (1997). Clade B-based HIV-1 vaccines elicit 
cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad 
Sci US A, 94(4):1396-401. 
Figueroa, J.P., Brathwaite, A.R. , Wedderburn, M., Ward, E., Lweis-Bell, K., Amon, J.J., Williams, 
Y. and Williams, E. (1998). Is HIV/STD control in Jamaica making a difference? A/OS, 
12(Suppl 2):S89-98. 
Fleury, B., Janvier, G., Pialoux, G., Buseyne, F., Robertson, M.N., Tartaglia, J., Paoletti, E., Kieny, 
M.P., Excler, J.L. and Riviere, Y. (1996). Memory cytotoxic T lymphocyte responses in 
human immunodeficiency virus type 1 (HIV-1 )-negative volunteers immunized with a 
recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant 
gp160. J Infect Dis, 174(4):734-8. 
Foresman, L., Jia, F., Li, Z., Wang, C., Stephens, E.B., Sahni, M., Narayan, 0. and Joag, S.V. 
(1998). Neutralizing antibodies administered before, but not after, virulent SHIV prevent 
infection in macaques. A/OS Res Hum Retroviruses, 14(12):1035-43. 
Fouchier, R.A., Groenink, M., Kootstra, N.A., Tersmette, M., Huisman, H.G., Miedema, F. and 
Schuitemaker, H. (1992). Phenotype-associated sequence variation in the third variable 
domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol, 66(5):3183-
7. 
193 
Frankel, S.S., Steinman, R.M ., Michael, N.L., Kim, S.R., Bhardwaj, N., Pope, M., Louder, M.K., 
Ehrenberg, P.K., Parren, P.W., Burton, D.R., Katinger, H., Vancott, T.C., Robb, M.L., Birx, 
D.L. and Mascola, J.R. (1998). Neutralizing monoclonal antibodies block human 
immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J 
Viral, 72(12):9788-94. 
Fuller, D.H ., Corb, M.M., Barnett, S., Steimer, K. and Haynes, J.R. (1997). Enhancement of 
immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. 
Vaccine , 15(8):924-6. 
Fynan, E.F., Webster, R.G ., Fuller, D.H., Haynes, J.R., Santoro, J.C. and Robinson, H.L. (1993). 
DNA vaccines: protective immunizations by parenteral, mucosa!, and gene-gun 
inoculations. Proc Natl Acad Sci US A, 90(24):11478-82. 
Gao, F., Yue, L. , White, A.T., Pappas, P.G., Barchue, J., Hanson, A.P ., Greene, B.M., Sharp, 
P.M. , Shaw, G.M., Hahn, B.H. (1992). Human infection by genetically diverse SIVSM-
related HIV-2 in west Africa. Nature, 358(6386):495-9. 
Gao, F., Yue, L. , Craig, S., Thornton, C.L., Robertson, D.L. , Mccutchan, F.E., Bradac, J.A., 
Sharp, P.M.and Hahn, B.H. (1994). Genetic variation of HIV type 1 in four World Health 
Organization-sponsored vaccine evaluation sites: generation of functional envelope 
(glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO 
Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses, 10(11 ):1359-
68. 
aGao, F. , Morrison, S.G., Robertson, D.L., Thornton, C.L., Craig, S., Karlsson, G., Sodroski, J., 
Morgado, M., Galvao-Castro, B., van Briesen, H., et al. (1996). Molecular cloning and 
analysis of functional envelope genes from human immunodeficiency virus type 1 
sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and 
Characterization . J Virol. 70(3):1651-67. 
bGao, F., Robertson, D.L., Morrison, S.G., Hui, H., Craig, S., Fultz, P.N., Decker, J., Girard, M., 
Shaw, G.M., Hahn, B.H. and Sharp ,P.M. (1996) . The heterosexual human 
immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) 
recombinant of African origin. J. Viral, 70(10):7013-7029. 
Gao, F., Robertson, D.L., Carruthers, C.D., Li, Y. , Bailes, E., Kostrikis, L.G ., Salminen, M.O., 
Bibollet-Ruche, F., Peeters, M., Ho, D.D., Shaw, G.M., Sharp, P.M. and Hahn, B.H. (1998). 
An isolate of human immunodeficiency virus type 1 originally classified as subtype I 
represents a complex mosaic comprising three different group M subtypes (A, G, and I). J 
Viral, 72(12):10234-41 . 
Gao, F., Bailes, E., Robertson, D.L., Chen, Y., Rodenburg, C.M., Michael, S.F., Cummins, L.B., 
Arthur, L.O., Peeters, M., Shaw, G.M., Sharp, P.M. and Hahn, B.H. (1999). Origin of HIV-1 
in the chimpanzee Pan troglodytes troglodytes . Nature, 397(6718):436-41 . 
Garrity, R.R. , Rimmelzwaan, G., Minassian, A. , Tsai, W.P., Lin , G., de Jong, J.J ., Goudsmit, J. 
and Nara, P.L. (1997). Refocusing neutralizing antibody response by targeted dampening 
of an immunodominant epitope. J lmmunol, 159(1 ):279-89. 
Gauduin, M.C., Glickman, R.L. , Means, R. and Johnson, R.P. (1998). Inhibition of simian 
immunodeficiency virus (SIV) replication by CD8(+) T lymphocytes from macaques 
immunized with live attenuated SIV. J Viral, 72(8):6315-24. 
194 
Gehring, S., Maayan, S., Ruppach, H., Balfe, P., Juraszczyk, J., Yust, I., Vardinon, N., Rimlawi, 
A., Polak, S., Bentwich, Z. , Rubsamen-Waigmann, H. and Dietrich, U. (1997). Molecular 
epidemiology of HIV in Israel. J Acquir Immune Defic Syndr Hum Retrovirol, 15(4):296-
303. 
Gelderblom, H.R., Hausmann, E.H., Ozel, M., Pauli, G. and Koch, M.A. (1987). Fine structure of 
human immunodeficiency virus (HIV) and immunolocalization of structural proteins. 
Virology, 156(1 ):171 -6. 
Gelderblom, H.R. (1997). Fine structure of HIV and SIV. Human Retroviruses and AIDS: A 
Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Eds. Korber, B., 
Hahn, 8 ., Foley, B., Mellors, J.W., Leitner, T. , Myers, G., Mccutchan, F. and Kuiken, C.L. 
Theoretical Biology and Biophy$ics Group, Los Alamos National Laboratory, Los Alamos, 
New Mexico. pplll 31-44. 
Gnann, J.W. Jr, Nelson, J.A., Oldstone, M.B. (1987) . Fine mapping of an immunodominant 
domain in the transmembrane glycoprotein of human immunodeficiency virus. J Viral, 
61 (8):2639-41 . 
Goldstein, G. (1996). HIV-1 Tat protein as a potential AIDS vaccine. Nat Med, 2(9):960-4. 
Gorny, M.K., Vancott, T.C., Hioe, C., Israel, Z.R. , Michael, N.L., Conley, A.J ., Williams, C., 
Kessler, J.A. 2nd, Chigurupati, P., Burda, S. and Zolla-Pazner, S. (1997). Human 
monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J 
lmmunol, 159(10):5114-22. 
Gorny, M.K., Mascola, J.R., Israel, Z.R., Vancott, T.C., Williams, C., Balfe, P., Hioe, C., Brodine, 
S. , Burda, S. and Zolla-Pazner, S. (1998). A human monoclonal antibody specific for the 
V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. AIDS Res Hum 
Retroviruses, 14(3):213-21 . 
Gorse, G.J., Schwartz, D.H., Graham, S.S., Matthews, T.J., Stablein, D.M., Frey, S.E. , Belshe, 
R.B., Clements, M.L., Wright, P.F., Eibl, M., et al. (1994). HIV-1 recombinant gp160 
vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network. 
Clin Exp lmmunol, 98(2):178-84. 
Gorse, G.J. , Keefer, M.C., Belshe, R.B., Matthews, T.J., Forrest, B.D., Hsieh, R.H ., Koff, W.C., 
Hanson, C.V., Dolin, R., Weinhold, K.J., Frey, S.E., Ketter, N. and Fast, P.E. (1996). A 
dose-ranging study of a prototype synthetic HIV-1 MN V3 branched peptide vaccine. The 
National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J 
Infect Dis, 173(2):330-9. 
Gottlinger, H.G., Sodroski, J.G. and Haseltine, W.A. (1989). Role of capsid precursor processing 
and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 
1. Proc Natl Acad Sci US A, 86(15):5781-5. 
Goudsmit, J. (1995). The role of viral diversity in HIV pathogenesis. J Acquir Immune Defic Syndr 
Hum Retrovirol, 10 Suppl 1 :S 15-9. 
Gould-Fogerite, S. (1998). Cochelate vaccines for mucosal and systemic immunisation . In 
Retroviruses of Human AIDS and Related Animal Diseases. Eds. Girard, M. and Dodet, 8 . 
11 e Colloque des Cent Gardes, 1997, Marnes-La-Coquette, Paris. Elsevier, Amsterdam, 
Oxford, Paris, New York, Tokyo. pp215-220. 
Goulder, P.J ., Phillips, R.E ., Colbert, R.A., McAdam, S., Ogg, G., Nowak, M.A. , Giangrande, P., 
Luzzi, G., Morgan, 8 ., Edwards, A., McMichael, A.J . and Rowland-Jones, S. (1997). Late 
195 
escape from an immunodominant cytotoxic T-lymphocyte response associated with 
progression to AIDS. Nat Med, 3(2) :212-7. 
Graham, B.S., Belshe, R.B ., Clements, M.L., Dolin, R. , Corey, L. , Wright, P.F., Gorse, G.J., 
Midthun, K., Keefer, M.C., Roberts, N.J. Jr, et al. (1992). Vaccination of vaccinia-naive 
adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a 
blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J 
Infect Dis, 166(2):244-52. 
Graham, B.S., McElrath, M.J., Connor, R.I., Schwartz, D.H ., Gorse, G.J., Keefer, M.C., Mulligan, 
M.J., Matthews, T.J., Wolinsky, S.M., Montefiori, D.C., Vermund, S.H., Lambert, J.S., 
Corey, L. , Belshe, R.B., Dolin, R. , Wright, P.F. , Korber, B.T. , Wolff, M.C. and Fast, P.E. 
(1998). Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I 
and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the 
Correlates of HIV Immune Protection Group. J Infect Dis, 177(2):310-9. 
Granelli-Piperno, A. , Delgado, E., Finkel , V., Paxton, W. and Steinman, R.M . (1998). Immature 
dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency 
virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J 
Virol, 72(4 ):2733-7. 
Gray, G.E., McIntyre, J.A. and Lyons, S.F. (1996). The effect of breastfeeding on vertical 
transmission of HIV-1 in Soweto, South Africa . XI International AIDS Conference, 
Vancouver. abs Th.C.415. 
Graziosi , C., Paolucci , S., Daucher, M.B., Centeno, G., Fauci , A.S. and Pantaleo, G. (1998). Role 
of glycosylation in HIV infection. 121h World AIDS Conference, Geneva. abs 21131. 
Grene, E., Mezule, G., Borisova, G., Pumpens, P., Bentwich, Z. and Amon, R. (1997). 
Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core 
particles carrying HIV type 1 epitopes. AIDS Res Hum Retroviruses, 13(1 ):41-51 . 
Grez, M., Dietrich, U., Balfe, P., van Briesen, H., Maniar, J.K., Mahambre, G., Delwart, E.L., 
Mullins, J.I. and Rubsamen-Waigmann, H. (1994). Genetic analysis of human 
immunodeficiency virus type 1 and 2 {HIV-1 and HIV-2) mixed infections in India reveals a 
recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. J Virol, 
68(4):2161-8. 
Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, Mayaud P, Changalucha J, 
Nicoll A, ka-Gina G, et al. (1995). Impact of improved treatment of sexually transmitted 
diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet, 
346(8974):530-6 . 
Haas, G., Samri, A., Gomard, E., Hosmalin, A., Duntze, J., Bouley, J.M., lhlenfeldt, H.G., Katlama, 
C. and Autran , B. (1998). Cytotoxic T-cell responses to HIV-1 reverse transcriptase, 
integrase and protease. AIDS, 12( 12): 1427-36. 
Hadida, F., Haas, G., Zimmermann, N., Hosmalin, A., Spohn, R., Samri , A. , Jung, G., Debre, P. 
and Autran , B. (1995). CTLs from lymphoid organs recognize an optimal HLA-A2-restricted 
and HLA-B52-restricted nonapeptide and several epitopes in the C-terminal region of HIV-
1 Nef. J lmmunol, 154(8):417 4-86. 
Hammond, S.A., Obah, E., Stanhope, P., Monell , C.R. , Strand, M., Robbins , F.M., Bias, W.B. , 
Karr, R.W., Koenig, S. and Siliciano, R.F. (1991 ). Characterization of a conserved T cell 
epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells . J lmmunol, 
146(5):1470-7. 
196 
Hammond, M.G., du Toit, E.D., Sanchez-Mazaz, A., Adrien, M., Coluzzi, M., de Pablo, M.R., de 
Stefano, G., Kaplan, C., Kennedy, L.J., Louie, L. and Migot, F. (1997). HLA in sub-Saharan 
Africa. 121h IHWC SSAF report. 
aHarrer, T., Harrer, E., Kalams, S.A., Barbosa, P., Trocha, A., Johnson, R.P., Elbeik, T., Feinberg, 
M.B., Buchbinder, S.P. and Walker, B.D. (1996). Cytotoxic T lymphocytes in asymptomatic 
long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and 
relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. 
J lmmunol, 156(7):2616-23. 
bHarrer, T., Harrer, E., Kalams, S.A., Elbeik, T., Staprans, S.I., Feinberg, M.B., Cao, Y., Ho, D.D., 
Yilma, T., Caliendo, A.M., Johnson, R.P., Buchbinder, S.P. and Walker, B.D. (1996). 
Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons 
with stable nonprogressing HIV type 1 infection . AIDS Res Hum Retroviruses, 12(7):585-
92. 
Haynes, B.F. (1996). HIV vaccines: where we are and where we are going. Lancet, 
348(9032):933-7. 
He, J., Chen, Y., Farzan, M., Choe, H., Ohagen, A., Gartner, S., Busciglio, J., Yang, X., Hofmann, 
W. , Newman, W., Mackay, C.R., Sodroski, J. and Gabuzda, D. (1997). CCR3 and CCR5 
are co-receptors for HIV-1 infection of microglia. Nature, 385(6617):645-9. 
Heyndrickx, L., Janssens, W., Franssen, K., Nkengasong, J., Vereecken, K., Loussert-Ajaka, I., 
Gurtler, L. and van der Groen, G. (1996). Specific diagnosis of HIV-1 group O by restriction 
analysis of the pol gene fragment. XI International Conference on AIDS, Vancouver 7-12 
July. 
Hengel, R.L., Kennedy, M.S., Steketee, R.W., Thea, D.M., Abrams, E.J., Lambert, G. and 
McDougal, J.S. (1998). Neutralizing antibody and perinatal transmission of human 
immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative 
Study Group. AIDS Res Hum Retroviruses, 14(6):475-81. 
Higgens, D.G., Bleasby, A.J. and Fuchs, R. (1992). CLUSTAL V: improved software for multiple 
sequence alignment. Comput. Appl. Biosci, 8:189-191. 
Hinkula, J., Svanholm, C., Schwartz, S., Lundholm, P., Brytting, M., Engstrom, G., Benthin, R., 
Glaser, H., Sutter, G., Kohleisen, 8., Erfle, V., Okuda, K., Wigzell, H. and Wahren, 8. 
(1997). Recognition of prominent viral epitopes induced by immunization with human 
immunodeficiency virus type 1 regulatory genes. J Virol, 71 (7):5528-39. 
Hirsch, M.S., Nahmias, A.J., Murphy, F.A., Kramer, J.H. (1968). Cellular immunity in vaccinia 
infection of mice. Anti-thymocyte serum effects on primary and secondary responsiveness. 
J Exp Med, 128(1):121-32. 
Hirsch, V.M., Olmsted, R.A., Murphey-Corb, M., Purcell , R.H. and Johnson, P.R. (1989). An 
African primate lentivirus (SIVsm) closely related to HIV-2. Nature, 339(6223):389-92. 
HIV sequence database. (1999). Eds. Carr, J.K., Gao, F., Holmes, E., Learn, G.H., Leitner, T., 
Lukashov, V.V., Peeters, M., Pieniazek, D., Robertson, D., Salminen, M., Seillier-
Moiseiwitsch, F., Zhang, L. http://hiv-web.lanl.gov/ 
Ho, D.D. (1996). Viral counts count in HIV infection . Science, 272(5265):1124-5. 
197 
Ho, D.D. (1998). Toward HIV eradication or remission: the tasks ahead. Science, 280(5371):1866-
7. 
Hoffman, S.L., Doolan, D.L. , Sedegah, M., Wang, R., Scheller, L.F. , Kumar, A., Weiss, W.R., Le, 
T.P., Klinman, D.M., Hobart, P., Norman, J.A. and Hedstrom, R.C. (1997). Toward clinical 
trials of DNA vaccines against malaria. lmmunol Cell Biol, 75(4):376-81 . 
Honda, M. , Matsuo, K., Nakasone, T., Okamoto, Y., Yoshizaki, H., Kitamura, K., Sugiura, W., 
Watanabe, K., Fukushima, Y., Haga, S., et al. (1995). Protective immune responses 
induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium 
bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency 
virus type 1 in small animals. Proc Natl Acad Sci US A, 92(23):10693-7. 
Hu, D.J., Buve, A., Baggs, J., van der Groen, G. and Dondero, T.J. (1999). What role does HIV-1 
subtype play in transmission and pathogenesis? An epidemiological perspective. AIDS 
13:873-81 . 
Huang, Y., Paxton, W.A., Wolinsky, S.M., Neumann, A.U., Zhang, L., He, T., Kang, S., Ceradini, 
D., Jin, Z., Yazdanbakhsh, K., Kunstman, K., Erickson, D., Dragon, E., Landau, N.R., 
Phair, J., Ho, D.D. and Kaup, R.A. (1996). The role of a mutant CCR5 allele in HIV-1 
transmission and disease progression. Nat Med, 2(11 ):1240-3. 
Hunt, J.C., Golden, A.M., Lund, J.K., Gurtler, L.G., Zekeng, L. , Obiang, J., Kaptue, L. and Hampl, 
H., Vallari , A. and Devare, S.G. (1997). Envelope sequence variability and serologic 
characterization of HIV type 1 group O isolates from equatorial guinea. AIDS Res Hum 
Retroviruses, 13(12):995-1005. 
IAVI (International AIDS Vaccine Initiative) Report (1998). An lnteview with Salim Abdool Karim: 
AIDS in South Africa. In A newsletter on International AIDS Vaccine Research, 3(3):7-9. 
lnchauspe, G., Major, M.E., Nakano, I. , Vitvitski , L. and Trepo, C. (1997). DNA vaccination for the 
induction of immune responses against hepatitis C virus proteins. Vaccine , 15(8):853-6. 
Irwin, K.L. , Pau, C.P., Lupo, D., Pienazek, D., Luo, C.C., Olivo, N., Rayfield, M., Hu, D.J., Weber, 
J.T., Respess, R.A., Janssen, R., Minor, P. and Ernst, J. (1997). Presence of human 
immunodeficiency virus (HIV) type 1 subtype A infection in a New York community with 
high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America. 
Centers for Disease Control and Prevention-Bronx Lebanon HIV Serosurvey Team. J 
Infect Dis, 176(6): 1629-33. 
Ishii, N., Fukushima, J., Kaneko, T., Okada, E., Tani, K., Tanaka, S.I., Hamajima, K., Xin, K.Q., 
Kawamoto, S., Koff, W., Nishioka, K., Yasuda, T. and Okuda, K. (1997). Cationic 
liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 
1. AIDS Res Hum Retroviruses, 13(16):1421-8. 
Iwasaki, A. , Torres, C.A. , Ohashi, P.S., Robinson, H.L. and Barber, B.H. (1997). The dominant 
role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at 
different sites. J lmmunol, 159(1):11-4. 
Jackson, D.J., Rakwar, J.P., Richardson, B.A., Mandaliya, K., Chohan , B.H., Bwayo, J.J ., Ndinya-
Achola, J.O., Martin, H.L. Jr, Moses, S. and Kreiss, J.K. (1997). Decreased incidence of 
sexually transmitted diseases among trucking company workers in Kenya: results of a 
behavioural risk-reduction programme. AIDS, 11 (7):903-9. 
Jameel, S., Zafrullah, M., Ahmad, M., Kapoor, G.S., Sehgal, S., Tripathy, S., Renjifo, B., Wang, 
W.K., Mclane, M.F., Bollinger, R., Rodrigues, J., Osterman, J., Tripathy, S. and Essex, M. 
198 
(1995). A genetic analysis of HIV-1 from Punjab, India reveals the presence of multiple 
variants. A/OS, 9(7):685-90. 
Janini, L.M., Pieniazek, D., Peralta, J.M., Schechter, M., Tanuri, A., Vincente, A.C., dela Torre, N., 
Pieniazek, N.J. , Luo, C.C., Kalish , M.L., Schochetman, G. and Rayfield, M.A. (1996). 
Identification of single and dual infections with distinct subtypes of human 
immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. 
Virus Genes, 13(1 ):69-81 . 
Janssens, W. , Buve, A. and Nkengasong, J.N. (1997). The puzzle of HIV-1 subtypes in Africa. 
A/OS, 11 (6):705-12. 
Johnson, RP.and Walker, B.D. (1994). Cytotoxic T lymphocytes in human immunodeficiency 
virus infection: responses to structural proteins. Curr Top Microbiol lmmunol, 189:35-63. 
Johnson, J.E., Schnell , M.J., Buonocore, L. and Rose, J.K. (1997). Specific targeting to CD4+ 
cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus 
envelope proteins. J Viral, 71 (7):5060-8. 
Johnson, M.I. (1997). HIV Vaccines: problems and prospects. In Hospital Practice, May15. 
Johnson, R.P ., Glickman, R.L., Yang, J.Q., Kaur, A. , Dion, J.T., Mulligan, M.J . and Desrosiers, 
R.C. (1997). Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated 
simian immunodeficiency virus. J Viral, 71(10):7711-8. 
Jonassen, T.O., Stene-Johansen, K., Berg, E.S., Hungnes, 0 ., Lindboe, C.F., Froland, S.S. and 
Grinde, B. (1997). Sequence analysis of HIV-1 group O from Norwegian patients infected 
in the 1960s. Virology, 231(1):43-7. 
Jones, D.H., Carris, S. , McDonald, S., Clegg, J.C. and Farrar, G.H. (1997). Poly(DL-lactide-co-
glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to 
encoded protein after oral administration. Vaccine, 15(8):814-7. 
Jordan Report (1998). Accelerated Development of Vaccines. 
http://www. n iaid .n ih .gov/publications/pdf/jordan .pdf. 
Kahn, J.O., Sinangil , F., Baenziger, J., Murcar, N., Wynne, D., Coleman, R.L. , Steimer, K.S. , 
Dekker, C.L. and Chernoff, D. (1994). Clinical and immunologic responses to human 
immunodeficiency virus (HIV) type 1 SF2 gp120 subunit vaccine combined with MF59 
adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-
HIV-infected human volunteers. J Infect Dis, 170(5):1288-91. 
Kaleebu, P., Morgan, D., Oram, J., Rutebemberwa, A. , Lyagoba, F., Biryahwaho, B. and 
Whitworth, J. (1998). HIV-1 heterosexual transmission: relationship with HIV-1 subtypes in 
Uganda. 12th World AIDS Conference, Geneva, abs 23357. 
Kalyan, N.K., Lee, S.G., Wilhelm, J., Pisano, M.R. , Hum, W.T., Hsiao, C.L., Davis, A.R., Eichberg, 
J.W., Robert-Guroff, M. and Hung, P.P. (1994). lmmunogenicity of recombinant influenza 
virus haemagglutinin carrying peptides from the envelope protein of human 
immunodeficiency virus type 1. Vaccine , 12(8):753-60. 
Kanki, P.J., Hamel, D.J. , Sankale, J.L., Hsieh, C.C., Thior, I., Sarin , F., Woodcock, S.A., Gueye-
Ndiaye, A., Zhang, E., Montano, M., Siby, T., Marlink, R. , NDoye, I., Essex, M.E. and 
MBoup, S. (1999). Human immunodeficiency virus type 1 subtypes differ in disease 
progression. J Infect Dis, 179(1):68-73. 
199 
Katz, E. and Moss, B. (1997). lmmunogenicity of recombinant vaccinia viruses that display the 
HIV type 1 envelope glycoprotein on the surface of infectious virions. AIDS Res Hum 
Retroviruses, 13(17): 1497-500. 
Katzenstein , D.A., Mbizvo, M., Zijenah, L., Gittens, T., Munjoma, M., Hill, D., Madzime, S. and 
Maldonado, Y. (1999) Serum level of maternal human immunodeficiency virus (HIV) RNA, 
infant mortality, and vertical transmission of HIV in Zimbabwe. J Infect Dis, 179(6):1382-7. 
Kawasaki, E.S. (1990). Sample preparation from blood, cells and other fluids. In PCR protocols: a 
guide to methods and applications. Eds. Innis, M.A., Gelfand, O.H., Sninsky, J.J. and 
White, T.J. Academic Press, Inc., Berkeley, California, pp.148. 
Keefer, M.C., Graham, B.S., Belshe, R.B., Schwartz, D., Corey, L., Bolognesi, D.P., Stablein, 
D.M., Montefiori, D.C., McElrath, M.J., Clements, M.L., et al. (1994). Studies of high doses 
of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate 
vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials 
Network.A/OS Res Hum Retroviruses, 10(12):1713-23. 
Keefer, M.C., Graham, B.S., McElrath, M.J., Matthews, T.J., Stablein, D.M., Corey, L., Wright, 
P.F., Lawrence, D., Fast, P.E., Weinhold, K., Hsieh, R.H., Chernoff, D., Dekker, C. and 
Dolin, R. (1996). Safety and immunogenicity of Env 2-3, a human immunodeficiency virus 
type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID 
AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses, 12(8):683-93. 
Kelleher, AD., Emery, S., Cunningham, P., Duncombe, C., Carr, A, Golding, H., Forde, S., 
Hudson, J., Roggensack, M., Forrest, B.D. and Cooper, D.A. (1997). Safety and 
immunogenicity of UBI HIV-1 MN octameric V3 peptide vaccine administered by 
subcutaneous injection. AIDS Res Hum Retroviruses, 13(1):29-32. 
Kent, S.J., Zhao, A, Best, S.J., Chandler, J.D., Boyle, D.B. and Ramshaw, I.A. (1998). Enhanced 
T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 
vaccine regimen consisting of consecutive priming with DNA and boosting with 
recombinant fowlpox virus. J Viral, 72(12):10180-8. 
Kerkau, T., Bacik, I., Bennink, J.R., Yewdell, J.W., Hunig, T., Schimpl, A and Schubert, U. (1997). 
The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step 
in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp 
Med, 185(7): 1295-305. 
aKim, J.J ., Ayyavoo, V., Bagarazzi, M.L., Chattergoon, M.A., Dang, K., Wang, B., Boyer, J.D. and 
Weiner, D.B. (1997). In vivo engineering of a cellular immune response by 
coadministration of IL-12 expression vector with a DNA immunogen. J lmmunol, 
158(2):816-26. 
bKim, J.J. , Ayyavoo, V., Bagarazzi , M.L., Chattergoon, M.A., Dang, K., Wang, B., Boyer, J.D. and 
Weiner, D.B. (1997). Development of a multicomponent candidate vaccine for HIV-1. 
Vaccine, 15(8):879-83. 
Kimura, M. (1980). A simple model for estimating evolutionary rates of base substitutions through 
comparative studies of nucleotide sequences. J Mo/ Evol, 19:111-120. 
Klavinskis, L.S., Gao, L., Barnfield, C., Lehner, T. and Parker, S. (1997). Mucosal immunization 
with DNA-liposome complexes. Vaccine, 15(8):818-20. 
Klein, M.R., Veenstra, J., Holwerda, AM., Roos, M.T., Gow, I., Patou, G., Coutinho, R.A., de Wolf, 
F. and Miedema, F. (1997). Gag-specific immune responses after immunization with 
200 
p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals. AIDS Res Hum 
Retroviruses, 13(5):393-9. 
Kondo, M., Saito, T.S., Ito, A.I. , Kawata, K.K., Sagara, H.S., Kihara, M.K., Sato, H.S., Takebe, 
Y.T., Nishioka, K.N . and Imai, M.I. (1998). Simple method for typing HIV-1 (8, E) by PCR: 
Chronological shift of subtype distribution of HIV-1 (B to E) in Japan. 12th World AIDS 
Conference, Geneva, abs 13138. 
Korber, B., Loussert-Ajaka, I. , Blouin, J, and Saragosti, S. (1996). A comparison of HIV-1 group 
M and group O functional and immunogenic domains in the Gag p24 protein and the C2V3 
region of the Env protein. Human Retroviruses and AIDS: A compilation and analysis of 
nucleic acid and amino acid sequences. Eds. Myers, G., Korber, B.T., Foley, B.T., Jeang, 
K-T., Mellors, J.W. and Wain-Hobson, S. Theoretical Biology and Biophysics Group, Los 
Alamos National Laboratory, Los Alamos, New Mexico. pplll 61-77. 
Korber, B., Hahn, B., Foley, B., Mellors, J.W., Leitner, T., Myers, G., Mccutchan, F. and Kuiken, 
C.L. Eds. (1997). Human Retroviruses and AIDS: A compilation and analysis of nucleic 
acid and amino acid sequences. Theoretical Biology and Biophysics Group, Los Alamos 
National Laboratory, Los Alamos, New Mexico. 
Korber, B., Hahn, B., Foley, B., Mellors, J.W., Leitner, T., Myers, G., Mccutchan, F. and Kuiken, 
C.L. Eds. (1997). HIV Molecular Immunology Database. Theoretical Biology and 
Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico. 
Kostrikis, L.G ., Bagdades, E., Cao, Y., Zhang, L. , Dimitriou, D. and Ho, D.D. (1995). Genetic 
analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: 
Identification of a new subtype designated subtype I. J. Viral, 69:6122-6130. 
Kubota, M., Miller, C.J., lmaoka, K., Kawabata, S., Fujihashi, K., McGhee, J.R. and Kiyono, H. 
(1997). Oral immunization with simian immunodeficiency virus p55gag and cholera toxin 
elicits both mucosa! lgA and systemic lgG immune responses in nonhuman primates. J 
lmmunol, 1;158(11):5321-9. 
Kuiken, C.L. , Zwart, G., Baan, E., Coutinho, R.A. , van den Hoek, J.A. and Goudsmit, J. (1993). 
Increasing antigenic and genetic diversity of the V3 variable domain of the human 
immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl 
Acad Sci US A, 90(19):9061 -5. 
Kuiken, C. and Pillai, S. (1997). Reagents of HIV SIV vaccine studies. Human Retroviruses and 
AIDS: A compilation and analysis of nucleic acid and amino acid sequences. Theoretical 
Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico. 
pplll 45-54 
Kusagawa, S., Sato, H., Watanabe, S., Nohtomi, K., Kato, K., Shino, T., Thwe, M., 00, K.Y. , 
Lwin, S., Mra, R., Kywe, B., Yamazaki, S. and Takebe, Y. (1998). Genetic and serologic 
characterization of HIV type 1 prevailing in Myanmar. AIDS Res Hum Retroviruses, 
14( 15): 1379-85. 
Kwong, P.D. , Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J. and Hendrickson, W.A. (1998). 
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a 
neutralizing human antibody. Nature, 393(6686):648-59. 
Lacasse, R.A. , Follis, K.E., Trahey, M., Scarborough, J.D., Littman, D.R. and Nunberg, J.H. 
(1999). Fusion-competent vaccines: Broad neutralization of primary isolates of HIV. 
Science, 283:357-362. 
201 
Laga, M. (1995). STD control for HIV prevention--it works! Lancet, 346(8974):518-9. 
Lagranderie, M., Balazuc, A.M., Gicquel, B. and Gheorghiu, M. (1997) . Oral immunization with 
recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local 
and systemic cytotoxic T-lymphocyte responses in mice. J Virol, 71 (3):2303-9. 
Lagranderie, M., Winter, N., Balazuc, A.M., Gicquel, B. and Gheorghiu, M. (1998). A cocktail of 
Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens 
induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. 
AIDS Res Hum Retroviruses, 14(18):1625-33. 
Lara, C., Sallberg, M., Johansson, B., de Rivera, I.L. and Sonnerborg, A. (1997). The Honduran 
human immunodeficiency virus type 1 (HIV-1) epidemic is dominated by HIV-1 subtype B 
as determined by V3 domain sero- and genotyping. J Clin Microbial, 35(3):783-4. 
Lasky, L.A., Groopman, J.E., Fennie, C.W., Benz, P.M., Capon, D.J., Dowbenko, D.J., Nakamura, 
G.R. , Nunes, W.M., Renz, M.E. and Berman, P.W. (1986). Neutralization of the AIDS 
retrovirus by antibodies to a recombinant envelope glycoprotein. Science, 233(4760):209-
12. 
Lasky, M., Perret, J.L., Peeters, M., Bibollet-Ruche, F., Liegeois , F. , Patrel, D., Molinier, S., Gras, 
C. and Delaporte, E. ( 1997). Presence of multiple non-B subtypes and divergent subtype B 
strains of HIV-1 in individuals infected after overseas deployment. AIDS, 11 (1 ):43-51 . 
Layne, S.P., Merges, M.J., Dembo, M., Spouge, J.L., Conley, S.R. , Moore, J.P., Raina, J.L., 
Renz, H., Gelderblom, H.R. and Nara, P.L. (1992). Factors underlying spontaneous 
inactivation and susceptibility to neutralization of human immunodeficiency virus . Virology, 
189(2):695-714. 
Leitner, T.B., Korber, D. and Robertson, D., Gao, F. and Hahn, B. (1997). Updated Proposal of 
Reference Sequences of HIV-1 Genetic Subtypes. Human Retroviruses and AIDS: A 
compilation and analysis of nucleic acid and amino acid sequences. Korber, B., Hahn, B., 
Foley, B., Mellors, J.W., Leitner, T., Myers, G., Mccutchan, F. and Kuiken, C.L. Eds. 
Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, 
New Mexico. pplll pp19-26. 
Lekutis, C., Shiver, J.W., Liu, M.A. and Letvin , N.L. (1997). HIV-1 env DNA vaccine administered 
to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-
gamma and TNF-alpha. J lmmunol, 158(9):4471-7. 
Leroy, V., Newell, M.L., Dabis, F., Peckham, C., van de Perre, P., Bulterys, M., Kind, C., Simonds, 
R.J ., Wiktor, S. and Msellati , P. (1998). International multicentre pooled analysis of late 
postnatal mother-to-child transmission of HIV-1 infection . Ghent International Working 
Group on Mother-to-Child Transmission of HIV. Lancet, 352(9128):597-600. 
Letvin , N.L., Montefiori, D.C., Yasutomi, Y., Perry, H.C., Davies, M.E., Lekutis, C. , Alroy, M., 
Freed, D.C. , Lord, C.I., Handt, L.K. , Liu , M.A. and Shiver, J.W. (1997). Potent, protective 
anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein 
vaccination. Proc Natl Acad Sci US A, 94(17):9378-83. 
Letvin , N.L. (1998). Progress in the development of an HIV-1 vaccine. Science, 280(5371 ):1875-
80. 
Levy, J.A., Hoffman, A.O., Kramer, S.M., Landis, J.A., Shimabukuro, J.M. and Oshiro, L.S. (1984). 
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science, 
225( 4664 ):840-2. 
202 
Levy, J.A. , Pan, L.Z., Beth-Giraldo, E., Kaminsky, L.S., Henle, G., Henle, W. and Giraldo, G. 
(1986). Absence of antibodies to the human immunodeficiency virus in sera from Africa 
prior to 1975. Proc Natl Acad Sci US A, 83(20):7935-7. 
Liao, F., Alkhatib, G., Peden , K.W., Sharma, G., Berger, E.A. and Farber, J.M. (1997). STRL33, A 
novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-
tropic and T cell line-tropic HIV-1. J Exp Med, 185(11 ):2015-23. 
Liitsola, K. , Tashkinova, I., Laukkanen, T., Korovina, G., Smolskaja, T., Momot, 0 ., Mashkilleyson, 
N., Chaplinskas, S., Brummer-Korvenkontio, H., Vanhatalo, J. , Leinikki, P. and Salminen, 
M.O. (1998). HIV-1 genetic subtype A/8 recombinant strain causing an explosive epidemic 
in injecting drug users in Kalin ingrad. A/OS, 12(14):1907-19. 
Lim, E.M., Lagranderie, M., Le Grand, R., Rauzier, J., Gheorghiu, M., Gicquel, 8 . and Winter, N. 
(1997). Recombinant Mycobacterium bovis BCG producing the N-terminal half of 
SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte 
responses in mice and guinea pigs. A/OS Res Hum Retroviruses, 13(18):1573-81. 
Liu, H.J., Giambrone, J.J. and Dormitorio, T. (1994). Detection of genetic variations in serotype 1 
isolates of infectious bursal disease virus using polymerase chain reaction and restriction 
endonuclease analysis . Virmet, 48:281-291 . 
Liu, R., Paxton, W.A. , Choe, S., Ceradini, D., Martin, S.R. , Horuk, R., MacDonald, M.E., 
Stuhlmann, H., Kaup, R.A. and Landau, N.R. (1996). Homozygous defect in HIV-1 
coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. 
Cell, 86(3):367-77. 
Liu, M.A., McClements, W., Ulmer, J.B., Shiver, J. and Donnelly, J. (1997). Immunization of non-
human primates with DNA vaccines. Vaccine, Jun;15(8):909-12. 
Lale, K.S ., Boll inger, R.C., Paranjape, R.S., Gadkari, D., Kulkarni, S.S., Novak, N.G., Ingersoll, R., 
Sheppard, H.W. and Ray, S.C. (1999). Full-length human immunodeficiency virus type 1 
genomes from subtype C-infected seroconverters in India, with evidence of intersubtype 
recombination . J Virol, 73(1 ):152-60. 
Laue, S., Bounlu, K., Pholsena, V. and Mastro, T.D. (1998). HIV seroprevalence and HIV-1 
subtype E among pregnant women in Vientiane, Laos. A/OS, 12(11 ):1403. 
Loussert-Ajaka, I., Ly, T.D., Chaix, M.L., lngrand, D., Saragosti, S., Courouce, A.M., Brun-Vezinet, 
F. and Simon, F. ('1994). HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. 
Lancet, 343(8910):1393-4. 
Loussert-Ajaka, I., Menu, E., Apetrei , C., Peeters, M., Damond, F., Mauclere, P., Eberle, J., 
Brengues, C., Saragosti , S., Barre-Sinoussi, F., Brun-Vezinet, F. and Simon, F. (1998). 
HIV type 1 diversity and the reliability of the heteroduplex mobility assay. A/OS Res Hum 
Retroviruses, 14(10):877-83. 
Louwagie, J., Mccutchan, F.E., Peeters, M., Brennan, T.P., Sanders-Buell , E., Eddy, G.A., van 
der Groen, G., Fransen, K., Gershy-Damet, G.M., Deleys, R. , et al. (1993). Phylogenetic 
analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple 
genotypes. A/OS, 7(6):769-80. 
Louwagie, J., Janssens, W., Mascola, J., Heyndrickx, L. , Hegerich, P., van der Groen, G., 
Mccutchan, F.E. and Burke, D.S. (1995). Genetic diversity of the envelope glycoprotein 
from human immunodeficiency virus type 1 isolates of African origin. J Virol, 69(1 ):263-
271 . 
203 
Lu, S., Santoro, J.C., Fuller, D.H., Haynes, J.R. and Robinson, H.L. (1995). Use of DNAs 
expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in 
mice. Virology, 209:147-54. 
Lu, S., Wyatt, R. , Richmond, J.F.L., Mustafa, F., Wang, S., Weng, J. , Montefiori, D.C. , Sodroski, J. 
and Robinson, H.L. (1998). lmmunogenicity of DNA vaccines expressing human 
immunodeficiency virus type 1 envelope glycoprotein with and without deletions in V1/2 
and V3 regions. A/OS Res Hum Retroviruses, 14(2):151-5. 
LO, X., Kiyono, H., Lu, D., Kawabata, S., Torten, J., Srinivasan, S., Dailey, P.J., McGhee, J.R., 
Lehner, T. and Miller, C.J. (1998). Targeted lymph-node immunization with whole 
inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen 
vaccines does not reliably protect rhesus macaques from vaginal challenge with 
SIVmac251 . A/OS, 12(1):1-10. 
Lubeck MD, Natuk RJ, Chengalvala M, Chanda PK, Murthy KK, Murthy S, Mizutani S, Lee SG, 
Wade MS, Bhat BM, et al. (1994). lmmunogenicity of recombinant adenovirus-human 
immunodeficiency virus vaccines in chimpanzees following intranasal administration. A/OS 
Res Hum Retroviruses, 10(11 ):1443-9. 
Published erratum appears in A/OS Res Hum Retroviruses, (1995) 11 (1 ):189. 
Lubeck, M.D., Natuk, R. , Myagkikh, M., Kalyan, N., Aldrich, K., Sinangil, F., Alipanah, S., Murthy, 
S.C., Chanda, P.K., Nigida, S.M. Jr., Markham, P.D. , Zolla-Pazner, S., Steimer, K., Wade, 
M., Reitz, M.S. Jr. , Arthur, L.O., Mizutani, S., Davis, A., Hung, P.P., Gallo, R.C. , Eichberg, 
J. and Robert-Guroff, M. (1997). Long-term protection of chimpanzees against high-dose 
HIV-1 challenge induced by immunization. Nat Med, 3(6):651-8. 
Luciw, P.A. (1996). Chapter 60: Human Immunodeficiency Viruses and Their Replication . In 
Fields Virology 2(3). Eds. Fields, B.N ., Knipe, D.M. and Howley, P.M. Ass . Eds. Chanock, 
R.M ., Melnick, J.L. , Monath, T.P., Roizman, B. and Straus, S.E. Lippincott-Raven 
Publishers, Philadelphia, PA, 19106, USA. pp1881-1952. 
Lukashov, V.V., Cornelissen, M.T., Goudsmit, J., Papuashvilli , M.N., Rytik, P.G., Khaitov, R.M., 
Karamov, E.V., de Wolf, F. (1995). Simultaneous introduction of distinct HIV-1 subtypes 
into different risk groups in Russia , Byelorussia and Lithuania. A/OS, 9(5):435-9. 
Lukashov, V.V., Kuiken, C.L. , Boer, K. and Goudsmit, J. (1996). HIV type 1 subtypes in The 
Netherlands circulating among women originating from AIDS-endemic regions . A/OS Res 
Hum Retroviruses, 12(10):951-3. 
Lukashov, V.V., Karamov, E.V., Eremin, V.F., Titov, L.P., Goudsmit, J. (1998). Extreme founder 
effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus. 
AIDS Res Hum Retroviruses, 14(14):1299-303. 
Luo, C.C., Tian, C., Hu, D.J., Kai, M., Dondero, T. and Zheng, X. (1995). HIV-1 subtype C in 
China. Lancet, 345(8956): 1051-2. 
Luo, C.C., Downing, R.G., Dela Torre, N., Baggs, J. , Hu, D.J., Respess, R.A., Candal, D., Carr, L., 
George, J.R., Dondero, T.J., Biryahwaho, B. and Rayfield , M.A. (1998). The development 
and evaluation of a probe hybridization method for subtyping HIV type 1 infection in 
Uganda. A/OS Res Hum Retroviruses, 14(8):691-4. 
Lynch, C.E. , Madej, R. , Louie, P.H. and Rodgers, G. (1992). Detection of HIV-1 DNA by PCR: 
Evaluation of primer pair concordance and sensitivity of a single primer pair. J. AIDS, 
5:433-440. 
204 
Lynch, J.A., deSouza, M., Robb, M.D., Markowitz, L., Nitayaphan, S., Sapan, C.V., Mann, D.L., 
Birx, D.L. and Cox, J.H. (1998). Cross-clade cytotoxic T cell response to human 
immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. 
J Infect Dis, 178(4):1040-6. 
Lyons, S.F., Schoub, B.D., McGillivray, G.M., Sher, R. and Dos Santos, L. (1985). Lack of 
evidence of HTLV-111 endemicity in southern Africa. N Engl J Med, 312(19):1257-8. 
MacGregor, R.R., Boyer, J.D., Ugen, K.E., Lacy, K.E., Gluckman, S.J ., Bagarazzi, M.L., 
Chattergoon, M.A., Baine, Y., Higgins, T.J., Ciccarelli, R.B ., Coney, L.R. , Ginsberg, R.S. 
and Weiner, D.B. (1998). First human trial of a DNA-based vaccine for treatment of human 
immunodeficiency virus type 1 infection: safety and host response. J Inf Diseases, 178: 92-
100. 
Majello, B., Napolitano, G. and Lania, L. (1998). Recruitment of the TATA-binding protein to the 
HIV-1 promoter is a limiting step for Tat transactivation. AIDS, 12(15):1957-64. 
MAP (Monitoring the AIDS Pandemic) Report. (1997). The staus and trends of the HIV/AIDS/STD 
epidemics in sub-Saharan Africa. Official Satellite Symposium of the Xth International 
Conference on STD and AIDS in Africa, Abidjan . 
Marseille, E., Kahn, J.G. and Saba, J. (1998). Cost-effectiveness of antiviral drug therapy to 
reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS, 12(8):939-48. 
Martinon, F., Gras-Masse, H., Boutillon, C., Chirat, F., Deprez, B., Guillet, J.G., Gomard, E., 
Tartar, A. and Levy, J.P. (1992). Immunization of mice with lipopeptides bypasses the 
prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency 
virus envelope glycoprotein. J lmmunol, 149(10):3416-22. 
Mas, A. , Quinones-Mateu, E., Soriano, V. and Domingo, E. (1996). Env gene characterization of 
the first HIV type 1 group O Spanish isolate. AIDS Res Hum Retroviruses, 12(17):1647-9. 
Mascola, J.R., Louwagie, J. , Mccutchan, F.E. , Fischer, C.L., Hegerich, P.A., Wagner, K.F., 
Fowler, A.K., McNeil , J.G. and Burke, D.S. Two antigenically distinct subtypes of HIV-1 : 
viral genotype predicts neutralization serotype. J Infect Dis 1994, 169(1 ): 48-54. 
Mastro, T.D. and de Vincenzi, I. (1996) . Probabilities of sexual HIV-1 transmission. AIDS, 
1 O(Suppl A):S75-82. 
McAdam, S. , Kaleebu, P. , Krausa, P., Goulder, P., French, N., Collin , B., Blanchard, T. , 
Whitworth, J., McMichael, A. and Gotch, F. (1998). Cross-clade recognition of p55 by 
cytotoxic T lymphocytes in HIV-1 infection. AIDS, 12(6):571-9. 
McCarthy, M. (1996). DNA vaccination: a direct line to the immune system. Lancet, 
348(9036): 1232. 
McClements, W.L. , Armstrong, M.E. , Keys, R.D. and Liu , M.A. (1997). The prophylactic effect of 
immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced 
disease in guinea pigs. Vaccine , 15(8):857-60. 
Mccutchan, F.E. , Ungar, B.L., Hegerich, P., Roberts, C.R. , Fowler, A.K., Hira, S.K., Perine, P.L. 
and Burke, D.S. (1992). Genetic analysis of HIV-1 isolates from Zambia and an expanded 
phylogenetic tree for HIV-1 . J Acquir Immune Defic Syndr, 5(5):441-9. 
205 
Mccutchan, F.E., Carr, J.K., Bajani, M., Sanders-Buell, E., Harry, T.O., Stoeckli, T.C., Robbins, 
K.E., Gashau, W., Nasidi, A. (1999). Subtype G and multiple forms of A/G intersubtype 
recombinant human immunodeficiency virus type 1 in Nigeria. Virology, 254(2):226-34. 
Janssens W, Kalish ML McDermott, D.H., Zimmerman, P.A., Guignard, F., Kleeberger, C.A. , 
Leitman, S.F. and Murphy, P.M. (1998). CCR5 promoter polymorphism and HIV-1 disease 
progression. Multicenter AIDS Cohort Study (MACS). Lancet, 352(9131):866-70. 
McDonnell, W.M. and Askari, F.K. (1996). DNA vaccines. N Engl J Med, 334(1 ):42-5. 
Mebatsion, T., Finke, S., Weiland, F. and Conzelmann, K.K. (1997). A CXCR4/CD4 pseudotype 
rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell, 
90(5):841-7. 
Meltzer, M.S., Nakamura, M. , Hansen, B.D., Turpin, J.A., Kalter, D.C. and Gendelman, H.E. 
(1990). Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in 
tissue, and key immunoregulatory cells that control levels of virus replication and extent of 
disease. AIDS Res Hum Retroviruses, 6(8):967-71 . 
Menu, E., Truong, T.X. , Lafon, M.E., Nguyen, T.H., Muller-Trutwin, M.C., Nguyen, T.T., 
Deslandres, A. , Chaouat, G., Duong, Q.T., Ha, B.K., Fleury, H.J. and Barre-Sinoussi , F. 
(1996). HIV type 1 Thai subtype E is predominant in South Vietnam. AIDS Res Hum 
Retroviruses, 12(7):629-33. 
Mervis, R.J ., Ahmad, N., Lillehoj, E.P., Raum, M.G., Salazar, F.H., Chan, H.W. and Venkatesan, 
S. (1998). The gag gene products of human immunodeficiency virus type 1: al ignment 
within the gag open reading frame, identification of posttranslational modifications, and 
evidence for alternative gag precursors. J Virol, 62(11 ):3993-4002. 
Miller, C.J., Alexander, N.J., Sutjipto, S., Lackner, A.A., Gettie, A., Hendrickx, A.G ., Lowenstine, 
L.J ., Jennings, M. and Marx, P.A. (1989). Genital mucosa! transmission of simian 
immunodeficiency virus: animal model for heterosexual transmission of human 
immunodeficiency virus . J Virol, 63(10):4277-84. 
Miller, C.J., McChesney, M.B., Lu, X., Dailey, P.J., Chutkowski , C. , Lu, D., Brosio, P., Roberts, B. 
and Lu, Y. (1997). Rhesus macaques previously infected with simian/human 
immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. 
J Virol, 71(3):1911-21 . 
Miller, R.H. and Sarver, N. (1997). HIV accessory proteins as therapeutic targets. Nat Med, 
3(4 ):389-94. 
Montagnier, L. (1996). Environmental pathogenesis of human retroviruses. AIDS Res Hum 
Retroviruses, 12(5):357-9. 
Moodley, D., Smith, T.L., Van Rensburg, E.J ., Moodley, J. and Engelbrecht, S. (1998). HIV type 1 
V3 region subtyping in KwaZulu-Natal , a high-seroprevalence South African region . AIDS 
Res Hum Retroviruses, 14(11 ):1015-8. 
Mooij, P., van der Kolk, M., Bogers, W.M., ten Haaft, P.J ., van der Meide, P., Almond, N., Stott, J., 
Deschamps, M., Labbe, D., Momin, P., Voss, G., Von Hoegen, P., Bruck, C. and Heeney, 
J.L. (1998). A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in 
vivo passaged simian-human immunodeficiency virus infection . AIDS, 12(5):F15-22. 
206 
Moore, J.P., Trkola, A., Korber, B., Boots, L.J. and Kessler, J.A. 2nd, Mccutchan FE, Mascola J, 
Ho DD, Robinson J, Conley AJ . (1995). A human monoclonal antibody to a complex 
epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad 
reactivity within and outside clade B. J Viral, 69(1 ):122-30. 
Moore, J. and Trkola, A. ( 1997). HIV type 1 coreceptors, neutralization serotypes, and vaccine 
development. A/OS Res Hum Retroviruses, 13(9):733-6. 
Moore, J.P. and Binley, J. (1998). HIV. Envelope's letters boxed into shape. Nature, 
393(6686):630-1. 
Montano, M.A., Nixon , C.P. and Essex, M. (1998). Dysregulation through the NF-kappaB 
enhancer and TATA box of the human immunodeficiency virus type 1 subtype E promoter. 
J Viral, 72(10):8446-52. 
Morgado, M.G., Guimaraes, M.L., Gripp, C.B., Costa, C.I., Neves, I. Jr, Veloso, V.G., Linhares-
Carvalho, M.I. , Castello-Branco, L.R. , Bastos, F.I., Kuiken, C., Castilho, E.A. , Galvao-
Castro, B. and Bongertz, V. (1998). Molecular epidemiology of HIV-1 in Brazil : high 
prevalence of HIV-1 subtype Band identification of an HIV-1 subtype D infection in the city 
of Rio de Janeiro, Brazil. Evandro Chagas Hospital AIDS Clinical Research Group. J 
Acquir Immune Oefic Syndr Hum Retraviral, 18(5):488-94. 
Mortara, L., Letourneur, F., Gras-Masse, H., Venet, A. , Guillet, J.G. and Bourgault-Villada, I. 
(1998). Selection of virus variants and emergence of virus escape mutants after 
immunization with an epitope vaccine. J Viral, 72(2):1403-10. 
Moss, B. , Carroll, M.W., Wyatt, L.S., Bennink, J.R., Hirsch, V.M., Goldstein, S., Elkins, W.R., 
Fuerst, T.R., Lifson, J.D., Piatak, M., Restifo, N.P., Overwijk, W., Chamberlain, R. , 
Rosenberg, S.A. and Sutter, G. (1996). Host range restricted, non-replicating vaccinia 
virus vectors as vaccine candidates. Adv Exp Med Biol, 397:7-13. 
Moss, RB. , Giermakowska, W.K., Savary, J.R., Theofan, G., Daigle, A.E., Richieri , S.P., Jensen, 
F.C. and Carlo, D.J. (1998). A primer on HIV type 1-specific immune function and 
REMUNE. A/OS Res Hum Retroviruses, 14(Suppl 2):S167-75. 
Muster, T., Steindl, F., Purtscher, M., Trkola, A. , Klima, A. , Himmler, G., Ruker, F. and Katinger, 
H. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus 
type 1. J Viral, 67(11):6642-7. 
Myers, G. , Korber, B., Hahn, B.H., Jeang, K.T., Mellors, J.W., Mccutchan, F.E., Henderson, L.E. 
and Pavlakis, G.N. Eds. (1995). Human Retroviruses and AIDS: A Compilation and 
Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biology and Biophysics 
Group, Los Alamos National Laboratory, Los Alamos, New Mexico. 
Myers, G., Korber, B.T. , Foley, B.T., Jeang, K-T., Mellors, J.W. and Wain-Hobson, S. Eds. (1996). 
Human Retroviruses and AIDS: A compilation and analysis of nucleic acid and amino acid 
sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 
Los Alamos, New Mexico. 
Nakamura, Y., Kameoka, M., Tobiume, M., Kaya, M., Ohki, K., Yamada, T. and Ikuta, K. (1997). A 
chain section containing epitopes for cytotoxic T, B and helper T cells within a highly 
conserved region found in the human immunodeficiency virus type 1 Gag protein . Vaccine, 
15(5):489-96. 
207 
Nasioulas, G., Paraskevis, D., Paparizos, V., Lazanas, M., Karafoulidou, A. and Hatzakis, A. 
(1998). Genotypic characterization of human immunodeficiency virus type 1 in Greece. 
Multicentre Study on HIV-1 Heterogeneity. AIDS Res Hum Retroviruses, 14(8):685-90. 
Neilson, J.R., John, G.C., Carr, J.K., Lewis, P., Kreiss, J.K., Jackson, S., Nduati, R.W., Mbori-
Ngacha, D., Panteleeff, D.D., Bodrug, S., Giachetti, C., Bott, M.A., Richardson, B.A., 
Bwayo, J., Ndinya-Achola, J. and Overbaugh, J. (1999). Subtypes of human 
immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Viral, 
73(5):4393-403. 
Newell, M.L., Dunn, D.T., Peckham, C.S., Semprini, A.E. and Pardi, G. (1996). Vertical 
transmission of HIV-1: maternal immune status and obstetric factors. The European 
Collaborative Study. AIDS, 10(14):1675-81 . 
Newell, M.L. , Gray, G. and Bryson , Y.J . (1997) . Prevention of mother-to-child transmission of HIV-
1 infection. AIDS, 11 (Suppl A}:S165-72. 
Newell, M.L. (1998). Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS, 
12(8):831-7. 
Nixon, D.F., Hioe, C., Chen, P.O., Bian, Z., Kuebler, P., Li, M.L., Qiu, H., Li, X.M., Singh, M., 
Richardson, J., McGee, P., Zamb, T. , Koff, W., Wang, C.Y. and O'Hagan, D. (1996). 
Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine, 
14(16):1523-30. 
Ngugi, E.N., Wilson, D. , Sebstad , J., Plummer, F.A. and Moses, S. (1996). Focused peer-
mediated educational programs among female sex workers to reduce sexually transmitted 
disease and human immunodeficiency virus transmission in Kenya and Zimbabwe. J Infect 
Dis, 174(Suppl 2):S240-7. 
Nkengasong, J.N., Willems, B., Janssens, W. , Cheingsong-Popov, R., Heyndrickx, L., Sarin, F., 
Ondoa, P., Fransen, K., Goudsmit, J. and van der Groen, G. (1998). Lack of correlation 
between V3-loop peptide enzyme immunoassay serologic subtyping and genetic 
sequencing. AIDS, 12(12):1405-12. 
Norman, J.A. , Hobart, P., Manthorpe, M., Feigner, P., Wheeler, C. (1997). Development of 
improved vectors for DNA-based immunization and other gene therapy applications. 
Vaccine, 15(8):801-3. 
Novitsky, V.A., Montano, M.A., Essex, M., Subbarao, S., Luo, C.C., Limpakarnjanarat, K., 
Bhumisa-wasdi, J., Young, N.L., Mastro, T.D., Schochetman, G. and Kalish , M.L. (1998). 
Molecular epidemiology of an HIV-1 subtype A subcluster among injection drug users in 
the Southern Ukraine. AIDS Res Hum Retroviruses, 14(12):1079-85. 
Novitski, V.A., Montano, M.A., Mclane, M.F., Renjifo, B. , Vannberg, F., Foley, B.T., Ndung'u, 
T.P., Rahman, M., Makhema, M.J., Marlink, R. and Essex, M. (1999). Molecular cloning 
and phylogenetic analysis of Human immunodeficiency virus type 1 subtype C: a set of 23 
full length clones from Botswana. J Viral, 73(5):4427-4432. 
Nyambi, P.N., Gorny, M.K., Bastiani, L., van der Groen, G., Williams, C. and Zolla-Pazner, S. 
(1998). Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-
1) virions: a new strategy for studying the immunologic relatedness of HIV-1 . J Virol, 
72(11 ):9384-91 . 
O' Brien, T.R. , Padian, N.S., Hodge, T., Goedert, J.J., O'Brien, S.J. and Carrington, M. (1998). 
CCR-5 genotype and sexual transmission of HIV-1 . AIDS, 12(4):444-5. 
208 
Omar, M.A.K., Hammond, M.G. and Asmal , A.C. (1984). HLA-A, B, C and DR antigens in young 
South African blacks with Type 1 (insulin-dependent) diabetes mell itus . Diabetologica 
26:20-23. 
Orloff, G.M., Kalish , M.L., Chiphangwi , J., Potts, K.E., Ou, C.Y. , Schochetman, G., Dallabetta, G. , 
Saah, A.I. and Miotti, P.G. (1993). V3 loops of HIV-1 specimens from pregnant women in 
Malawi uniformly lack a potential N-linked glycosylation site. AIDS Res. Hum. Retroviruses, 
9(7):705-706. 
Ou, C.Y. , Takebe, Y., Luo, C.C., Kalish , M., Auwanit, W., Bandea, C., de la Torre, N., Moore, J.L., 
Schochetman, G., Yamazaki, S., et al. (1992). Wide distribution of two subtypes of HIV-1 in 
Thailand . AIDS Res Hum Retroviruses, 8(8):1471-2. 
Ou, C.Y. , Takebe, Y., Weniger, B.G., Luo, C.C., Kalish, M.L., Auwanit, W. , Yamazaki , S., Gayle, 
H.D., Young, N.L., Schochetman and G. (1993). Independent introduction of two major 
HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet, 341 (8854 ): 1171-4. 
Published erratum appears in Lancet, 1993 342(8865):250. 
Page, R.D.M. TreeView for Windows Version 1.2. (1996). Division of Environmental and 
Evolutionary Biology. IBLS, University of Glasgow. 
Paladin, F.J., Monzon, O.T., Tsuchie, H., Aplasca, M.R., Learn, G.H. Jr, Kurimura, T. (1998). 
Genetic subtypes of HIV-1 in the Philippines. AIDS, 12(3):291-300. 
Pantaleo, G., Menzo, S., Vaccarezza, M., Graziosi, C., Cohen, O.J., Demarest, J.F., Montefiori, 
D., Orenstein, J.M., Fox, C., Schrager, L.K., et al. (1995). Studies in subjects with long-
term nonprogressive human immunodeficiency virus infection. N Engl J Med, 332(4):209-
16. 
Pantaleo, G. and Fauci, A.S. (1996). lmmunopathogenesis of HIV infection. Annu Rev Microbial, 
50:825-54. 
Paoletti , E. (1996). Applications of pox virus vectors to vaccination : an update. Proc Natl Acad Sci 
US A, 93(21 ):11349-53. 
Parren, P.W., Gauduin, M.C., Koup, R.A. , Poignard, P., Fisicaro, P., Burton, D.R. and Sattentau, 
Q.J. (1997). Relevance of the antibody response against human immunodeficiency virus 
type 1 envelope to vaccine design. lmmunol Lett, 57(1-3):105-12. 
Published erratum in lmmunol Lett (1997) 58(2):125-32. 
Parren, P.W., Wang, M., Trkola, A., Binley, J.M., Purtscher, M., Katinger, H., Moore, J.P. and 
Burton, D.R. (1998). Antibody neutralization-resistant primary isolates of human 
immunodeficiency virus type 1. J Virol, 72(12):10270-4. 
Pastinen, T., Liitsola, K., Niini, P., Salminen, M. and Syvanen, A.C. (1998). Contribution of the 
CCR5 and MBL genes to susceptibility to HIV type 1 infection in the Finnish population. 
AIDS Res Hum Retroviruses, 14(8):695-8. 
Paxton, W.A., Dragic, T. , Koup, R.A. and Moore, J.P. (1996). The beta-chemokines, HIV type 1 
second receptors, and exposed uninfected persons. AIDS Res Hum Retroviruses, 
12(13): 1203-7. 
209 
Paxton, W.A., Liu, R., Kang, S., Wu, L., Gingeras, T.R., Landau, N.R. , Mackay, C.R. and Koup, 
R.A. (1998). Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected 
individuals: association with low expression of CCR5 and high production of p-chemokines. 
Virology, 244(1 ):66-73. 
Paxton, W.A., Kang, S. and Koup, R.A. (1998). The HIV type 1 coreceptor CCR5 and its role in 
viral transmission and disease progression. AIDS Res Hum Retroviruses, 14(Supp11):S89-
92. 
Peeters, M., Nkengasong, J., Willems, B., Karita, E. , Delaporte, E., Van den Haesevelde, M., Piot, 
P. and van der Groen, G. (1994). Antibodies to V3 loop peptides derived from chimpanzee 
lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different 
geographic regions . AIDS, 8(12):1657-61 . 
Peeters, M., ESU-Williams, E., Nzila, E., Mpoudi, E., Yaounde, C., Mboup, S., Saragosti, S. and 
Delaporte, E. (1998). Molecular epidemiology of HIV-1 genetic subtypes in West and 
Central Africa. 12th World AIDS Conference, Geneva, abs 11163. 
Penny, M.A., Thomas, S.J ., Douglas, N.W. , Ranjbar, S., Holmes, H., Daniels, R.S. (1996). env 
gene sequences of primary HIV type 1 isolates of subtypes B, C, D, E, and F obtained 
from the World Health Organization Network for HIV Isolation and Characterization. AIDS 
Res Hum Retroviruses, 12(8):741-7. 
Petry, H., Stahl-Hennig, C., Dittmer, U., Jones, D., Farrar, G., Wachter, H., Fuchs, D., Nisslein, T., 
Jurkiewicz, E., Hunsmann, G. and Luke, W. (1998). A subunit vaccine consisting of gp130 
oligomers but not of gp130 monomers protects rhesus macaques against productive 
infection with SIVmac32H. AIDS, 12(3):329-30. 
Pialoux, G., Excler, J.L., Riviere, Y., Gonzalez-Canali, G., Feuillie, V., Coulaud, P., Gluckman, 
J.C., Matthews, T.J., Meignier, B., Kieny, M.P., et al. (1995). A prime-boost approach to 
HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 
(MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and 
l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses, 11 (3):373-81 . 
Published erratum appears in AIDS Res Hum Retroviruses, (1995) 11 (7):875. 
Pieniazek, D., Janini, L.M., Ramos, A., Tanuri, A., Shechter, M., Peralta, T.M., Vicente, A.C.P ., 
Pieniazek, N.J., Schochetman, G. and Rayfield, M.A. (1995). HIV-1 patients may harbour 
viruses of different phylogenetic subtypes: implications for evolution of the HIV/AIDS 
pandemic. Emerg. lnfec. Dis, (1 )3:86-88. 
Pieniazek, D., Ramos, A., Tanuri, A., Hu, D. , Baggs, J. and Rayfield, M. (1998). HIV-1 dual 
infections and recombinants are an integral part of the HIV epidemic in Brazil. 12th World 
AIDS Conference, Geneva, abs 13156. 
Pincus, S.H., Messer, K.G ., Cole, R., Ireland, R., Vancott, T.C., Pinter, A. , Schwartz, D.H., 
Graham, S.S. and Gorse, G.J. (1997). Vaccine-specific antibody responses induced by 
HIV-1 envelope subunit vaccines. J lmmunol, 158(7):3511-20. 
Pleskoff, 0 ., Treboute, C., Brelot, A., Heveker, N., Seman, M. and Alizon, M. (1997). Identification 
of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. 
Science, 276(5320):1874-8. 
Pleskoff, 0 ., Treboute, C. and Alizon, M. (1998). The cytomegalovirus-encoded chemokine 
receptor US28 can enhance cell-cell fusion mediated by different viral proteins. J Viral, 
72(8):6389-97. 
210 
Poignard, P., Gulizia, R.J ., Picchio, G., Wang, M., Parren, P.W.H., Mosier, D.E. and Burton, D.R. 
(1998). Study of the impact of neutralising antibodies on the course of established infection 
with HIV-1 primary isolates in the hu-PBL-SCID mouse model. 12th World AIDS 
Conference, Geneva, abs 31103. 
Pope, M., Frankel, S.S., Mascola, J.R., Trkola, A., lsdell, F., Birx, D.L., Burke, D.S. , Ho, D.D. and 
Moore, J.P. (1997). Human immunodeficiency virus type 1 strains of subtypes B and E 
replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific 
tropism. J Virol, 71 (10):8001-7. 
Popovic, M., Sarngadharan, M.G., Read, E. and Gallo, R.C. (1984). Detection, isolation, and 
continuous production of cytopathic retroviruses (HTLV-111) from patients with AIDS and 
pre-AIDS. Science, 224(4648):497-500. 
Poss, M., Gosink, J., Thomas, E., Kreiss, J.K., Ndinya-Achola, J., Mandaliya, K., Bwayo, J. and 
Overbaugh, J. (1997). Phylogenetic evaluation of Kenyan HIV type 1 isolates. A/OS Res 
Hum Retroviruses, 13(6):493-9. 
Premack, B.A. and Schall, T.J. (1996). Chemokine receptors: gateways to inflammation and 
infection. Nat Med, 2(11):1174-8. 
Price, D.A., Goulder, P.J., Klenerman, P., Sewell, A.K., Easterbrook, P.J., Troop, M., Bangham, 
C.R. and Phillips, R.E. (1997). Positive selection of HIV-1 cytotoxic T lymphocyte escape 
variants during primary infection. Proc Natl Acad Sci US A, 94(5):1890-5. 
Prince, A.M., Whalen, R. and Brotman, 8. (1997). Successful nucleic acid based immunization of 
newborn chimpanzees against hepatitis B virus . Vaccine, 15(8):916-9. 
Quillent, C., Oberlin, E., Braun, J., Rousset, D. , Gonzalez-Canali, G., Metais, P., Montagnier, L., 
Virelizier, J.L., Arenzana-Seisdedos, F. and Beretta, A. (1998). HIV-1-resistance 
phenotype conferred by combination of two separate inherited mutations of CCR5 gene. 
Lancet, 351 (9095):14-8. 
Quinn, T.C. (1996). Global burden of the HIV pandemic. Lancet, 348(9020):99-106. 
Published erratum appears in Lancet, 348(9022):276. 
Quinones-Mateu, M.E., Dopazo, J., Este, J.A., Rota, T.R. and Domingo, E. (1995). Molecular 
characterization of human immunodeficiency virus type 1 isolates from Venezuela. A/OS 
Res Hum Retroviruses, 11(5):605-16. 
Race, E., Frezza, P., Stephens, D.M., Davis, D., Polyanskaya, N., Cranage, M. and Oxford, J.S. 
(1995). An experimental chemically inactivated HIV-1 vaccine induces antibodies that 
neutralize homologous and heterologous viruses. Vaccine, 13(1 ):54-60. 
Radaelli, A. and De Giuli Morghen, C. (1994). Expression of HIV-1 envelope gene by recombinant 
avipox viruses. Vaccine, 12(12):1101-9. 
Radaelli, A., Gimelli, M., Cremonesi, C., Scarpini, C. and De Giuli Morghen, C. (1994). Humoral 
and cell-mediated immunity in rabbits immunized with livenon-replicating avipox 
recombinants expressing the HIV-1SF2 env gene. Vaccine , 12(12):1110-7. 
Ras, G.J., Simson, I.W., Anderson, R., Prozesky, O.W. and Hammerson, T. (1983). Acquired 
immunodeficiency syndrome: a report of two South African cases. S Afr Med J, 64:140-
142. 
211 
Ray, N.B., Ewalt, LC. and Lodmell, D.L. (1997). Nanogram quantities of plasmid DNA encoding 
the rabies virus glycoprotein protect mice against lethal rabies virus infection . Vaccine, 
15(8):892-5. 
Rayfield , M.A., Downing, R.G ., Baggs, J., Hu, D.J. , Pieniazek, D., Luo, C.C., Biryahwaho, B., 
Otten, R.A. , Sempala, S.D. and Dondero, T.J. (1998). A molecular epidemiologic survey of 
HIV in Uganda. HIV Variant Working Group. AIDS, 12(5):521-7. 
Rayfield , M.A., Sullivan, P., Bandea, C.I., Britvan, L. , Otten, R.A. , Pau, C.P., Pieniazek, D., 
Subbarao, S., Simon, P., Schable, C.A. , Wright, A.C., Ward, J. and Schochetman, G. 
(1996). HIV-1 group O virus identified for the first time in the United States. Emerg Infect 
Dis, 2(3):209-12. 
Raz, E., Carson, D.A., Parker, S.E., Parr, T.B., Abai , A.M., Aichinger, G., Gromkowski, S.H., 
Singh, M., Lew, D. and Yankauckas, M.A. et al. (1994). lntradermal gene immunization: the 
possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad 
Sci US A, 91 (20):9519-23. 
Reeves, J.D., McKnight, A., Potempa, S., Simmons, G., Gray, P.W., Power, C.A., Wells, T., 
Weiss, R.A. and Talbot, S.J . (1997). CD4-independent infection by HIV-2 (ROD/B): use of 
the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology, 231 (1 ):130-
4. 
Rencher, S.D. and Hurwitz, J.L. (1997). Effect of natural HIV-1 envelope V1-V2 sequence 
diversity on the binding of V3-specific and non-V3-specific antibodies. J Acquir Immune 
Defic Syndr Hum Retrovirol, 16(2):69-73. 
Rencher, S.D., Lockey, T.D., Srinivas, R.V., Owens, R.J. and Hurwitz, J.L. (1997). Eliciting HIV-1 
envelope-specific antibodies with mixed vaccinia virus recombinants . Vaccine , 15(3):265-
72. 
Renjifo, B., Chaplin, B. , Mwakagile, D., Shah, P., Vannberg, F. , Msamanga, G., Hunter, D., Fawzi, 
W. and Essex, M. (1998). Epidemic expansion of HIV-1 subtype C and recombinant 
subtypes in Tanzania. AIDS Res. Hum. Retroviruses, (14)7:635-8. 
Richardson, T.M. Jr, Stryjewski, B.L., Broder, C.C., Hoxie, J.A. , Mascola, J.R. , Earl, P.L. and 
Dams, R.W. (1996). Humoral response to oligomeric human immunodeficiency virus type 1 
envelope protein. J Viral, 70(2):753-62. 
Richmond, J.F. , Mustafa, F., Lu, S., Santoro, J.C., Weng, J., O'Connell, M., Fenyo, E.M. , Hurwitz, 
J.L., Montefiori, D.C. and Robinson, H.L. (1997). Screening of HIV-1 Env glycoproteins for 
the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia 
virus boosting. Virology, 230(2):265-7 4. 
Rinaldo, C., Huang, X.L., Fan, Z.F., Ding, M., Beltz, L. , Logar, A., Panicali, D., Mazzara, G., 
Liebmann, J., Cottrill , M., et al. (1995). High levels of anti-human immunodeficiency virus 
type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated 
with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 69(9):5838-42. 
Rizzuto, C.D., Wyatt, R. , Hernandez-Ramos, N., Sun, Y., Kwong, P.O., Hendrickson, W.A. and 
Sodroski, J. (1998). A conserved HIV gp120 glycoprotein structure involved in chemokine 
receptor binding. Science, 280(5371 ):1949-53. 
Rhodes, D., Solomon, A., Carr, A., Cooper, D., Kaldor, J. and Deacon, N. (1998). Identification 
and characterisation of nef deleted viruses from three long term non-progressors. 12th 
World AIDS Conference, Geneva, abs 11143. 
212 
Robinson, N.J., Mulder, D.W., Auvert, B. and Hayes, R.J . (1995). Modelling the impact of 
alternative HIV intervention strategies in rural Uganda. AIDS, 9(11 ): 1263-70. 
aRobinson, H.L. (1997). DNA vaccines for immunodeficiency viruses. AIDS, 11 (Suppl A):S109-19. 
bRobinson, H.L. (1997). Nucleic acid vaccines: an overview. Vaccine , 15(8):785-7. 
Rousset, D. , Soares, J.L., Reynes, J.M., Caruz, A., Flye Sainte Marie, F. and Virelizier, J.L. 
(1999). High frequency of the 3'A mutation of the SDF-1 gene in Cambodia. AIDS, 
13(3):420-1 . 
Rovinski, B., Haynes, J.R., Cao, S.X., James, 0., Sia, C., Zolla-Pazner, S., Matthews, T.J. and 
Klein, M.H. (1992). Expression and characterization of genetically engineered human 
immunodeficiency virus-like particles containing modified envelope glycoproteins: 
implications for development of a cross-protective AIDS vaccine. J Viral, 66(7):4003-12. 
Rovinski, B., Rodrigues, L. , Cao, S.X., Yao, F.L., McGuinness, U., Sia, C., Cates, G., Zolla-
Pazner, S., Karwowska, S., Matthews, T.J. , et al. (1995). Induction of HIV type 1 
neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered 
HIV type 1-like particles containing unprocessed gp160 glycoproteins. AIDS Res Hum 
Retroviruses, 11(10):1187-95. 
Rowland-Jones, S.L., Nixon, D.F., Aldhous, M.C., Gotch, F., Ariyoshi, K., Hallam, N., Kroll , J.S., 
Froebel, K. and McMichael, A. (1993). HIV-specific cytotoxic T-cell activity in an HIV-
exposed but uninfected infant. Lancet, 341 (8849):860-1. 
Rowland-Jones, S., Sutton, J., Ariyoshi , K., Dong, T., Gotch, F., McAdam, S., Whitby, D., Sabally, 
S., Gallimore, A. , Corrah, T., et al. (1995). HIV-specific cytotoxic T-cells in HIV-exposed 
but uninfected Gambian women . Nat Med, 1 (1 ):59-64. 
Published erratum appears in Nat Med (1995) 1(6):598. 
Rubinstein, A. , Goldstein, H., Pettoello-Mantovani , M., Mizrachi, Y., Bloom, B.R., Furer, E., 
Althaus, B., Que, J.U. , Hasler, T. and Cryz, S.J. (1995). Safety and immunogenicity of a V3 
loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative 
volunteers. AIDS, 9(3):243-51 . 
Rubsamen-Waigmann, H., van Briesen, H., Holmes, H., Bjorndal, A., Korber, B., Esser, R., 
Ranjbar, S., Tomlinson, P., Galvao-Castro, B., Karita, E., et al. (1994). Standard 
conditions of virus isolation reveal biological variability of HIV type 1 in different regions of 
the world. AIDS Res Hum Retroviruses, 10(11 ):1401-1408. 
Rucker, J., Edinger, A.L. , Sharron, M., Samson, M. , Lee, B., Berson , J.F., Yi, Y., Margulies, B., 
Collman, R.G., Doranz, B.J ., Parmentier, M. and Dams, R.W. (1997). Utilization of 
chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse 
human and simian immunodeficiency viruses. J Viral, 71 (12):8999-9007. 
Ruprecht, R.M ., Baba, T.W., Liska, V., Bronson, R., Penninck, D. and Greene, M.F. (1996). 
"Attenuated" simian immunodeficiency virus in macaque neonates. AIDS Res Hum 
Retroviruses, 12(5):459-60. 
Sabino, E.C., Diaz, R.S., Brigida, L.F., Learn, G.H., Mullins, J.I., Reingold, A.L. , Duarte, A.J ., 
Mayer, A. and Busch, M.P. (1996). Distribution of HIV-1 subtypes seen in an AIDS clinic in 
Sao Paulo City.Brazil. AIDS, 10(13):1579-84. 
213 
Salmon-Ceron, D., Excler, J.L. , Sicard, D., Blanche, P., Finkielstzjen, L., Gluckman, J.C., Autran , 
B., Matthews, T.J., Meignier, B., Kieny, M.P., et al. (1995). Safety and immunogenicity of a 
recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-
negative volunteers . AIDS Res Hum Retroviruses, 11 (12):1479-86. 
Sambruck, J., Fritsch, E.F. and Maniatus, T. Eds. (1989). Molecular cloning:A laboratory manual. 
Cold Spring Harbour Laboratory Press. 
Samson, M., Libert, F., Doranz, B.J., Rucker, J., Liesnard, C., Farber, C.M., Saragosti, S., 
Lapoumeroulie, C., Cognaux, J., Forceille, C., Muyldermans, G., Verhofstede, C., 
Burtonboy, G., Georges, M., Imai, T., Rana, S., Yi, Y., Smyth, R.J ., Collman, R.G., Doms, 
R.W., Vassart, G. and Parmentier, M. (1996). Resistance to HIV-1 infection in caucasian 
individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 
382(6593):722-5. 
Samson, M., Edinger, A.L. , Stordeur, P. , Rucker, J. , Verhasselt, V., Sharron, M., Govaerts, C., 
Mollereau, C., Vassart, G., Doms, R.W. and Parmentier, M. (1998). ChemR23, a putative 
cherrioattractant receptor, is expressed in monocyte-derived dendritic cells and 
macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J lmmunol, 
28(5):1689-700. 
Sanger, F. , Niklen, S. and Coulson, A.R. (1977). DNA sequencing with chain-terminating 
inhibitors. Proc. Natl. Acad. Sci. USA, 74:5463-5467. 
Sarzotti, M., Dean, T.A., Remington, M.P., Ly, C.D., Furth, P.A. and Robbins, D.S. (1997). 
Induction of cytotoxic T cell responses in newborn mice by DNA immunization . Vaccine, 
15(8):795-7. 
Sasaki, S., Fukushima, J., Arai, H., Kusakabe, K.I., Hamajima, K., Ishii, N., Hirahama, F., Okuda, 
K., Kawamoto, S., Ruysschaert, J.M., Vandenbranden, M., Wahren, B. and Okuda, K. 
(1997). Human immunodeficiency virus type-1-specific immune responses induced by 
DNA vaccination are greatly enhanced by mannan-coated diC14-amidine. Eur J lmmunol, 
27:3121 -9. 
Sato, Y., Roman, M., Tighe, H., Lee, D., Corr, M., Nguyen, M.D., Silverman, G.J., Lotz, M., 
Carson, D.A. and Raz, E. (1996). lmmunostimulatory DNA sequences necessary for 
effective intradermal gene immunization. Science, 273(5273):352-4. 
Sauzet, J.P., Moog, C., Krivine, A., Martinon, F., Bossus, M., Gras-Masse, H., Tartar, A., Guillet, 
J.G. and Gomard, E. (1998). Adjuvant is required when using Env lipopeptide construct to 
induce HIV type 1-specific neutralizing antibody responses in mice in vivo. AIDS Res Hum 
Retroviruses, 14(10):901-9. 
Schable, C., Zekeng, L. , Pau, C.P., Hu, D., Kaptue, L., Gurtler, L. , Dondero, T., Tsague, J.M., 
Schochetman, G. and Jaffe, H., et al. (1994). Sensitivity of United States HIV antibody 
tests for detection of HIV-1 group O infections. Lancet,344(8933):1333-4. 
Schinkel, J., Langendam, M.W., Coutinho, R.A. , Krol , A., Brouwer, M. and Hanneke 
Schuitemaker. (1999). No Evidence for an Effect of the CCR5 32/+ and CCR2b 641/+ 
Mutations on Human Immunodeficiency Virus (HIV)-1 Disease Progression among HIV-1 
Infected Injecting Drug Users. J Infect Dis, 179:825-831 . 
Schneider, J., Gilbert, S.C., Blanchard, T.J ., Hanke, T. , Robson, K.J ., Hannan, C.M., Becker, M., 
Sinden, R., Smith, G.L.and Hill, A.V.S. (1998). Enhanced immunogenicity for CD8+ T cell 
induction and cmplete protective efficacy of malaria DNA vaccination by boosting with 
modified vaccinia virus Ankara. Nature Medicine (4)4:397-402. 
214 
Schnell, M.J., Johnson, J.E., Buonocore, L. and Rose, J.K. (1997). Construction of a novel virus 
that targets HIV-1-infected cells and controls HIV-1 infection . Ce//, 90(5):849-57. 
Sette, A. and Sidney, J. (1998). HLA supertypes and supermotifs a functional perspective on HLA 
polymorphism. Curr Opin lmmunol, 10(4):478-82. 
Shafer, RW., Eisen, J.A., Merigan, T.C. and Katzenstein, D.A. (1997). Sequence and drug 
susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 
1 seroconverters in Zimbabwe. J Virol, 71 (7):5441-8. 
Shao, Y. Zhao, Q., Guan, Y., Zeng, Y., Chang, J. and Koestler, J. (1996). Follow-up studies on 
molecular epidemiology of HIV-1 strains in Ruili region of south-west China. XI 
International Conference on AIDS, abs We.C.341. 
Shao, Y., Su, L., Zhao, F., Xing, H., Zhang, Y.Z., Wolf, H. and Zhang, L.L. (1998). Genetic 
recombination of HIV-1 strains identified in China. 12th World AIDS Conference, Geneva, 
abs 11179. 
Sher, R (1985). AIDS in Johannesburg. S Afr Med J, 68(3):137-8. 
Sher, R, de Miranda, D.S., Metz, J., Sifris, D., Lyons, S.F. and Schoub, B.D. (1986). Lack of 
evidence of HIV infection in drug abusers at present. S Afr Med J, 70(12):776-7. 
Published erratum appears in S Afr Med J 1987, 71(1):60. 
Sher, R, Antunes, S., Reid, B. and Falcke, H. (1987). Seroepidemiology of human 
immunodeficiency virus in Africa from 1970 to 1974. N Engl J Med, 317(7):450-1 . 
Sher, R (1989). HIV infection in South Africa, 1982-1988--a review. S Afr Med J, 76(7):314-8. 
Shibata, R, Siemon, C., Czajak, S.C., Desrosiers, RC. and Martin, M.A. (1997). Live, attenuated 
simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a 
human immunodeficiency virus type 1 chimeric virus. J Viral, 71 (11 ):8141-8. 
Shiver, J.W. , Davies, M.E., Yasutomi, Y., Perry, H.C., Freed, D.C., Letvin, N.L. and Liu, M.A. 
(1997). Anti-HIV env immunities elicited by nucleic acid vaccines. Vaccine, 15(8):884-7. 
Sidney, J., del Guercio, M.F., Southwood, S., Engelhard, V.H., Appella, E., Rammensee, H.G., 
Falk, K., Rotzschke, 0 ., Takiguchi, M. and Kubo, RT., et al. (1995). Several HLA alleles 
share overlapping peptide specificities. J lmmunol, 154(1 ):247-59. 
Sidney, J., Grey, H.M., Kubo, RT. and Sette, A. (1996). Practical, biochemical and evolutionary 
implications of the discovery of HLA class I supermotifs . lmmunol Today, 17(6):261-6. 
Sidney, J., Grey, H.M., Southwood, S., Celis, E., Wentworth, P.A., del Guercio, M.F., Kubo, RT., 
Chesnut, RW. and Sette, A. (1996) . Definition of an HLA-A3-like supermotif demonstrates 
the overlapping peptide-binding repertoires of common HLA molecules. Hum lmmunol, 
45(2):79-93. 
Siegrist, C.A. (1997). Potential advantages and risks of nucleic acid vaccines for infant 
immunization. Vaccine, 15(8):798-800. 
Simon, F., Loussert-Ajaka, I. , Damond, F., Saragosti, S., Sarin , F. and Brun-Vezinet, F. (1996). 
HIV type 1 diversity in northern Paris, France. AIDS Res Hum Retroviruses, 12(15):1427-
33. 
215 
Simon, F., Mauclere, P., Roques, P., Loussert-Ajaka, I., Muller-Trutwin, M.C., Saragosti, S., 
Georges-Courbot, M.C., Barre-Sinoussi, F. and Brun-Vezinet, F. (1998). Identification of a 
new human immunodeficiency virus type 1 distinct from group M and group 0 . Nat Med, 
4(9):1032-7. 
Smith, M.W., Dean, M., Carrington, M., Winkler, C., Huttley, G.A., Lomb, D.A., Goedert, J.J., 
O'Brien, T.R., Jacobson, L.P., Kaslow, R., Buchbinder, S., Vittinghoff, E., Vlahov, D., 
Hoots, K., Hilgartner, M.W. and O'Brien, S.J. (1997). Contrasting genetic influence of 
CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth 
and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter 
Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. 
Science, 277(5328):959-65. 
Sonnerborg, A., Durdevic, S., Giesecke, J. and Sallberg, M. (1997). Dynamics of the HIV-1 
subtype distribution in the Swedish HIV-1 epidemic during the period 1980 to 1993. AIDS 
Res Hum Retroviruses, 13(4):343-5. 
Soto-Ramirez, L.E., Renjifo, 8 ., Mclane, M.F., Marlink, R., O'Hara, C., Sutthent, R., Wasi, C., 
Vithayasai, P., Vithayasai, V., Apichartpiyakul, C., Auewarakul, P., Pena Cruz, V., Chui, 
D.S., Osathanondh, R., Mayer, K., Lee, T.H. and Essex, M. (1996). HIV-1 Langerhans' cell 
tropism associated with heterosexual transmission of HIV. Science, 271(5253):1291-3. 
Sperling, R.S. , Shapiro, D.E., Coombs, R.W., Todd, J.A., Herman, S.A. , McSherry, G.D., 
O'Sullivan, M.J., Van Dyke, R.B., Jimenez, E., Rouzioux, C., Flynn, P.M. and Sullivan, J.L. 
(1996). Maternal viral load, zidovudine treatment, and the risk of transmission of human 
immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group 
Protocol 076 Study Group. N Engl J Med, 335(22):1621-9. 
Spearman, P., Horton, R., Ratner, L. and Kuli-Zade, I. (1997). Membrane binding of human 
immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl 
switch mechanism. J Virol, 71 (9):6582-92. 
Special conference issue. (1997). International Meeting on Nucleic Acid Vaccines for the 
Prevention of Infectious Diseases. Bethesda, Maryland, 5-7 February 5-7, 1996. Vaccine 
15(8):vii-viii, 785-933. 
Spira, A.I., Marx, P.A., Patterson, B.K., Mahoney, J., Koup, R.A., Wolinsky, S.M. and Ho, D.D. 
(1996). Cellular targets of infection and route of viral dissemination after an intravaginal 
inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med, 
183(1 ):215-25. 
Staats, H.F., Nichols, W.G . and Palker, T.J . (1996) . Mucosa! immunity to HIV-1 : systemic and 
vaginal antibody responses after intranasal immunization with the HIV-1 C4N3 peptide 
T1 SP10 MN(A). J lmmunol, 157(1 ):462-72. 
Staats, H.F., Montgomery, S.P. and Palker, T.J. (1997). Intranasal immunization is superior to 
vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV 
antibody responses. AIDS Res Hum Retroviruses, 13(11 ):945-52. 
Stott, E.J., Chan, W.L., Mills, K.H., Page, M., Taffs, F., Cranage, M. and Greenaway, P. (1990). 
Preliminary report: protection of cynomolgus macaques against simian immunodeficiency 
virus by fixed infected-cell vaccine. Lancet, 336(8730): 1538-41. 
Subbarao, S., Luo, C.C., Limpakarnjanarat, K., Bhumisa-wasdi, J. , Young, N.L., Mastro, T.D., 
Schochetman, G. and Kalish, M.L. (1996). Evaluation of oligonucleotide probes for the 
determination of the two major HIV-1 env subtypes in Thailand. AIDS, 10(3):350-1. 
216 
Subbarao, S., Limpakarnjanarat, K., Mastro, T.D., Bhumisawasdi, J. , Warachit, P., Jayavasu, C., 
Young, N.L., Luo, C.C., Shaffer, N., Kalish , M.L. and Schochetman, G. (1998). HIV type 1 
in Thailand, 1994-1995: persistence of two subtypes with low genetic diversity. AIDS Res 
Hum Retroviruses, 14(4):319-27. 
Suzue, K. and Young, R.A. (1996). Adjuvant-free hsp70 fusion protein system elicits humoral and 
cellular immune responses to HIV-1 p24. J lmmunol, 156(2):873-9. 
Swanevelder, R. (1995). Fifth National HIV survey of women attending antenatal clinics , South 
Africa. Department of Health and Welfare, October/November 1994. In Epidemiological 
Comments. Ed. Kustner, H. 22(5):90-107. 
Tan, K., Liu , J., Wang, J. , Shen, S. and Lu, M. (1997). Atomic structure of a thermostable 
subdomain of HIV-1 gp41. Proc Natl Acad Sci US A, 94(23):12303-8. 
Tanuri, A, Swanson, P., Devare, S., Berro, O.J., Savedra, A , Costa, L.J., Telles, J.G., Brindeiro, 
R., Schable, C., Pieniazek, D. and Rayfield, M. (1999). HIV-1 subtypes among blood 
donors from Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol, 20(1 ):60-
6. 
Tartaglia, J. (1998). Potential improvments for poxvirus-based immunisation vehicles . In 
Retroviruses of Human AIDS and Related Animal Diseases. Eds. Girard, M. and Dodet, B. 
11 e Colloque des Cent Gardes, 1997, Marnes-La-Coquette, Paris. Elsevier, Amsterdam, 
Oxford, Paris, New York, Tokyo.pp187-97. 
Threlkeld, S.C., Wentworth , P.A., Kalams, S.A. , Wilkes, B.M., Ruhl, D.J ., Keogh, E., Sidney, J., 
Southwood, S., Walker, B.D. and Sette, A (1997). Degenerate and promiscuous 
recognition by CTL of peptides presented by the MHC class I A3-like superfamily: 
implications for vaccine development. J lmmunol, 159(4):1648-57. 
Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F. and Higgins, D.G. (1997). The 
CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided 
by quality analysis tools. Nucleic Acids Res, 25(24):4876-82. 
Tien, P.C., Chiu, T. , Latif, A, Ray, S., Batra, M., Contag, C.H., Zejena, L., Mbizvo, M., Delwart, 
E.L. , Mullins, J.I. and Katzenstein , D.A. (1999). Primary subtype C HIV-1 infection in 
Harare, Zimbabwe J Acquir Immune Defic Syndr Hum Retrovirol, 20(2):147-53. 
Tobery, T.W. and Siliciano, R.F. (1997). Targeting of HIV-1 antigens for rapid intracellular 
degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de 
novo CTL responses in vivo after immunization. J Exp Med, 185(5):909-20. 
Tobin, G.J., Li, G.H., Fong, S.E. , Nagashima, K. and Gonda, M.A. (1997). Chimeric HIV-1 virus-
like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag-
and SU-specific murine cytotoxic T-lymphocyte activities. Virology, 236(2):307-15. 
Toda, S., Ishii , N., Kusakabe, K.I., Arai, H. , Hamajima, K. , Gorai, I., Nishioka, K. and Okuda, K. 
(1997). HIV-1-specific cell-mediated immune responses induced by DNA vaccination were 
enhanced by mannan-coated liposomes and inhibited by anti-interferon-y antibody. 
lmmunol, 92:111 -7. 
Tripathy, S. , Renjifo, B., Wang, W.K., Mclane, M.F., Bollinger, R. , Rodrigues, J. , Osterman, J. , 
Tripathy, S. and Essex, M. (1996). Envelope glycoprotein 120 sequences of primary HIV 
type 1 isolates from Pune and New Delhi, India. AIDS Res Hum Retroviruses, 
12(12):1199-202. 
217 
Trkola, A., Dragic, T., Arthos, J., Binley, J.M., Olson, W.C., Allaway, G.P., Cheng-Mayer, C., 
Robinson, J., Maddon, P.J. and Moore, J.P. (1996). CD4-dependent, antibody-sensitive 
interactions between HIV-1 and its co-receptor CCR-5. Nature, 384(6605):184-7. 
Truong, C., Brand, D., Mallet. F., Roingeard, P., Brunet, S. and Sarin, F. (1996). Assembly and 
immunogenicity of chimeric Gag-Env proteins derived from the human immunodeficiency 
virus type 1. AIDS Res Hum Retroviruses, 12(4 ):291-301. 
Tscherning, C., Alaeus, A. , Fredriksson, R. , Bjtirndal , A., Deng, H., Littman, D.R., Fenyo, E.M. 
and Albert, J. (1998). Differences in chemokine coreceptor usage between genetic 
subtypes of HIV-1 . Virology, 241(2):181-8. 
UNAIDS (The Joint United Nations Programme on HIV/AIDS), (1999) http://www.unaids .org/ 
UNAIDS and WHO (World Health Organisation), (1998). Report on the global HIV/AIDS epidemic. 
http://www.unaids.org/ 
Ugen, K.E., Nyland, S.B., Boyer, J.D., Vidal, C. , Lera, L. , Rasheid, S., Chattergoon, M., Bagarazzi, 
M.L. , Ciccarelli, R. , Higgins, T., Baine, Y., Ginsberg, R., Macgregor, R.R. and Weiner, D.B. 
(1998). DNA vaccination with HIV-1 expressing constructs elicits immune responses in 
humans. Vaccine, 16(19):1818-21 . 
Vancott, T.C., Mascola, J.R., Kaminski, R.W., Kalyanaraman, V., Hallberg, P.L. , Burnett, P.R., 
Ulrich, J.T., Rechtman, D.J . and Birx, D.L. (1997). Antibodies with specificity to native 
gp 120 and neutralization activity against primary human immunodeficiency virus type 1 
isolates elicited by immunization with oligomeric gp160. J Viral, 71 (6):4319-30. 
Valentine, F.T., Kundu, S., Haslett, P.A., Katzenstein, D., Beckett, L. , Spino, C., Borucki, B., 
Vasquez, M., Smith, G., Korvick, J., Kagan, J. and Merigan, T.C. (1996) . A randomized, 
placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) 
rgp160 vaccine in HIV-infected subjects with >or= 400/mm3 CD4 T lymphocytes (AIDS 
Clinical Trials Group Protocol 137). J Infect Dis, 173(6): 1336-46. 
Valentine, P.J., Meyer, K., Rivera, M.M., Lipps, C., Pauza, D., Maziarz, R.T. , So, M. and Heffron, 
F. (1996). Induction of SIV capsid-specific CTL and mucosal slgA in mice immunized with 
a recombinant S. typhimurium aroA mutant. Vaccine, 14(2):138-46. 
van de Peer, Y. , de Wachter, R. (1994). TREECON for Windows: A softward paackage for the 
constuction and drawing of evolutinary trees for the Microsoft Windows environment. 
Comput. Applic. Biosci, 10:569-570. 
Van Haldenwang, B.B. (1996). International migration: a case study of South Africa. Development 
Southern Africa, 13(6): 
van Harmelen, J., Wood, R., Lambrick, M., Rybicki, E.P. and Williamson, C. (1997). An 
association between HIV-1 subtype and mode of transmission in Cape Town, South 
AFrica . AIDS, 11 :81-87. 
a van Harmelen, J., van der Ryst, E. , Wood, R. , Lyons, S.F. and Williamson, C. (1999). 
Restriction fragment length polymorphism analysis for rapid gag subtype determination of 
human immunodeficiency virus type 1 in South Africa . J Viral Methods, 78(1-2):51-9. 
b van Harmelen, J.H., van der Ryst, E., Loubser, A.S., York, D., Madurai, S. , Lyons, S., Wood, R. 
and Williamson, C. (1999). A predominantly HIV type 1 subtype C-restricted epidemic in 
South African urban populations. AIDS Res Hum Retroviruses, 15(4 ):395-8. 
218 
van Rij, R.P., de Roda Husman, A.M ., Brouwer, M., Goudsmit, J., Coutinho, R.A. and 
Schuitemaker, H. (1998). Role of CCR2 genotype in the cl inical course of syncytium-
inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to 
conversion to SI virus variants. J Infect Dis, 178:1806-1811 . 
Veenstra, J., Williams, I.G., Colebunders, R., Dorrell, L., Tchamouroff, S.E., Patou, G., Lange, 
J.M., Weller, I.V., Goeman, J., Uthayakumar, S., Gow, I.R., Weber, J.N. and Coutinho, 
R.A. (1996). Immunization with recombinant p17/p24:Ty virus-like particles in human 
immunodeficiency virus-infected persons. J Infect Dis, 174(4):862-6. 
Vorndam, V. , Kuna, G. and Rosado, N. (1994) A PCR-restriction enzyme technique for 
determining dengue virus subgroups within serotypes. Virmet. 48:237-244. 
Wang, B., Ugen, K.E., Srikantan, V., Agadjanyan, M.G., Dang, K., Refaeli , Y., Sato, A.I., Boyer, J., 
Williams, W.V. and Weiner, D.B. (1993). Gene inoculation generates immune responses 
against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA, 90: 4156-60. 
Wang, B., Boyer, J., Srikantan, V., Ugen, K., Gilbert, L., Phan, C., Dang, K. , Merva, M., 
Agadjanyan, M.G., Newman, M., et al. (1995). Induction of humoral and cellular immune 
responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo 
DNA inoculation . Virology, 211 (1):102-12. 
Wang, B., Dang, K., Agadjanyan, M.G., Srikantan, V., Li, F., Ugen, K.E., Boyer, J., Merva, M., 
Williams, W.V., Weiner, D.B. (1997). Mucosal immunization with a DNA vaccine induces 
immune responses against HIV-1 at a mucosal site. Vaccine, 15(8):821-5. 
Wang, R., Doolan, D.L., Le, T.P., Hedstrom, R.C., Coonan, K.M., Charoenvit, Y., Jones, T.R., 
Hobart, P., Margalith, M., Ng, J., Weiss, W.R. , Sedegah, M., de Taisne, C. , Norman and 
J.A., Hoffman, S.L. (1998). Induction of antigen-specific cytotoxic T lymphocytes in 
humans by a malaria DNA vaccine. Science, 282(5388):476-80. 
Wasi , C., Herring, B., Raktham, S., Vanchenseni, S., Mastro, T.D, Young, N.L., Rubsamen-
Waigmann, H., van Briesen, H., Kalish , M.L., Luo, C.C., Pau, C., Baldwin, A., Mullins, J., 
Delwart, E., Esparza, J. , Heyward, N.L. and Osmanov, S. (1995). Determination of HIV-1 
subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme 
immunoassay and heteroduplex mobility assay: evidence of increasing infection with 
subtype E. A/OS, 9(8):843-851. 
Wawer, M.J., Gray, R.H ., Sewankambo, N.K., Serwadda, D., Paxton, L., Berkley, S., McNairn, D., 
Wabwire-Mangen, F., Li, C., Nalugoda, F. , Kiwanuka, N., Lutalo, T., Brookmeyer, R., Kelly, 
R. and Quinn, T.C. (1998). A randomized, community trial of intensive sexually transmitted 
disease control for AIDS prevention, Rakai, Uganda. A/OS, 12(10):1211-25. 
Weber, J., Cheinsong-Popov, R., Callow, D., Adams, S., Patou, G., Hodgkin, K. , Martin, S., 
Gotch, F. and Kingsman, A. (1995). lmmunogenicity of the yeast recombinant p17/p24:Ty 
virus-like particles (p24-VLP) in healthy volunteers. Vaccine, 13(9):831-4. 
Weber, J. (1998). A phase I strudy of rgp120w61 D with novel adjuvant/immunostimulants in normal 
healthy volunteers. In Retroviruses of Human AIDS and Related Animal Diseases. Eds. 
Girard, M. and Dodet, B. 11 e Colloque des Cent Gardes, 1997, Marnes-La-Coquette, Paris. 
Elsevier, Amsterdam, Oxford, Paris, New York, Tokyo.pp287-92. 
Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J. and Wiley, D.C. (1997). Atomic 
structure of the ectodomain from HIV-1 gp41 . Nature , 387(6631 ):426-30. 
219 
Weniger, B.G., Takebe, Y., Ou, C.Y.and Yamazaki, S. (1994). The molecular epidemiology of HIV 
in Asia. A/OS, 8 Suppl 2:S13-28. 
Whalen, R. (1997-1999). The DNA Vaccine Web, http://www.genweb.com/Dnavax/ 
Whatmore, A.M., Cook, N., Hall, G.A., Sharpe, S., Rud, E.W. and Cranage, M.P. (1995). Repair 
and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Viral, 
69(8):5117-23. 
WHO (World Helath Organisation) (1998). Weekly Epidemiological Record. 73:381-388. 
Williams, B. and Campbell , C. (1996). Mines, migrancy and HIV in South Africa--managing the 
epidemic. S Afr Med J, 86(10):1249-51 . 
Williamson, C., Engelbrecht, S., Lambrick, M., van Rensburg, E.J ., Wood, R. , Bredell , H. and 
Williamson, A-L. (1995). HIV-1 subtypes in different risk groups in South Africa. Lancet, 
346, 782 (letter). 
Wilson, S.E., Pedersen, S.L., Kunich, J.C., Wilkins, V.L., Mann, D.L., Mazzara, G.P., Tartaglia, J., 
Celum, C.L. and Sheppard, H.W. (1998). Cross-clade envelope glycoprotein 160-specific 
CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. A/OS Res 
Hum Retroviruses, 14( 11 ):925-37. 
Winkler, C., Modi, W., Smith, M.W., Nelson, G.W., Wu, X., Carrington, M., Dean, M., Honjo, T., 
Tashiro, K., Yabe, D., Buchbinder, S., Vittinghoff, E., Goedert, J.J., O'Brien, T.R. , 
Jacobson, L.P., Detels, R., Danfield, S., Willoughby, A., Gomperts, E., Vlahov, D., Phair, J. 
and O'Brien, S.J. (1998). Genetic restriction of AIDS pathogenesis by an SDF-1 
chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study 
(HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study 
(MHCS), San Francisco City Cohort. Science, 279(5349):389-93. 
Wong-Staal, F. and Gallo, R.C. (1985). Human T-lymphotropic retroviruses. Nature, 
317(6036):395-403. 
Wood, R., O'Keefe, E.A. and Maartens, G. (1996) The changing pattern of transmission and 
clinical presentation of HIV infection in the Western Cape region of South Africa (1984-
1995). SA J of Epi Infect, 11 (4 ):96-8. 
Wu, L., Gerard, N.P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A., Cardoso, A.A., 
Desjardin, E., Newman, W., Gerard, C. and Sodroski, J. (1996). CD4-induced interaction of 
primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature, 
384(6605):179-83. 
Wyatt, R., Kwong, P.O., Desjardins, E., Sweet, R.W. , Robinson, J., Hendrickson, W.A. and 
Sodroski, J.G. (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. 
Nature, 393(6686):705-11 . 
Wyatt, R. and Sodroski, J. (1998). The HIV-1 envelope glycoproteins: fusogens , antigens, and 
immunogens. Science, 280(5371 ):1884-8. 
Xiao, L. , Rudolph, D.L., Owen, S.M., Spira, T.J. and Lal , R.B. (1998). Adaptation to promiscuous 
usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease 
progression. A/OS, 12(13):F137-43. 
220 
Xu, X.N., Screaton, G.R., Gotch, F.M., Dong, T., Tan, R., Almond, N., Walker, B. , Stebbings, R. , 
Kent, K., Nagata, S., Stott, J.E. and McMichael, A.J. (1997). Evasion of cytotoxic T 
lymphocyte (CTL} responses by net-dependent induction of Fas ligand (CD95L) 
expression on simian immunodeficiency virus-infected cells . J Exp Med, 186(1):7-16. 
Wang, B., Boyer, J., Srikantan, V., Ugen, K., Gilbert, L. , Phan, C., Dang, K., Merva, M., 
Agadjanyan , M.G., Newman, M., et al. (1995). Induction of humoral and cellular immune 
responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo 
DNA inoculation. Virology, 211 (1 ):102-12. 
Yasutomi, Y., Koenig, S., Haun, S.S., Stover, C.K., Jackson, R.K. , Conard, P., Conley, A.J. , 
Emini, E.A., Fuerst, T.R. and Letvin, N.L. (1993). Immunization with recombinant BCG-SIV 
elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J lmmunol, 150(7):3101-7. 
Yu , X., Yuan, X. , Matsuda, Z., Lee, T.H. and Essex, M. (1992). The matrix protein of human 
immunodeficiency virus type 1 is required for incorporation of viral envelope protein into 
mature virions . J Virol, 66(8):4966-71 . 
Yu , X.F., Wang, Z., Beyrer, C., Celentano, D.D., Khamboonruang, C., Allen, E. and Nelson, K. 
( 1995). Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 
from patients with AIDS in northern Thailand. J Virol, 69(8):4649-55. 
Yu , X.F., Wang, Z. , Beyrer, C., Celentano, D.D., Khamboonruang, C. and Nelson, K. (1997). 
Diversity of full-length subtype E HIV type 1 env sequences in early seroconvertors from 
northern Thailand . AIDS Res Hum Retroviruses, 13( 16): 1439-41 . 
Yu , X.F., Chen, J., Shao, Y. , Beyrer, C. and Lai, S. (1998). Two subtypes of HIV-1 among 
injection-drug users in southern China. Lancet, 351 (9111 ):1250. 
Yusibov, V., Modelska, A., Steplewski, K., Agadjanyan, M., Weiner, D., Hooper, D.C. and 
Koprowski, H. (1997). Antigens produced in plants by infection with chimeric plant viruses 
immunize against rabies virus and HIV-1 . Proc Natl Acad Sci US A, 94(11 ):5784-8. 
Zaitseva, M., Blauvelt, A. , Lee, S., Lapham, C.K., Klaus-Kovtun, V., Mostowski, H., Manischewitz, 
J. and Golding, H. (1997). Expression and function of CCR5 and CXCR4 on human 
Langerhans cells and macrophages: implications for HIV primary infection. Nat Med, 
3(12):1369-75. 
Zekeng, L., Takehisa, J., Kuaban, C., Afaneze, E., Hayami, M., Kaptue, L. and Gurtler, L. (1998). 
HIV-1 group M and group O co-infections in Cameroon. 12th World AIDS Conference, 
Geneva, abs 11187. 
Zhou, W. and Resh, M.D. (1996). Differential membrane binding of the human immunodeficiency 
virus type 1 matrix protein . J Viro/, 70(12):8540-8. 
Zhu, T., Korber, B.T., Nahmias, A.J ., Hooper, E., Sharp, P.M. and Ho, D.D. (1998). An African 
HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature, 
391 (6667):594-7. 
Zimmerman, D.H., Ulrich, J.T., Wright, C., Lloyd, J.P., Winship, M.D. and Sarin, P.S. (1998). 
Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic 
peptide antigen from HIV type 1 p17. A/OS Res Hum Retroviruses, 14(9):741-9. 
221 
Zolla-Parzner, S. (1998). The role of antibodies in preventing HIV infection. In Retroviruses of 
Human AIDS and Related Animal Diseases. Eds. Girard, M. and Dodet, B. 11 e Colloque 
des Cent Gardes, 1997, Marnes-La-Coquette, Paris . Elsevier, Amsterdam, Oxford, Paris, 
New York, Tokyo.pp121-6. 
Zun ich , K.M., Lane, H.C. , Davey, RT., Falloon, J. , Polis, M., Kovacs, J.A. and Masur, H. (1992).1 
Phase 1/11 studies of the toxicity and immunogenicity of recombinant gp160 and p24 
vaccines in HIV-infected individuals. A/OS Res Hum Retroviruses, 8(8):1335. 
222 
